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 i 
ABSTRACT 
 
 Nineteenth century philosophy and anatomy regarded the nervous system 
as the only pathway of communication between the brain and body but now, 
research in the field of psychoneuroimmunology (PNI) has provided evidence to 
prove the age-old belief that there is a connection between the mind (or 
mental/emotional states) and the body. Researchers in PNI have now shown that 
the communication between the nervous and immune systems is bi-directional – 
i.e. there is a psychological reaction to physical disease and a somatic presentation 
of psychological disorders - and that the immune system, the autonomic nervous 
system, the endocrine system and the neuropeptide systems all communicate with 
each other by means of chemicals called messenger molecules or ligands.   
 
 This paper outlines research into the treatment of Irritable Bowel 
Syndrome (IBS) with hypnotherapy, taking into account the mind-body 
connection and treating both the patient’s physiological and 
emotional/psychological symptoms rather than treating the physiological 
symptoms only. In other words, using a more holistic approach to the treatment of 
IBS. 
 IBS is probably the most common functional gastrointestinal disorder 
encountered by both gastroenterologists and physicians in primary care. It is 
estimated that from 10% to 25% of the general population suffer from this 
condition and that it comprises about 30-50% of the gastroenterologists’ 
workload, yet the aetiology of IBS is unknown and, so far, there is no cure.  
 
 Researchers are beginning to view IBS as a multi-faceted disorder in 
which there appears to be a disturbance in the interaction between the intestines, 
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brain, and autonomic nervous system, resulting in an alteration in the regulation 
of bowel motility and/or sensory function. Most researchers agree that a subset of 
IBS sufferers have a visceral hypersensitivity of the gut or, more specifically, an 
increased perception of sensations in the gut.  
 
 To date, studies of IBS have proposed previous gastroenteritis, small 
intestine bacterial overgrowth, psychosocial factors, a genetic contribution, and an 
imbalance of neurotransmitters as either possible causes or playing a part in the 
development of IBS. It is generally agreed that a patient’s emotional response to 
stress can exacerbate the condition. 
 
 
 In section 1 of the thesis, the introduction, a detailed description and 
background appropriate to the study undertaken are provided, including aspects of 
epidemiology, diagnostic symptom criteria and clinical relevance of the Irritable 
Bowel Syndrome. Previous studies of various forms of treatment for IBS are 
discussed with the main emphasis being on treatment with hypnotherapy.  All 
these therapies have concentrated on either mind or body treatments whereas this 
study demonstrates how hypnotherapy, and the use of imagery, addresses both 
mind and body. Finally, the rationale for the current study and the specific aims of 
the thesis are outlined. 
 
 In section 2, the methodology and assessment instruments used in the 
clinical trial are discussed, as well as recruitment processes, research plan and 
timetable, and treatment schedule. Statistical analyses are provided and the main 
outcomes measures of the clinical trial, its limitations and scientific implications 
are addressed. 
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CHAPTER 1   INTRODUCTION 
 
 
1.1 The Mind-Body Connection 
 
 
 
  Mind-body interaction (or psychoneuroimmunology) is a relatively new area 
of research and is best described as a scientific investigation of how the mind (or 
mental states) affects one’s health and how one’s health can be affected by behaviour 
(Solomon, 1987). Scientific evidence for the mind’s influence on the body now 
comes from three diverging areas of research: 
 
• physiological research, which investigates the biological and biochemical 
connections between the brain and the body’s systems; 
• epidemiological research, which shows correlations between certain 
psychological factors and certain illnesses in the population at large; and 
• clinical research, which tests the effectiveness of mind-body approaches in 
preventing, alleviating, or treating specific diseases (Goleman & Gurin, 
1995). 
 
The area of focus for this thesis is in the area of clinical research. Rather than 
focusing on the cause of disease, the emphasis of this research (as in most clinical 
research) will be on the more positive aspect of testing the effectiveness of mind-body 
approaches on illnesses. The mind-body approach to be tested is hypnotherapy: the 
illness is Irritable Bowel Syndrome. 
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Interest in the mind-body connection has grown because research from studies 
on brain-immune-nervous system interactions and clinical results from both health 
professionals and researchers have substantiated not only the psychological effects on 
health and disease but also the effect of diseases on the psyche.  As Achterberg so 
aptly states: 
 “There is little argument about the negative power of the imagination on 
health… Since nature creates few one-way passages, if we can become ill through our 
misbehaviours, even die from hexes and broken hearts, then we must also be able to 
make ourselves well”  (Achterberg, 1985). 
 
There is now a substantial amount of evidence from research in the field of 
psychoneuroimmunology which demonstrates how the mind and the neurological and 
immunological systems of the body communicate through the bi-directional flow of 
hormones, neuropeptides and cytokines (Martin, 1997; Watkins, 1997). 
 
1.2       A Short History of the Mind-Body Connection 
  
 1.2.1 From Hippocrates to the Middle Ages 
 
More than 4,000 years ago, Chinese physicians were aware of the fact that 
periods of emotional upset were often followed by physical illness and Egyptian 
physicians of the same period noted that by having an optimistic attitude, one could 
avoid poor health (Achterberg, 1985). Hippocrates taught his students to consider 
their patients’ life circumstances and emotions as part of the treatment and Aristotle 
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believed that the soul was inseparable from the body and that all bodily systems 
worked together to serve the whole organism (Lyons & Petrucelli, 1987). This 
concept of a mind-body connection is also seen in the writings of the 2nd century 
Greek physician, Galen, who noted that melancholic women were more prone to 
malignancies of the breast than cheerful women (Locke & Colligan, 1986). 
 
During the Middle Ages, there was no serious practice of medicine in most of 
the Western world except for that carried out by members of religious orders or folk 
medicine which was mainly practised by women and which included the use of 
imagination (Watson, 1971). 
 
 1.2.2 The Split in the Mind-Body Connection 
 
In the 17th century, however, the holistic ancient medical beliefs (or mind-
body connections) were discarded because of changes in the philosophy and 
technology of medicine – the most powerful influences of this period being Francis 
Bacon (who asserted that science should be used to gain mastery over nature) and the 
French philosopher-scientist, Rene Descartes.  Descarte’s view (which came to be 
known as the reductionist method) was that there were two separate substances in the 
world – matter (which behaved according to physical laws) and spirit: the body was 
matter, and the mind, spiritual.  This split between the body and the mind came to 
dominate not only medical philosophy but religious philosophy as well (Lyons & 
Petrucelli, 1987). 
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Another theory, the theory of specific aetiology, came into being in France 
around the same time.  This theory was strongly supported by research carried out by 
Robert Koch, whose experiments showed that only anthrax germs caused anthrax and 
no other disease and so he theorised that germs were the specific cause of every 
disease (Graham, 1995; Hafen, Karren, Frandsen, & Smith, 1996). Interestingly, 
Rudolf Virchow (a respected medical authority of the time), although agreeing that 
germs played a role in disease, disagreed with the simplicity of Koch’s theory, 
arguing that there were other factors involved in disease such as heredity, pre-existing 
health, nutrition, environmental factors, stress, and the person’s psychological state.  
His views, unfortunately, went unheeded and evidence for the theory that pathogens 
alone caused disease continued to grow (Locke & Colligan 1986). 
 
 1.2.3 A Renewed Interest in the Mind-Body Connection 
 
However, even though this biomedical approach had been dominant for this 
period of medical history (and still is to a great extent, to this day), other forces were 
at work which would once again arouse interest in the mind and its influence on the 
body. At around the same time as the theory of specific aetiology was evolving out of 
the research of Pasteur and Koch, Sir William Osler, a Canadian physician who 
practised in Britain believed that it was much more important to know what sort of 
patient had the disease than what sort of disease the patient had (Dreher, 1995) and 
the French physiologist, Claude Bernard, talked of the milieu interieur or balance of 
the body which, when disturbed, resulted in sickness or death.  Bernard believed that 
a person did not have a disease because germs managed to gain access to the body, 
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but instead, that the person became ill because the germs had found a hospitable 
home in a weakened terrain (Pelletier, 1995). 
    
During the 1930s and 1940s, another physiologist, Walter Cannon, built on 
Bernard’s concept and coined the term homoeostasis to describe the body’s self-
maintenance of health – the built-in mechanism that helps sustain a vital balance.  
Cannon also showed how stress can alter bodily functions via the nervous system and 
coined the term “fight or flight” response to explain the reaction of the sympathetic 
branch of the autonomic nervous system to threatening situations (Rice, 1992).  
 
Hans Selye followed on Walter Cannon’s concept of “fight or flight” with 
more investigations on the physical effects of psychological stress and how it is 
tranduced into psychosomatic problems by the hormones of the hypothalamic-
pituitary-adrenal axis of the endocrine system (Rice, 1992). 
 
Sigmund Freud also brought the mind-body connection back to the fore with 
his concept of conversion neurosis, which he believed to be a result of repressed 
emotions resulting in physical problems (Hall & Lindzey, 1970). This concept was 
elaborated on in the 1940s by his student Franz Alexander, a Chicago psychiatrist 
whose ideas were to evolve into the discipline of psychosomatic medicine.  
Alexander believed that many chronic disturbances were not caused by external, 
mechanical, chemical factors or by micro-organisms, but by the continuous functional 
stress arising during the everyday life of the organism in its struggle for existence 
(Dreher, 1995).   
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Others such as Jung and Adler took up, and added to, this particular concept 
of a mind-body connection which was to become known as the theory of 
psychoanalysis (Hall & Lindzey, 1970). 
 
It appears then that the reductionist method which began with Rene Descartes, 
and the theory of specific aetiology which resulted from the research of Pasteur and 
Koch, were beginning to lose ground as more research started to come up with 
evidence suggesting (as the ancient medical practitioners and philosophers had stated 
thousands of years before) that there was indeed some connection between the mind 
and the body. 
 
Researchers such as Bernard, Cannon and Selye had come up with 
physiological evidence for this connection, and Freud and his followers had 
demonstrated a psychological connection.  However, there was still a couple of 
missing links: there was no sound knowledge of either the immune system or the 
enteric nervous system.  No-one as yet sufficiently understood the workings of these 
systems enough (nor had the scientific instruments) to prove how the fight and flight 
response, stress, or emotions could have reactions at a cellular level (see Figure 1). 
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Figure 1.     The Missing Links in the Mind-Body Connection. 
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1.3 The Immune System 
 
 1.3.1 Research & Anatomy 
 
The first sustained programme of research in this area was on the classical 
conditioning of immune responses carried out by Russian researchers Metal’nikoff 
and Chorine, who were working at the Pasteur Institute in the 1920s and, since then, 
scientists have learnt that immune cells could attack microbes with the same 
efficiency in a test tube as in the body (giving rise to the belief that the immune 
system functioned independently), that the immune system could distinguish between 
cells belonging to its own body and those which were foreign, and that it had a 
biochemical memory that helped it recognise and destroy foreign cells (Ader, Felton 
& Cohen, 1991).  But it wasn’t until the late 1950s that finer details about the 
immune system were discovered.   
 
 In 1957, Aaron Frederick Rasmussen, a microbiologist, Norman Brill, a 
behavioural scientist, and an associate, J.T. Marsh carried out various animal studies 
which demonstrated the pathogenic effect of emotional stress; and research by a 
British biochemist, Rodney Porter and American immunologist, Gerald Edelman 
(1960/70s) resulted in the finding of the precise molecular structure of an antibody 
(Locke & Colligan 1986; Ader et al., 1991). 
 
George Solomon, a Stanford psychiatrist, is considered the first to seriously 
consider the influence of mental states and traits on the immune system and began 
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research on the mind-body connection in the 1960s in collaboration with his 
colleague Rudolf Moos. Their research involved critical observations of the life 
histories and personality characteristics of the patients. Solomon became convinced 
that a connection between the brain and the immune system existed and, if this were 
so, it would conflict with the long-standing belief that the immune system network 
functioned independently of any other body system. Because his experiments 
indicated a link between the mind and the immune system, Solomon suggested the 
new science be called psychoimmunology (Locke & Colligan, 1986; Ader et al., 
1991; Dreher, 1995). 
 
Other evidence showing the effects of the mind on the body began 
accumulating in the 1960s. Lawrence LeShan (1960, 1966) suggested that mental 
states could have definite, physical repercussions on other diseases and, after 
interviews with a vast number of cancer patients, came to the conclusion that there 
was a “cancer personality.” Also at this time Herbert Benson (Benson & Klipper, 
1975; Benson et al., 1978), a cardiologist at Harvard Medical School was carrying out 
research on the relationship between stress and hypertension and reasoned that if 
stress could turn on hypertension, some other factor might be able to turn it off.   
 
In 1969, radiation oncologist, Carl Simonton and Stephanie Matthews-
Simonton (whose background was in motivational counselling), began looking at the 
possibilities of the influence of the mind to induce and enhance the “will to live” in 
cancer patients.  They explored a number of psychological techniques and claimed to 
have achieved quite dramatic results through the use of visual imagery techniques 
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which, to them, indicated that patients had a much larger influence over the course of 
their disease than they were given credit for.  These findings were considered to be 
purely anecdotal evidence as well as being methodologically flawed and were not 
published in mainstream journals (Simonton, Matthews-Simonton & Creighton, 
1978; Kidman, 1983; Sheard, 1994). 
 
However, even though experiments and research were suggesting there was a 
link between the mind and the body, the way to control or direct this influence had 
not as yet been discovered.  A serendipitous observation on mortality in a 
conditioning study being carried out by Robert Ader in 1974 finally resulted in the 
hypothesis that classical conditioning could modify the immune system. 
 
Ader and his colleague, Nicholas Cohen, had been conducting standard 
Pavlovian conditioning experiments with rats, instilling in the animals an aversion to 
saccharin-flavoured water by injecting them with cyclophosphamide after they had 
drunk the water.  As was expected, the rats continued to experience the nausea caused 
by this drug even when the sweetened water alone was given to them.  It was only 
after many of the animals had died during the experimental process, that Ader and 
Cohen realised that as well as causing nausea, cyclophosphamide was also a powerful 
immunosuppressant and that they had inadvertently taught the rats to suppress their 
immune system whenever they drank the sweetened water (Locke & Colligan, 1986; 
Ader et al., 1991). Their findings, however, did not make an impact on the 
biomedical community of that time because the belief still existed that there were no 
connections between the brain and the immune system. 
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Still more findings of a connection between the brain and the immune system 
began to appear in the 1970s.  Edwin Blalock discovered that lymphocytes were a 
source of brain peptide neurotransmitters and pituitary hormones.  Further studies 
revealed that supernatant fluids from human lymphocytes contained  
adrenocorticotropic hormone and endorphins, a result which, for the researchers at 
that time, was surprising since peptides were thought to exist in the brain and 
pituitary gland only.  This discovery suggested that a relationship could exist between 
the brain and the immune system as they apparently spoke the same chemical 
language (Ader et al., 1991). 
 
Karen Bulloch discovered that the thymus gland in the rat contained fibres of 
the vagus nerve which descends directly from the brain, and David Felten expanded 
on this finding by using fluorescent dyes to trace the pathways of these same nerve 
fibres.  As well as finding connections to the thymus, he also found connections to 
the spleen, lymph nodes and bone marrow and networks of nerves near blood vessels 
through which the immune cells passed. This latter finding suggesting that nerve 
impulses could directly influence the behaviour of cells (Ader et al., 1991; Dreher, 
1995). 
 
However, even though researchers had found an anatomical connection 
between the lower brain and the immune and nervous systems, they had not fully 
explained how the immune cells in the blood and lymph nodes could be influenced by 
the central nervous system.   
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This breakthrough occurred in the early 1980s when Candace Pert and 
colleague, Michael Ruff, discovered that neuropeptides acted as messengers between 
the mind/brain and the immune system by way of receptors on the molecular surface 
of monocytes.  These receptors are designed to receive substances which can change 
the growth patterns or activities of cells.  Therefore, this discovery by Pert and Ruff 
indicated that brain chemicals present in the bloodstream could alter the behaviour of 
immune cells and, because these neuropeptides were believed to be the chemical 
carriers of emotions, it followed that changes in one’s emotions could result in 
changes in one’s immune system.  Thus Pert’s view that neuropeptides and their 
receptors are part of a psychosomatic network has brought about a new understanding 
of mind-body integration and has successfully challenged the commonly held 
assumption of an autonomous immune system (Pert, Ruff, Weber & Herkenham, 
1986; Dreher; 1995; Pert, 1997).  
 
Ader (1991) believed that the nervous system was also involved in the 
relationship between the brain and the immune system and changed Solomon’s 
original name for this new science from psychoimmunology to psycho-
neuroimmunology. 
 
Research conducted over the past several years has substantiated these 
findings of a connection and interaction between the behavioural, neural, endocrine 
and immune systems and there now appears to be an attempt by more scientists to 
understand the workings of the mind-body function (Aziz & Thompson, 1998; Bunk, 
1998; Theoharides, 2002).  
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 1.3.2  The Immune System and Irritable Bowel Syndrome 
 
IBS symptoms are widely accepted as being generated by abnormalities of the 
gut function – the major ones being abnormal gastrointestinal motility and increased 
sensitivity of the intestine (Camilleri, Coulie & Tack, 2001; Jarret et al., 2000). One 
of the reasons for this occurring is an involvement with the immune system.  
Research has now focused attention on the putative role of low-grade mucosal 
inflammation in IBS (Collins, Piche & Rampal, 2001). This inflammatory response is 
largely restricted to the colonic and ileal mucosa with evidence showing that patients 
with IBS have an increased number of inflammatory cells in this area - the result 
being disturbances in gut motility, myoelectricity and smooth muscle contractility as 
well as changes in the function of enteric nerves (Barbara, De Giorgio, Stanghellini, 
Cremon & Corinaldesi, 2002; Gui, 1998).  
 
Research in this area points to a number of factors which may play a role in 
the development of this low-grade inflammatory process – the most prevalent being 
previous acute episodes of gastroenteritis (Gwee et al., 1999). Other possibilities 
include undiagnosed food sensitivities (Locke, Zinsmeister, Talley, Fett & Melton, 
2000), changes in bacterial flora (Pimentel, Chow & Lin, 2000) and genetic factors 
(Gonsalkorale et al., 1999). 
 
Collins et al. (2001) suggest two scenarios for the role of inflammation in the 
pathogenesis of IBS: the development of IBS in patients following gastroenteritis 
(post-infective IBS) and the observation that IBS-like symptoms occur with a higher 
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than expected frequency in patients in remission from inflammatory bowel disease 
(IBD). 
 
On taking the history of patients with IBS, it is frequently found that they 
refer to a previous incidence of an enteric infection and that their IBS symptoms 
developed soon afterwards (Gwee et al. 1999; Neal, Hebden & Spiller, 1997).  Neal 
et al. (1997) carried out a study in which patients who had had a laboratory-
confirmed diagnosis of a bacterial gastrointestinal pathogen were given a 
questionnaire which included questions on the episode of food-poisoning, their bowel 
habit six months before it had occurred as well as questions about their current bowel 
habit. They were also asked about their general health, diet and allergies.  At the 
completion of the trial it was found that 25% of the participants reported persistently 
altered bowel habits.  
 
These findings have been confirmed by recent studies showing that persistent 
IBS symptoms develop in between 7% and 32% of subjects after enteritis caused by 
Salmonella (Mearin et al., 2005), Shigella (Wang, Fang & Pan, 2004), or 
Campylobactor (Garg et al., 2006).  However, Marshall et al. (2004) contradicted 
these findings when the results of their study suggested that IBS symptoms were 
associated with a subtle increase in intestinal permeability irrespective of prior 
gastroenteritis. 
 
  Collins et al. (2001), suggest that it is the inflammatory response to these 
infections rather than the infective agent itself, which alters colonic physiology and 
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generates IBS symptoms. It has also been proposed that the inflammation associated 
with acute infection and subsequent chronic visceral hypersensitivity, results in the 
possibility of these sensitised immune cells being activated by psychological stress 
which increases intestinal permeability (Chang et al., 2000; Collins, 2001). Earlier 
studies by Solomon and Roos (Solomon, 1987) on rheumatoid arthritis also showed 
an apparent association between psychological factors (such as emotional states) with 
the onset or exacerbation of inflammation, indicating a link between the mind and the 
immune system (Ader et al., 1991). 
 
The second scenario postulated by Collins et al. (2001) is that symptoms 
similar to IBS occur with higher than expected frequency in patients in remission 
from inflammatory bowel disease (IBD), in particular ulcerative colitis (Minderhoud, 
Oldenburg, Wismeijer, van Berge Henegouwen & Smout, 2004; Simren et al., 2002). 
Shahbazkhani et al. (2003) have also found that coeliac disease may easily mimic 
symptoms (such as diarrhoea, abdominal cramps, distension, and improvement by 
defecation) which are parts of the criteria used for diagnosing IBS.  
 
Both IBS and IBD share symptoms of altered bowel motions associated with 
abdominal pain and discomfort – the difference proposed by the majority of 
researchers is that in IBS a characteristic cluster of symptoms occurs in the absence 
of detectable structural abnormalities of the intestine whereas in IBD the symptoms 
occur in conjunction with a chronic mucosal and/or transmural inflammation of the 
intestine (Bradesi, McRoberts, Anton & Meyer, 2003).  Recent studies, however, 
have suggested that an on-going low-grade inflammatory/immune response may also 
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be part of the IBS symptomatology (Barbara et al., 2002; Collins et al., 2001; 
Quigley, 2005). It is proposed that similarities and differences between the two 
syndromes can best be addressed within the framework of interactions between the 
central nervous system and the gut immune system (Bradesi et al., 2003). 
 
IBS patients have been shown to have an increase in the numbers of T 
lymphocytes and macrophages in the colonic mucosa. These immunocytes evoke 
changes in neuromuscular function in the intestinal tract and have been shown to 
result in abnormal intestinal permeability in subgroups of diarrhoea-predominant IBS 
(Collins, 1996; Dunlop, 2006).   
 
Ohman, Isaksson, Lundgren, Simren & Siovall (2005) investigated the 
characteristics of colonic and peripheral blood lymphocytes in 71 patients (33 
patients with IBS, 23 with ulcerative colitis and 15 control subjects) and found that 
all 33 patients with IBS exhibited an enhanced immune activity in the gut and an 
increased frequency of integrin beta7+ T lymphocytes in the peripheral blood – a 
result which further supports the hypothesis of an underlying inflammatory condition 
in IBS.   
 
A study by Chadwick et al. (2002) also showed increased numbers of 
activated lymphocytes in the intestinal mucosa of all 77 IBS patients after 
immunohistologic studies on colonoscopic biopsy specimens had been taken from the 
participants. These results again implicating the mucosal immune system and 
possible mucosal barrier defects in the pathogenesis of IBS. 
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 Studies have also demonstrated an increased number of mast cells in the colon 
or terminal ileum of IBS patients (O’Sullivan et al., 2000; Wood, 2006). Mast cells 
release heparin, serotonin, bradykinin and histamine in response to injury or infection 
– the most important effects of histamine and serotonin occurring early in the 
inflammatory process.  Stimulation of mast cells and basophils also leads to the 
release of arachidonic acid metabolism, the products of which (leukotriene C4, D4 
and E4) induce smooth muscle contraction and are important in delayed changes in 
vascular permeability at sites of inflammation (Rubin & Faber, 1988).  
 
 Histamine has been shown to be involved in the regulation of intestinal 
secretion and motility, processes that, when dysregulated, cause clinical symptoms 
such as diarrhoea and abdominal pain (Barbara et al., 2004). More specifically, 
Sander et al. (2004) have demonstrated that histamine receptor expression was altered 
in patients with gastrointestinal diseases.  Biopsies were taken from the terminal 
ileum, caecum and rectum of 30 patients with IBS who fulfilled the Rome II criteria, 
and 14 control patients.  In 19 of the IBS patients, a diagnosis of intestinal food 
allergies was confirmed - the remaining 11 patients were classified as having IBS 
according to the Rome II criteria.  Both patients with IBS, and IBS + food allergy 
exhibited significantly higher levels of mRNA encoding for histamine receptors 1 and 
2 compared with controls. 
 
 As well as being an important brain neurotransmitter, serotonin (5-hydroxy-
tryptamine – 5HT) is involved in the local regulation of gastrointestinal motility, 
secretion, and perception of urge and pain (Kilkens, Honig, van Nieuwenhoven, 
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Riedel & Brummer, 2004). In the GI tract, 5-HT is found within the majority of 
enterochromaffin cells, as well as mast cells, smooth-muscle cells and neurons 
(Gershon, 1991; 1999).  Animal studies have shown that 5-HT is implicated in 
enhancing inflammatory reactions in the gastrointestinal tract (Magro, Fraga, 
Azevedo & Soares-da-Silva, 2006; Oshima & Fujimora, 1999) and, in a study 
involving both mouse bone marrow-derived mast cells and human derived mast cells, 
Kushnire-Sukhov et al. (2006) found that 5-HT promoted inflammation by increasing 
mast cells at the site of tissue injury.  
  
 The extent to which inflammation contributes to the pathogenesis of some 
IBS patients remains under investigation but there are morphological data implicating 
immune activation in the myenteric plexus of patients with severe IBS. To take this 
one step further, Barbara et al. (2004) as well as identifying an increase of mast cells 
in the colonic mucosa of IBS patients compared to controls, also found that there was 
a closer anatomical proximity between nerve trunks and lymphocytes or mast cells, 
suggesting that abnormal neuroimmune interactions may contribute to the altered 
gastrointestinal physiology and hypersensitivity in the pathogenesis of IBS. 
Inflammatory neuropathy of the enteric nervous system is now emerging as an 
important research area in the field of neurogastroenterology. 
 
 
 
 
 
 20 
1.4       The Enteric Nervous System 
  
 1.4.1 Research & Anatomy 
  
 The first differentiation of enteric neurons into three morphological types on 
the basis of the different shapes and lengths of their dendrites was done by the 
Russian histologist, A.S. Dogiel in the late 19th century (Brehmer, Schrodl & 
Neuhuber, 1999) and, in the 1860s, Auerbach found that the bowel contained a 
complex network (plexus) of cells and fibres (Wood, 1970), but the beginnings of 
serious research into neurogastroenterology is associated with two English 
investigators, Bayliss and Starling (1902), whose work with dogs resulted in a 
surprising discovering.  Initially, they isolated a loop of intestine in anaesthetised 
dogs and found that, when the internal cavity of the bowel was stimulated and the 
internal pressure was raised sufficiently, the bowel would exhibit muscular 
movements which would propel the contents of the bowel in a one-way direction 
towards the anus.   
 
 The researchers then took this one step further and cut all nerves entering or 
leaving the loop of dog bowel, knowing that if this were done to nerves to other parts 
of the body, such as the limbs or other organs, all reflexes would be lost.  Bayliss and 
Starling found, however, that when the internal pressure was increased, the bowel 
continued to exhibit muscular movements in exactly the same way as it had done 
before the nerves were cut.  They came to the conclusion that nerves inside, rather 
than outside, the gastrointestinal tract were involved, as the reflex behaviour they had 
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observed had occurred after all input from the brain and spinal cord had been 
eliminated. Since this research, most of the knowledge about the functional features 
of enteric neurons has been derived from studies in the guinea-pig small intestine. 
 
 In 1958, Bulbring, Burnstock, & Holman carried out a series of experiments 
on isolated intestinal smooth muscle of the guinea-pig to find out whether responses 
to electrical stimulation were “all or none” and whether they were graded and, 
secondly, what the mechanism of conduction was.  Their results showed that 
excitation appeared to be able to spread in two ways – by slow waves (where each 
cell might be stimulated by the contraction of the cell behind it) and by conducted 
response, thereby supporting the view that conduction takes place by electrical 
transmission from cell to cell. 
 
 No further substantial progress in the knowledge about the functional features 
of the enteric nervous system such as electrophysiological behaviour or neuronal 
connectivity of the neurons was made, however, until the early 1970s.   
 
 Wood (1970) published the first reports of single unit activity in the myenteric 
plexus and Nishi & North (1973) began intracellular recording from myenteric 
neurons with micro-electrodes. The study distinguished three types of cells and, with 
an intracellular injection of a fluorescent dye, discovered that the neurons had one to 
seven processes.  
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  Hirst, Holman & McKirdy (1975) contributed to further understanding of the 
enteric nervous system by their findings that excitatory synaptic potentials could be 
evoked in most neurons by distension of the attached intestinal segment and that it 
was possible to distinguish two distinct firing patterns of synaptic potentials in 
response to distension.  Their study suggests that distension may cause both 
descending inhibition and, after a delay, descending excitation of the guinea-pig 
small intestine. 
 
 In the 1990s research continued to identify enteric neurons that responded to 
physiological stimuli by using activity-dependent dyes. Furness, Johnson, Pompolo & 
Bornstein (1995) found evidence that enteric motility reflexes can be initiated 
through entirely intrinsic mechanisms in the guinea-pig small intestine by examining 
reflexes in segments of guinea-pig intestine in which extrinsic denervation, 9-11 days 
before the intestine was removed, and isolation of the intestine in vitro, were 
combined. They evoked both ascending and descending reflexes by distortion or 
distension of the mucosa and found that reflex responses recorded after denervation 
were no different to those recorded from control tissue. The researchers subsequently 
concluded that cell bodies of primary sensory neurons for mucosal reflexes in the 
small intestine of the guinea-pig were intrinsic to the organ. 
 
 In the same year, Kunze, Bornstein & Furness (1995) found direct evidence 
that some sensory neurons were contained entirely with the peripheral nervous 
system and, not as it was commonly believed, associated with the central nervous 
system or within the central nervous system itself.  They recorded the response of 
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myenteric neurons in the guinea-pig small intestine to physiological stimuli applied to 
neighbouring mucosa and found that the myenteric plexus contained a population of 
chemosensitive sensory neurons and that these neurons corresponded to neurons with 
AH electrophysiological properties. 
 
 Chemical changes and distortion of the mucosa, however, are not sensed 
directly by the mucosal endings of the intrinsic primary afferent neurons but require 
the release of 5-HT from the entero-endocrine cells of the intestinal mucosa. 
Approximately 95% of 5-HT is located in the GI tract and enteric nervous system (the 
remaining 5% being in the central nervous system) and, in physiological studies of 
gut smooth muscle, 5-HT has made the bowel contract or relax through stimulating 
neurons to release acetylcholine or nitric oxide (Gershon, 1991, 1998).  
  
 Liu, Geddis, Wen, Setlik & Gershon (2005) carried out a study in the mouse 
enteric nervous system to identify the subtypes of 5-HT receptor that are expressed in 
the intestines, and to determine their locations and actions.  As well as finding that 
transcripts encoding four 5-HT4 receptor isoforms were present in the mouse gut, the 
researchers observed that 5-HT4 agonists strengthened neurotransmission in 
excitatory pathways.  
  
 The two principal divisions of the nervous system are the central nervous 
system (CNS) and the peripheral nervous system (PNS) which is subdivided into 
three parts: 
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• the somatic nervous system; 
• the autonomic nervous system (the motor portion is further subdivided into 
the sympathetic and parasympathetic divisions) and; 
• the enteric nervous system -“the brain of the gut” (Costa, Brookes & Henning 
2000).  (See Figure 2). 
  
 The enteric nervous system (ENS) is often regarded as a displaced part of the 
central nervous system and communication between the two takes place via the 
sympathetic and parasympathetic afferent and efferent neurons, providing neural 
control of all functions of the gastrointestinal (GI) tract (Goyal & Hirano, 1996). The 
ENS extends the entire length of the GI tract and is composed of approximately 100 
million neurons - approximately the number found in the spinal cord (Costa et al., 
2000; Tortora, G.J. & Grabowski, S.R., 2000). 
 
 The ENS is a complex network of neurons and neuroglia (or glia) within the 
bowel wall that controls intestinal functions (such as motility, epithelial transport and 
secretion  and  blood flow)  and  modulates  immune  and  endocrine  functions.   The 
movements of the intestine are determined by the interaction of the muscular 
apparatus, which consists of large collections of electrically interconnected layers of 
smooth muscle, and the neural apparatus which is composed of a large number of 
enteric neurons which can be identified according to their neurochemistry, 
electrophysiological properties, location, shape, proportions, connections, and 
function (Costa et al., 2000; Johnson, Alpers, Christensen, Jacobsen & Walsh, 1994). 
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 Sensory neurons of the ENS monitor chemical changes within the GI tract and 
the stretching of its walls, and enteric motor neurons govern contraction of GI tract 
smooth muscle, secretions of the GI tract organs such as acid secretion by the 
stomach, and activity of GI tract endocrine cells (Goyal & Hirano, 1996; Gershon, 
1999). Although the ENS communicates with the CNS via sympathetic and 
parasympathetic neurons, it can also perform many functions independently of both 
the autonomic and central nervous systems to some extent (Gariepy, 2001). 
 
 The four categories of nerves in the ENS are: 
 
• extrinsic neurons - found primarily in the regions for the ingestion of food 
(mouth and oesophagus) and the expulsion of faeces (anal region); 
• intrinsic motorneurons - release neurotransmitters (the main ones being 
substance P and acetylcholine) which cause contractions of both circular and 
longitudinal smooth muscles and secretion of water and electrolytes from the 
mucosa of the intestine; 
• intrinsic interneurons - connect sensory neurons with motor and secretory 
neurons via synapses forming networks which process sensory information 
and control motor neurons; and 
• sensory neurons - provide some intrinsic control of smooth muscle 
contractions and gastric juice secretion (Goyal & Hirano, 1996; Smith & 
Morton, 2001). 
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 Figure 2.      Organisation of the Nervous System.  
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 In the ENS, neurons are grouped into small ganglia which are connected by 
bundles of nerve processes forming two major plexi (together with lesser plexi) in the 
wall of the GI tract.  The major plexi are the myenteric plexus (Auerbach’s plexus), 
which is situated between the layers of longitudinal and circular smooth muscle, and 
the sub-mucous plexus (Meissner’s plexus), which lies in the mucosa.  The myenteric 
plexus is involved mainly in the control of GI motility whereas the sub-mucous 
plexus is involved in the control of secretion and blood flow and also receives 
sensory information from the gut epithelium and from stretch receptors in the wall of 
the tract (Anderson et al. 1998; Smith & Morton, 2001).  
 
 An absence of intramural ganglion cells from a region of the myenteric plexus 
can result in symptoms of poor, or absent peristalsis and subsequent severe 
constipation as evidenced in Hirschsprung’s disease (a congenital abnormality) and 
Chaga’s disease (caused by parasitic toxins) (Gariepy, C.E. 2001).  The ENS can also 
be damaged in intestinal pseudo-obstruction syndromes and in some forms of chronic 
disease such as diabetes (Heuckeroth & Pachnis, 2006), and recent evidence indicates 
that a subset of individuals with IBS may have primary defects within the ENS 
(Koszycki, Torres, Swain & Bradwein, 2005). 
 
1.4.2 The Enteric Nervous System and Irritable Bowel Syndrome 
  
 The enteric nervous system (ENS) is a third division of the peripheral nervous 
system and has connections with both the central nervous system and the sympathetic 
and parasympathetic divisions of the autonomic nervous system. Gastrointestinal 
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function is controlled and co-ordinated by both extrinsic and intrinsic elements of the 
autonomic nervous system which can alter the activity of the GI tract via its 
influences on the ENS. In general, the sympathetic branch of the autonomic nervous 
system inhibits activity in the GI tract (e.g. movement of food through the GI tract 
can be completely blocked by strong activation of the sympathetic nervous system), 
whereas the parasympathetic branch stimulates secretion and motility (Costa et al., 
2000; Smith & Morton 2001; Tortora & Grabowski, 2000).  
 
 The ENS is unique in that it is able to mediate reflex activity independently of 
input from the brain or spinal cord through sensory receptors, primary afferent 
neurons, interneurons and motor neurons. The ENS can control (at least in part), 
motor activity, secretion, absorption and blood flow, as well as interacting with the 
gallbladder and pancreas (Tack, 2000). 
 
 Disorders of the ENS, therefore, may result in motor, secretory, and 
inflammatory and immunologic dysfunction of the gut.  Immune/inflammatory cells 
of the ENS are constantly changing during pathophysiological states, such as 
exposure to food antigens, bacteria, viruses and toxins, via information from both 
immune detection and signal transfer to the ENS.  The signal is interpreted by the 
ENS and the gut attempts to clear the antigenic threat by co-ordinated mucous 
secretion and increased motility – the side-effects being symptoms of abdominal pain 
and diarrhoea (Spiller, 2002; Wood, Alpers & Andrews, 1999).  Enteric mast cells 
may be responsible for functional gastrointestinal disorders, such as IBS, by 
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signalling the ENS and initiating inflammation that generates chemical mediators 
such as cytokines (Bueno, 2000; O’Sullivan et al., 2000). 
 
 Another system which may be responsible for functional GI disorders is the 
cholecystokinin (CCK) system of peptides and their receptors which are widely 
distributed in the GI tract and CNS. The CCKA receptors mediate pancreatic 
secretion, motility, and growth and are present in select nuclei of the CNS; and the 
CCKB receptors, found throughout the CNS, regulate anxiety, satiety, analgesia, and 
neuroleptic activity. Studies suggest that a dysfunction in this system may be 
involved in the pathophysiology of some enteric symptoms associated with IBS 
(Huppi, Siwarski, Pisegna & Wank, 1994; Koszycki et al., 2005). 
  
 Evidence of a relationship between emotional states and GI function has been 
reported by patients with functional bowel disorders, and studies in healthy 
volunteers have also shown alterations in GI function when they are subjected to 
experimental stressors (Mayer, E.A., 2000; Welgan & Meshkinpour, 2000). This, in 
part, can be explained by the fact that some afferent sensory fibres from the enteric 
nerves (which terminate in the sympathetic ganglia) and others from the GI tract 
(which have their cell bodies in the dorsal root ganglia of the spinal cord or in the 
cranial nerve ganglia) travel in the same nerve trunks as the autonomic nerves. These 
fibres transmit information to the medulla which transmits efferent signals back to the 
GI tract thereby influencing its functions (Costa et al., 2000; Smith & Morton, 2001). 
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1.5 The Mind-Body Connection in Irritable Bowel Syndrome:  
the Brain-Gut Axis 
 
 Studies have shown that emotions such as anger, fear, pain and anxiety can 
affect colonic motility more in IBS patients than in healthy controls (Welgan, 
Meshkinpour & Ma, 2000) and, for IBS, the most frequent comorbid psychiatric 
disorders are anxiety, depression and somatoform disorders (Drossman et al., 1999; 
Garakani et al., 2003).  
 
 The brain translates thoughts, feelings, beliefs and memories into complex 
patterns of nerve cell firing and chemical release which affect the physiology and 
biochemistry of the body (Salt & Neimark, 2002), and neuroimaging (functional 
magnetic resonance imaging (fMRI) and positron emission tomography (PET) scans) 
has provided evidence of physiological differences between healthy controls and 
subgroups of IBS patients in the way a visceral stimulus is processed in the brain 
(Wilder-Smith, Schindler, Lovblad, Redmond & Nirkko, 2004).  
 
 In non-IBS individuals undergoing balloon distension studies, PET scans 
show that when the bowel is stretched, certain areas of the brain that register pain 
respond and release neurotransmitters that suppress and lower the pain.  In IBS 
patients another area of the brain responds which is associated with anxiety 
(Drossman, 2000).   
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 Silverman et al. (2000) used PET scans to measure the changes in the pattern 
of blood flow in the brains of IBS patients in response to balloon distension of the 
rectum.  When rectal stimuli were delivered, it was found that different areas of the 
brain were activated in IBS patients as compared to controls. This suggests that, as 
well as having a bowel problem, IBS sufferers may have some difficulty in terms of 
the way their brain regulates pain. 
  
 The brain’s influence on GI function has also been demonstrated in reports of 
alteration in gut function after lesions of the CNS such as stroke and tumours. 
Dysphagia is common after a stroke and has been found to be more frequent in 
patients with haemorrhagic stroke than in patients with ischemic stroke (Mann, 
Hankey & Cameron, 1999). This condition is disabling to patients in that it 
compromises their diet, nutrition, and hydration as well as having the potential to 
cause serious complications such as dehydration and aspiration pneumonia (Paciaroni 
et al., 2004).  
  
 A case study by Wood, Camilleri, Low & Malagelada (1985) of an adult with 
a medullary glioma and unexplained vomiting documents the potential for brainstem 
lesions to present with symptoms of abnormal GI motor function, and Grant et al. 
(1999), using magnetic resonance imaging (MRI), detected an intra-axial mass lesion 
of the midbrain in children who presented with vomiting as well as other signs and 
symptoms of hydrocephalus.  
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 Further evidence of a brain-gut connection is the existence of two major 
regulatory peptides, gastrin and CCK, which are synthesised (predominantly) in the 
human GI tract as a gut hormone, and in brain tissue as a neurotransmitter.  They act 
on central and peripheral CCK receptors to mediate secretion and motility in the GI 
tract, and on receptors in the CNS where they contribute to the regulation of satiety, 
anxiety, and analgesia (Wank, 1995). Research also suggests that these peptides also 
play an important role in tumour growth regulation (Rehfeld & van Solinge, 1994; 
Schaer and Reubi, 1999).   
 
 Another mediator of the brain-gut axis is serotonin. As well as being involved 
in the local regulation of GI motility and secretion, it is an important neurotransmitter 
that is relevant to cognition, mood and depression (Kim & Camilleri, 2000; Kilkens 
et al., 2004).  
 
 Stress has been shown to exacerbate IBS symptoms (Levy, Cain, Jarrett & 
Heitkemper, 1997; Locke, Weaver, Melton & Talley, 2004). The initial step of the 
stress response activates the hypothalamus of the limbic system of the brain causing it 
to send chemicals and nerve signals (which can either activate or inhibit certain 
glands and organs) to the pituitary gland, which then communicates with the adrenal 
glands – a linkage called the hypothalamic-pituitary-adrenal (HPA) axis.   
 
 Two parallel pathways then emerge from the HPA axis – the epinephrine 
(adrenalin) and cortisol pathways. When epinephrine is released from the adrenal 
medulla, blood flows from the digestive tract to the muscles, the heart rate increases, 
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and blood pressure rises. The release of cortisol begins with the release of 
corticotropin releasing factor (CRF) from the hypothalamus which triggers the 
pituitary to release adrenocorticotropic hormone (ACTH) which stimulates the 
adrenal cortex to release cortisol. As well as increasing blood sugar for energy, 
cortisol causes the pituitary to turn off the release of CRF which then slows down the 
effects of epinephrine thereby lowering the heart rate and blood pressure, and sending 
blood back to the digestive system (Rice, 1992; Salt, 2002).   
 
 Research on interactions among neurotransmitters and neuromodulators in the 
brain is ongoing and recent studies have centred on the mast cell as being of interest 
because of its involvement in IBS (Bose & Farthing, 2001; Barbara et al., 2004). 
Stress is known to exacerbate many neuroinflammatory conditions and acute stress 
results in intestinal mast cell activation through the release of CRF (Theoharides, 
2002). Studies have also shown an increased number of mast cells in the colon and 
terminal ileum of IBS patients (Rubin & Faber, 1988) and stimulation of these mast 
cells leads to the release of arachidonic acid metabolism which induces smooth 
muscle contraction (O’Sullivan et al., 2000).   
 
 The mast cell also appears to link emotional states to irritability of the GI tract 
as informational input processed by the enteric midbrain is not only derived from 
mast cells, but also by local sensory receptors and the CNS (Gui, 1998).   
 
 Degranulation of the mast cell and release of chemicals triggered by input 
from local sensory receptors and the CNS will have the same effect on motility and 
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secretory behaviour as degranulation triggered by antigen detection – i.e. bowel 
discomfort and diarrhoea.  This may explain the similarity of bowel symptoms 
between patients whose symptoms are the result of noxious insults in the lumen of the 
bowel and those whose symptoms are associated with stress (Wood et al., 1999).  
 
 Another interesting brain-gut connection is that scientific data using 
neuroimaging (PET scans or fMRI) has shown that the same parts of the brain are 
activated whether participants were experiencing certain events or recalling them from 
memory. In other words, visual imagery and visual perception draw on the same neural 
machinery (Kosslyn et al., 1993, 1996). Following on this then, one can understand how 
stressful thoughts and feelings, as well as perceived stressful situations, can lead to 
disturbances in the GI tract.   
 
 1.6 Summary 
 
  It is evident from the above information that the brain and the GI tract 
are intricately connected to one another by pathways that are continuously monitoring 
and modulating gut function through complex patterns of nerve cell firing and 
chemical release (Salt & Neimark, 2002; Wank, 1995).  Non-invasive techniques 
such as fMRI and PET scans have allowed researchers to study brain-gut pathways 
and assess interactions between the two (Kosslyn et al., 1993, 1996; Wilder Smith et 
al., 2004). 
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 The immune system has long been regarded as operating, to a large degree, 
independently of the mind and behaviour, but it is now known that the body’s three 
main regulatory systems – the nervous system, the endocrine system and the immune 
system – are intimately connected and interact with each other in a bi-directional flow 
along the various biological pathways (Martin, 1997; Watkins, 1997). Activity within 
the immune system can therefore influence the brain, mental state and behaviour.  
 
There is also a greater understanding of the enteric nervous system of the GI 
tract and how it can function more or less independently of the CNS (Gariepy, 2001; 
Tack, 2000).  Increasing knowledge of how the ENS controls or modulates motility, 
exocrine and endocrine secretions, and immune and inflammatory processes is 
contributing to the creation of new approaches in treatment (Goleman & Gurin, 1995; 
Rossi & Cheek, 1998).  However, more research is needed in this area to reduce 
human morbidity and mortality associated with chronic dysfunctioning in the ENS 
structure such as that observed in functional bowel disorders such as IBS.   
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CHAPTER 2  IRRITABLE BOWEL SYNDROME 
 
2.1       Irritable Bowel Syndrome 
  
  Irritable Bowel Syndrome (IBS) which is sometimes referred to as spastic 
colon, mucous colitis, spastic colitis, nervous stomach or irritable colon, is probably 
the most common disorder encountered by both gastroenterologists and physicians in 
primary care (Everhart & Renault, 1991; Lee et al., 1999).  Depending on the criteria 
used to define the disease, it is estimated that from 10% to 25% of the general 
population suffer from this condition and that it comprises about 30-50% of the 
gastroenterologists’ workload (Farthing, 1995; Camilleri & Choi, 1997). Several 
conditions can masquerade as IBS and require a proper diagnosis (see Table 1). 
 
 After a complete history has been taken, patients usually undergo a complete 
physical examination and a series of tests which can include blood tests, blood-
chemistry tests, liver-function tests, barium enema + flexible sigmoidoscopy or 
colonoscopy, and measurement of thyrotropin. In patients with diarrhoea, a biopsy 
from the mucosa of the descending colon is often carried out to rule out colitis. The 
diagnosis of IBS is suggested when a patient’s symptoms meet the Rome II criteria 
(see Table 6). 
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      Table 1                             Differential Diagnosis of IBS 
 
• inflammatory bowel disease 
• diverticulitis 
• mechanical obstruction of the colon or small intestine 
• enteric infection 
• bacterial overgrowth 
• ischaemia 
• lactose intolerance 
• gluten intolerance 
• food intolerances 
• malabsorption syndromes (e.g coeliac disease) 
• endocrine disorders (e.g. thyroid) 
• endometriosis 
• medications which affect bowel pattern 
• overuse of antibiotics 
• colorectal cancer 
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 IBS is generally classified as a functional disorder where the primary 
abnormality is not an identifiable structural or biochemical cause such as an 
inflammatory, infectious or structural abnormality but rather an altered physiological 
function (Bradesi et al., 2003; Van Vorous, 2000). All routine investigations are 
found to be normal. Unfortunately, this form of diagnosis – one of exclusion of 
organic disease – often resulted in having negative connotations for both patients and 
clinicians (Bose & Farthing, 2001; Letson & Dancey, 1996).  
  
 Nowadays, there is a better understanding of IBS (and other functional 
gastrointestinal disorders) with a subsequent moving away from a disease-based 
model to a biopsychosocial one.  This model takes into account not only the 
numerous physiological symptoms (e.g. altered motility, hypersensitivity of the gut 
and brain-gut dysfunction) but also the effects that sociocultural and psychosocial 
influences have on these symptoms.  This has come about because of the growth in 
investigative techniques that support the conception of interactions between the brain 
and the enteric nervous system of the gut (Bennett et al., 1998; Drossman et al., 1999; 
Farhadi, Bruninga, Fields & Keshavarzian, 2001). 
 
 Symptoms of IBS can range from a slight annoyance to extreme cases where a 
person’s social life can be severely affected and it can also disrupt a person’s career 
because of numerous days off work (Dean et al., 2005; Drossman et al., 1993).  As 
well as these restrictions in recreational and work-related activities, studies have 
demonstrated that IBS patients report lower overall quality of life compared to 
controls (Creed et al., 2000; Hahn, Yan & Strassels, 1999). Patients with IBS have 
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also been found to have higher levels of depression and anxiety relative to the general 
population (Garakani et al., 2003; Sykes, Blanchard, Lackner, Keefer & Krasner, 
2003). 
 
 IBS is characterised by a group of symptoms in which abdominal pain or 
discomfort and bloating is associated with disturbances in bowel pattern. The 
common symptoms are diarrhoea, constipation or alternating diarrhoea and 
constipation (see Table 2).  The stool form is often altered - lumpy and hard or loose 
and watery, and stool passage can be affected with straining, urgency, or a feeling of 
incomplete evacuation.  The presence of mucus in the stool may be observed and the 
symptoms are typically continuous or intermittent (Drossman, 2000; Lynn, 1993). 
IBS symptoms are often accompanied by a number of extra-colonic symptoms which 
include nausea, vomiting, dysphagia, lethargy, backache and urinary symptoms 
(Whorwell, McCallum, Creed & Roberts, 1986).  (See Table 2).  
 
 Researchers are beginning to view IBS as a multi-faceted disorder - one in 
which there appears to be a disturbance in the interaction between the intestines, the 
brain, and the autonomic nervous system resulting in an alteration in the regulation of 
bowel motility and/or sensory function (Smith & Morton 2001; Tortora & 
Grabowski, 2000). Triggering factors in this brain-gut condition may be responsible 
for causing symptoms of diarrhoea in some IBS sufferers, constipation in others, and 
alternating diarrhoea and constipation in the remainder (Wood et al., 1999; Zar, 
Benson & Kumar, 2006). 
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        Table 2                                      Symptoms of IBS 
 
 
• constipation 
 
• diarrhoea 
 
• variation in bowel habit from constipation to diarrhoea 
 
• pain associated with constipation, diarrhoea 
 
• excessive flatulence 
 
• ineffectual urging 
 
• abdominal pain relieved by passage of bowel motion 
 
• more/less frequent bowel motions when pain begins 
 
• looser/harder bowel motions when pain begins 
 
• abdominal bloating/distension 
 
 
 
CURRENT THEORIES. 
 
 
• hypersensitivity of the GI tract 
 
• previous gastroenteritis/bacterial infection 
 
• imbalance in microflora 
 
• imbalance in neurotransmitters 
 
• stress (inability to cope with stress) exacerbates the condition 
 
 
 
 
 
  
 43 
 Although many people have IBS symptoms, only a small portion (25-30%) 
ever seek medical attention (Schuster, Crowell & Talley, 2000). Some research 
suggests that psychological factors rather than symptoms drive IBS sufferers to seek 
medical advice (Blomhoff, Spetalen, Jacobsen & Malt, 2001; Whitehead, Bosmajian, 
Zonderman, Costa & Schuster, 1988) but when Talley, Zinsmeister, Van Dyke & 
Melton (1991) carried out a survey of 1021 local residents in Minnesota, U.S.A. and 
measured presentation for medical care, they found that even though only a minority 
had presented for medical evaluation, it was the duration and severity of the 
abdominal pain that were among the factors that prompted IBS patients to seek 
medical attention.  It appeared that psychological problems or a history of abuse did 
not increase the chance of IBS patients to seek medical attention. Other studies have 
also shown that abdominal pain and diarrhoea instigated consultation (Drossman et 
al., 1988; Heaton et al., 1992). 
  
 Increasing evidence appears to suggest that the pathology of IBS is not only 
limited to the gut, brain, or autonomic nervous system but that all three systems may 
be involved (Costa et al., 2000).  Therefore, any potential new therapy should be 
aimed at addressing all three. 
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2.2   Epidemiology of Irritable Bowel Syndrome 
  
 2.2.1 Prevalence 
  
 IBS is the most common disease diagnosed by gastroenterologists and affects 
about 20% of all people at any one time, accounting for 10% of visits to primary care 
doctors and at least 50% of visits to gastroenterologists (Camilleri, 1997; Salt, 2002; 
Drossman, 2000).  
 
 IBS affects nearly one out of five people in the US including children, 
teenagers, young adults, the middle-aged and the elderly - the average age of onset of 
IBS being between 20 and 29 years of age with the majority of sufferers being young 
and middle-aged (Salt, 2002; Ruigomez, Wallander, Johansson & Rodriguez, 1999). 
About half of those affected have alternating diarrhoea and constipation, about 30% 
will usually have only diarrhoea, and about 20% usually only constipation 
(Thompson et al., 1999; Drossman, 2000).  However, in two studies carried out in 
Asian populations in Singapore and Hong Kong (Gwee et al., 2004; Lau et al., 2002), 
results showed that chronic constipation was more common than chronic diarrhoea in 
the IBS subjects. The majority of sufferers were similar to Caucasians in that they 
were also young and middle-aged. 
  
 As mentioned previously, a high percentage of people are known to be 
affected with this disorder but most of them (60-75%) do not consult a physician 
(Jones & Lydeard, 1992; Farthing, 1995).  In terms of severity, therefore, IBS appears 
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to be a relatively minor health problem but when the effects that sociocultural and 
psychosocial influences have on these symptoms are taken into account, it can be a 
major one to some patients who suffer major distress on a daily basis.  
 
 2.2.2 Gender 
  
 In many clinical and population studies, women report symptoms of IBS more 
than men  (Farthing 1995; Horwitz & Fisher, 2001).  This difference is unexplained 
but may be due to a hormonal (Houghton, Lea, Jackson & Whorwell, 2002; Palsson 
& Whitehead, 2002), genetic (Camilleri, 2004; Pata et al., 2004; Yeo et al., 2004), or 
physiological difference between women and men that influences their IBS 
symptoms. Moreover, women seek medical care more often than men (Camilleri & 
Choi, 1997; Heitkemper et al., 2001). Thompson (2001) agrees with the latter 
statement but also suggests that the reason for the difference might also be a 
misperception about IBS and/or a “macho” attitude among men.   
 
 Gwee et al. (2004) suggest that the difference might be because the Manning 
criteria have a greater diagnostic sensitivity for women in that they include non-pain-
related bowel symptoms (cf Rome I and II criteria) thus Heaton et al. (1992) and 
Thompson (2001) observed, non-pain-related bowel symptoms were more common 
in female than male subjects. In India, however, it appears that men with IBS are 
more likely than women to consult doctors (Camilleri, 1997; Kang, 2005) suggesting 
that there must be cultural and other reasons for the healthcare-seeking behaviour of 
men and women who have IBS symptoms. 
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 Houghton, Jackson, Whorwell & Morris (1999) looked at gender difference 
from a different perspective when they investigated the possibility that male sex 
hormones could be protective from IBS.  In this study, the investigators measured a 
series of male sex hormone levels in men with IBS compared to the hormone levels 
of men without IBS.  They found that luteinising hormone was lower in men with 
IBS and that the men’s pain threshold decreased with higher testosterone levels even 
though testosterone levels were the same in both groups.  Yet another dimension to 
the role of gender in IBS was added when the results of a study by Miller, Whitaker, 
Morris & Whorwell (2004) indicated that men with IBS exhibited fewer male 
characteristics compared with controls.   
  
 There are conflicting data regarding the effect of menstrual hormones on IBS 
symptoms.  Female patients with IBS often report more pain and exacerbation of their 
symptoms with menses (Houghton, Lea, Jackson & Whorwell, 2002; Drossman, 
2000) yet a study by Meier et al. (1995) showed that menstrual hormones influenced 
colonic transit times and that more pain was experienced at the time of menstruation 
in non-IBS sufferers.   
 
 Another study by Degen & Phillips (1996), which was also carried out on 
healthy women, concluded that there were doubtful clinical significances of the 
influence of menstrual hormones. This conflicting data could be confounded by 
misdiagnosis as it is sometimes difficult to ascertain whether the discomfort is 
coming from the pelvic organs or from the GI tract (Thompson, 2001; Williams, 
Hartman, Sandler, Miller & Steege, 2004). 
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 Some studies suggest that men have different responses to pain than women 
(Naliboff et al., 2003; Pedersen, 2004) but, according to Thompson (2002), the 
answer is more likely to be found in the psychosocial, cultural, and other 
characteristics of the affected person rather than in the nature of the symptoms 
themselves.    
 
 2.3 Aetiology 
  
 The aetiology of IBS is unknown and, as yet, there is no cure.  Most 
researchers agree that a subset of IBS sufferers have a visceral hypersensitivity of the 
gut or, more specifically, an increased perception of sensations in the gut 
(Bouchoucha, Choufa, Faye, Berger & Arsac, 1999; Camilleri, Coulie & Tack, 2001). 
There is also altered bowel motility that may cause symptoms like cramping 
abdominal pain, diarrhoea and constipation (Spiller, 2002). However, previous 
gastroenteritis, small intestine bacterial over-growth, psychosocial factors, a genetic 
contribution, and an imbalance of neurotransmitters have all been proposed as either 
possible causes or playing a part in the development of IBS (Gershon, 2004; Neal, 
Hebden & Spiller, 1997; Pimentel, Chow & Lin, 2000).  It is generally agreed that a 
patient’s emotional response to stress can exacerbate the condition (Gorard, 
Gomborone, Libby & Farthing, 1996; Salt, 2002). 
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 2.3.1    Visceral hypersensitivity 
  
 When the colon is stimulated by eating, the secretion of cholecystokinin, or by 
balloon distension, the colon of patients with IBS is more likely to be hypersensitive 
and hyperreactive.  Anorectal manometry is widely used to investigate the physiology 
of continence and defecation and gives data on anal pressure, rectal sensitivity and 
anorectal co-ordination. Bouchoucha et al. (1999) and Hammonds et al. (1998) found 
that anal pressure waves of patients with IBS have altered organisation and respond 
differently to distension as compared to controls.  
 
 In the study by Hammond et al. (1998), no difference was found in patients 
with constipation-predominant and diarrhoea-predominant IBS. Both appeared to 
have increased sensitivity to balloon distension throughout the GI tract with the 
jejunum being the site most likely to exhibit this phenomenon.   
 
 Camilleri (1997) on the other hand, found that there was excessive sensitivity 
at several sites (ileum, rectosigmoid and anorectum) in IBS patients and that there 
was a difference between constipation-predominant and diarrhoea-predominant IBS 
patients.  The diarrhoea-predominant IBS patients exhibited lower thresholds for 
sensation of gas, stool and discomfort in the anorectum, and urgency was developed 
at lower volumes of distension of an intrarectal balloon.  Patients with constipation-
predominant IBS, however, developed discomfort at greater distension volumes than 
healthy controls.   
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 His observations suggest that since the increased sensitivity of the anorectum 
was accompanied by the development of excessive reflex motor activity in the 
rectum, there could be possible interactions between excessive sensation and motor 
responsiveness.  This being so, Camilleri suggests that the symptoms of pain before 
bowel movement, and the sense of incomplete evacuation may be explained by 
increased anorectal sensitivity, and that increased motor response to these stimuli 
may result in the increased frequency of bowel movements.  
 
 The different outcomes in the above-mentioned studies appear to illustrate 
why there is disagreement among researchers as to whether or not visceral 
hypersensitivity can be considered a biological marker for IBS.  
 
 Measurements.  Two different types of measurements are generally used to 
evaluate visceral sensations.  The first uses standardised symptom-based 
questionnaires (visual analogue scale or adjectival scale) to determine thresholds or 
severity of symptoms which are induced by balloon distension or electrical stimuli 
within the gut. During distensions, the individual is asked to complete a questionnaire 
pertaining to the symptoms that are of interest (e.g. pain and gas in the colon, pain 
and urgency in the rectum; or bloating, nausea and pain in the stomach).  
 
 The second method uses PET scans and fMRI during visceral stimulation to 
measure changes in cerebral blood flow.  
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 In an fMRI study using a validated method of counter-irritation during rectal 
distension pain, Wilder-Smith et al. (2004) found that there were differences in 
activation of endogenous noxious inhibitory pathways between healthy controls and 
subgroups of IBS patients.  
 
 The results suggest impaired activation of inhibitory controls in both 
subgroups as there was an absence of a significant inhibitory effect on visceral pain.  
The researchers found that not only were brain activation patterns in IBS patients 
markedly different from healthy controls but that there were differences between IBS 
subgroups as well.  
  
 In non-IBS individuals undergoing balloon distension studies, PET scans 
show that when the bowel is stretched, certain areas of the brain that register pain 
respond and release neurotransmitters that suppress and lower the pain.  In IBS 
patients, another area of the brain responds which is associated with anxiety 
(Drossman, 2000).   
  
 Silverman et al. (2000) used PET scans to measure the changes in the pattern 
of blood flow in the brains of IBS patients in response to balloon distension of the 
rectum.  When rectal stimuli were delivered, it was found that different areas of the 
brain were activated in IBS patients as compared to controls. This suggests that, as 
well as having a bowel problem, IBS sufferers may have some difficulty in terms of 
the way their brain regulates pain. 
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 Studies have also shown two other aspects of heightened visceral sensation in 
functional gastrointestinal disease. Firstly, it is not site-specific as patients presenting 
with one functional gastrointestinal syndrome often have additional symptoms in 
other parts of the gut (Trimble, Farouk, Pryde, Douglas & Heading, 1995; Constantini 
et al., 1993). Secondly, patients with IBS who have enhanced sensation and 
perception of bowel function were found to exhibit disturbed visceral nociception in 
other areas of the body.  
 
 A large proportion of IBS patients also complain of other functional disorders 
such as headaches, dysuria and non-cardiac chest pain (Azpiroz et al., 2000; 
Botoman, 2002; Scott et al., 1993), suggesting that internal pain thresholds are lower 
in patients with IBS (and other functional GI disorders). 
 
 Francis et al. (1997) found that a higher proportion of patients seen in the 
urology clinic have IBS compared to patients seen at other clinics (e.g. 
dermatology/ear, nose & throat) and a high prevalence of IBS (and upper GI 
symptoms) has been found in patients with chronic renal failure (Cukier, 1997; 
Kahvecioglu et al., 2005).  
  
 As mentioned previously, there are conflicting data regarding the effect of 
menstrual hormones on IBS symptoms. Women with IBS often report more 
significant exacerbation of their symptoms with menses, often making it difficult to 
determine whether the pain is coming from the pelvic organs or from the GI tract.   
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This can sometimes result in an incorrect diagnosis of endometriosis when the 
complaint is actually IBS (Kumar, 2004; Houghton et al., 2002).  
 
 Houghton et al. (2002) carried out a study where the data appeared to confirm 
that IBS symptomatology is exacerbated at menses and showed that, in contrast to 
healthy women, rectal sensitivity changes with the menstrual cycle. They measured 
rectal response to balloon distension during the follicular, luteal and premenstrual 
phases and found that there was a worsening of abdominal pain and bloating during 
menses, bowel habits also became more frequent, and patients tended to have a lower 
general well-being.  Rectal sensitivity also increased at menses compared with all 
other phases of the cycle. These findings suggest that compared to healthy females, 
women with IBS respond differently to sex hormone fluctuations.  
 
 2.3.2 Previous Gastroenteritis 
  
 Gastrointestinal infection has also been implicated in the pathophysiology of 
IBS but, to date, no virus, bacteria, or parasite has been found to directly cause IBS. It 
has, however, been hypothesised that these microbes may indirectly cause IBS or at 
least exacerbate its symptoms.  
  
 Studies have shown that there is a subgroup of patients presenting with IBS 
who can relate the start of their symptoms to a previous episode of infective diarrhoea 
(Neal et al., 1997; Rodriguez & Ruigomez, 1999; Spiller et al., 2000). One 
explanation for this is that these patients may have been unable to down-regulate the 
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mucosal inflammation associated with the acute infection efficiently, and that this 
might have induced visceral hypersensitivity.   This hypersensitivity may have come 
about because of neuroplastic changes in visceral afferent pathways because of low-
grade inflammatory infiltration and activation of mast cells in proximity to nerves in 
the colonic mucosa (Bose & Farthing, 2001; Barbara et al., 2004). Psychological 
stress may later activate sensitised immune cells which may possibly induce a chronic 
low-grade or pre-inflammatory state which then modulates on visceral afferents in a 
chronic manner (Chang et al., 2000).  
  
 Mucosal evidence of an activated immune response in patients who develop 
IBS as a result of acute gastroenteritis has also been reported by Gwee et al. (1996; 
2003) who found evidence of an increased number of intraepithelial lymphocytes in 
post-infectious IBS patients. 
 
 2.3.3 Microflora 
  
 In most IBS sufferers, abdominal bloating, distension and diarrhoea are 
extremely common complaints regarded by some researchers as possibly being 
caused by an overgrowth of small intestinal bacteria (Dapoigny et al., 2004; Salt & 
Neimark, 2002; Chang, Lee, Naliboff, Schmulson & Mayer, 2001). 
 
  A study of 202 patients meeting the Rome criteria for IBS by Pimentel et al. 
(2000) showed an apparent association between the increased prevalence of small 
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intestine bacterial overgrowth with IBS. As a testing procedure, the researchers used 
the lactulose hydrogen breath test.   
 
 This test is based on the fact that bacteria are usually only found in very high 
concentration in the large intestine with the production of gas occurring about 90 
minutes after the ingestion of lactose. When there is bacterial overgrowth in the small 
intestine, the bacteria will digest the lactose sooner and produce an earlier excretion 
of hydrogen (and methane) in the lungs which is then measured.  Patients may also 
develop symptoms of gas, bloating and diarrhoea.  
 
 The lactulose hydrogen breath test (as well as the glucose breath test) for the 
diagnosis of small intestine bacterial overgrowth is controversial. Obtaining a direct 
culture is limited because bacterial overgrowth occurs in the more distal portions of 
the small intestine making access difficult. 
  
 In this study by Pimental et al. (2000), the lactulose hydrogen breath test was 
used for both assessment of overgrowth and as a follow-up test to confirm 
eradication, and those participants with a positive breath test were treated with a 10-
day course of antibiotics. The results showed that 78% of the participants had 
overgrowth and on the follow-up testing, 48% had eradication of small intestine 
bacterial overgrowth. However, there were limitations to the study. One issue was the 
small number of subjects returning for follow-up lactulose hydrogen breath test.  Of 
the 202 IBS patients, 157 had overgrowth and only 47 of these had follow-up testing.  
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 Parisi (2003) questioned the use of the lactulose hydrogen breath test as a 
diagnostic tool for small intestine bacterial overgrowth as the sensitivity can be as 
low as 16% and was of the opinion that the glucose breath test was more reliable. 
Whereas the results of a study by Wang, Bei & Pan (1995) found that the lactulose 
hydrogen breath test had a sensitivity of 71.4% and regarded it as a simple, non-
invasive and relatively reliable method of diagnosis of small intestine bacterial 
overgrowth.  
 
 Parisi also queried the use of antibiotics in the treatment as they could be 
detrimental to intestinal bacteria and perhaps influence the development of functional 
bowel syndromes. This was demonstrated in a study by Noverr, Noggle, Toews & 
Huffnagle (2004) which showed that the use of antibiotics resulted in increases in GI 
enteric bacteria and GI Candida albicans in mice. Mishkin & Mishkin (2001), on the 
other hand, were of the opinion that a subgroup of IBS patients who had small 
intestine bacterial overgrowth would benefit from a course of antibiotics. This was 
also the conclusion reached by Attar et al. (1999) who found the antibiotics 
Norfloxacin and Amoxicillin-clavulanic acid to be effective in the treatment of 
bacterial overgrowth-related diarrhoea.  
  
 Mishkin & Mishkin (2001) found that their experience and data did not 
support the very high prevalence of small intestine bacterial overgrowth stated in the 
research by Pimentel et al., and pointed out the fact that patients with abnormal small 
intestine bacterial overgrowth could possibly have other disorders such as diabetes 
mellitus with complications, as well as a history of previous GI infections. They also 
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drew attention to the premise that if, on routine testing, IBS patients have no organic 
pathology, a positive lactulose hydrogen breath test or glucose breath test which 
indicated small intestine bacterial overgrowth would, in their view, be pathological. 
  
 Other researchers agreed that Pimentel et al. had ignored the fact that the 
diagnosis of IBS always presumes the absence of a structural or biochemical 
explanation for the symptoms (Jones, Craig & Olinger, 2001; Cuoco, Cammarota, 
Jorizzo & Gasbarrini, 2001). Jones et al. also criticised the fact that Pimentel et al. did 
not also evaluate for other recognised risk factors for bacterial overgrowth such as 
hypo- or achlorhydria, diabetes with neuropathy, small bowel dysmotility, 
malnutrition and immuno-deficiency states, and alcoholism. 
 
 Pimental et al. corroborated their findings of an apparent association between 
the increased prevalence of small intestine bacterial overgrowth with IBS in a further 
study in 2003 where they set out to evaluate whether hydrogen and methane patterns 
on lactulose breath testing coincided with diarrhoea and constipation symptoms in 
IBS and IBD. The 551 participants in the study - 296 (53.7%) of whom fulfilled 
Rome I criteria for IBS - were referred for a lactulose breath test (LBT). The 
researchers found that methane secretion among subjects with small intestinal 
bacterial overgrowth and IBS was associated with higher constipation severity scores 
and lower diarrhoea severity scores. They also found that diarrhoea, and conditions 
that produce this symptom such as IBD, are associated with hydrogen production on 
LBT. 
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 Lin (2004) takes the apparent link between small intestine bacterial 
overgrowth and IBS a little further. He suggests that the GI and immune effects 
which small intestine bacterial overgrowth has on the patient may explain not only 
bloating, distension and abdominal pain but other symptoms of IBS such as altered 
motility, visceral hypersensitivity and immune activation, as well.   
 
 2.3.4 Neurotransmitter Imbalance 
 
 The enteric nervous system modulates GI function via the action of 
neurotransmitters and neuromodulators including serotonin, norepinephrine, 
dopamine and melatonin and that dysfunction of these can lead to gastrointestinal 
disorders. Of these, serotonin is generally considered to be the main candidate in the 
modulation of motor and sensory function in the GI tract and its involvement in the 
pathogenesis of IBS is being supported by accumulating evidence (Wade, Tamir, 
Kirchgessner & Gershon, 1994; Gershon, 1999; Crowell, 2001).  Serotonin is 
involved in the local regulation of GI motility, secretion, and perception (of urge and 
pain) as well as being an important brain neurotransmitter that is relevant to 
cognition, mood, depression, and other neuropsychiatric illnesses. It is hence a key 
denominator of the brain-gut axis (Kim & Camilleri, 2000; Kilkens et al., 2004).  
 
 It has been estimated that approximately 95% of serotonin is located in the GI 
tract and enteric nervous system - the remaining 5% being in the central nervous 
system.  In the GI tract, serotonin is found within the majority of enterochromaffin 
cells, as well as neurons, mast cells, and smooth-muscle cells.  When 
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enterochromaffin cells release serotonin, vagal afferent nerve fibres and intrinsic 
enteric afferent nerve fibres are stimulated resulting in intestinal secretion and the 
peristaltic reflex.  
  
 In physiological studies of gut smooth muscle, serotonin can make the bowel 
contract or relax by stimulating cholinergic neurons to release acetylcholine, which 
results in smooth muscle contraction, or by stimulating inhibitory nitrergic neurons to 
release nitric oxide, which results in smooth muscle relaxation (Gershon, 1991; 
1998). Any alterations to enterochromaffin cells and/or serotonin signalling can 
potentially result in GI dysmotility, visceral hypersensitivity and secretomotor 
abnormalities in the gut (Kim & Camilleri, 2000; Howitz & Fisher, 2001; Houghton, 
Atkinson, Whitaker, Whorwell & Rimmer, 2003).  
 
 Evidence is beginning to link disturbed serotonin physiology with the 
pathophysiology of diarrhoea. Studies have found a significantly higher postprandial 
serotonin concentrations and a longer duration of serotonin in diarrhoea-predominant 
IBS (dIBS) patients than in healthy volunteers. These findings indicated that there 
might be a difference in the way that serotonin is released in dIBS patients (Bearcroft, 
Perrett & Farthing, 1998; Houghton et al., 2003; Singh, Pandey & Singh, 2003). 
Houghton et al. (2003) also suggested that increased stores of platelet depleted 
plasma serotonin may act as a useful marker for the diagnosis and management of 
dIBS. 
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 Melatonin (5-methoxy-N-acetyltryptamine) is a pineal gland neurohormone 
and a close derivative of serotonin.  It is synthesised from the amino acid, tryptophan 
and secreted from the pineal gland into the blood in a circadian rhythm. Melatonin is 
known to modulate gut motility and alleviate stress as well as having an effect on 
many physiological and pathophysiological functions, including sleep, analagesia and 
anti-inflammation (Harlow & Weekley, 1986; Song, Gwee, Moochhala & Ho, 2005).  
It is thought to alleviate stress by exerting both excitatory and inhibitory effects on 
gut smooth muscle although, in an animal study by Harlow & Weekley (1986), the 
researchers suggested that the action may not be directly on smooth muscle 
contraction but, instead, be the result of an indirect action which inhibits the 
contractile response of serotonin. Bubenik (2002) suggested that this may occur via 
the central nervous system and the sympathetic and parasympathetic nerves. 
 
 In his research on the GI tract of vertebrate species, Bubenik (2002; Bubenik 
& Brown, 1997) found that the concentration of melatonin in GI tissues surpassed 
blood levels by 10-100 times and that there was at least 400 times more melatonin in 
the GI tract than in the pineal gland. These findings add to the evidence that 
melatonin may play an important role in modulating the digestive system. He also 
proposed that melatonin may serve as an endocrine, paracrine, or autocrine hormone 
which influences the regeneration and function of epithelium and which may also 
reduce the tone of GI muscle and enhance the immune system of the gut.  
 
 Messner, Huether, Lorf, Ramadori & Schworer (2001) studied the distribution 
of melatonin in the human hepatobiliary-gastrointestinal tract by measuring 
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melatonin concentrations in human bile, GI and liver tissue and in portal blood 
samples, and comparing them with plasma concentrations.   
 
 They found that, compared to concentrations of melatonin in the whole colon, 
the mucosal concentration of melatonin in the GI tissues was about five times higher - 
a similar concentration to that found by Bubenik (1997, 2002) in his studies on the GI 
tract of vertebrate species. The findings of Messner et al. (2001) also suggest that 
melatonin may act as a mediator of inter-organ communication between the GI tract 
and the liver. 
 
 Other neurotransmitters such as calcitonin gene-related peptide, acetylcholine, 
substance P, pituitary adenylate cyclase – activating polypeptide, nitric oxide, and 
vasoactive intestinal peptide, may also play an important role in functional 
gastrointestinal disorders. Horwitz & Fisher (2001) suggest that these neuro-
transmitters may provide links not only between bowel contractility and visceral 
sensitivity, but also between the enteric and central nervous systems.  
 
 2.3.5 Genetic Influences 
  
 Researchers have found that IBS clusters in families (Kalartar, Locke, 
Zinsmeister, Beighley & Talley, 2003; Morris-Yates, Talley, Boyce, Nandurkar & 
Andrews, 1998) but Levy, Whitehead, von Korff & Field (2000) suggest that part of 
this may be due to parental reinforcement and modelling which eventually results in 
learnt illness behaviour.  Their study compared 631 children whose parents were 
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diagnosed with IBS during one calendar year with a control group of 646 children 
whose parents did not receive a diagnosis of IBS during the same year.   
 
 They found that the case children had significantly more healthcare visits for 
all causes and more visits for GI symptoms than controls, and that outpatient health 
care costs were also significantly higher for case than control children.  They also 
found that IBS parents made more health care visits than control parents for non-GI 
complaints and also incurred substantially higher health care costs than control 
parents. The gender of the IBS parent was not related to children’s GI visits – both 
mothers and fathers appeared to be as effective at modelling GI-related illness 
behaviour.  
 
 The researchers came to the conclusion that perhaps IBS parents might not be 
specifically modelling GI illness behaviour to their children but modelling a general 
pattern of illness behaviour instead. Unfortunately, this study did not examine 
whether the health complaints of the parents were the same as those exhibited by their 
children. 
 
 A study on twins, however, suggests that a proportion of the liability for 
functional bowel disorders (FBD) may be under genetic control. Morris-Yates et al. 
(1998) carried out a study on 686 individual twins from same-sex pairs enrolled in the 
Australian Twin Registry. In this study the participants completed a structured 
interview that included questions related to symptoms consistent with FBD: 
abdominal pain, diarrhoea, constipation, excessive gas or bloating, and nausea. 
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Thirty-three of the participants (4.8%) had one or more symptoms diagnosed by a 
medical practitioner as FBD.  
  
 Other studies suggesting a genetic tendency have been carried out by 
Gonsalkorale, Miller, Afzal & Whorwell, (2003) and Yeo et al., (2004).  Research 
has shown that inflammation may play a role in the pathogenesis of IBS (Bose & 
Farthing, 2001; Barbara et al., 2004).  Persistent inflammation is thought to result 
from an imbalance of cytokines, and the elaboration of cytokines is under genetic 
control.  
 
 Gonsalkorale et al. (2003) designed a study to establish whether there might 
be a genetic predisposition to an altered pattern of anti-inflammatory cytokine 
production in patients with IBS.  Their results showed that patients with IBS had 
significantly reduced frequencies of the high producer genotype for the anti-
inflammatory cytokine, interleukin 10, than controls.  This suggests that at least some 
IBS patients may be genetically predisposed to produce lower amounts of this 
cytokine and that there may then be an increased inflammatory component in some 
cases of IBS. 
 
 Yeo et al. (2004) carried out a study on 194 North American Causasian 
female diarrhoea-predominant IBS (dIBS) patients and 448 female Caucasian 
controls to assess the potential association between the serotonin reuptake transporter 
(SERT) polymorphisms and the dIBS phenotype.  
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 As mentioned previously, serotonin plays in important part in gut functions 
such as intestinal peristalsis and secretion, and in the sensory signalling in the brain-
gut axis (Gershon, 1999; Kim & Camilleri, 2000). SERT is a specific protein which 
mediates removal from the synapse. Polymorphisms in the SERT gene affect 
transcriptional activity which results in altered serotonin reuptake efficiency, 
indicating that the SERT polymorphism may play a role in the development of IBS. 
The researchers observed a strong genotypic association between the SERT-P 
deletion/deletion genotype and the dIBS phenotype, suggesting that the serotonin 
transporter was a potential candidate gene for dIBS in women.  
 
2.4  Symptom Criteria 
  
 IBS is a functional disorder which can exhibit symptoms (especially in older 
people) similar to those of serious organic illness such as weight loss, rectal bleeding, 
recent changes in bowel pattern, and pain or bowel movements that wake the patient 
– a symptom which is often considered a warning sign of organic disease, yet can 
occur with functional disorders as well. In patients with IBS, weight loss may be due 
to depression, and rectal bleeding is commonly attributed to haemorrhoids or anal 
fissure caused by straining with a hard bowel movement (Manning, Thompson, 
Heaton & Morris, 1978).  
  
 Food allergies, gluten intolerance disorders such as coeliac disease, 
inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, colon 
cancer, endometriosis, can all mimic the symptoms of IBS and must be conclusively 
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ruled out (Van Vorous, 2000). Because of the similarity of IBS and organic illness, a 
thorough evaluation is necessary applying both suitable criteria and laboratory and 
clinical testing to arrive at a conclusive diagnosis (Licht, 2000; Talley et al., 1990).  
 
 2.4.1 Manning Criteria 
  
 Diagnostic criteria for IBS were first developed by a study by Manning et al. 
in 1978 (Manning criteria) and later by a consensus meeting in Rome in 1988 (Rome 
criteria).  Both criteria consist of a set of symptoms that, in the absence of structural 
or biochemical disorders of the GI tract, are consistent with IBS.  
 
 Between August 1975 and May 1976, Manning et al. (1978) recruited 109 
patients who were complaining of abdominal pain, constipation, or diarrhoea. Each 
participant was given a questionnaire containing 15 symptoms thought to be 
characteristic of IBS (see Table 3).  
 
 Seventeen to twenty-six months later, 106 of the participants were reviewed 
independently by two gastroenterologists to establish a final diagnosis of the original 
complaints and a definite diagnosis was reached in 79 patients.  Fourteen of these had 
diverticular disease of the colon and were excluded because their symptoms might be 
regarded as either organic or functional, leaving 32 patients with IBS and 33 with 
organic disease.  
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 Table 3                  Symptoms Believed to be Characteristic of IBS 
 
Looser stools at onset of pain                                 Nocturnal bowel movement 
 
More frequent bowel mvts at onset of pain            Urgency of defecation 
 
Pain eased after bowel movement (often)               Pain worse after bowel movement 
 
Visible distension                                                    Pain eased with flatus 
 
Feeling of distension                                                > 2 bowel movements between 
meals 
 
Mucus per rectum                                                    Harder stools at onset of pain 
 
Feeling of incomplete emptying (often)                  Less frequent bowel movements at                                    
                                                                                 onset of pain 
Bowel movement before breakfast 
 
 
Adapted from Manning et al. 1978 
  
 None of the 15 symptoms tested was more common in patients with organic 
disease but four were more common in patients with IBS: abdominal distension, pain 
relief with bowel action, more frequent stools with onset of pain, looser stools with 
onset of pain. Two further symptoms – passage of mucus and the sensation of 
incomplete evacuation – were more common in the patients with IBS and when these 
two symptoms were added to the four listed above, the discrimination between the 
two groups was increased (see Table 4). 
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Table 4                                          Manning Criteria 
                                     1.    pain eased after bowel movement 
                                     2.    looser stools at onset of pain 
                                     3.    more frequent bowel movements at onset of pain 
                                     4.    abdominal distension or bloating 
                                     5.    mucus per rectum 
                               6.    feeling of incomplete rectal emptying    
    Adapted from Manning et al. 1978 
  
2.4.2 Rome Criteria 
  
 Following the 12th International Congress of Gastroenterology in 1984, the 
need for further guidelines for the diagnosis and study of IBS was discussed and a 
working team was set up in 1986 to develop these guidelines.  The ensuing draft was 
sent to 16 colleagues (in seven different countries) who were noted for their research. 
The document was revised in light of their comments and presented at the 13th 
International Congress in Rome in 1988 (Thompson, Dotevall, Drossman, Heaton & 
Kruis, 1989). 
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Table 5                                            Rome I Criteria 
 
 
Continuous or recurrent symptoms of: 
 
1. abdominal pain, relieved with defecation, or associated with a change in frequency 
or consistency of stool; 
 
AND/OR 
 
2. disturbed defecation (two or more of): 
 
a) altered stool frequency 
b) altered stool form (hard or loose/watery) 
c) altered stool passage (straining of urgency, feeling of incomplete evacuation) 
d) passage of mucus 
 
USUALLY WITH 
 
3. bloating or feeling of abdominal distension. 
 
 
 
Adapted from Thompson et al., 1989. 
Rome I 
 A committee was set up in the same year to look at subgroups of IBS and, as a 
result, the project was expanded to include all of the functional GI disorders. The 
members of the committee then developed a system to classify the functional GI 
disorders into 21 entities in five anatomical regions of the gut (oesophageal, 
gastroduodenal, bowel, biliary, and anorectal).  From 1990-1995, further committees 
were formed to work on the classification system and the third revision, which 
included the IBS criteria (which now required pain for the diagnosis), was published 
in 1992 and is now known as Rome I criteria (Drossman, 2000; Thompson, 2000).  
(See Table 5). 
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     Table 6                                          Rome II Criteria 
 
IBS can be diagnosed based on at least 3 months continuous or recurrent symptoms in the 
preceding 12 months of: 
a. abdominal discomfort or pain that has two out of three of these features: 
a. relieved with defecation; and/or 
b. onset associated with a change in frequency of stool; and/or 
c. onset associated with a change in consistency of stool; and 
 
2.   two or more of the following, at least a quarter of occasions or days: 
  a.  altered stool frequency (either more than 3 bowel movements per  
       day or fewer than 3 bowel movements per week; 
b. altered stool form (lumpy/hard or loose/watery stool); 
c. altered stool passage (straining, urgency, or feeling of incomplete 
evacuation); 
d. passage of mucus; 
e. bloating or feeling of abdominal distension. 
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 Rome II 
 New committees were set up (including basic science, physiology, psycho-
social and paediatric committees) and a series of articles was produced as a 
supplement in Gut 4: 16-26, 1999.  The expanded information from the work of these 
committees was then published in the Rome II book in 2000 (Drossman, 2000; 
Thompson, 2000). (See Table 6). 
 
 Rome III 
 A co-ordinating committee was set up in 2001 for Rome III. Most of the 
Rome II committees were retained and additional ones (pharmacology, gender, 
culture, society and the patient, two paediatric committees, functional abdominal 
pain) added.  By December 2002, all committee members were selected and the 
publication was released in 2006 (Drossman, 2000; Thompson, 2000). 
 
2.5  Impact on Quality of Life and Economic Cost 
  
 IBS typically affects those of working age and imposes a substantial 
economic burden in both direct medical costs and in indirect social costs. It poses a 
financial burden on the patient both through loss of pay and the added cost of 
healthcare (such as physician visits, investigations and treatments) and is also costly 
to the employer because of absenteeism, lost productivity, and medical, 
pharmaceutical and disability claims from employees (Cash, Sullivan & Barghout, 
2005; Leong et al., 2003). There is also the less-measurable costs of decreased quality 
of life (Hulisz, 2004; Drossman et al., 2007). 
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 In a 12-month study, Zacker, Chawla, Wang & Albers (2004) compared 
patterns of illness or disability-related absence from work in participants in the U.S. 
who had been diagnosed with IBS with a sample of patients with no GI disorders, and 
estimated that the absences were 3.27% greater for participants with IBS once they 
had been diagnosed with the disorder.  
 
 Dean et al. (2005) found IBS to be associated with a 21% reduction in work 
productivity in the U.S. (equivalent to working less than 4 days in a 5-day work 
week) and Hahn et al. (1999), in a study involving the U.S. and the U.K., found that 
in both countries, nearly 1/3 of those surveyed missed at least one day of work due to 
IBS in the previous 4 weeks and a greater percentage cut back in their work or 
activities due to IBS. More people in the UK experienced changes in jobs or declined 
opportunities for promotion or advancement due to IBS.  
 
 Leong et al. (2003) carried out a study to measure both the direct and indirect 
costs of treating IBS by analysing all medical, pharmaceutical, and disability claims 
for a U.S. company’s employees and their dependents during 1998.  They found that 
the average total cost per patient with IBS was $4,527 compared with $3,276 for 
controls, the average physician visit costs were $524 and $345 for patients with IBS 
and controls, respectively, and that the average out-patient care costs to the employer 
were $1,258 and $742 for patients with IBS and controls, respectively.  On average, 
each employee with IBS cost the employer $901 as a result of absenteeism compared 
to $528 for those employees not suffering for IBS, indicating a significant financial 
burden on the employer. These costs were attributed to more visits to medical 
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practitioners and hospital out-patients care, a greater use of prescription medications 
and a subsequent increase in work absenteeism.  
 
 Current research shows a substantial economic burden on society as a result of 
IBS but the true economic burden is still unclear. Direct healthcare costs are clearly 
defined but, apart from absenteeism from work and lost productivity, there is 
insufficient data on indirect social costs because, even though a high percentage of 
people is known to be affected with this disorder, most IBS sufferers (60-75%) do not 
consult a physician (Jones & Lydeard, 1992; Farthing, 1995).  
 
 Suggested strategies to reduce direct costs include physician/patient 
education, avoidance of unnecessary investigations, the setting-up of support groups 
and the early consideration of psychosocial issues and psychological treatments 
(Camilleri & Williams, 2000). 
 
 Diminished quality of life (QOL) is another aspect of IBS. As well as having 
a possible financial impact on employers through reduced productivity, it affects the 
day-to-day functioning of the employee. Employees with IBS were found to have 
significantly lower scores on all domains of the SF-36 health survey, indicating 
poorer functional outcomes (Akehurst et al., 2002; Dean et al., 2005).   
 
 Hahn et al. (1999) compared health-related QOL of IBS sufferers in the U.S. 
and the U.K. and found that the general health status of participants with IBS in both 
countries was poorer compared to that of the general populations and that the effect 
 72 
on QOL appeared to be greater in the U.K.  They also found that healthcare 
utilisation was similar in both countries, as was the percentage of IBS patients using 
prescription drugs – approximately 75% in each group.  
 
  Badia et al. (2002) carried out a cross-sectional study on a representative 
sample of the Spanish population to compare health-related QOL in 146 participants 
meeting the Rome I criteria and 65 meeting the Rome II criteria, and found that 
participants meeting Rome II criteria reported worse health-related QOL scores than 
those meeting exclusively Rome I criteria.  Of the Rome II individuals, 67.7% had 
consulted some type of healthcare professional in the previous 12 months (Rome I 
group 41.8%); drug consumption was 70.8% (Rome I group 45.2%) and reduced 
performance in main activity was 60% (Rome I group 27.4%). Overall, the study 
sample reported significantly worse health-related QOL scores than the general 
population in four dimensions of the SF-36 (bodily pain, vitality, social functioning 
and role-emotional).  
 
 IBS imposes a large medical burden on society in terms of consultations, 
investigations, treatments and drug consumption and the burden is further increased 
by social costs such as absenteeism from work and loss of productivity. As well as 
healthcare costs, there is a significant reduction in the quality of life of IBS sufferers 
and, since the number of people with this condition and the burden of illness appear 
to be so large, IBS should be looked upon more seriously by the medical community 
and society.  
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2.6 Psychosocial Factors and Irritable Bowel Syndrome 
 
 2.6.1 Life Stress 
  
 Studies have shown that life stress contributes to the onset and exacerbation of 
symptoms for the majority of patients with IBS and other functional disorders such as 
functional dyspepsia (FD) (Levy et al., 1997; Locke et al., 2004). 
 
 Bennett et al. (1998) recruited 117 IBS/FD outpatients to test the relation of 
chronic life stress the participants had experienced during the six months or more 
prior to the trial, to subsequent symptom intensity over time.  To determine life stress 
and symptom intensity measures, patients were interviewed and asked to complete a 
self-report which was collected at the commencement of the two-week trial, and 
again at 6 and 16 months.  
 
 Stressors included divorce, relationship difficulties, serious illness (of self or 
others), lawsuits, business failures, housing difficulties, forced redundancies, and 
caring for a family member with significant physical and/or emotional problems. The 
results suggested that chronic life stress was a powerful predictor of subsequent 
symptom intensity and that the relation was not influenced by personality, age, sex, 
anxiety, or depression. 
 
 In a stress management trial, Corney and Stanton (1990) measured psychiatric 
symptoms, psychosocial distress and symptom severity over a period of a week in 42 
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patients suffering from IBS. The researchers found that 52% of patients had had 
symptoms continuously and the remainder had had symptom-free periods. Of the 
latter group, 45% felt that reoccurrence of symptoms was related to life stress and 
55% of all the participants linked the initial onset of illness with stressful events such 
as employment difficulties, a family death, a medical operation, and marital stress.  
  
 Creed’s research (1992; 1994) also suggested a strong association between 
IBS and psychological disorder.  The findings showed that about half the IBS patients 
in a hospital clinic had a psychiatric disorder. This was two or three times greater 
than the prevalence among patients with organic GI conditions such as peptic ulcers 
or IBD, and healthy controls.  Also, two-thirds of patients with IBS had experienced 
stressful events such as bereavement, marital separation or major argument leading to 
a broken family relationship, before the onset of abdominal symptoms. 
 
 Herschbach, Henrich & Von Rad (1999) carried out a study on a 
representative sample of the German population (2,201 volunteers – 52.9% 
women/47.1% men) with IBS or FD or both, to elucidate the role of psychological 
factors in the frequency of physician consultations by individuals with functional GI 
disorders. Of the volunteers, 288 (13.1%) suffered with IBS and/or FD. The subjects 
with IBS or FD, with and without physician visits, were compared with each other 
and with the general population.  
 
 The participants completed a questionnaire on physical symptoms, illness 
behaviour, living conditions, personality features, and sociodemographic status, and 
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were assigned to one of two groups – those with IBS and FD (FGD group), and the 
general population.   
 
 Those in the FGD group had significantly higher scores for depression, 
emotionality, and physical symptoms, were more worried about their health, and had 
more negative life stress in the previous twelve months than the general population. 
The study also showed that those participants who consulted a physician for their GI 
disorders (59.6%), and those who did not (40.4%), differed on psychological 
measures.  Those participants who had not consulted a physician had higher scores 
for somatisation, emotionality, quality of life, health rating, and social support, but 
they did not differ from the general population on depression, concerns about health, 
and life events. Those participants who consulted a physician differed from the non-
consulters with respect to somatisation, depression, emotionality, life events, and 
health rating.  
  
 The researchers suggest that, in view of the results of their trial, 
gastroenterologists, when seeing patients with functional GI disorders, should be 
aware that there may be a psychological component. 
  
 2.6.2 Anxiety and Depression 
 
 Hazlett-Stevens, Craske, Mayer, Chang & Naliboff (2003) examined the 
relationships between the presence of IBS and generalised anxiety disorder, chronic 
worry, neuroticism, anxiety sensitivity and anxiety about visceral sensations in a 
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sample of 905 university students.  The participants completed a questionnaire 
containing measures of the afore-mentioned psychological symptoms, and IBS 
diagnostic status was determined according to the Rome II criteria. 
 
 The researchers found that there was a significant association of IBS and 
anxiety-related measures, especially anxiety about visceral sensations and that the 
prevalence of IBS reported by the university students was similar to that reported by 
adult population surveys. 
 
 In a Japanese study, Masanori, Hideyuki, Katsumi & Chiharu (2004) focused 
on functional pain in 128 outpatients with IBS.  The participants were assigned to two 
groups: the first group of 99 patients whose main symptom was abdominal pain, and 
the second group of 29 patients in which the main symptom was abdominal 
discomfort, not pain.  All participants completed a validated self-report questionnaire 
for anxiety (STAI-I) and depression (Zung’s Self-rating Depression Scale – ZSDS). 
 
 According to the DSM III-R criteria, psychiatric disorders (depression, 
anxiety, conversion disorder, eating disorder, and pain disorder) were diagnosed in 51 
(51.5%) of the 99 pain IBS patients and 13 (44.8%) of the 29 discomfort IBS patients.  
Anxiety disorder was diagnosed in 22.7%, and depressive disorder in 25% of all IBS 
patients.  The rate of anxiety disorder in pain IBS patients was found to be higher 
than that in the discomfort IBS patients. 
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 Studies have shown that treatment-seeking patients have higher levels of 
depressive symptoms than normal controls (Herschbach et al., 1999; Latimer, 1983) 
but, although IBS is often accompanied by depression, the mechanism underlying the 
relationship is not known. Also unknown is the nature of any influence pain 
catastrophising has on IBS symptoms (Drossman et al., 2003). 
 
 Lackner, Quigley & Blanchard (2004) carried out a study on 244 participants 
(196 (80.3%) female and 48 (19.7%) males) who satisfied the Rome II criteria for 
IBS and had undergone a medical examination and laboratory tests (when necessary) 
to exclude those volunteers who had inflammatory bowel disease or lactose 
malabsorption syndrome. Volunteers were also excluded if they had a history of 
current or past psychiatric disorders. 
 
 The purpose of the study was to test the mediational role of catastrophising 
(i.e. the patients’ beliefs regarding pain) in the link between depression and pain 
severity.  Catastrophising was measured using the subscale of the Coping Strategies 
Questionnaire (Rosenstiel & Keefe, 1983) and participants were asked to rate the 
frequency in which they engage in various beliefs during an episode of pain (0= never 
do to 6= always do) on the six items of the subscale.  The severity of pain was 
measured on the Bodily Pain subscale of the SF-36 Health Survey (Ware & 
Sherbourne, 1992), trait anxiety by using the Trait subscale of the State-Trait  
Anxiety Inventory (Speilberger et al., 1970), and depression was measured using the 
Beck Depression Inventory (Beck et al., 1961). 
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 The results showed that patients with IBS who experience higher levels of 
depression engage in more catastrophic thinking and, partly through this thinking 
style, experience more intense pain and greater activity limitations due to pain 
severity. 
  
 Gorard et al. (1996) carried out a study to determine whether patients with 
anxiety and depression had objective evidence of abnormal intestinal transit 
irrespective of any bowel symptoms.  The participants for the study were 21 
psychiatric outpatients, who fulfilled the criteria for generalised anxiety disorder 
and/or major depression, and 21 healthy controls.  Orocaecal transit time was 
measured by the lactulose hydrogen breath test and whole gut transit time by 
abdominal radiography.  Median range whole gut transit time was shorter in patients 
with anxiety (14 hours) than in patients with depression (49 hours) and controls (42 
hours); and orocaecal transit time was shorter in patients with anxiety (60 minutes) 
than in patients with depression (110 minutes) and controls (75 minutes).  The results 
indicated that anxiety was associated with diarrhoea and depression with 
constipation: mood has an effect on intestinal motor function. 
  
 2.6.3 Sexual and Physical Abuse 
  
 Researchers have also examined the relationship between a history of sexual 
or physical abuse and functional bowel disorders (Longstreth & Wolde-Tsakik, 1993; 
Reilly, Baker, Rhodes & Salmon 1999; Ross, 2005).   
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 Dill, Sibcy, Dill & Brende (1997) designed a study to determine the 
percentage of patients in a medical practice who had both IBS and a history of sexual 
abuse.  Sixty-five patients aged from 24 to 84 years participated in the study, 79% of 
whom were women.  The participants were assigned to one of three groups: a) no 
reported history of sexual abuse; b) reported history of sexual abuse without history 
of being threatened with sexual abuse; and c) reported history of sexual abuse with 
history of being threatened with sexual abuse.  Sixty-eight percent of the patients who 
had a history of childhood or adult sexual abuse also reported that they had been 
exposed to the threat of abuse, and had much higher symptoms scores than those 
exposed to abuse alone.   
 
 The results of the study suggest that threat combined with abuse is more  
likely to affect IBS symptom severity, and is a more significant predictor of IBS 
symptomatology. 
 
 Drossman et al. (1990) recruited 206 female patients from a university-based 
GI practice over a 2-month period. On completion of a questionnaire (which 
requested information about demographics, functional GI symptoms, health-care 
utilisation, and a history of abuse), 89 participants (43.2%) reported a history of 
sexual or physical abuse in childhood or adulthood.  All but one of the physically 
abused patients had been sexually abused. The study also found that almost one third 
of the abused patients had never discussed their experiences with anyone and only 
17% had informed their doctors. 
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 The results indicated that patients with functional disorders were more likely 
than those with organic disease diagnoses to report a history of sexual and physical 
abuse, chronic or recurrent abdominal pain, and more surgical intervention; and that 
abused patients were more likely than non-abused patients to report pelvic pain, 
multiple somatic symptoms and more surgical intervention. 
 
 Ali et al. (2000) were interested in determining whether the experience of 
emotional abuse (which includes various forms of psychological maltreatment, 
trauma, and non-physical aggression) was associated with IBS beyond the 
syndrome’s association with a history of physical and/or sexual abuse.  
 
 The researchers investigated the presence of emotional abuse, self-blame, and 
self-sacrificing, in a sample of 25 women who had been diagnosed with IBS to a 
comparison sample of 25 women who had been diagnosed with IBD.   
 
 Emotional abuse was assessed using a psychometrically validated measure, 
the Abusive Behaviour Inventory (Shepard & Campbell, 1992), self-blame was 
assessed through a series of validated self-blame scenarios (Janoff-Bulman, 1979), 
and self-silencing was measured with the Silencing the Self Scale (Jack, 1991).   
Physical/sexual abuse was assessed using questions previously used with a female GI 
population (Drossman et al., 1990). 
 
 The results showed that women in the IBS sample scored significantly higher 
physical/sexual abuse (IBS–mean=2.24, SD=1.85; IBD–mean=0.360, SD=0.810), 
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emotional abuse (IBS–mean=39.5, SD=12.4; IBD–mean=29.4, SD=6.94), self-blame 
(IBS–mean=24.6, SD=7.92; IBD–14.2, SD=5.47), and self-silencing (IBS–
mean=77.2, SD=20.5; IBD–mean=64.7, SD=13.8) than the women in the IBD sample, 
suggesting that this difference went beyond the differences accounted for by physical 
and/or sexual abuse history. 
 
 Psychological variables such as anxiety, anxiety sensitivity, depression, and 
physical and/or sexual abuse, have been shown to play a substantial role in the IBS 
condition of many patients and should be carefully assessed in order to achieve 
satisfactory clinical outcomes with these patients. Gastroenterologists would also 
benefit through this assessment by increasing work satisfaction and reducing the 
difficulty and frustration in working with IBS patients (Norton, Norton, Asmundson, 
Thompson & Larson, 1999; Palsson & Drossman, 2005). 
 
2.7 Current Management of Irritable Bowel Syndrome 
   
 There is no single pathophysiological marker and, therefore, no effective 
treatment for the whole symptom complex in IBS patients but there are some 
treatment options which have been shown to be successful in treating the various 
symptoms of IBS.  These treatments include pharmacological treatments (Baker, 
2005; De Ponti & Malagelada, 1998; Mertz, 2003), dietary modification (Dainese, 
Galliani, De Lazzari, Di Leo & Naccarato, 1999; Shanahan, & Whorwell, 2005; Van 
Vorous, 2000), relaxation training (Blanchard, Greene, Scarff & Schwarz-McMorris,  
1993; Boyce, Talley, Balaam, Koloski & Truman, 2003), cognitive-behavioural 
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therapy (Boyce et al., 2003; Hutton, 2005; Read. 1999), psychotherapy (Kohutis, 
1998; Spiller, 2005), and hypnotherapy (Gonsalkorale, Houghton & Whorwell, 2002; 
Palsson, Turner, Johnson, Burnett & Whitehead, 2002; Palsson, Turner & Whitehead, 
2006; Whorwell 1984, 1987, 2006). (See Table 7). 
  
 2.7.1 Pharmocological Treatments 
  
 Medications mainly include antidepressants, anticholinergics/antispasmodic 
agents, antidiarrhoeal and laxative agents, serotonin-receptor agonists for contipation-
predominant IBS, serotonin-receptor antagonists for diarrhoea-predominant IBS, and 
selective serotonin reuptake inhibitors (SRRIs) for associated psychological disorders 
such as anxiety, depression, and obsessive-compulsive behaviour (Foxx-Orenstein, 
2006; McGuire & Towers, 2006).  
 
 2.7.1.1    Antidepressants                                                                                   
  
 Tricyclic antidepressants such as amitriptyline (Endep), paroxetine (Aropax), 
desipramine (Norpramin), clomipramine (Anafranil), doxepin, (Sinequan) and 
trimipramine (Surmontil), and selective serotonin reuptake inhibitors (SSRIs) such as 
sertraline (Zoloft), have been shown to decrease IBS symptoms and are 
recommended (in low-dosage) for moderate-to-severe IBS syndrome in which pain is 
predominant or when other therapies have failed (Jackson et al., 2000; Morgan, 
Pickens, Gautam, Kessler & Mertz, 2005). Side-effects include constipation, urinary 
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retention, fatigue, somnolence, weight gain, cardiac toxicity and haematological 
abnormalities (Mertz, 2003; Talley, 2003). 
  
 Serotonin is an important neurotransmitter in both the brain and the GI tract, 
where it plays a key role in the regulation of sensory and motor functions. As patients 
with IBS (and other functional GI disorders) often have comorbid psychiatric 
diagnoses such as anxiety, depression, and somatoform disorders (Drossman et al., 
1999), selective serotonin-reuptake inhibitors (SSRIs) (such as Buspirone, and 
Paroxetine), and serotonin and noradrenaline reuptake inhibitors (SNRIs) (such as 
Vanlafaxine-XR) may be useful when IBS is accompanied and exacerbated by mood 
disorder. Some SSRIs (Prozac, Celexa, Zoloft, and Paxil), however, can trigger 
severe IBS attacks in diarrhoea-predominant patients. Other side-effects include 
nausea, headache, restlessness, anxiety, perspiring, and sexual dysfunction (Chial et 
al., 2003; Kim & Camilleri, 2000).  
 
 2.7.1.2    Antispasmodic agents 
  
 Abdominal pain is a major symptom in IBS and, therefore, the most 
frequently prescribed drugs for IBS are antispasmodics, the most common ones being 
dicyclomine (Bentyl), belladonna/phenobarbital (Donnatal), mebeverine (Colofac), 
propantheline, and hyoscyamine (Levsin, Anaspaz). These drugs affect gut motor 
activity and reduce the colon’s response to both eating and stress. Antispasmodic 
agents may reduce abdominal pain or bloating through anticholinergic pathways (by 
blocking the effects of acetylcholine, the chemical transmitter that nerves release in 
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order to cause muscles to contract) and, in refractory cases, nitrates are occasionally 
useful for direct relaxation of smooth muscles (Horwitz, 2001; Poynard, Regimbeau 
& Benhamou, 2001).  
 
 2.7.1.3    Antidiarrhoeal agents 
  
 Loperamide (Imodium) and diphenoxylate (Lomotil) are the classic anti-
diarrhoeal agents for predominant-IBS patients for whom diarrhoea is the 
predominant symptom. They enhance intestinal water and ion absorption, increase 
resting anal sphincter tone, and slow GI transit time by acting on the circular and 
longitudinal muscle of the intestine, thereby increasing stool consistency and 
reducing frequency (Camilleri, 1999; Efskind, Bernklev & Vatn, 1996).  
 
 Alosetron (Lotronex), the serotonin-3-receptor antagonist, prescribed for 
women with diarrhoea, was withdrawn from the market in November, 2000 because 
of serious, life-threatening, GI side-effects. In June, 2002 it was approved again by 
FDA for marketing but in a restricted manner (Chang et al., 2006). 
 
 2.7.1.4    Laxative Agents 
  
 The most common pharmacological treatments are serotonergic agents such as 
Mosapride, Renzapride, and Tegaserod (Zelnorm) which enhance the upper GI 
motility; opioid agonists and antagonists (e.g. Asimadoline), which reduce sensation 
responses to gastric and colonic extension, and chloride-channel activators such as 
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Lubriprostone (Amitiza) which accelerate small intestinal and colonic transit (Camilleri 
et al., 2006; Delgado-Aros et al., 2003; Harris, Hansel, DiBaise & Crowell, 2006). 
Chemical laxatives such as Milk of Magnesia or ExLax tend to stimulate the bowel 
by causing irritation of the intestinal lining and can easily lead to dependency. 
Constipation-predominant IBS patients with mild constipation may benefit from non-
prescription soluble fibre supplements such as Metamucil, Citrucel, Fibercon, or 
Psyllium (Fernandez-Banares, 2006; Hadley & Gaarder, 2005).   
 
2.7.1.5    Other Agents 
 
  
 Antibiotics.  Antibiotics have been suggested as a treatment of refractory 
diarrhoea where there is evidence of overgrowth by enteric bacteria in the small 
bowel and bacterial infection is suspected. Antibiotics are not indicated for long-term 
use because they may increase diarrhoea through changes in the bowel flora (Hadley 
& Gaarder, 2005; Viera, Hoag & Shaughnessy, 2002), or may result in short-term 
inflammatory response in the colon which may produce a hypersensitive state similar 
to that of post-infective IBS (Collins, Barbara & Vallance, 1999). 
 
 In a study on antibiotics by Maxwell, Rink, Kumar & Mendall (2002), the 
researchers found that antibiotics increased functional abdominal symptoms in 
subjects (recruited from the general population) who had been given a course of 
antibiotics by their general practitioners, and that the subjects, when compared to 
controls, were more than three times as likely to report more bowel symptoms four 
months later. 
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 Prebiotics. Prebiotics are non-digestible food ingredients such as non-
digestible carbohydrates (oligo- and polysaccharides), some peptides and proteins, 
and certain lipids (both ethers and esters).  They beneficially affect the host by 
selectively stimulating the growth and/or activity of one or a limited number of 
bacterial species already resident in the colon (Gibson & Roberfroid, 1995; 
Ouwehand, Derrien, de Vos, Tiihonen & Rautonen, 2005). Among the colonic 
bacterial capable of metabolising prebiotic oligosaccharides, and whose growth is 
stimulated, are species of Lactobacillus and Bifodobacterium (Santos, San Mauro & 
Diaz, 2006; Shoaf, Mulvey, Armstrong & Hutkins, 2006).   
 
 A study by Shoaf et al. (2006) has suggested that some prebiotic oligo-
saccharides may have anti-adhesive activity and directly inhibit the adherence of 
enteric pathogens to the host epithelial cell surface, thereby preventing infection; and 
Furrie et al. (2005) carried out a pilot study in which they showed a reduction in 
inflammation, and regeneration of epithelial tissue, in patients with ulcerative colitis 
by using a synbiotic (a combination of a prebiotic and a probiotic).  
 
 Probiotics. Probiotics consist of a preparation containing a single or mixed 
culture of live microbes that are presumed to restore normal bowel microflora, and 
studies indicate that they may be beneficial to IBS (Gill & Guarner, 2003; Nanda, 
James, Smith, Dudley & Jewell, 1999). 
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Table 7   Examples of Pharmacological & Other Agents in the 
Therapeutic Management of IBS 
         
        Antidepressants. 
                Amitriptyline  (Elavil) 
                Sertraline (Zoloft) 
                Paroxetine (Aropax) 
                Desipramine (Norpramin) 
                Clomipramine (Anafranil) 
                Doxepin (Sinequan) 
                Trimipramine (Surmontil) 
                Selective serotonin-reuptake inhibitors (SSRIs) 
 
        Anti-spasmodic Agents. 
                Dicyclomine (Bentyl) 
                Propantheline 
                Belladonna/Phenobarbital (Donnatal) 
                Hyoscyamine (Levsin, Anaspaz) 
                Mebeverine (Colofac) 
 
        Antidiarrhoeal agents. 
                Loperamide (Imodium) 
                Diphenoxylate (Lomotil)  
               Alosetron (Lotronex) – with caution 
 
        Laxative Agents. 
                Milk of Magnesia/ExLax 
                Lactulose 
                Polyethylene glycol solution 
                Tegaserod (Zelnorm) (5-HT4 agonist) – with caution  
                Mosapride (5-HT4 agonist, 5-HT3 antagonist) 
                Renzapride (5-HT4 agonist, 5-HT3 antagonist) 
                Lubiprostone (Amitiza) (chloride channel activator) 
                Methylnaltrezone (opioid receptor agent) 
                Alvimopan (opioid receptor agent) 
 
        Other Agents. 
               Antibiotics 
                Prebiotics/Probiotics 
               Fibre  
                Bulking agents (Psyllium, Metamucil, Guar Gum) 
                Peppermint Oil 
                Herbal Medicine 
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  In a double-blind, randomised, crossover design, Bifidobacterium animalis 
reduced the colonic transit time in a group of healthy women aged 18-45 years 
(Marteau et al., 2002), and a study by Koebnick, Wagner, Leitzmann, Stern & Zunft,  
(2003) indicated a significant improvement in severity of constipation and stool 
consistency in a group of 70 patients with chronic constipation who had ingested a 
probiotic beverage containing Lactobacillus casei Shirota.   
 
 Probiotics may also be useful in the prevention and treatment of antibiotic-
associated diarrhoea (D’Sousa, Rajkumar, Cooke & Bulpitt, 2002) and in modulating 
inflammation and the immune system in the gut (Bradesi, et al., 2003; Harris et al., 
2006). 
 
 Fibre.  The administration of fibre to the diets of IBS patients has had mixed 
results with the type of fibre (soluble or insoluble) rarely being considered. The 
proposed mechanism of action of fibre is the enhancement of the stool’s water-
holding properties, gel formation to provide lubrication, bulking of the stool, and 
binding of agents such as bile (Friedman, 1991). 
 
 In a study of 100 IBS patients by Miller, Lea, Agrawal & Whorwell (2006), 
participants were asked to consume bran and then complete a self-report 
questionnaire.  The assessment showed that 27% of the participants said that bran had 
improved their symptoms compared with 22% who claimed it made them worse, and 
51% reported that bran had had no positive or negative effect on their symptoms. 
Forty-eight of the participants had previously tried one or more commercial fibre 
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products and of these, 56% reported no change in symptoms, 25% reported an 
improvement, and 19% a deterioration in symptoms.   
 
 In a six-month trial of 72 IBS patients by Lambert et al. (1991), patients with 
constipation, mucus, urgency or watery stools at the beginning of the study, and who 
were consuming more than 30g of fibre by the end of the trial, reported an 
improvement in symptoms. 
 
 However, in a study by Francis & Whorwell (1994) 55% of the 100 
participants were made worse by consuming bran and only 10% found it to be 
helpful. All symptoms of IBS were exacerbated by bran, with bowel disturbance most 
often adversely affected. 
 
 Most researchers appear to carry out trials on insoluble fibre and not soluble 
fibre or a combination of both. Van Vorous, (2000) has suggested that both soluble 
and insoluble fibre should be part of the diet for an IBS sufferer and that insoluble 
fibre should not be eaten alone or on an empty stomach but should be eaten with a 
larger quantity of soluble fibre. This hypothesis, however, has not been tested in 
clinical trials.  
 
 Bulking agents.  Bulking agents are a concentrated form of non-starch 
polysaccharides useful for patients who cannot take adequate dietary fibre.  Available 
bulking agents include psyllium (Ispaghula husk), wheat bran, calcium polycarbophil, 
methylcellulose, guar gum, and sterculia (Indian tragacan or karaya) (Fernandes-
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Banares, 2006).  Placebo-controlled trials using psyllium as a bulking agent have 
demonstrated increases in stool frequency and improved stool consistency in patients 
with idiopathic constipation (Ashraf, Park, Lof & Quigley, 1995; Jalihal & Kurian, 
1990).  
 
 Guar gum has been shown to be effective for GI problems, functional status, 
and psychological distress, after just one month of administration (Parisi et al., 2005). 
In a trial comparison between wheat bran and partially hydrolysed guar gum 
(PHGG), both bran and PHGG improved abdominal pain and bowel motions but 
PHGG was better tolerated by the participants (Parisi et al., 2002). 
 
 
 Peppermint Oil. Clinical trials have demonstrated the variable efficacy of 
peppermint oil to act as a smooth muscle relaxation in patients with IBS.  Kline, 
Kline, Di Palma & Barbero (2001) carried out a two-week study on 42 children with 
IBS to investigate the efficacy and clinical usefulness of pH-dependent, enteric-
coated, peppermint oil capsules.  Their results showed that the peppermint oil 
capsules reduced the pain the children experienced during acute phases of IBS but did 
not alter heartburn, gas, urgency of stools, belching, stool pattern or stool 
consistency.   
  
 In a previous study on 101 adults with symptoms of IBS by Liu, Chen, Yeh, 
Huang & Poon (1997) the experimental group (n=52), taking an enteric-coated 
peppermint oil formulation (Colpermin), showed significant improvement over the 
placebo group (n=49). In the experimental group, 79% experienced reduced 
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abdominal pain (placebo, 43%), 83% had less abdominal distension (placebo, 29%), 
83% had reduced stool frequency (placebo, 32%), and 79% had less flatulence 
(placebo, 22%).  
 
 Herbal Medicine. The most frequently used complementary medicine is 
herbal medicine which also includes a variety of Western herbal supplements such as 
peppermint oil, aloe and ginger (Spanier, Howden & Jones, 2003; Kline, 2001). 
Trials on herbal medicine have shown varying results and consist of either studies on 
specific herbs, combinations of herbs, or herbs in combination with either a 
pharmacological agent or bulking agent. 
  
 Brinkhaus et al. (2005) carried out a trial on 106 IBS patients using two herbs, 
curcuma (part of the ginger family) and fumitory (part of the poppy-seed family) and 
found that neither herb showed any therapeutic benefit over placebo.   
  
 Vejdani et al. (2006) carried out a study on 28 IBS patients to evaluate the 
effectiveness of adding the herbal medicine Carmint, or its placebo, to either 
loperamide (for participants with diarrhoea-predominant IBS) or psyllium (for 
participants with constipation-predominant or alternating IBS) for the relief of 
abdominal pain/discomfort and bloating in IBS patients. The results of the study 
showed a decrease in the severity of abdominal pain/discomfort, and significantly less 
bloating in the Carmint group compared to the placebo group. 
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 In a trial by Bensoussan et al. (1998), 116 patients were randomly allocated to 
one of three treatment groups: individualised Chinese herbal formulations, a standard 
Chinese herbal formulation, and placebo, to determine whether Chinese herbal 
medicine was of any benefit in the treatment of IBS.  Compared to patients in the 
placebo group, patients in both treatment groups (standard and individualised Chinese 
herbal medicine) had significant improvement in bowel severity symptom scores. On 
follow-up (14 weeks after completion of treatment), only the individualised treatment 
group had maintained improvement.  
 
 However, the results of a trial by Leung et al. (2006), using standardised 
Chinese herbal medicine only on IBS patients with predominant diarrhoea symptoms, 
were not as effective. One hundred and nineteen participants were randomly assigned 
to two groups: 60 who received standardised Chinese herbal medicine, and 59 who 
received a placebo.  The researchers found that the herbal formulation for diarrhoea-
predominant IBS did not lead to global symptom improvement. 
 
 2.7.2 Dietary Modifications 
  
 Initial recommendations to the IBS patient generally focus on modifying the 
diet by excluding trigger foods to lessen symptoms, and often by placing emphasis on 
a more fibre-enriched diet. Food diaries are recommended to help patients identify 
and avoid dietary triggers (Fernandez-Banares, 2006; Lynn & Friedman, 1993). 
However, a complicating factor is that patients may experience symptoms as a 
generalised effect to eating any foods (Hadley & Gaarder, 2005). 
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 There are few studies to substantiate exact diets for IBS sufferers, so broad 
dietary plans are recommended for the different symptoms of IBS.  A precise dietary 
history should be taken and a 7-day prospective dietary analysis. The food diary 
should include the type of food consumed, chronological sequence and nature of 
symptoms, and the nature and frequency of bowel movements (Floch & Narayan, 
2002; Friedman, 1991).   
 
 The perception of adverse reactions to food is much higher in IBS with 20-
65% of patients attributing their symptoms to food hypersensitivity (Bischoff, 
Herrmann & Manns, 1996; Young, Stoneham, Petruckevitch, Barton & Rona, 1994). 
(See Table 8). Studies have shown positive skin prick tests for food to be higher in 
IBS patients than controls (Jun et al., 2006) and Serum IgG4 antibodies to common 
foods like wheat, beef, pork, and lamb are elevated in IBS patients (Zar, Benson & 
Kumar, 2005). Food intolerance may also be related to an abnormal intestinal 
microflora (Drisko, Bischoff, Hall & McCallum, 2006; King, Bia & Hunter, 1998) 
and recent studies have shown the benefit of bacterial manipulation by probiotics as a 
therapeutic approach (Gill & Guamer, 2003; Madden & Hunter, 2002).   
 
Table 8.  Suspected Trigger Foods For IBS. 
             
            red/dark meat                 dairy products 
            citrus juices                      egg yolks 
            fried foods                        coconut milk 
            oils                                     shortening 
            butter                                fats 
            solid chocolate                  coffee 
            caffeine                              alcohol 
            carbonated beverages      artificial sweeteners 
            refined sugar                     processed foods 
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 Some vitamin and mineral supplements are also known to cause GI problems 
for people with IBS.  Vitamin C can cause gas, abdominal cramps and diarrhoea; 
calcium can have a constipating effect; and magnesium a laxative effect.  Iron can 
also cause stomach upsets and constipation, especially in the form of ferrous sulphate 
(Mahan & Stump, 2000). 
 
 Lactose malabsorption could be a dietary cause for some IBS patients. 
Without the enzyme lactase, lactose cannot be hydrolysed in the small intestine and 
thus could be fermented in the colon causing diarrhoea, gas, bloating and abdominal 
cramps (Tortora & Grabowski, 1993).  An association between lactose or fructose 
malabsorption and early signs of mental depression has been shown in trials by 
Ledochowski, Sperner-Unterweger & Fuchs (1998) and Ledochowski, Sperner-
Unterweger, Propst, Vogel & Fuchs (2000). Another trial by the same researchers 
suggests that non-absorbed carbohydrates may interfere with tryptophan metabolism, 
which may explain the development of anxiety, mental depression, and other signs of 
serotonin deficiency (Ledochowski, Widner, Murr, Sperner-Unterweger & Fuchs, 
2001). 
  
 Other causes in the development of IBS in lactose-intolerant patients might 
include alterations to colonic microflora, low-grade inflammation of the colon, and 
the effects of post-infective enteritis (Barbara et al., 2002; McGuire & Towers, 2006). 
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2.7.3 Psychological Approaches  
  
 Conventional medical treatment of IBS has left a large proportion of patients 
without significant relief and, therefore, studies have been carried out on alternative 
therapies to identify those that can complement current medical care and improve 
clinical outcomes (Poitras et al., 2002; Tillisch, 2006).   
 
 Studies also indicate that psychological disorders (especially depression and 
generalised anxiety disorder) are present in the majority of IBS patients who actively 
seek medical care (American College of Gastroenterology Functional Gastrointestinal 
Disorders Task Force, 2002) and, because of this overlap between psychological 
disorders and IBS, numerous studies have been done to evaluate the benefits of 
behavioural therapies such as cognitive-behavioural therapy, psychotherapy, 
relaxation therapy, and hypnotherapy, to reduce IBS symptoms (Drossman et al, 
2003; Guthrie, Creed, Dawson & Tomenson, 1993; Blanchard et al., 1993; Whorwell,  
Prior & Faragher, 1984;  Whorwell, 2006).  
  
 The most studied psychological/behaviours interventions in IBS have been 
cognitive-behavioural therapy and hypnotherapy with most of these studies 
demonstrating that individual IBS symptoms improved and that this improvement 
frequently correlated with improvement in anxiety symptoms and depression 
symptoms (Harris & Chang, 2006). 
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 2.7.3.1   Cognitive-Behavioural Therapy 
  
 Cognitive-behavioural therapy (CBT) addresses misinterpretations patients 
may have in their responses to life events. These responses are cognitive (what the 
patient thinks), behavioural (how the patient reacts), and physiological (what the 
patient feels).  In IBS, patients might misinterpret the visceral sensations and 
reactions that are brought on by their response to stress, and respond with illness 
behaviour (Read, 1999).  Treatment involves problem identification and solving 
which gives patients a sense of confidence and control over their condition (Van 
Dulmen, Fennis & Bleijenberg, 1996).   
 
 In a study by Drossman et al. (2003), 215 female patients with IBS were 
randomly assigned to treatment with either CBT or education (where patients 
reviewed symptom diaries, read educational material on functional bowel disorders, 
and discussed the information with a therapist). Results showed a highly significant 
response in the CBT group (70%) compared to those patients receiving education 
only (30%). The least beneficial effect was found for IBS patients with depression. 
 
 Two studies by Boyce, Gilchrist, Talley & Rose (2000) and Boyce et al., 
(2003), however, showed different results when treating IBS patients with CBT.  In 
the first study, eight participants with a diagnosis of IBS underwent eight sessions of 
CBT and maintained daily records of symptom severity.  CBT appeared to reduce the 
distress and disability associated with IBS (but not the frequency of bowel symptoms) 
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and, after treatment, five of the eight patients no longer met the Rome diagnostic 
criteria for IBS.   
 
 In the second study, however, where 105 patients with IBS were randomly 
assigned to three treatment groups (routine clinical care, relaxation training, and 
CBT) there were no significant differences among the treatment groups, suggesting 
that CBT does not have an advantage over relaxation training or routine clinical care. 
All subjects in the study improved significantly over the course of the study in terms 
of their self-reported bowel symptoms (frequency, distress and impairment), 
psychological symptoms (particularly anxiety and depression) as well as quality of 
life, irrespective of the treatment received. 
 
 Van Dulmen et al. (1996) carried out a study with 25 patients receiving CBT 
treatment in a group (rather than as individual patients) and 20 patients in a waiting-
list control condition.  The results showed that cognitive-behavioural group treatment 
was as effective in alleviating IBS, in stimulating coping strategies, and in reducing 
avoidance behaviour, as was individual treatment, thereby making the treatment more 
cost-effective. 
 
 Some researchers have combined CBT with other treatments and obtained 
positive results (Heymann-Monnikes et al., 2000; Gonsalkorales, Toner & Whorwell, 
2004). 
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 Heymann-Monnikes et al. (2000) compared a combination of standardised 
multicomponent behavioural therapy plus standard medical treatment with standard 
medical treatment only. The multicomponent behavioural therapy included IBS 
information and education, progressive muscle relaxation, training in illness-related 
cognitive coping strategies, problem-solving, and assertiveness training. Twenty-four 
patients were randomly allocated to one of the two groups for 10 weekly sessions. 
  
 The results showed significantly greater IBS symptom reduction and 
significant improvement in overall well-being in the multicomponent behavioural 
therapy group than in the standard medical group, suggesting that the combination of 
medical treatment plus CBT was superior to medical treatment alone in the therapy of 
IBS. 
  
 Gonsalkorale et al. (2004) designed a study to determine whether the 
improvement in treating IBS with hypnotherapy was associated with cognitive 
change. The study supported the findings shown in previous research (Whorwell et 
al., 1984, 1987; Houghton, 1996) – i.e. that hypnotherapy reduced both IBS 
symptoms and associated extra-colonic manifestations, and improved the patients’ 
quality of life and psychological well-being.  More specifically, it showed that 
symptom improvement with hypnotherapy was associated with a change in 
cognitions (see Chapter 4). 
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 2.7.3.2  Psychotherapy 
  
 Psychotherapy attempts to help both therapist and patient understand the 
reason why the patient has developed psychological symptoms and what the 
symptoms might mean, so that the patient might gain insight and view the problem 
realistically. The expectation is that the insight gained will cause changes in attitudes 
and behavioural patterns within the patient thereby alleviating the symptoms (Read, 
1999).  In various studies, psychotherapy has been compared to other modalities 
including supportive listing (Guthrie et al., 1993) and medical treatment (Corney, 
Stanton, Newell, Clare & Fairclough, 1991), and patients have been treated either 
individually or in groups. 
 
 One hundred and two patients with refractory IBS took part in a randomised 
trial comparing psychotherapy with supportive listening (Guthrie et al., 1993) in 
which psychotherapy was found to be superior to supportive listening in terms of an 
improvement in both physical and psychological symptoms.  The control group were 
offered psychotherapy on completion of the trial; 33 accepted treatment and, after 
therapy, demonstrated a marked improvement in their symptoms.  The researchers 
suggested that these results showed that psychotherapy was effective in the majority 
of IBS patients with chronic symptoms that were unresponsive to standard medical 
treatment. 
 
 A group psychotherapy programme was carried out on 47 patients who were 
suffering from functional gastrointestinal disorder (FGID) as defined by Rome I 
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criteria – 40 of whom were suffering from IBS (Poitras et al., 2002).  The treatment 
programme combined patient education (diet, medical or psychiatric management) 
and counselling intervention.  
 
 The programme consisted of ten two-hour sessions over 10-12 weeks (10-12 
patients in each group) and the main aim of the study was to facilitate and emphasise 
recognition of the influence of emotions on the biopsychosocial attitude including GI 
symptoms. The control group consisted of 17 patients who were on a waiting list 
before starting the group psychotherapy programme. Researchers monitored the 
natural evolution of the disease during this period where participants weren’t 
receiving treatment.   
 
 Patients showed significant improvement in GI symptoms and quality of life 
with psychotherapeutic intervention compared to controls. The data showed the 
relationship between GI symptomatology and quality of life in patients with FGID 
and also demonstrated that both criteria could be improved by psychotherapy. 
  
 However in a trial by Corney et al. (1991) where 42 IBS patients were 
randomly assigned to receiving either medical treatment or psychotherapy, no 
significant differences were found between treatment groups, but a significant 
correlation was found between improvement in stomach pain and diarrhoea and 
improvement in psychological symptoms, suggesting a close interrelationship 
between the two. 
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 2.7.3.4  Relaxation Training 
  
 As stress is thought to be a major factor in the aetiology of IBS (Levy et al., 
1997; Locke et al., 2004), the rationale behind relaxation training is that reducing the 
emotional tension by relaxation will help reduce symptoms (Deckro et al., 2002; 
Nakao et al., 2001). 
 
 Blanchard et al. (1993) carried out a study on 16 patients with IBS who were 
assigned to two groups – eight participants in each group. One group received 
training in muscle relaxation over 10 sessions (plus regular home practice), the other 
merely monitored GI symptoms.  All patients started on a daily GI symptoms diary 
on which they rated the severity of seven GI symptoms – abdominal pain, abdominal 
tenderness, diarrhoea, constipation, bloating, flatulence, and nausea. Based on these 
daily GI symptom diaries (which were collected for 4 weeks before and 4 weeks after 
treatment), participants in the relaxation group showed significantly more 
improvement than those participants who were only monitoring symptoms.  Fifty 
percent of the relaxation group were clinically improved at the end of treatment 
compared to controls.  
 
 In a later study consisting of 13 participants, Keefer & Blanchard (2001) 
compared relaxation response meditation (RRM) plus symptom monitoring, with 
symptom monitoring alone.  The participants receiving RRM were asked to keep a 
record of their relaxation practice, to rate the level of relaxation before and after 
practice, and to note the length of practice time.  After six weeks, patients in the 
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symptom monitoring only group were crossed over into the treatment plus symptom- 
monitoring group and received six weeks of treatment.    
 
 The relaxation training protocol proved to be superior (67% clinically 
improved) to the waiting-list symptom monitoring condition in the reduction of 
flatulence, belching, diarrhoea, constipation, and bloating; and those who crossed 
over into the treatment after being on the waiting-list improved significantly (86% 
clinically improved), suggesting that the improvement was due to the relaxation 
training.   
 
 A one-year follow-up of this study (Keefer & Blanchard, 2002) was carried 
out to determine whether the effects of relaxation training on IBS symptom reduction 
had been maintained over the long-term, and significant reductions were noted for the 
symptoms of abdominal pain, diarrhoea, flatulence, and bloating. 
 
 2.7.3.5  Hypnotherapy 
  
 The first controlled trial in the field of gastroenterology using hypnotherapy 
as a treatment for IBS (Whorwell et al., 1984) showed significant improvement in 
both the patients’ symptoms and well-being.  The trial generated more interest in 
hypnosis as a treatment option for this condition and further research and 
hypnotherapy trials were carried out with similar outcomes (Gonsalkorale et al., 
1999, Gonsalkorale et al., 2002, Gonsalkorale, Miller, Afzal & Whorwell, 2003, 
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Gonsalkorale et al., 2004; Palsson, 1998, 2002, 2006; Whorwell, 1987, 1991, 2006) 
(see Chapter 3). 
 
 Imagery is a major component of hypnosis, and research has provided 
numerous examples of the physiological effects imagery has on the body. In two 
separate studies, Gemignani et al. (2000) and Gemignani, Sebastiani, Simoni, 
Santarcangelo & Ghelarducci (2006) observed changes in autonomic and EEG 
patterns induced by hypnotic imagination of aversive stimuli; Hunt et al. (2006) 
showed the positive effect of imagery in the treatment of snake phobia; and Zitman 
(1992) demonstrated the use of imagery in hypnosis as a treatment to alleviate tension 
headaches. These findings suggest the possibility that physiological functions usually 
regarded as autonomic or involuntary may be controlled by imagery, and that this link 
between the conscious intent and the autonomic function could be used in the 
treatment of illness.   
  
 There are a number of different treatments for IBS, most of which appear to 
fall into two distinct categories: those that deal with the mind and those that deal with 
the body. It appears, then, that once again the mind-body connection has become 
detached to some extent.  
 
 Compared to the various treatment options for IBS, which focus on either the 
psychological or physiological aspects of an illness, hypnotherapy is a more holistic 
treatment in that it addresses both. When one takes into account that both 
psychological and abdominal symptoms are associated with impaired health-related 
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quality of life in patients with IBS, and that hypnosis can change both psychological 
and physiological symptoms through the use of imagery, hypnotherapy then, has the 
potential of being the optimal treatment for IBS sufferers. 
 
2.8 Summary 
 
 IBS affects approximately 20% of all people at any one time and is probably 
the most common disorder encountered by both gastro-enterologists and physicians in 
primary care (Farthing, 1995; Camilleri & Choi, 1997).  The disorder typically affects 
those of working age and imposes an economic burden on the patient through 
healthcare costs and loss of income through illness (Dean et al., 2005). There is also 
the less-measurable cost of decreased quality of life (Creed et al., 2000). 
 
 The aetiology of IBS is yet unknown but most researchers agree that a subset 
of IBS sufferers have a visceral hypersensitivity of the gut (Bouchoucha et al., 1999; 
Camilleri et al., 2001).  Other possible causes that have been proposed include 
previous gastroenteritis, small intestine bacterial overgrowth, psychosocial factors 
such as life stress, a genetic contribution, and an imbalance of neurotransmitters 
(Gershon, 2004; Neal et al., 1997; Pimentel et al., 2000). 
 
 Researchers are beginning to view IBS as a multi-faceted disorder in which 
there appears to be a disturbance in the interaction between the intestines, brain, and 
autonomic nervous system, resulting in an alteration in the regulation of bowel 
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motility and/or sensory function (Smith. & Morton, 2001; Tortora & Grabowski, 
2000).  Studies  have  shown  that  emotions  such as anger, fear, pain and anxiety can 
affect colonic motility more in IBS patients than in healthy controls and, for IBS, the 
most frequent comorbid psychiatric disorders are anxiety, depression and somatoform 
disorders (Creed, 1992, 1994). 
 
 IBS continues to be a therapeutic challenge both because of its diverse 
symptomatology and because there is no effective treatment for the whole symptom 
complex - less than half of IBS patients are satisfied with the outcome of standard 
medical treatments (Schuster et al., 2000). 
 
 There are, however, some treatment options which have been successful in 
treating the various symptoms of IBS.  These treatments include pharmacological 
treatments (Baker, 2005), prebiotics (Ouwehand et al., 2005), probiotics (Gill & 
Guarner, 2003), fibre supplements (Lambert et al., 1991), bulking agents (Ashraf et 
al., 1995), peppermint oil (Kline et al., 2001), herbal medicine (Bensoussan et al., 
1998), dietary modification (Shanahan & Whorwell, 2005), cognitive-behavioural 
therapy (Boyce et al., 2003), psychotherapy (Spiller, 2005), relaxation training 
(Blanchard et al., 1993), and hypnotherapy (Gonsalkorale et al., 2002). (See Figure 
3). 
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 Increasing evidence appears to suggest that the pathology of IBS is not only 
limited to the gut, brain, or autonomic nervous system but that all three systems may 
be involved.  The links between mind and body and the influence of the mind on the 
body is becoming more widely acknowledged, therefore, any potential new therapy 
should be aiming at addressing all three (Costa et al., 2000). Successful interventions 
aimed at breaking cycles within the brain-gut axis include antidepressants, 
behavioural therapy, relaxation therapy and hypnotherapy.  
 
 The mechanisms responsible for the therapeutic success of hypnotherapy are 
largely unknown, but research has shown that it may act affecting visceral sensitivity, 
GI motor function and psychological distress.  As mentioned previously, imagery is a 
major component of hypnosis, and research has provided numerous examples of the 
physiological effects imagery has on the body. Unlike other treatment options which 
separate the mind/body connection by focusing on either the psychological or the 
physiological aspects of IBS, hypnotherapy addresses both via the brain-gut axis. 
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CHAPTER 3  HYPNOSIS AND HYPNOTHERAPY 
 
 
3.1   Imagery in Healing 
  
 The mind’s power to affect the body has long been known in medicine in the 
form of the placebo effect – the power for healing that can stem simply from a 
patient’s belief that a treatment will be effective (Macedo, Farre & Banos, 2003).  
Physicians have been using this for centuries and the power of the placebo is still 
very real – not only is it acknowledged in medical journals but scientific method now 
requires a placebo to be used in drug trials (Papakostas & Daras, 2001).  Medical 
researchers have long been puzzled by the fact that a substantial portion of symptoms 
improve when patients are given a placebo, but what is more puzzling is that they 
often regard the result as an interference or something that has to be controlled rather 
than investigating it and identifying how it could best be used in health care 
(Achterberg, 1985; Goleman & Gurin, 1995). 
 
 Research has shown that different feelings, emotions, or states of mind 
produce different and quite specific chemicals in the brain which travel via the blood 
to the cells of the immune system and attach to specific receptor sites on the outer 
membranes of those cells thereby altering their function (Pert, 1997; Pert, Ruff, 
Weber & Herkenham, 1986).  Furthermore, lymphocytes also produce their own 
specific chemicals which travel via the bloodstream to the brain, giving feedback and 
thereby completing the bidirectional communication between the brain and the 
immune system (Ader et al., 1991; Pert, 1997). 
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 Research also suggests that immune functioning may be influenced by 
imagery.  Graham (1995) cites numerous examples of the physiological effects of 
imagery including: the ability of the mnemonist Shereshevskii (1920) to increase his 
heart-rate by imagining himself running, and alter the size of his pupils and his 
cochlear reflex by imagining sights and sounds; experiments by Jacobsen (1929) and 
Shaw (1946) demonstrating the increase in muscle tension when subjects imagine 
lifting progressively heavy weights. The use of imagery can also elicit changes in 
blood sugar levels (Weller, Linder, Nuland & Kline, 1961), GI activity (Barabasz & 
Barabasz, 2006), and blister formation (Paul, 1963) as well as demonstrate the 
physiological effect of phobic imagery (Brown, 1993). 
 
 These findings suggest the possibility that physiological functions that are 
usually regarded as autonomic or involuntary may be controlled by imagery.  In other 
words, imagery may provide a link between the conscious intent and the autonomic 
function and could, in fact, be used in the treatment of illness. 
 
 In history, the healers with the most experience in dealing with the inner 
world are the shaman and the Buddhist monk.  According to Achterberg (1985), 
shamanism is the older of the two and is the most widespread method of healing with 
the imagination with archaeological evidence suggesting that imagery (the process of 
the imagination) is the product of what is now known as the “subconscious mind” 
and, inner conditions that are usually hidden to ordinary consciousness, are often 
revealed.  They used either a person’s spontaneous imagery or instructed the patient 
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in the use of deliberate imagery, sometimes working directly on both the 
psychological and the physical aspects of the disease.   
 
 The monks, on the other hand, used their imagery of a deity to achieve 
spiritual growth or enlightenment but found that by practising exercises that have 
been perfected over thousands of years, they could also exert powerful effects on the 
body’s physiology thereby healing illness (Achterberg, 1985; Graham, 1995; Samuels 
& Samuels, 1990).  
 
 Other healing systems using imagery include Ayurveda, a health system 
which is believed to be some 3,000 years old and which includes yoga as its central 
practice.  Many different forms of yoga are practised but one of these, Mantra yoga, 
is based on the inherent healing power of sound and vibration which is achieved 
through repetition of divine names or phrases (mantras).  Mantras can be used alone 
but more often than not are combined with other techniques including imagery such 
as imagining a healing light or visualising a mandala - a geometric pattern 
representing wholeness (one’s relationship to the infinite) which is used to aid in 
meditation and trance induction (Cunningham, 2000). 
 
 Healing practices in Tibetan Buddhism also incorporate visualisation such as 
one in the form of the mandala of the medicine Buddha.  As the visualisation of light 
is an important part of Tibetan medicine, light is imagined as radiating from a deity 
and flowing through a person’s body, cleansing and healing it both mentally and 
physically.  The light can be directed by the person to a diseased area of his or her 
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body, or outwards into the universe if healing others – this is still used in meditation 
and healing today (Gawler, 1984, 1997; Hay, 1991).  
 
 In Chinese medicine a similar technique is used.  Chi (vital energy or breath) 
is directed and redirected around the body in various ways through the use of 
imagery.  In Chinese martial arts, for example, a common exercise is to imagine 
breathing in light and directing it to various parts of the body (Graham, 1995). 
 
 It appears then that in the East the mind is considered a very important, if not 
the primary, consideration in the treatment of disease, whereas in the West, mind and 
body are still generally regarded as two distinct entities, the mind (and especially the 
imagination) having little, if anything, to do with health and illness.   
 
 Ironically, the Hippocratic Oath begins with a dedication to mythical figures – 
one of whom, Asclepius, was the founder of a famous healing family whose 
treatment involved the use of imagination and, more specifically, the use of dreams as 
a diagnostic and therapeutic tool.  Both Aristotle and Hippocrates were trained in this 
tradition and the staff with the snake curled around it, that Asclepius is said to have 
carried, is still the emblem used by physicians today (Achterberg, 1985; Graham, 
1995). 
 
 Freud (1856-1939) and Jung (1875-1961) recognised the mind’s role in illness 
and health and, in particular, the role of imagery – Freud in his dream analysis which 
was the core of his psychotherapy and Jung in his belief that the subconscious can 
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only be known indirectly through images and symbols encountered in dreams, 
fantasies and visions.   
  
 Others at this time who used imagery were Carl Happich, who was influenced 
by Freud and Jung and viewed the symbolic subconscious as fundamental to all 
creative production and the healing process; Walter Frederking, who encouraged 
patients to engage in fantasy during progressive relaxation and describe their 
experiences; and Roberto Assagioli, who used guided imagery, daydreams or 
symbols to assist his patients in mediating between conscious and subconscious 
material (Achterberg, 1985; Graham, 1995; Samuels, 1990). 
 
 During the late 1960s Carl and Stephanie Simonton approached the mind-
body connection from a different angle.  Their research involved looking at the 
possibilities of the influence of the mind to induce the will to live in cancer patients – 
in other words, to give the patients more control over their illness.  They 
experimented with a number of techniques and claimed to have achieved quite 
dramatic results through the use of imagery techniques (Kidman, 1983; Simonton, 
Matthews-Simonton & Creighton, 1978).   
 
 At the same time in Australia, Ainslie Meares was also experimenting with 
the effect of mind on disease (especially that of cancer) and, following this line of 
exploration, developed a form of meditation which he called Mental Ataraxis.  He 
believed that the natural restorative activities of the mind and body, including the 
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immune system, were regenerated if a state of inner stillness could be achieved 
(Meares, 1977; 1978).   
 
 Today, there are numerous health professionals both overseas and in Australia 
who have incorporated into their various treatments the use of imagery for the healing 
and prevention of a number of diseases.  One such profession is that of hypnotherapy 
where imagery – either guided or spontaneous – is often used in the treatment of both 
psychological and physiological illnesses while the patient is in a hypnotic trance.  
 
3.2   A Brief History of Hypnosis and Hypnotism 
  
 One of the oldest forms of medicine is healing by trance state (hypnosis).  
Early man believed that the gods were responsible for curing the patient and the 
‘sleep temples’ of the ancient Egyptians and Greeks, where patients were supposedly 
healed by sleep and incantations, are well-documented (Cunningham, 1980).  Sleep 
temples appeared a hundred years later in Rome and continued functioning during the 
golden period of the Roman Empire. Hippocrates and Hippocratic medicine were 
descendants of this form of medicine (Heap, 1996).  
 
 The beginnings of modern hypnosis is associated with two men: the Austrian 
physician Anton Mesmer from whom the term mesmerism came and the Scottish 
surgeon, James Braid, who was responsible for changing the term mesmerism to 
hypnotism. Their early work was tested and expanded by various practitioners such as 
James Esdaile, Ambroise Liebeault, Hippolyte-Marie Bernheim, Jean Charcot, Josef 
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Breuer, Sigmund Freud, Carl Jung, Milton Erickson, and John Grinder and Richard 
Bandler (Frank & Mooney, 2002). 
 
 Franz Anton Mesmer (1734-1815) believed that illness resulted from an 
imbalance or blockage of ‘ethereal fluid’ within the patient and that healing could be 
effected by restoring the balance and releasing the blockages by the use of magnetic 
forces. He used various techniques such as passing his hands over a patient’s body, 
‘magnetising’ inanimate objects or trees which the patients had to touch or embrace 
and, in his practice in Paris, treating people in groups gathered around large tubs 
(baquets) filled with ‘magnetised’ substances and protruding iron rods which patients 
applied to the affected parts (Heap, 1996; Manusov, 1990). The results were often 
quite dramatic, as many patients experienced hysterical reactions and then went into a 
state of drowsiness or stupor, and also surprising, as patients with numerous ailments 
appeared to have been cured.  
 
 His reputation grew throughout Europe until he was first forced to leave 
Vienna by his medical colleagues, and then was struck off the medical register in 
Paris when a commission appointed by King Louis XVI to investigate mesmerism 
failed to discover any concrete evidence of either animal magnetism or of the 
invisible fluid.  This resulted in the practice of animal magnetism being made illegal 
and, although Mesmer’s ideas continued to spread throughout Europe and North 
America, many of his followers dispensed with both the hysterical aspect of his 
treatment and the notion that an ‘ethereal fluid’ existed (Best, Neuhauser & Slavin, 
2006; Waterfield, 2002). 
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 James Braid (1795-1860), who popularised the term ‘hypnosis’ and 
introduced the technique of visual fixation and eye fatigue to induce hypnosis, first 
became interested in mesmerism in 1841. He did not believe that the trance had 
anything to do with magnetic fluids nor the theatrical performances Mesmer was 
renowned for, but that it was instead due to suggestion acting on the subject whose 
suggestibility had been increased by having the patient fixate on an object. Braid 
maintained that the trance state was a form of sleep brought about by tiring the eyes 
and possibly paralysing the optic-nerve centres, causing a condition that resembled 
sleep (Frank & Mooney, 2002; Rossi & Cheek, 1988). However, James Esdaile, a 
Scottish physician who practised in India in the 1840s and performed operations such 
as amputations on his patients using hypnosis instead of anaesthetic, did so without 
using either verbal suggestion or eye contact (Forest, 1999; Zahourek, 2001). 
 
 The concept of the subconscious was not in existence in the time of Braid or 
his contemporaries, but he appeared to sense intuitively what researchers and 
practitioners in the field of hypnosis now know today – that the trance is a 
combination of the effects and influence of the hypnotist and the subconscious 
reactions of the subject. In 1843 Braid published a book entitled Neurypnology, (also 
known as the Rationale of Nervous Sleep Considered in Relation to Animal 
Magnetism), in which he introduced the terms: hypnotism, hypnotise, and hypnotic 
(Zilboord, 1969). 
  
 Ambroise August Liebeault (1823-1904) tested Braid’s method of fixed 
attention in his clinic in Nancy, France, and is said to have been the first to 
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demonstrate the value of hypnosis as a means of cure on thousands of patients. 
Professor Hippolyte-Marie Bernheim from the University of Nancy Medical School, 
who was a famous neurologist at the time, tried to discredit Liebeault but on learning 
more about his work, Bernheim both accepted and put into practice Liebeault’s views 
(Watson, 1971; Zilboorg, 1969). 
 
 Jean Martin Charcot (1825-1893) and his colleagues in Paris used hypnosis 
for treating patients who were suffering from epilepsy and hysteria.  He still believed 
in the idea of magnetism and was convinced that only hysterical patients could be 
hypnotised and that the hypnotic state, itself, was a form of hysteria. These views, 
which put him at odds with the Bernheim school of thought, were finally exposed as 
being unscientific (Watson, 1971). Charcot did, however, suggest the existence of 
what is now known as post-traumatic stress disorder and, through his investigations, 
dispelled the idea that hysteria only occurred in women – he showed that the 
condition could manifest itself in both sexes (Goetz, 1999).  
 
 Josef Breuer (1842-1925), one of Freud’s colleagues, suggested that these 
“hysterical” symptoms were in fact suppressed emotions or memories buried within 
the subconscious and that these symptoms could be eliminated or relieved by having 
the patient talk about them while under hypnosis (Temes, 2000). 
 
 Sigmund Freud (1856-1939) visited Charcot in Paris to study neurology and 
also the clinic of Liebeault and Bernheim in Nancy where, through observing post-
hypnotic suggestions being carried out by the patients after they had been hypnotised, 
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he gained insight into the idea of there being hidden memories and emotions in the 
subconscious which determined human behaviour (Hall & Lindzey, 1970).  Freud, at 
first, used hypnosis to uncover these hidden memories and emotions but later found 
that he had more success in getting patients to talk about these forgotten memories 
without formally hypnotising them – a talking cure which he called psychoanalysis 
(Waterfield, 2002).  
  
 After Freud abandoned hypnosis, it started to lose favour in the medical world 
and was instead mainly practised by lay practitioners and stage entertainers, until a 
brief resurgence during World Wars I and II where, because of a shortage of 
psychiatrists, it was used both for direct symptom removal and the treatment of post-
traumatic stress disorder (Frank & Mooney, 2002; Zahourek, 2001).  
 
 Milton H. Erickson (1901-1980), the founding president of the American 
Society of Clinical Hypnosis, is considered as probably being the most famous 
American hypnotherapist of the second half of the 20th century. Like Freud, Erickson 
achieved various levels of hypnosis in patients, often without formally hypnotising 
them and, through giving suggestions, could bring the patients into a very light 
trance-state known as a hypnoidal state, without the usual signs of relaxation (Gorton, 
2005; Kirmayer, 1988).  
 
 He had an acute observation of non-verbal behaviour and, during the trance 
state, used language in a deliberately vague way so that his patients could choose the 
meaning that was appropriate for them. He also used the technique of pacing – i.e. to 
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use language in such a way as to tune into the patients’ world by describing what they 
must be feeling, hearing and seeing at the time – and then, through suggestions, 
gradually lead them into hypnosis (Rosen, 1984).  
 
 By using this technique, he could both induce and maintain a trance state in 
order to uncover hidden memories and emotions that may be affecting the patients’ 
health and, at the same time, help patients discover and utilise their own inner 
resources (which he believed all individuals had) in order to make the necessary 
changes in their lives (Gorton, 2005). Erickson’s approach eventually came to be the 
basis of a therapy known as Neuro-linguistic Programming (O’Connor & Seymour, 
1990). 
 
 Neuro-Linguistic Programming (NLP) began in the early 1970s as a 
collaboration between John Grinder and Richard Bandler as a result of their studying 
three well-known therapists; Fritz Perls (originator of Gestalt therapy), family 
therapist, Virginia Satir, and Milton Erickson.  The principal basis of this therapy was 
Erickson’s unique approach to hypnotherapy. In NLP (as in Freud’s psychoanalysis) 
the word “hypnosis” is not used, but NLP practitioners still communicate with their 
patients on the subconscious level, therefore having something in common with 
practitioners such as Erickson in the hypnotherapeutic field (Bandler & Grinder, 
1982; Barnett, 1990). 
 
 The number of practitioners using hypnosis has dropped considerably since 
the late nineteenth century, mainly because of the rise of therapies such as 
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psychoanalysis and behaviourism, the stage shows, and the controversy as to whether 
its application was based on a sound scientific theory.  Fortunately, interest has been 
increasing in the therapeutic use of hypnosis as its application is becoming more and 
more acceptable because of supportive evidence achieved through academic research 
(Heap, 1996; Manusov, 1990). Its potential and place in modern medicine, however, 
has yet to be realised. 
 
3.3   What is Hypnosis? 
  
 Many definitions and theories that have been put forward by both researchers 
and practitioners in the field of hypnotherapy as to what hypnosis is.  It is generally 
defined as a state of mind or altered state of consciousness (trance) which is enhanced 
through relaxation and the use of imagery. Through the use of therapeutic hypnosis, 
patients are able to be freed from limiting inhibitions and opinions that may have 
been brought about by social conditioning (Frank & Mooney, 2002; Waterfield, 
2002). The hyper-suggestibility of the individual appears to be an important 
component of the hypnotic state.  
 
 Hypnotherapists use the trance state to enable the subconscious mind to 
communicate with the conscious mind, through a heightened and focused 
concentration, and through the use of suggestion to maximise the potential, or change 
the cognition, of the patient (Francis & Houghton, 1996; Manusov, 1990).   
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 In hypnosis, the patient first achieves a meditative state and then, through the 
use of imagery and/or suggestion, works on changing a thought, idea, or behaviour.  
The difference between hypnosis and meditation is that in meditation, one simply 
stays in that meditative state (Temes, 2000).  (See table 9). 
 
 
 
     Table 9                          Comparison of Meditation and Hypnosis 
 
                                        Meditation                                             Hypnosis 
 
1. Motivation            To focus on yourself                            To focus on something 
                                                                                               outside yourself 
 
2. Goal                       No goal                                                To change your behaviour                                             
 
3. Process                   Enter an altered state and                    Enter an altered state and 
                                   then focus on yourself                         then receive suggestions 
 
(Table with kind permission of Temes, R. 2000). 
  
 The word “hypnosis” comes from the Greek word, hypnos, meaning sleep, as 
it was believed that patients were supposedly healed by sleep and incantations, both 
in the ‘sleep temples’ of the ancient Egyptians and Greeks and, a hundred years later, 
in sleep temples which existed during the Rome Empire (Cunningham, 1980; Heap, 
M., 1996).   
 
 During hypnosis, a patient may appear to be asleep because the eyes are 
closed and the person is often sitting motionless but EEG studies show that the mind 
is extremely alert – in hypnosis the brain waves have high alpha activity (indicative 
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of alertness) whereas in sleep, the brain waves show little alpha activity (Esposito, 
Nielsen & Paquette, 2004; Kawano, 1994). (See Table 10). 
 
 Williams & Gruzelier (2001) also demonstrated that high-hypnotically 
susceptible participants had greater alpha power than low-hypnotically susceptible 
participants - both preceding and during hypnosis, indicating an association of alpha 
with hypnotic susceptibility.   
 
 
    
 Table 10                           Comparison of Sleep and Hypnosis 
 
 
                     Sleep                                                                    Hypnosis 
 
Eyes closed                                                      Eyes may be closed, but can remain  
                                                                          open 
 
Body relaxed                                                    Body usually relaxed, but can be           
                                                                          instructed to become tense 
 
 No attention paid to surrounding                     No attention paid to surrounding  
 environment                                                     environment 
 
Will not hear conversations                              Will hear the therapist’s voice 
 
Usually moves around                                       Remains still; too much effort to move 
 
No ability to concentrate                                   Extremely high ability to concentrate 
 
EEG studies show brain waves of sleep           EEG studies show brain waves during 
have little alpha activity                                    hypnosis have high alpha activity,                
                                                                           indicative of alertness 
                                                                       
 
(Table with kind permission of Temes, R. 2000) 
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 EEG studies have also shown that greater theta power in the more frontal 
areas of the cortex is displayed by high-hypnotic suggestible participants during the 
baseline period and that in the periods preceding and following a hypnotic induction, 
low-susceptible participants displayed an increase in theta activity and high-
susceptible participants displayed a decrease (Graffin, Ray & Lundy, 1995). During 
the hypnotic induction itself, theta power significantly increased for both groups in 
the more posterior areas of the cortex, whereas alpha activity increased across all sites 
(De Pascalis, Ray, Tranquillo & D’Amico, 1997).  
 
 Research has also indicated that brain wave changes associated with hypnosis 
can also be triggered by other methods of deep concentration, such as the relaxation 
response - the difference being that there is higher theta activity in relaxation and 
higher alpha activity in the hypnotic experience (Jacobs & Friedman, 2004; Williams 
& Gruzelier, 2001). 
 
 A hypnotic state is a natural-occurring experience and can spontaneously 
occur many times a day. Daydreaming, not being aware of the passage of time, 
“automatic” driving, being absorbed in a book or movie, listening to music, being 
able to shut out one’s surroundings by concentrating very hard on something else, are 
all examples of a hypnotic state, and people often recognise this difference (Olness, 
1995; Roet, 1986). (See Table 11). What separates hypnotherapy from the above 
activities is how the practitioner uses the hypnotic state. 
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Table 11                        Naturally-occurring Hypnotic Experiences 
 
1. Being in a room full of people, supposedly taking part in the group yet mentally 
being far away from it. 
 
2. Being unsure whether you did something or just thought about having to do it 
(e.g. not knowing whether you either mailed a certain letter or just thought about 
mailing it). 
 
3. Being so lost in thought that you did not understand what people said to you, even 
when they were talking directly to you and even when you nodded in agreement. 
 
4. Staring off into space, actually thinking of nothing and hardly being aware of the 
passage of time. 
 
5. Driving somewhere and not remembering part of the journey or which route you 
took because you were thinking of something else. 
 
6. Being able to shut out your surroundings from your mind by concentrating very 
hard on something else. 
 
7. Being lulled into a groggy state or put to sleep by a lecture or a concert, even 
though you were not otherwise fatigued or tired. 
 
8. Wandering off in your own thoughts while doing a routine task so that you 
actually forgot you were doing the task and then found, a few minutes later, that 
you had completed it without even being aware that you were doing it. 
 
 
 
 As mentioned previously, hypnosis is an altered state of high suggestibility 
(Francis & Houghton, 1996; Manusov, 1990), and the hypnotherapist makes use of 
this quality by offering suggestions to the patient whilst under hypnosis to 
improve/change a sensation, belief, or behaviour, or some other aspect of his or her 
mental or physical functioning (Palsson, 2002).  The theory is that in the hypnotic 
state, the power of criticism (which is restricted largely to the conscious mind), is 
either fully or partially suppressed, enabling the suggestions to by-pass the conscious 
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mind and enter the subconscious mind which has little or no power of criticism - the 
patient, being unable to reject suggestions, will usually act upon them.  The effect the 
suggestions have on the patient depends on how much criticism is suppressed and 
how much rejection from the conscious mind is removed (Hartland, 1979; McGill, 
1996). 
 
  Suggestions are usually given in the form of imagery which can be any 
perception that comes through any of the senses – the patient may see, hear, smell, 
taste, or touch something while under hypnosis (McGill, 1996; Olness, 1995). The 
body is thought to be unable to discriminate between sensory images in the mind and 
reality, and interprets these images as almost real events.  While in this altered state, 
the patient’s attention is focused on, and has a heightened sensitivity to, one 
particular thing (or closely-related things) and, at the same time, a decreased 
awareness of other activities or sounds going on around (Gindes, 1976; Naparstek, 
1994). 
 
 Suggestions can also be given to the patient, post-hypnotically.  These 
suggestions are given during the trance state and take effect either immediately after 
the patient has come out of hypnosis or at a future date with little or no interference 
from the conscious mind. They are usually in the form of therapeutic suggestions to 
help patients overcome difficulties or problems but can also be used in facilitating 
future trance induction (Hartland, 1979; Roet, 1986). 
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 The success of suggestions used in hypnosis depends on the careful selection 
of the words used.  Words can make one feel better, more confident, and strengthen 
one’s will but they can also have the opposite effect and make one feel belittled or 
embarrassed. The success of the hypnotherapy sessions and of the goal the patient 
wishes to achieve is very much dependent on the words used (Cunningham & Ralph, 
1980). 
 
3.4 Misconceptions about hypnosis 
  
 There is nothing supernatural about hypnosis.  As mentioned previously (see 
Table 11), it is a natural-occurring phenomena, in tune with the natural suggestive 
behaviour of humans. Unfortunately, the use of hypnosis for entertainment – both 
stage hypnosis and in horror movies - has trivialised a serious therapeutic tool and 
promoted misconceptions which range from the belief that it is a stunt or some form 
or magic, to the notion that it is a panacea for all illnesses (mental and physical) and 
that one visit to a hypnotist is all that is needed to cure even a chronic condition 
(Olness, 1995; Van Pelt, 1979).  
  
 The most common misconceptions are: that it is dangerous; that the person is 
under the hypnotist’s control and could be hypnotised to say or do something against 
one’s will; the person loses control in hypnosis; or that the person will be 
unconscious while in the trance. 
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 3.4.1 Hypnosis is dangerous 
  
 Practitioners and researchers have become more sophisticated in their 
understanding of the hypnotic process and there is a developing conviction that the 
hypnotic state is not considered dangerous when under the guidance of a qualified 
hypnotherapist but, as in any counselling or therapeutic method, therapy carried out 
by an unqualified therapist could result in a distressful situation for the patient 
(Barber, 1994; Yapko, 1994).  
 
 One example of this is the self-reports of childhood trauma that may be 
“uncovered” during the hypnotherapy treatment sessions which, although considered 
by the patient as being real are, more often than not, “false memories” (Barber, 1995; 
Brandon, Boakes, Glaser & Green, 1998; Lyle & Johnson, 2006).  
 
 Another possible danger of hypnosis is posed by Gindes (1976) who is of the 
opinion that an unethical person could, with adequate conditioning, strong 
suggestion, and an adaptable mind, facilitate criminal acts through the use of 
hypnosis. This view, however, is hypothetical.  
 
 3.4.2 While in a hypnotic state, the person is under the hypnotist’s  
                         control and can say or do something against his/her will 
  
 The capacity to influence people to do things against their will does exist in 
certain conditions such as brainwashing, but this necessitates very powerful 
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influences (hypnosis being only one of them) which rarely surface in a therapeutic 
session involving clinical hypnotherapy (Yapko, 1995). 
 
 In clinical hypnosis the patient does not surrender his or her will - the 
relationship between the hypnotherapist and patient is one of mutual responsiveness 
rather than one of control – the hypnotherapist acts as a guide and uses 
communications skills in such a way as to make the patient more likely to accept 
suggestions.  
 
 The only control is the degree of control the patient gives the hypnotherapist. 
Through suggestions, the hypnotherapist may direct the patient’s experience under 
hypnosis, but only to the degree that the patient permits. If the suggestions conflict 
with the person’s tendencies or moral nature, he or she will either refuse to respond to 
them and/or will come out of hypnosis (Cunningham, 1980; McGill, 1996; Yapko, 
1995).   
 
 Wall, (2000) regards the mutual responsiveness between hypnotherapist and 
patient as more of a process which depends on an agreed transfer of authority – the 
patient handing over to the practitioner the responsibility for deciding how the session 
will ensue – and, since this is done voluntarily, there is no conflict of the patient’s 
standards. The successful outcome of the session, however, still depends on the 
relationship the patient has with the hypnotherapist. 
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 Roet (1986), Borysenko & Borysenko, (1994) and Naparstek (1994), 
however, are of the opinion that all hypnosis is self-hypnosis and, even though the 
patient is being guided by the practitioner, he or she is actually being instructed on 
how to achieve an altered state and may subsequently be able to do it either alone or 
with the help of a self-hypnosis CD.  In other words, the patient is both the subject 
and the hypnotist or, as Borysenko & Borysenko (1994) view it, the hypnotist who 
controls the patient is within the patient, himself. 
 
3.4.3 People lose control in hypnosis and will be unconscious 
  
 This misconception has unfortunately come about because of stage shows 
involving hypnosis where people appear to be under the control of the hypnotist. 
Most jokes played on people during these shows are similar and the volunteers have 
quite a good idea of what will happen. So, by volunteering, the person is actually 
giving permission for what is about to take place - an agreed transfer of authority - 
the person handing over to the hypnotist the responsibility for deciding what will 
ensue (Shinkarovsky, 1996; Wall, 2000). 
 
 A person under hypnosis remains in full control.  He/she is aware of what is 
happening, is able to talk (Frank & Mooney, 2002; Mongan, 2005) and, as mentioned 
previously (Cunningham, 1980; McGill, 1996; Yapko, 1995), is quite able to refuse 
to respond to any conflicting or amoral suggestions, will often come out of hypnosis, 
and can get up and walk away.  
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 The idea that the person is unconscious during hypnosis is an erroneous one. 
Although in a trance state, the person is aware of what is happening around them but 
may choose not to focus on it (Olness, 1995).  In the HypnoBirthing programme 
(Mongan, 2005) for example, where expectant mothers learn self-hypnosis, they are 
taught to narrow their field of attention and focus on internal images during the 
birthing process so as not to be distracted by what might be going on around them or 
by other people in the room. However, if their partner, the midwife or obstetrician 
instruct them to do something, they will respond by either remaining under hypnosis 
or by bringing themselves out, doing what is necessary, and then often putting 
themselves back under hypnosis again. 
 
3.4.4 Only a few people can undergo hypnosis 
  
 Research suggests that about 60% of the population can be hypnotised (Frank 
& Mooney, 2002; Waterfield, 2002) and most people naturally enter hypnosis 
countless times every day without realising it (see Table11). In general, those with 
normal learning skills can learn self-hypnosis - some have a greater ability to focus 
their attention than others but this ability can be achieved through practice (Olness, 
1995). Research has also shown that subjects who were considered to have a low 
susceptibility for hypnosis could be trained to achieve a much higher hypnotic 
responsivity (Gfeller et al., 1987; Spanos et al., 1986).  
 
 Some people are more difficult to put under hypnosis than others mainly 
because of their misconceptions and fears about hypnosis (which the hypnotherapist 
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should recognise and resolve in the first hypnosis session) and also because of their 
personality. The practitioner needs to take into account various facets of the patient’s 
personality in order to choose the appropriate hypnotic induction (Gindes, 1976; 
Yapko, 1995). 
 
 Hypnosis then, may be regarded as the means of inducing a subconsciously 
responsive state of mind where, through suggestions given by the hypnotherapist, 
there is a narrowing of attention (or focus) on a small range of stimuli, and sensory 
perceptions appear to be more enhanced (McGill, 1996). Misconceptions about 
hypnosis are gradually being dispelled and hypnotherapy has now become more 
widely accepted in various areas of clinical medicine such as psychology, psychiatry, 
dentistry and social work, and shown to be successful in the treatment of pain control, 
habit disorders and many other medical problems (Burrows & Stanley, 1995; Lynn, 
Kirsch & Rhue, 1996).   
 
 
3.5      Clinical Studies in Hypnotherapy 
 
 Research on hypnotherapy moved slowly until World War II when it was 
found to alleviate pain and help in the treatment of post-traumatic stress disorder.  
Since then, more scientific investigation has been undertaken with the result that 
more health-care professionals now regard hypnosis as a legitimate form of treatment 
(Shinkarovsky, 1996; Zahourek, 2001).  
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 Unfortunately, hypnosis is still sometimes misunderstood and undervalued. 
Although mostly known because of stage shows and as a treatment for giving up 
smoking and losing weight, hypnosis has cured or alleviated a wide range of illnesses 
and ailments such as tension headaches and migraines (Zitman, van Dyck, 
Spinhoven, Corrie & Linssen, 1992; Matthews & Flatt, 1999), dermatological 
disorders (Rucklidge & Saunders, 1999; Shenefelt, 2000; Willemson, Vanderlinden, 
Deconinck & Roseeuw, 2006) and gynaecological and obstetrical problems (Simon & 
Schwartz, 1999; Younus, Simpson, Collins & Wang, 2003).  
 
 It has primarily shown, however, to be effective in the alleviation of pain, 
addressing stress-related and psychological problems, boosting the immune system 
and, more recently, as a treatment option for GI problems (Handel, 2000; Waterfield, 
2002; Gonsalkorale et al., 2003). 
 
3.5.1 Hypnosis in the treatment of pain 
  
 One of the widest applications of hypnosis is that of pain control – the pain 
response referring to both physical (somatogenic) and psychological variables such as 
anxiety and expectation (Manusov, 1990) – and a number of studies has been 
undertaken to examine changes in pain perception in hypnotised subjects.   
  
 Arendt-Nielsen, Zachariae & Bjerring (1990) induced both analgesia and 
hyperaesthesia in eight highly hypnotisable subjects in the same experimental trial in 
order to study aspects of hypnotic-suggested analgesia. Brief and well-defined argon 
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laser pulses were used to elicit pain after sensory and pain thresholds to laser 
stimulation had been determined, and the laser-evoked brain potentials had been 
measured in three conditions: the waking state, with suggestion of hyperaesthesia, 
and with suggestion of analgesia. They found that pain thresholds were reduced 
during induced hyperaesthesia and increased during analgesia, and that the amplitude 
of the evoked brain potentials increased during hyperaesthesia and decreased during 
analgesia. Their results showed that both analgesia and hyperaesthesia could be 
hypnotically induced.  
  
 In another study by Sharav & Tal (2004), hypnotic analgesia was also induced 
and two different types of hypnotic suggestion - generalised relaxation and focused 
analgesia - were examined.   
 
 Hypnotic susceptibility was tested and the 15 subjects were assigned to low- 
and high-susceptibility groups – eight subjects and seven subjects respectively. Each 
subject was tested twice, once under generalised relaxation and once under focused 
analgesia. Both groups were initially given suggestions of physical relaxation, 
relaxing guided imagery, and a feeling of tranquillity and restfulness before being 
given more specific suggestions of either feeling relaxed at the time of the stimuli 
(generalised relaxation) or suggestions creating focused analgesia.  Painful electrical 
stimuli were randomly delivered in five ascending intensities and rated on visual 
analogue scales by the participants.   
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 The researchers found that both focused analgesia and generalised relaxation 
decreased pain intensity significantly but that as stimulus intensity became higher, 
pain reduction was enhanced under focused analgesia, while a constant reduction 
occurred under generalised relaxation. Pain reduction was also found to be 
significantly higher in the highly-hypnotisable subjects. 
 
3.5.1.1  Surgery and Invasive Medical Procedures 
  
 Hypnosis can help patients overcome pre-operative anxiety and fear (Saadat et 
al., 2006); can be a means of managing adverse surgical side-effects such as pain, 
nausea and distress (Faymonville et al., 1997); has been shown to accelerate post-
surgical wound healing (Ginandes, Brooke, Sando, Jones & Aker, 2003); and is very 
often considered as an adjunctive therapy to help ameliorate pain during invasive 
medical procedures (Astin, 2004). 
 
 Research supports the use of hypnosis as an adjunctive approach to surgery 
(hypnosedation) where patients receive standard surgical and anaesthesia procedures 
as well as hypnosis (Lang et al., 2000; Astin, 2004). Hypnosis is usually established 
by an induction where the patients are given suggestions of physical relaxation 
followed by guided imagery which focuses on creating a feeling of peacefulness. This 
both distracts the patient from aversive stimuli and makes them more open to 
therapeutic suggestions such as reduced pain or stress (Montgomery, David, Winkel, 
Silverstein & Bovbjerg, 2002; Sharav & Tal, 2004). 
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 In 1995, after successfully performing more than 1,000 procedures under 
hypnosedation, Meurisse et al. (1999) decided to apply this procedure in endocrine 
cervical surgery.  Thirty-one subjects agreed to hypnosedation for hyper-
parathyroidism and the hypnotic state was induced by eye-fixation and progressive 
muscle relaxation. Suggestions of well-being were given by the anaesthetist with the 
exact words of the induction and suggestions varying according to patient behaviour.   
 
 During hypnosis, the patients appeared mobile and relaxed and experienced 
increased pain thresholds and intense subjective well-being.  Hypnosis was induced 
within 10 minutes and, at the completion of the procedure, a fully conscious state was 
obtained in several seconds.  All patients reported altered perception of time during 
the operation (the length of the operation appeared to be shorter) and all had pleasant 
experiences involving recollections of past events. None regretted choosing hypnosis 
for the operation and would request the same again, if necessary.  No conversion to 
general anaesthesia was needed and no complications were observed.  
 
 The researchers found that hypnosedation provided excellent perioperative 
pain and anxiety relief, reduced the incidence of side-effects associated with general 
anaesthesia and allowed rapid post-operative recovery. 
  
 Hypnosis has also been found to be beneficial for children both in reducing 
distress in invasive medical procedures, and lessening pain and anxiety during 
examinations.  In a study by Butler, Symons, Henderson, Shortliffe & Spiegel (2005) 
children undergoing voiding cystourethrography for bladder abnormalities such as 
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urinary tract infections and vesicoureteral reflux were randomised to receive either 
hypnosis (21 children) or routine care (23 children). The children in the hypnosis 
group were given a one-hour session in self-hypnosis and visual imagery by a trained 
therapist and then instructed to practise (with their parents) several times daily in 
preparation for the procedure.  The children in the routine care group participated in a 
programme which included relaxation and breathing techniques as well as 
demonstration of the procedure on dolls.   
 
 Results of the study indicated hypnosis to be more beneficial than routine care 
in that, compared to the routine care group, children in the hypnosis group were 
reported as being less traumatised by this procedure than by the previous one; their 
distress levels were significantly lower; medical staff reported less difficulty in 
conducting the procedure; and the total procedural time was significantly shorter by 
almost 14 minutes. 
 
 After observing children in the emergency department of a Mexican hospital 
having forearm fractures set without any form of sedation or anaesthesia (because of 
lack of equipment and personnel), Iserson (1999) suggested trying hypnosis prior to 
the procedure. Over a five-week period, four children presented with forearm 
fractures while the author was on duty and were hypnotised prior to the manipulation.  
The children were asked to concentrate on their toes and imagine sensations of 
heaviness or warmth flowing up the body.  They were then given suggestions of 
relaxation and sleep and told to travel in their mind to a pleasant place followed by 
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the suggestion that they would not remember the process or the pain during the 
fracture reduction. 
 
 All four children appeared to be awake at the height of the fracture 
manipulation and seemed to experience pain and three of the four appeared to fall 
asleep immediately afterwards. Two hours post reduction, the children were 
questioned about their memory of the procedure and whether they had experienced 
pain.  All of the children appeared confused about what had happened and none of 
them remembered the procedure or the cast being applied.  They all denied having 
any pain. 
 
3.5.1.2  Dental Surgery 
  
 The main advantages of using hypnosis in dental surgery are to lessen anxiety, 
pain and discomfort, minimise blood loss, and achieve rapid healing. An added 
advantage is that the facial muscles can be relaxed and held in position for long 
periods without pain or fatigue (Ambrose & Newbold, 1980; Yapko, 1995). 
 
 In a controlled trial using hypnosis as an adjunct treatment for the surgical 
removal of third mandibular molars, Enqvist & Fischer (1997) had the 33 patients in 
the experimental group listen to an audiotape containing a hypnotic relaxation 
induction followed by suggestions of healing and recovery and ways of achieving 
control over stress and pain. The control group of 36 patients received no hypnotic 
intervention.  Their findings showed that preoperative anxiety remained at baseline 
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level in the experimental group but increased significantly in the control group. They 
also found that postoperative consumption of analgesics was significantly reduced in 
the patients using hypnosis and that there was also reduced nausea and vomiting.   
 
 Ghoneim, Block, Sarasin, Davis & Marchman (2000) also carried out a study 
on the use of hypnosis in third molar surgery in which the experimental group of 24 
patients used a similar self-hypnosis tape, supplied by Enqvist, which included 
suggestions on enhancement of perioperative well-being such as control of bleeding 
and healing and alleviation of pain. Once again, the control group (22 participants) 
did not receive hypnotic intervention. As in the study by Enqvist & Fischer, Ghoneim 
et al. found that anxiety in the experimental group was reduced but they also found an 
increase in the incidence of postoperative vomiting and no improvement in the 
severity of postoperative pain or reduction in postoperative consumption of 
analgesics.   
  
 There were two limitations to this study cited by the researchers. The first was 
that whereas Enqvist, a clinical hypnotherapist, personally introduced hypnosis to the 
patients before presenting them with the tape, Ghoneim et al., (2000) because of a 
busy hospital setting, considered it impractical to introduce hypnosis separately to 
each patient and induced self-hypnosis by means of the audiotape alone.  Secondly, 
Ghoneim et al. (2000) could not ascertain whether hypnosis had actually occurred in 
each patient as there had been no observer present to recognise a trance state when 
the patients listened to the tape.   
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 Another possible flaw in the study is that on the tape the patients were also 
given suggestions that they would feel hunger, thirst, and a desire to eat and drink 
after surgery - the researchers assumed that these sensations would be incompatible to 
vomiting.  However, there is a possibility that no specific time was given as to when 
these suggestions would take effect, with the result that the patients ate and drank too 
soon after surgery when they had not fully recovered from sedation and anaesthesia. 
 
3.5.1.3  Burns 
  
 As well as suffering anxiety and disfigurement, patients with burn injuries 
often have to endure intense pain during burn care procedures which typically include 
washing wound sites, debridement, topical application of medication and dressing 
changes (Frenay et al., 2001; Wright & Drummond, 2000). As medication is not 
always efficient in diminishing the discomfort of burn dressing changes (Perry & 
Heidrich, 1982), and burn patients can also develop some degree of tolerance to 
analgesic drugs (Patterson, Everett, Burns & Marvin, 1992), hypnosis has been 
trialled as a viable adjunct treatment for burn pain. 
 
 Frenay et al. (2001) conducted a trial designed to compare hypnosis and 
stress-reducing strategies (SRS) for anxiety and pain management during burn care 
procedures. The 11 patients in the hypnosis group were asked to choose a pleasant 
life experience to recall during the dressing change and a hypnotic state was then 
induced using eye fixation and muscle relaxation. Positive suggestions to transform 
sensations and to dissociate the patient from his or her pain were then given.  The 
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word ‘hypnosis’ was not used in order to avoid any positive or negative bias based on 
preconceived notions the patient may have – instead, the hypnotic state was explained 
as being a state in which patients could distract themselves by thinking about the 
pleasant life experience they had chosen.  The 15 patients in the SRS group were 
given instruction in deep breathing and relaxation by the burn unit psychologist who 
also focused the patients on a pleasant memory as well as using any coping strategies 
the patients were naturally using. 
 
 The results showed that in the hypnosis group, anxiety levels were 
significantly lower during wound care than in the SRS group, and that pain 
perception before, during and after wound care was also consistently lower in the 
hypnosis group - although these results did not reach statistical significance. 
 
 In their studies, both Patterson et al., (1992) and Wright & Drummond (2000) 
used a technique called “rapid induction analgesia’ (RIA) for the treatment of pain in 
burn care. This technique includes suggestions which aim to reduce tension, anxiety 
and sensations of pain. In the study by Patterson et al. (1992), 87 participants were 
randomly assigned to three groups with both patients and nursing staff remaining 
blind to group assignment throughout the study.   
 
 Group one participants underwent their first dressing change (Day 1) with 
pain medication only and then before their second dressing change (Day 2), they 
received the hypnotic intervention using the RIA procedure.  The subjects were asked 
to imagine walking down a staircase with 20 steps while the psychologist gave them 
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indirect suggestions of increasing comfort and relaxation. When they had reached the 
bottom of the staircase, they were given further suggestions which were designed to 
elicit confusion and amnesia.  This was followed by a post-hypnotic suggestion that 
when either the psychologist or the nurse touched the patients’ shoulder during the 
dressing change, they would experience a deep level of comfort. 
 
 Group two participants also underwent their first dressing change (Day 1) 
with pain medication only and, before their second dressing change (Day 2), were 
told they would undergo a hypnotic intervention but instead, were given information 
regarding the emotional effects of burn injuries and the nature of burn pain. They 
were also informed that their pain (described as ‘sensation’) was a positive sign of 
healing.  Towards the end of the session the subjects were told that, prior to the 
dressing change, it would be useful for them to close their eyes, count to 20 and 
imagine themselves in a relaxing place.  They were also told that the nurse would 
prompt them to begin ‘hypnosis’ by giving some instructions followed by a touch on 
the shoulder.  None of the subjects questioned whether they had been actually 
hypnotised. The control group (group three), received medication only for both Day 1 
and Day 2. 
  
 The results indicated that patients in the hypnosis group (group one) gave 
significantly lower pain ratings than patients in both the control group (group three) 
and participants of group two who had equivalent time and attention from the burn 
psychologist and believed they had undergone hypnosis. Staff ratings were consistent 
with those of the patients. 
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 Wright (2000) investigated sensory and affective pain ratings before, during 
and after dressing changes in patients who received RIA and whether RIA had a 
cumulative effect on pain ratings and anticipatory anxiety over two consecutive 
sessions. They also evaluated the effect of RIA on analgesic intake.   
 
 The 30 participants were randomly assigned to two groups – the experimental 
group and the control group.  No changes were made to normal pain-relieving 
medication during the study and all patients were free to request additional analgesic 
medication.  Staff were asked to leave the room while the participants in the 
experimental group were administered a 15-minute hypnotic induction (RIA) 
followed by suggestions for progressive deepening of comfort and relaxation as well 
as suggestions for analgesia. They were told to imagine a staircase and when they had 
reached to the count of 20 (indicating the bottom of the staircase), they were 
requested to enjoy their state of relaxation and comfort, with their eyes remaining 
closed if they wished.  
 
 Throughout the burn care session, the investigator repeated the suggestions 
for analgesia and relaxation.  Patients remained aware of the activities undertaken but 
were observed to be in a calm, relaxed and comfortable state.  Dressing changes 
proceeded as usual for patients in the control group. 
 
 The major finding of the study was that the experimental group experienced 
decreased pain perception and anticipatory anxiety during and after burn care 
compared to the control group.  In addition, analgesic requirements in the 
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experimental group were also decreased, suggesting that the therapeutic effects of 
RIA persisted for at least several hours after treatment. The study appears to confirm 
RIA as a viable adjunct to medication for pain control during burn care. 
 
3.5.1.4  Childbirth 
  
 The management of labour pain is one of the main goals of maternity care but 
the two models of care - the medical model, whose focus is mainly the elimination of 
pain; and the midwifery model, where the emphasis is largely on the prevention of 
suffering – have very different goals.   
 
 The medical model involves pain (and other) medications, interventions and 
complex technology which places the burden of pain control solely on medical 
professionals. This results in the woman’s role becomings one of passive compliance, 
dependency and powerlessness because she views the control and management of 
pain relief (as well as other aspects of labour and birth) to be held by others.   
 
 The midwifery model, on the other hand, takes into account the psychological 
elements – such as the feeling of helplessness, distress, and loss of control - as well as 
the management of labour pain (Simkin & Bolding, 2004). 
 
 The latter model has been addressed in programmes such as HypnoBirthing in 
which the mother and her partner learn about the physiology of the birth process, the 
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‘fear-tension-pain’ syndrome and the fight-or-flight response, both of which usually 
accompany labour.  
 
 They then learn how to break this response, feel less anxious and more in 
control of the birthing process, and how to achieve a reduction in pain through 
hypnotic anaesthesia, breathing techniques and visualisation (Mongan, 2005).  As 
well as facilitating autonomy and giving the patient a sense of control, hypnosis has 
also been shown to reduce the need for analgesia requirements during labour which 
could result in minimising the need for epidural analgesia (Cyna, McAuliffe & 
Andrew, 2004; Harmon, Hynan & Tyre, 1990). 
 
 This is reflected in a study by Jensen & Karoly (1991) where their findings 
showed that the patients’ belief in personal control over pain and the strategies they 
used to manage pain had a direct impact on well-being and medication use. 
 
 Harmon et al. (1990) conducted a trial to ascertain the benefits of hypnotic 
analgesia as an adjunct to childbirth education in 60 nulliparous women. Subjects 
were divided into two groups with half the subjects in each group receiving a 
hypnotic induction at the beginning of each session and the other half receiving 
relaxation and breathing exercises typically used in childbirth education. The results 
showed that hypnosis resulted in shorter Stage 1 labours, less medication, more 
spontaneous deliveries and higher Apgar scores. 
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 In an Australian study by Cyna, Andrew & McAuliffe (2005), 77 women, 
who had undergone antenatal self-hypnosis preparation for labour analgesia at 37 
weeks’ gestation between August 2002 and August 2004, were compared to women 
matched for parity and gestation who had given birth at the Women’s and Children’s 
hospital in Adelaide in 2003 but had received no hypnosis preparation.  The 
researchers found that women who had used hypnosis had fewer epidurals than 
controls and required less augmentation with oxytocics - these data being consistent 
with those of a previous systematic review carried out by the same researchers in 
2004.  
 
 While more research is needed to understand in more detail the effects of 
hypnosis on labouring women and their infants, it has been shown to be a powerful 
intervention for women to use during childbirth with both positive physical and 
psychological maternal outcomes.  
 
 Chronic pain can lead to emotions such as anxiety, fear, frustration, 
depression, hopelessness and desperation in patients and can reduce their quality of 
life, especially if there appears to be no logical reason for its existence (Roet, 1986). 
Hypnosis can be of benefit in many cases by using distraction (where the patient 
recalls a pleasant place or event while in a trance thereby replacing pain from top 
priority); removing negative emotions that are connected with the pain and which 
may play a role in causing or maintaining the pain; and producing analgesia in the 
affected part (Mongan, 2005; Sharav & Tal 2004).   
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3.5.2 Stress-related/psychological problems 
 
3.5.2.1    Phobias/Anxiety 
  
 A phobia is an irrational, persistent fear of some specific object or 
circumstance (Brown, 1993). Among the common simple phobias are animal phobias 
(e.g. snakes, spiders, dogs), fear of heights or flying, fear of painful medical 
procedures and fear of lifts.  
 
 The most prevalent however, is agoraphobia, the fear of open, public places 
such as shops, stores and restaurants, or enclosed or confined places such as bridges, 
tunnels and public transport. The main feature of agoraphobia is anxiety about being 
far away from home (or from a ‘safe’ person) for fear of having panic attacks, and 
people with this phobia will eventually begin to avoid these anxiety-provoking 
situations, thereby restricting their activities and lifestyle, which in turn may lead to 
depression because of their feeling of lack of control over the condition (Bourne, 
2000).  
  
 The most severe anxiety reactions are panic attacks in which the person 
experiences a feeling of apprehension or terror together with physiological symptoms 
such as dyspnoea, perspiring, trembling, dizziness, nausea, rapid pulse, chest pain or 
palpitations (Anderson et al., 1998).  
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 In a case study by Harris (1991), hypnosis was used to eliminate panic attacks 
and agoraphobia in a 34 year-old woman. The patient, who was taught desensitising 
techniques and self-hypnosis, was able to obtained long-term relief from her 
symptoms, thus providing evidence for the efficacy of hypnosis in eliminating panic 
attacks. 
 
 Social phobia is one of the more common anxiety disorders where there is an 
irrational fear of situations that expose the person to public observation and possible 
embarrassment – the most common one being fear public-speaking or performing in 
public. Fear of blushing, using public toilets and taking examinations are also 
common social phobias all of which can eventually cause the person to avoid the 
situation altogether (Rice, 1992).  
 
 Studies show social phobia to be frequently comorbid with major depression.  
Stein et al. (2001) carried out a prospective, longitudinal epidemiological study of 
adolescents and young adults (aged 14-24 years) with social phobia for a period of 
34-50 months. A total of 3,021 participants were available at baseline with 2,548 
participants at the second follow-up. Results indicated that social phobia during 
adolescence or young adulthood was an important predictor of more serious 
depression in adulthood, with an increased risk of subsequent depressive episodes and 
an amplified risk of suicide. 
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3.5.2.2    Managing specific fears with desensitisation 
  
 Anxiety can affect a person on a physiological, behavioural, and psycho-
logical level. Therefore, in order for recovery to take place, a programme must be set 
in place which addresses all three levels - reducing physiological reactivity, 
eliminating avoidance behaviour and changing subjective interpretations or “self-
talk” (Bourne, 2000). This can be achieved through imagery desensitisation, a process 
where anxiety can be replaced by feelings of relaxation and calmness while 
visualising a phobic situation in a   hypnotic trance.   
 
 As anxiety and relaxation are incompatible responses, the goal of 
desensitisation is to learn to remain in the phobic situation and be relaxed at the same 
time.  The person first constructs a hierarchy which begins, through a sequence of 
steps, from a mild instance of the phobia to the most challenging scene relating to the 
phobia. Each step of the hierarchy is visualised repeatedly while under hypnosis until 
the person can view the phobic situation in a relaxed state. If the person begins to feel 
anxious at any time, he or she leaves the phobic situation, imagines being in a 
peaceful scene until the anxiety has subsided, and then returns to the phobic situation 
again. Being in control and allowing the situation or object to approach at a steady 
rate while in a relaxed state helps desensitise the fear (Bourne, 2000; Roet, 1986).   
 
 Hypnosis is an alternative to drug therapy in the treatment of performance 
anxiety. The therapist can either help undo a conditioned physiological response such 
as hyperventilation or nausea, or guide the patient through a desensitisation exercise 
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or mental rehearsal of the upcoming event whether it be public speaking, a sporting 
event or exams (Cunningham, 1980; Olness, 1995).  Gruzelier, Smith, Nagy & 
Henderson (2001) and Naito et al. (2003) found hypnosis to have both beneficial 
effects on mood and sizeable influences on cell-mediated immunity in their studies on 
the use of self-hypnosis in stress-reduction training before exams. 
 
 3.5.3 Stress and the Immune System 
  
 The adverse effect of emotions on physical health is not a new idea. 
Hippocrates taught his students to consider their patients’ life circumstances and 
emotions as part of the treatment (Lyons & Petrucelli, 1987) and the 2nd century 
Greek physician, Galen, noted that melancholic women were more prone to 
malignancies of the breast than cheerful women (Locke & Colligan, 1986). This in 
turn, has led to the recognition by modern-day health practitioners of the comorbidity 
of psychological and physical disorders and the belief that negative emotional states 
are associated with unhealthy patterns of physiological functioning such as increasing 
the susceptibility to infectious agents and influencing the severity of infectious 
disease (Glaser & Kiecolt-Glaser, 2005; Salovey, Detweiler, Stewart & Rothman, 
2000).  
 
 Researchers in the field of psychoneuroimmunology are providing evidence 
about the ways in which negative emotions generated by stressors can be translated 
into physiological changes (Webster et al., 2002; Padgett & Glaser, 2003).  There is 
now compelling evidence that: ligands (peptide hormones, peptide neurotransmitters 
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and cytokines) and their receptors form a bi-directional, biochemical information 
circuit between, and within, the immune and neuroendocrine systems; the 
hypothalamic-pituitary-adrenal axis and the autonomic nervous system provide the 
key pathways for immune system dysregulation; and that stressors can activate both 
the hypothalamic-pituitary-adrenal axis and the sympathetic-adrenal-medullary axis, 
releasing both the pituitary and adrenal hormones – commonly known as “stress” 
hormones (Blalock, 1994; Pert, 1997; Glaser & Kiecolt-Glaser, 2005).  
 
 Significant alteration of the immune response as measured by B-cells and 
helper T-cells has also been demonstrated in highly hypnotisable subjects exposed to 
hypnosis (Ruzyla-Smith et al., in Evans & Burrows 1998). 
 
 Hypnosis is commonly used in the treatment of stress disorders as it is thought 
to be able to strengthen the body’s immunological functions and assist in fighting off 
disease (Rossi, 1993; Wickramasekera, 1999).  Research has been carried out on 
medical students prior to exams to assess the influence of hypnosis on cellular 
immune function during a stressful event and to examine the effect of self-hypnosis 
on stress reduction before exams. 
 
 In a study by Glaser & Kiecolt-Glaser (2001), 42 medical students were 
randomly assigned to one of three protocols during the exam period: hypnosis, social 
contact, or no intervention. The experimental group receiving hypnotic intervention 
began their sessions with a series of deepening exercises, plus imagery exercises and 
suggestions of greater relaxation during the day and enhanced comprehension and 
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retention of academic material.  The sessions lasted 25-30 minutes and, prior to the 
sessions, students were asked to rate how they felt from 0 (extremely tense and 
anxious) to 10 (extremely calm and relaxed) and how often they had practised their 
self-hypnosis. Blood samples were also taken: the first at the beginning of the 
semester and the second three days before the first major academic exam of the 
semester.   
 
 The researchers found that, although all three groups started at comparable 
levels at the lower stress baseline, control participants’ lymphocyte proliferation 
decreased prior to the exams and, in contrast, the proliferative responses of hypnotic 
participants remained relatively stable or increased slightly. The data from this study 
provide encouraging evidence that hypnosis may reduce the immunological 
dysregulation associated with acute stressors. 
 
 Gruzelier et al. (2001) carried out a similar study on 28 pre-clinical medical 
students (17 males and 11 females).  As a condition for participation, students agreed 
to practise self-hypnosis three times a week and were monitored with a diary, so that 
frequency of practice was controlled.  Total white blood cell and lymphocyte counts 
were assessed. Blood samples were taken four weeks prior to the exams (baseline 
sample) and again during the exam period. Participants who were assigned to the 
hypnosis group attended a group hypnosis session three weeks prior to exams and 
were given an audiotape of the same hypnotic induction to practise at home for the 
remaining three weeks.  
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 The researchers’ findings showed that hypnosis moderated aspects of immune 
down-regulation induced by the stress of examinations. The self-hypnosis training 
was effective in buffering the decline of natural killer cells (which have antiviral and 
anti-tumour functions) and increased the number of helper cells which positively 
correlated to increased feelings of calmness.  Energy levels were also higher in the 
hypnosis group and the energy level was positively correlated with natural killer cell 
count. 
 
 Naito et al. (2003) also carried out a study using self-hypnosis as stress-
reduction training prior to exams and achieved similar results.  Forty-eight 
participants were recruited and randomly assigned to three groups – self-hypnosis, 
Johrei (a Japanese philosophy and healing method) or a mock neurofeedback 
relaxation control, and were instructed to attend weekly training sessions for a period 
of one month before their exams. The hypnosis group was taught a relaxation 
induction combined with immune imagery together with breathing control for acute 
anxiety and the Interrupt Distraction Procedure for worries and belief change to be 
used when appropriate.  Participants were provided with a taped relaxation induction 
that included imagery description and were asked to practise the self-hypnosis three 
times a day for the first fortnight and once a day after that. Absolute number and 
percentages of lymphocytes, natural killer cells and natural killer cell cytotoxic 
activity were measured by means of venous blood samples taken at baseline, post-
training and during the exam period. Results were in keeping with the beneficial 
effects of hypnosis and also suggested Johrei as being a possible procedure for stress 
reduction. 
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 Hypnotic-guided imagery has also been shown to be effective on immune 
function and psychological parameters in patients during stressful illnesses.  In a 
study by Bakke, Purtzer & Newton (2002), 25 patients being treated for Stage I or 
Stage II breast cancer undertook an eight-week imagery-training programme in which 
psychological and immunological data were obtained at baseline, after an 8-week 
intervention, and at a 3-month follow-up.   
 
 Subjects received eight one-hour individual imagery sessions in hypnotic 
guided imagery: in the first session, current ideas about the negative influence of 
stress and depression on the immune system were discussed; in the first and second 
sessions a standard progressive relaxation was taught and subjects were encouraged 
to develop specific images of their immune system being effective; and in the 
subsequent six sessions the subjects focused on making the images as vivid as 
possible by focusing on the details of their activated killer cells and on how exactly 
they removed the cancer cells.  
 
 The results showed a significant increase in improvement of depression and 
an increase in absolute number of natural killer cells during the 8-week programme, 
however these changes were not retained after treatment. 
 
 In a pilot study by Fox et al. (1999), the researchers investigated the effect of 
hypnotherapy on a variety of immune parameters such as natural killer cells, 
lymphocyte counts, cortisol levels and specific cellular cytotoxicity in response to the 
herpes simplex virus (HSV) on twenty subjects recruited from a clinic for the 
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treatment of frequently recurrent genital HSV-2. Psychological and immunological 
parameters were measured 6 weeks prior to, and 6 weeks after sessions of 
hypnotherapy during which patients kept a diary of symptoms. 
 
 Following hypnotherapy, subjects who showed improvement demonstrated 
significant rises in natural killer cell counts, HSV specific lymphokine-activated 
killer activity, and reduced levels of anxiety when compared to non-improvers and 
there was also a significant increase in CD3 and CD8 lymphocytes in all subjects. 
The study showed hypnotherapy as having the potential to produce significant 
immune changes, suggesting that it could have wider application as an investigative 
tool. 
 
3.5.4 Gastrointestinal disorders 
  
 Numerous early studies have reported on gastric function during hypnosis and 
the therapeutic effects of hypnosis on GI disorders (Hall, Herb, Brady & Brooks, 
1967; Kehoe, M., 1970) but it wasn’t until the first controlled trial in the field of 
gastroenterology by Whorwell et al. (1984) - where results showed a significant 
improvement in both symptoms and well-being in the patients receiving hypnosis - 
that more interest in hypnosis as a treatment option was generated.  Since then, more 
controlled trials have been carried out in this area with encouraging results. 
 
 Gastrointestinal disorders such as nausea and vomiting problems related to 
chemotherapy (Marchioro et al., 2000), after medication (Desdames, Marchand & 
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Moulin, 2002) and during pregnancy (Buckwater & Simpson, 2002) have been shown 
to improve with hypnosis, and Whorwell et al. (1992) demonstrated that hypnosis 
was also effective in suppressing or increasing gastric muscle activity depending on 
the patients’ emotions.    
 
 A study by Calvert, Houghton, Cooper, Morris & Whorwell (2002) 
successfully used hypnotherapy for the treatment of functional dyspepsia. The 126 
participants were randomly assigned to hypnotherapy, supportive therapy plus 
placebo medication, or medical treatment for a period of sixteen weeks.   
 
 The results indicated that in the hypnotherapy group both short-term and long-
term symptom scores improved more than in the other two groups, there was an 
improvement in quality of life, and no participant in the hypnotherapy group 
commenced medication during follow-up compared to 82% of participants in the 
supportive therapy group and 90% in the medical treatment group.  
 
 Hypnosis has also been trialled as a treatment option for children with 
functional abdominal pain (Anbar, 2001). Five children (aged from 8 to 16) with a 
primary diagnosis of functional abdominal pain (recurrent abdominal pain in the 
absence of an identifiable physiological cause) and whose medical therapy provided 
no significant relief, were taught self-hypnosis. The imagery used for hypnosis was 
developed with input from each patient and instruction in self-hypnosis included 
imagining a relaxing place of the patients’ choice, progressive relaxation, choosing an 
anchor (a post-hypnotic sign as a reminder of how to relax) and pain control.  
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 Following the first session of hypnotherapy, the abdominal complaints of four 
of the patients were resolved within three weeks. The fifth patient was sceptical about 
hypnosis, refused to practise on a regular basis and there was very little rapport with 
the therapist. The researcher suggested that, under different circumstances, this 
patient may also have responded to hypnotherapy. 
 
 Most research in the use of hypnosis in the field of gastroenterology, however, 
has been in its application as a treatment for IBS (Barabasz & Barabasz, 2006; 
Francis & Houghton, 1996; Gonsalkorale et al., 2002; Whorwell 1984, 1987, 2006).  
 
 The use of hypnosis as an adjunct to the treatment of IBS was pioneered by 
Whorwell et al. in 1984 and this approach has continued to develop within the 
Department of Medicine at the University Hospital of South Manchester in the U.K.  
The 1984 trial showed improvement in symptoms of pain, abdominal bloating, bowel 
disturbances and general well-being in the participants in the hypnosis group 
compared to those in the control group.   
 
 Further research and hypnotherapy trials (Whorwell (1987, 1991, 1992; 
Gonsalkorale et al., 1999, 2002, 2003, 2004) were carried out with similar outcomes.  
As a result, hypnosis was adopted as an additional treatment modality for IBS 
patients (especially for those who had failed to respond to the usual medical 
interventions for this condition) and a hypnotherapy unit was set up within the 
hospital in 1995.  
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 Palsson and Whitehead, from the University of North Carolina followed on 
from Whorwell’s findings and Palsson designed a seven-session hypnosis protocol to 
address the problems of IBS, which, after preliminary testing on co-workers, was 
further tested in two published research studies (Palsson et al., 2002). As with the 
Manchester Modal, application of the North Carolina protocol also showed 
improvement in IBS symptoms and was of benefit to patients who did not experience 
adequate relief of symptoms from standard medical interventions.   
 
 Numerous other studies on the therapeutic effects of hypnosis in the treatment 
of gastrointestinal symptoms and IBS have been carried out since Whorwell’s initial 
trial in 1984 (Forbes, Macauley & Chiotakakou-Faliakou, 2000; Ran, 2001; Galovski 
& Blanchard, 2002; Houghton et al., 2002; Simren et al., 2004; Barabasz & Barabaz, 
2006; Whitehead, 2006) and research in this specific area of medicine is ongoing. 
 
Summary 
  
 In the history of hypnotism, the word “hypnosis” has a long been associated 
with the occult and power control where the hypnotist appeared to have complete 
dominance over the subject – a concept which instilled fear, distrust, and avoidance 
of the situation altogether (Waterfield, 2002).  
 
 More recently, through research and clinical trials, hypnotherapy has now 
come to be regarded as a situation which involves co-operation and trust between the 
hypnotherapist and the patient – a form of therapeutic communication – where the 
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therapist recognises changes in states of awareness and makes a positive intervention 
to either initiate a change in the patient’s behaviour or alleviate symptoms while he or 
she is in a hypnotic trance (McGill, 1996; Roet, 1986).  
 
 Hypnosis is neither magical nor mysterious, it is a natural phenomenon. It is a 
dream-like state which can occur numerous times a day - a change in the level of 
awareness in which suggestibility is heightened and the resources of the subconscious 
mind can be accessed (Olness, 1995; Zahourek, 2001). 
 
 Hypnotherapy is a complementary treatment which is effective over a wide 
range of disorders such as phobias (Harris, 1991), anxiety (Bourne, 2000), depression 
(Stein et al., 2001), cancer (Kidman, 1983; Syrjala, Cummings & Donaldson, 1992), 
gastrointestinal disorders (Gonsalkorale et al., 2003; Whorwell et al., 1984, 2006), 
and the alleviation of pain (Frenay et al., 2001; Manusov, 1990).  
 
 The involvement of hypnosis with immune function has been illustrated in 
studies in the field of cancer research where women with metastatic breast cancer 
receiving hypnosis training for pain relief lived 18 months longer on average than the 
control group (Bakke et al., 2002), and in exam stress (Gruzelier, et al., 2001; Naito 
et al., 2003) where practising hypnosis prior to exams resulted in high T-cell 
percentages over baseline.  
 
 Studies on the effect of emotions such as anger, fear, pain and anxiety have 
been shown to affect the enteric nervous system in the colon by increasing motility 
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more in IBS sufferers than in healthy controls (Blomhoff et al., 2001; Welgan & 
Meshkinpour, 2000), and evidence also suggests the entire GI tract to be involved 
(Whorwell, 1992). 
 
 Unfortunately, hypnosis is often recognised by the public as the treatment of 
choice for only a small range of problems and it is usually considered as a last resort. 
However, successful outcomes from both anecdotal evidence and clinical trials have 
shown hypnosis to be a genuine and useful treatment which is slowly becoming 
acknowledged by medical authorities (Waterfield, 2002). 
 
 This change in attitude towards the application of hypnotherapy for a wider 
range of disorders is considered to be due to more information coming to light about 
the complexities of the brain systems and also to a more rigorous application of 
scientific methodology and experimental design (Gruzelier, 1996).   
 
 The links between mind and body and the influence of the mind on the body, 
in both psychosomatic disorders and conditions such as infections and inflammation 
(which can be influenced by stress and other emotional factors), are becoming more 
widely acknowledged (Gonsalkorale, 1996, 2003). The mind-body link also has 
resources for self-healing and hypnosis can unlock them (Waterfield, 2002). 
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CHAPTER 4 RATIONALE FOR CURRENT STUDY AND SPECIFIC 
AIMS OF TRIAL 
 
 
4.1      Clinical Studies in the Use of Hypnotherapy with Irritable Bowel 
Syndrome 
 
 Previous studies have demonstrated the effects and use of hypnosis on gastric 
motor and secretory function (Eichorn & Tracktir, 1955; Hall, Herb, Brady & 
Brooks, 1967) but the use of hypnosis as an adjunct to the treatment of IBS wasn’t 
really addressed until a trial was carried out by Whorwell et al. in 1984.  As a result, 
hypnosis was adopted as an additional treatment modality for IBS patients in the U.K. 
(especially for those who had failed to respond to the usual medical interventions for 
this condition) and, in 1995, a hypnotherapy unit was set up within the Department of 
Medicine at the University Hospital of South Manchester.  
 
 Following on from Whorwell’s findings, Palsson and Whitehead from the 
University of North Carolina designed a seven-session hypnosis protocol (between 
1994 and 1996) which was based on the Manchester model. This protocol also 
showed improvement in IBS symptoms and was of benefit to patients who did not 
experience adequate relief of symptoms from standard medical interventions.   
 
 In Whorwell’s 1984 trial, thirty patients with severe refractory IBS were 
randomly allocated to two groups for treatment with either hypnotherapy, or 
psychotherapy plus placebo.  Patients in the hypnotherapy group were given a simple 
account of intestinal smooth muscle physiology before hypnosis was induced and, 
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after the third session, were given a tape for daily autohypnosis.  All hypnotherapy 
sessions concluded with standard ego-strengthening suggestions. 
 
 The psychotherapy group showed a small but significant improvement in 
abdominal pain and distension, and in general well-being but not bowel activity 
pattern, whereas the hypnotherapy patients showed a dramatic improvement in all 
symptoms (pain, abdominal bloating, bowel disturbances and general well-being). 
There was a three-month follow-up period in which the participants continued to 
receive hypnosis sessions on a monthly basis and were asked to telephone if they 
experienced a relapse so that a further session of hypnotherapy could be arranged.  
 
 The study also showed that patients with evidence of psychopathology 
appeared to do less well than those without - the researchers suggesting that this 
might be the result of their techniques being much more directed towards the 
physiological symptoms rather than psychological ones. 
 
 
 In a follow-up study by Whorwell et al. in 1987, thirty-five patients with 
severe IBS symptoms who had proved refractory to conventional forms of therapy 
and who had received hypnotherapy for IBS, were added to the fifteen patients who 
had already been treated with hynotherapy in the 1984 trial. The fifty participants 
were divided into three groups: 
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i) classical cases of IBS exhibiting abdominal pain, abdominal distension, and 
an abnormal bowel habit (n=38); 
ii) atypical cases lacking one of two of the three criteria necessary for group 1 
(n=7) and; 
iii) patients with classical IBS plus significant psychopathology (n=5). 
 
 As in the 1984 trial, patients were given a simple account of intestinal smooth 
muscle physiology before hypnosis was induced, a tape for daily autohypnosis after 
the third session, and all sessions concluded with standard ego-strengthening 
suggestions. A control group for this study was considered inappropriate by the 
researchers as the previous controlled trial had shown a clear-cut advantage for 
hypnotherapy. Patients were judged as having improved only if their symptoms 
became mild or absent and they required no medication for IBS (with the exception 
of bulking agents). 
 
 The study showed an 84% success rate with classical cases responding best 
(95%). As in the 1984 trial, the researchers found that the response to hypnotherapy 
appeared to be dependent on the subject’s age and that patients with atypical 
symptoms (i.e. those with abdominal pain but without distension or bowel 
disturbance), and those with psychological problems, were less likely to respond. All 
non-responders were women. After completing the ten weekly sessions, the subjects 
were encouraged to continue with regular autohypnosis but also received three 
monthly hypnotherapy sessions to maintain remission. 
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 Harvey, Hinton, Gunary & Barry (1989) suggested that the success of the 
study by Whorwell et al. (1987) may have depended on the skill of a particular 
hypnotherapist and set out to compare the results obtained by two different 
hypnotherapists in the treatment of refractory IBS. The researchers also compared 
group hypnotherapy with individual treatment.   
 
 Of the thirty-three patients treated, twenty reported an improvement in 
symptoms and thirteen found no benefit.  No significant difference was found in the 
response rate between men and women, hypnotherapists, or patients treated in groups 
or individually.  Hypnotherapy in groups of up to eight patients was shown to be as 
effective as individual therapy.  As in the Whorwell studies, Harvey et al. also found 
that patients with psychological problems were less likely to improve with 
hypnotherapy. 
 
 In addition to relieving the symptoms of IBS, hypnotherapy has been shown 
to profoundly improve the patient’s quality of life and reduce absenteeism from work.  
  
 In a study by Houghton, Heyman & Whorwell (1996), fifty patients with IBS 
were administered a validated quality of life questionnaire (SBQOL) and assigned to 
two groups of twenty-five patients each – one group receiving hypnotherapy and the 
other (the control), were patients on a waiting-list.  Patients treated with 
hypnotherapy reported less severe abdominal pain, bloating, bowel habit, nausea, 
flatulence, urinary symptoms, backache, and dyspareunia compared with controls.  
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Quality of life such as well-being (psychic and physical), mood, and work attitude 
were also favourably influenced by hypnotherapy.  
  
 In order to compare hypnotherapy and therapeutic audiotape, Forbes et al. 
(2000) carried out a randomised controlled trial in which subjects were assigned to 
either a course of gut-directed hypnotherapy (plus an audiotape of (usually) the third 
session which was to be listened to daily), or to receive a special audiotape recorded 
by the same therapist who carried out the hypnotherapy. The latter tape consisted of 
structured relaxation, suggestions on ways of reducing life stresses, and encouraged 
acceptance of symptoms. There were pauses on the tape but no background music or 
other sounds. The patients in this group were also advised to listen to the tape daily. 
Twenty-five patients were randomised to hypnotherapy and twenty-seven to the tape. 
The recruitment period extended over three years and there was a high “drop-out” 
rate after the initial consultation.  
 
 The researchers found that both procedures proved valuable in a modest 
majority of patients with resistant IBS and that, although a slightly smaller proportion 
responded to the audiotape, they suggested that, as hypnotherapy was time-
consuming and labour-intensive, the ease and economy of the tape should be 
considered as a second-line option in the treatment of IBS. The results of neither 
group, however, approached statistical significance.   
  
 Anbar (2001) used self-hypnosis rather than recorded tapes in a trial on five 
paediatric patients with a primary diagnosis of functional abdominal pain. The 
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imagery used was developed with input from each patient – i.e. imagination of what 
might be perceived by all five senses in a relaxing place of the patients’ choice. Each 
child was also asked to choose a sign (such as pressing index finger and thumb 
together) as a reminder of how to relax when not in a state of hypnosis and was 
complimented on his/her hypnotic abilities.   
 
 Following the first session of hypnotherapy instruction, the abdominal 
complaints of four of the patients resolved within three weeks.  The fifth patient was 
sceptical about hypnosis and, although being able to relax with the aid of hypnosis, 
refused to practise on a regular basis.  
 
 The researchers were aware that the study involved a very small number of 
participants and, as all the patients were referred for hypnotherapy, they represented a 
potentially non-representative sample. However, the relatively high success rate in 
this report suggests that children with functional abdominal pain might respond well 
to a brief hypnotherapeutic intervention. This is especially so considering that 
abdominal pain is thought to be the most common recurrent physical symptom 
attributable to psychological factors among children and adolescents (Fekkes, Pijpers 
& Verloove-Vanhorick, 2004; Stein, Crow, Abbott & Tanner, 2003). 
 
 Although only a single case, the study by Galovski & Blanchard (2002) 
continued to provide support for the efficacy of hypnotherapy in a very refractory 
IBS patient.  The patient suffered from refractory IBS and Generalised Anxiety 
Disorder and had suffered from IBS for thirty years. After six treatment sessions 
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using hypnosis, his IBS symptoms had improved (53%). He then continued treatment 
by listening to audiotapes provided by his therapist.  
 
 At the six-month follow-up, the subject rated his level of IBS symptom 
improvement on a visual analogue scale to be 70% and the two-year follow-up 
showed an improvement of 38% in IBS symptoms. The subject’s levels of depression 
and anxiety also showed significant improvement. The patient’s levels of depression 
(as measured by the Beck Depression Inventory - BDI) had decreased from a pre-
treatment score of 13 to 10 at the six-month follow-up, and 6 at the two-year follow-
up. His levels of anxiety (measured by the State Trait Anxiety Inventory - STAI) had 
decreased from a pre-treatment score of 49 to 38 at the six-month follow-up and 36 at 
the two-year follow-up, and he was also able to substantially decrease his medication 
regimen. 
 
 Ongoing research has been carried out by practitioners at the hypnotherapy 
unit of the University Hospital of South Manchester, U.K., the largest of which was a 
large-scale audit of hypnotherapy carried out by Gonsalkorale, Houghton & 
Whorwell (2002) in which 250 patients (aged 19-79 years) with IBS of at least two 
years’ duration and refractory to previous treatment, received a course of 
hypnotherapy.   
 
 At the first visit, participants completed questionnaires to measure the severity 
of IBS symptoms and psychological status over the preceding month.  This was 
followed by twelve weekly sessions of hypnotherapy using previous techniques 
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(Whorwell et al., 1984) over a period of three months, plus daily home practice 
between sessions.  At each session, interventions were reinforced or modified 
according to the patients’ needs and, after the last session, patients were asked to 
contact the unit if they needed any additional help.  
 
 A marked improvement was seen in IBS symptoms (abdominal pain, bloating 
and bowel habit disturbance), extra-colonic score (nausea/vomiting, headaches, 
backaches, lethargy, body aches, excess wind, heartburn, thigh pain, urinary 
symptoms), quality of life, and anxiety and depression, in all sub-groups with the 
exception of males with diarrhoea-predominant bowel habit who improved far less 
than the other participants for no known reason.  
 
 The outcome of therapy was measured after the last session and no long-term 
follow-up was pursued because of difficulties in obtaining date on such a large scale. 
No control group was included for comparison because this research was not a 
clinical trial, and previous studies that had included control groups had already 
demonstrated that hypnotherapy was superior to placebo or non-treatment. 
 
 The previous audit by Gonsalkorale et al. (2002) confirmed the beneficial 
effects of hypnotherapy in a large number of patients but outcome was only measured 
immediately after patients had completed the course of hypnotherapy. In order to 
determine the longer-term effects of therapy in terms of symptoms improvement, 
consultation rates, and use of medication, Gonsalkorale et al. (2003) carried out a 
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study to establish follow-up on a large group of patients who had previously been 
treated with hypnotherapy. 
 
 Two hundred and four patients, who had undergone a course of gut-directed 
hypnotherapy at least one year previously, completed questionnaires rating IBS 
symptoms, extra-colonic features, quality of life, anxiety, and depression before, 
immediately after, and up to six years following hypnotherapy treatment.  
Immediately after hypnotherapy, 71% of patients considered their symptoms very 
much or moderately better, and of these participants, 81% maintained benefit of 
treatment or reported further improvement over the follow-up period. The remaining 
19% of these participants had only slight or no improvement with hypnotherapy and 
little or no change in the follow-up period.  
 
  The study demonstrated that the beneficial effects of hypnotherapy for the 
majority of patients appear to last at least five years, thus making hypnosis a viable 
therapeutic option for the treatment of IBS, both because of its sustained effect and 
because of the possible ensuing reduction in the cost of medications and other 
healthcare demands. 
   
 Studies using cognitive and/or behavioural interventions have also reported 
reduction in IBS and psychological stress (symptoms (Boyce et al., 2000; Greene & 
Blanchard, 1994; Murray et al., 2004) but few have integrated cognitive-behavioural 
therapy (CBT) with hypnotherapy.  The combination of these two modalities has been 
shown to be successful in trials other than those concerning IBS.  In a meta-analysis 
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of 18 studies by Kirsch, Montgomery & Sapirstein (1995) in which CBT was 
compared to CBT plus hypnosis, it was concluded that hypnosis enhanced the 
effectives of CBT, and research by Bryant, Moulds, Guthrie & Nixon (2005) 
indicated that the addition of hypnosis to CBT substantially increased outcome in the 
treatment of acute stress disorder.   
 
 Gonsalkorale, Toner & Whorwell (2004) designed a study to determine 
whether the improvement in treating IBS with hypnotherapy was associated with 
cognitive change.  The specific aims of the study were to establish whether patients’ 
cognitions were related to the severity of the IBS symptoms, whether these cognitions 
changed after hypnotherapy, and if so, whether this change was related to 
improvements in symptoms.  
 
 Seventy-eight patients attended twelve sessions of hypnotherapy over a three-
month period. Before and after the treatment period, the participants completed 
questionnaires to measure severity of IBS symptoms, extra-colonic features and 
psychological status as well as IBS-related cognitions. The Cognitive Scale for 
Functional Bowel Disorders (Toner et al., 1998) which was designed specifically for 
use in this group of patients, was used to measure the IBS-related cognitions. It 
contains statements, derived from typical thoughts of IBS patients, and is subdivided 
into themes relating to bowel function and personal characteristics relevant to IBS. 
  
 The study supported the findings shown in previous research (Whorwell et al., 
1984, 1987; Houghton, 1996) – i.e. that hypnotherapy reduced both IBS symptoms 
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and associated extra-colonic manifestations, and improved the patients’ quality of life 
and psychological well-being. More specifically, it showed that symptom 
improvement with hypnotherapy was associated with a change in cognitions. In 
particular, the results showed that IBS-related cognitions were associated with 
symptom severity and quality of life and that these cognitions improved with 
hypnotherapy and this improvement correlated with improvement in symptoms.   
 
 The researchers also indicated the importance for healthcare professionals to 
consider functional disorders in the way that patients think about these symptoms 
rather than thinking about them in terms of symptomatology only. 
  
 As mentioned previously, Palsson and Whitehead from the University of 
North Carolina continued research on IBS and hypnosis, based on the Manchester 
model of Whorwell et al. (1984). Their initial investigations consisted of two studies 
(1997; 2000) in which hypnosis, as demonstrated in the Manchester study, was shown 
to substantially improve all the central symptoms of IBS in the majority of patients.   
 
 Previous to these two studies Palsson (in consultation with Whitehead), had 
written a seven-session hypnosis protocol (The North Carolina Protocol) designed to 
address the problems of IBS, plus a shorter session script for an audio recording for 
patients to use daily at home between clinic sessions. The nature of the protocol was 
that it had to be usable without customisation with all patients, regardless of their 
ability to visualise, their pace of hypnotic response, or their need for direct 
instruction. 
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 In their first study, Palsson, Burnett, Meyer & Whitehead (1997) evaluated the 
effects on rectal pain thresholds and muscle tone by having therapists read identical 
scripts to 18 patients with severe IBS symptoms while they were under hypnosis.  
Seventeen out of the eighteen patients showed significant improvement in their 
clinical symptoms however, as in the Manchester study, the gut pain thresholds and 
muscle tension remained unchanged after treatment.  
 
 In the second study, Palsson, Turner, & Johnson (2000) used the same 
treatment protocol and, in addition, measured the functioning of the autonomic 
nervous system and the blood levels of the gut hormone, vasoactive intestinal peptide.  
Twenty-one out of the twenty-four patients with severe IBS symptoms showed 
improvement in their clinical symptoms as well as improvement in their 
psychological well-being, but again, no changes in the physical measurements were 
evident after treatment. 
 
 Both studies demonstrated the verbatim delivery of hypnosis using written 
script. Most patients showed an improvement in clinical symptoms which lasted for 
at least ten months. Palsson et al. also intimated that suggestions or imagery 
specifically directed at reducing intestinal pain sensitivity seemed to be unnecessary, 
as they appeared to have had no measurable effect on bowel pain threshold or the 
degree of clinical pain improvement.  
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 Research on hypnosis as a treatment for IBS to date has shown consistent IBS 
symptom reduction as well as an improvement in patients’ psychosocial well-being 
and quality of life.  
 
4.2 Limitations of Previous Studies 
  
 Hypnotherapy, or more specifically, ‘gut-directed’ hypnotherapy, is the most 
frequently reported therapy shown to have a beneficial therapeutic impact on IBS 
symptoms (Francis & Houghton 1996; Locke et al., 1999).  The first evaluation of 
“gut-directed” hypnotherapy in the management of IBS (published by Whorwell et al. 
in 1984) indicated a significant benefit over placebo, and in 2003, Gonsalkorale et al. 
reported long-term benefits of the effect of hypnotherapy on IBS sufferers as well as 
a reduction in consultation rates and medication.  
 
 More recent reviews of studies on hypnotherapy as a treatment for IBS have 
found that published evidence still suggests that ‘gut-directed’ hypnotherapy is very 
effective in the management of IBS (Gholamrezael et al., 2006; Wilson, Maddison, 
Roberts, Greenfield & Singh, 2006).  In these reviews, the authors observed some 
methodological inadequacies in the studies such as lack of a control group and/or 
long-term follow-up, too small a sample size, and other aspects such as 
hypnotisability and expectancy of the patient not being taken into account.  
 
 For the purpose of the study in hand, however, one inadequacy the reviewers 
did not address was that the therapists in the various studies failed to specifically 
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target the patients’ psychological symptoms in the hypnosis sessions.  The effect that 
hypnosis has on the direct control of gut function, the reduction of visceral pain 
sensitivity, and somatisation, was acknowledged, and Gholamrezael et al. did suggest 
that one cannot rule out that hypnosis also partially reduces anxiety and depression, 
thereby improving symptomatology, but the importance of addressing this component 
of the IBS symptom picture was not identified. 
 
 Researchers have acknowledged that psychological factors play some part in 
the amelioration of IBS symptoms and, therefore, cannot be ignored (Whorwell et al., 
1987; Chapman, 2005) but, as yet, imagery specifically addressing the mental, 
psychological and emotional aspects of IBS, has not been part of the hypnosis 
sessions in these studies.  
  
 Psychological distress, which can trigger or exacerbate symptoms (Jarret et 
al., 1998; Koloski, Talley & Boyce, 2003), has been shown to be an important 
component of IBS symptoms (see Chapter 2) and should be considered when 
treatment strategies are designed.   To date, none of the researchers who have carried 
out studies on hypnotherapy as a treatment for IBS has taken this into account.  By 
using scripts that specifically target each individual patient’s emotional/psychological 
symptoms (in conjunction with scripts for the physiological aspects of the disease), 
the therapist addresses the whole patient profile.  The following studies highlight the 
absence of individual scripts pertaining to the psychological component of IBS in the 
researchers’ treatment protocol. 
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  Whorwell (1987) observed that IBS patients with evidence of 
psychopathology who were undergoing his treatment with hypnosis, appeared to do 
less well than those without, and attributes this to that fact that his techniques are 
much more directed towards physiology than psychology.  The hypnotherapy 
treatment Whorwell used was targeted at the gut and, although he admits that 
psychological factors cannot be ignored entirely, in his view, they very much take 
second place.  
 
 Hypnosis, according to Whorwell, can be used as either a predominantly 
physical, or a predominantly psychological treatment, and suggests that physicians 
would be more comfortable with the former approach (Whorwell, 1991). 
 
 Treatment by Whorwell et al. consisted of half-hour sessions of decreasing 
frequency over a three-month period, with hypnotherapy solely directed at general 
relaxation and control of intestinal motility. After a hypnotic induction, suggestions 
on improvement of health and well-being were given to patients. To control gut 
function, they were asked to place a hand on the abdomen and feel the sense of 
warmth while imagining the gut as a river – the aim being to make the river flow 
smoothly. The patients were also provided with an audiotape, which contained 
suggestions similar to those given in the session, for daily autohypnosis.  
 
 The imagery used in the sessions was the same for each patient and, although 
all hypnotherapy sessions concluded with standard ego-strengthening suggestions, 
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psychological problems such as anxiety and depression were not specifically 
addressed. 
  
 Both Harvey et al. (1989) and Forbes et al. (2000) utilised a specifically gut-
directed hypnotherapy technique which was closely derived from that of Whorwell et 
al. (1984) in which the patient placed a hand over the abdomen, was asked to imagine 
a river and relate it to the smooth rhythm action of their own GI tract, and was given 
an audiotape containing similar suggestions as those used in the sessions.  
 
 Again, all suggestions and visualisations in the sessions were targeted at the 
physiological symptoms of IBS, were the same for each patient, and no specific 
suggestions or imagery relating to psychological problems were given.  Forbes et al. 
also used an audiotape for the control group, which contained background 
information about IBS, structured relaxation, and suggestions on ways of reducing 
life stresses and accepting symptoms. However, the tape was the same for all 
participants and contained no specific suggestions regarding psychological 
symptoms. 
  
 Physical symptoms attributable to psychological stress are known to be 
present in children and adolescents, and functional abdominal pain is an example of a 
symptom that can respond to psychological intervention (Chapman, 2005; Egger, 
Costello, Alaattin & Angold, 1999).   
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 Anbar (2001) used self-hypnosis in a trial on five paediatric patients with a 
primary diagnosis of functional abdominal pain. The patients were taught how to go 
into hypnosis themselves rather than relying on the therapist, and practised the self-
hypnosis at home rather than relying on an audiotape. There was also more flexibility 
in the use of imagery in both the deepening segment of the hypnotherapy session and 
in the gut-directed therapy.  
 
 In the deepening segment of the hypnotherapy session, instead of using the 
same imagery for each patient, the imagery used was developed with input from each 
individual patient – i.e. imagination of what might be perceived by all five senses in a 
relaxing place of the patients’ choice.  The therapy was still directed by the therapist 
but each patient was able to visualise the specific problem (e.g. pain in the stomach) 
as he/she wished and then imagine a way of resolving it.   
 
 As all five patients attended only a one-hour session and four returned for 
only one or two follow-up sessions, Anbar suggested that, because of the brief time 
involved, psychopathology that may be associated with functional abdominal pain 
might not be identified and that the practitioner should remain vigilant for 
psychological problems including anxiety and depression. 
 
  In two studies by Gonsalkorale et al. (2002; 2004), hypnotherapy was 
carried out based on gut-directed techniques used in previously-mentioned trials 
(Whorwell et al., 1984; Harvey et al. 1989; Forbes et al. 2000) once again 
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demonstrating that hypnotherapy remains an extremely effective treatment for IBS 
and that symptomatic improvement is long-lasting.   
 
 Neither trial directly targeted psychological symptoms in the hypnotherapy 
sessions although the latter trial indicated a possible change in direction towards 
considering a more psychological approach to treatment.  It showed that symptom 
improvement with hypnotherapy was associated with a change in cognitions and that 
IBS-related cognitions were associated with symptom severity and quality of life.  
The researchers suggested that practitioners should take into account the way patients 
think about these symptoms rather than thinking about them in terms of 
symptomatology only. 
 
 Following on his doctoral research where he tested a scripted hypnosis 
protocol designed to treat chronic stress problems, Palsson (1998) designed a 
standardised hypnosis intervention for physical problems which eventually led to a 
seven-session hypnosis protocol to address the problems of IBS.  The entire course 
was designed for verbatim delivery both for scientific rigor and to make 
generalisation of the treatment easier. 
 
 His seven-session treatment consists of a therapist reading a script, verbatim, 
to each IBS patient at each session.  The seven scripts are basically the same format: 
induction, progressive relaxation, a deepening technique (e.g. therapist counting from 
1-20 while the patient imagines going down a staircase or lift), followed by 
visualisation and suggestions.   
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 The suggestions are mainly directed towards the physiology of IBS (in 
particular the pain and discomfort in the stomach and intestines) and, in each session, 
patients are told that their bowel sensations no longer bother them and that they are 
becoming less sensitive to pain and discomfort. Visualisations to this effect include 
imagining that there is a protective coating on their intestines, or that the thick walls 
of the log cabin they are visualising, protect them from the ice and wind outside in 
the same way as they are protected from pain or discomfort in the stomach and 
bowels. Other suggestions are targeted at getting away from troubles and cares by 
visualising a garden or a place in nature. The audiotape, given to patients at the 
completion of the second session, contains suggestions of the body learning how to 
maintain the feeling of comfort inside. 
 
 Although part of Palsson’s treatment involved visualising calm, relaxing 
places away from the tension of the day which could lessen anxiety, no other 
psychological issues such as depression, panic (Creed et al., 2005; Sykes et al., 2003), 
perceived stigma, or abnormal illness attitudes in IBS patients (Dancey et al., 2002; 
Gomborone et al., 1995) were addressed. 
 
 Psychological influences may act as predisposing or precipitating factors 
which eventually lead to symptoms that exacerbate or maintain the problem the IBS 
patient is suffering (Toner, Garfinkel & Jeejeebhoy, 1990; Whitehead & Palsson, 
1998). In addition, these symptoms may be a source of psychological distress (such 
as the patient feeling out of control, helpless and anxious) which, because of the 
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patients’ automatic thoughts or cognitions, may in turn exacerbate symptoms 
(Gonsalkorale et al., 2004).   
 
4.3 Rationale for Current Study and Hypotheses 
  
 The current interest in the mind-body connection has grown because current 
research has substantiated how the brain and the nervous system and immune systems 
of the body communicate through the bi-directional flow of hormones, neuropeptides 
and cytokines (Heitkemper et al., 2001; Leahy et al., 1999; Pert, 1997).  Nerve 
endings have been found in the thymus, lymph nodes, spleen and bone marrow, and 
immune cells respond directly to chemical signals produced by the nervous system 
and released into the bloodstream (Ader, 1991; Dreher, 1995).  
 
 For decades, health professionals have focused solely on the causes of disease 
rather than on the psychological effects on health and disease, and the effects of 
disease on the psyche.  In other words, emphasis has been more on pathology than on 
factors which promote health (Dreher, 1995).  
  
 There is now a great body of evidence suggesting that direct connections exist 
between parts of the body that had previously been thought of as being independent, 
and greater credibility is now being given to the notion that the mind is able to 
influence the body (Hannigan, 1999; Pelletier, 1995). Interest is being shown in the 
effects of imagery and hypnosis on the immune and nervous systems and research in 
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that area indicates that hypnotic intervention can moderate immune and nervous 
system functioning (Glaser & Kiecolt-Glaser, 2001; Whorwell et al., 1992).  
 
 Ernest Rossi (1993) suggests that hypnosis acts on the brain’s structures and 
chemistry to facilitate the communication process and aid healing by acting on the 
limbic-hypothalamic part of the brain.  This area of the brain can alter mind-body 
interactions by normalising the body’s ultradian rhythms which, when disrupted is a 
major cause of stress-related illnesses. 
 
 The nervous system is constantly maintaining homeostasis which can be 
disrupted by stressors. Stressors can be either physical such as temperature extremes, 
accident, injury, inflammation, infection, toxins, and surgery; or psychological such 
as major life events, trauma, abuse, loss, anxiety, and depression (Salt, 2002).  
 
 The stress-response is the body’s attempt at restoring equilibrium by secreting 
certain hormones, inhibiting others, and activating particular parts of the nervous 
system and the immune system. However, when these protective hormones are 
produced repeatedly, they create harmful physiological changes leading to an 
imbalance and disturbance of homeostasis, which in turn results in functional 
symptoms. Collections of these symptoms commonly lead to the diagnosis of IBS 
and other functional syndromes (Rice, 1992; Wood, Alpers & Andrews, 1999).   
 
 The brain translates a person’s perceptions, thoughts, beliefs, memories and 
emotions into patterns of nerve cell firing and chemical release. The system works in 
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reverse as well - pain that originates in the body can affect a patient’s mood and 
behaviour. The pathways connecting mind and body integrate responses to threats 
(behavioural, physiological or immunological) and enable homeostasis to be 
maintained (Pert, 1997; Watkins, 1997).   
  
 Studies have shown that hypnotherapy can normalise abnormal visceral 
sensitivity and lessen pain (Prior, Colgan & Whorwell, 1990; Houghton et al., 1999) 
suggesting, once again, the possible role the nervous system may play in this 
abnormality. Both PET scans (Silverman et al., 1997) and fMRI (Mertz et al., 2000) 
appear to support this by demonstrating the presence of abnormal cerebral processing 
of visceral stimuli.   
  
 A study by Whorwell, Houghton, Taylor & Maxton (1992) showed that 
hypnosis could be used to induce various emotions, and that different emotions could 
have different effects on colonic motility.  The researchers suggested that these 
observations might explain, for example, the frequency of defaecation and cramping 
during stressful events as well as their amelioration when the stressful event was 
over; and therefore, awareness of the emotional state of the patient should be taken 
into account when treating IBS.  However, even though the researchers made this 
observation, the emotional state of the patient was not specifically addressed in their 
hypnotherapy sessions. 
   
 IBS has a considerably negative impact on sufferers’ lives and is associated 
with psychological distress. Strong evidence exists that IBS has an important 
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psychological component. In an interview and questionnaire involving 180 
outpatients, Bennett et al. (1998) found that psychosocial disturbance was strongly 
related to the overall severity and extent of functional gut disturbance, and that 98% 
of patients had been exposed to at least one chronic social stressor for more than a 
year.  They found significant relationships between IBS, somatic symptoms, and 
severity of emotional distress such as anxiety, depression, anger, and goal frustration. 
They also found a relationship between IBS and absent or inadequate emotional 
support, and increasing age. 
  
 Two thirds of patients with IBS have been shown to have experienced a 
severe social stress before the onset of the abdominal symptoms, compared to a 
quarter of patients with organic disease and healthy controls (Creed et al., 1988; 
Dancey et al, 1997) and relationships between the presence of IBS and generalised 
anxiety disorder, chronic worry, neuroticism and anxiety about visceral sensations 
have been documented (Hazlett-Stevens, Craske, Mayer, Chang & Naliboff, 2003).  
  
 Psychological factors may be involved in both the onset and maintenance of 
GI symptoms and IBS patients with a lifetime psychopathology were significantly 
more likely to have developed psychiatric disorders before the onset of IBS (Sykes, 
Blanchard, Lackner, Keefer & Krasner, 2003). 
 
 Psychological treatments, such as hypnotherapy, are rarely suggested to IBS 
patients as, up until now, medication (such as antispasmodics, antidepressants, anti-
diarrhoeal and laxatives) has been the treatment of choice (Baker, 2005; De Ponti & 
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Malagelada, 1998). Considering the high cost of medication, repeated visits to 
medical practitioners (Cash, Sullivan & Barghout, 2005; Hahn et al., 1999), and the 
high prevalence of stress, IBS sufferers would obtain a great deal of benefit from 
programmes such as hypnotherapy.   
  
 To date, trials using hypnosis as a treatment for IBS have focused on the 
physiological symptoms of IBS and, although some researchers have used imagery of 
calm places away from the tension of the day (usually the same imagery for each 
patient) and/or concluded the hypnotherapy sessions with standard ego-strengthening 
suggestions, they have not addressed specific psychological disorders (such as 
anxiety and depression) that patients often present with at their first session. 
 
4.4 Specific Aims of the Trial 
  
 The primary aim of this trial was to achieve a more holistic approach when 
attending to IBS patients and to evaluate the effectiveness of hypnosis and imagery in 
the treatment of IBS in an Australian population.  More specifically, the study aimed 
at comparing the use of “gut-directed” imagery used in previous hypnosis trials 
(Gonsalkorale et al., 2002, 2003; Whorwell et al., 1984, 1987, 1991) with imagery 
that reflected the patients’ complete symptom picture – i.e. imagery addressing not 
only physiological symptoms but psychological/emotional symptoms as well. The 
main hypothesis being that patients who were treated holistically would have a better 
outcome in the improvement of their IBS symptoms than those whose physiological 
symptoms alone were treated. 
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 As previous clinical trials in IBS had noted that a variety of psychological 
conditions often co-existed with IBS (see Chapter 2), patients were asked to complete 
the Symptom Checklist-90-R (SCL-90-R) before commencement of treatment.  This 
questionnaire helps evaluate a broad range of psychological problems and symptoms 
of psychopathology, and is also useful in measuring patient progress or treatment 
outcomes (see Chapter 5).  
 
 For the purpose of this trial, four of the nine primary symptom dimensions of 
the SCL-90-R (anxiety, depression, interpersonal sensitivity, and obsessive-
compulsive) which most reflected the psychological symptoms of the majority of the 
participants, were measured, and scripts targeting these four symptoms were 
compiled and read to relevant participants during the hypnosis sessions. 
 
 Secondary aims of the trial were to test the following hypnotheses: 
 
a) participants who had been diagnosed with IBS would present with not only 
physiological symptoms but psychological ones as well; and that, at the end of the 
study, participants who underwent individualised hypnotherapy (using imagery which 
addressed both the psychological/emotional aspects and the physiological symptoms 
of the syndrome), would have a better outcome in the improvement of their IBS 
symptoms than participants who underwent  standard “gut-directed” hypnotherapy in 
which physiological symptoms alone were treated. Specific psychological symptoms 
were highlighted through administration of the SCL-90-R questionnaire to trial 
participants; 
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b) participants’ IBS symptoms would improve during the trial period and, as a result, 
their quality of life would subsequently improve. To measure their general health 
status, participants completed the SF-36 both throughout the trial and during the 
follow-up period;    
 
c) participants who had a support system in place would improve more quickly than 
those who hadn’t. To outline which functions or behaviours, if any, had produced a 
beneficial effect on their health and well-being, trial participants were administered 
the Duke-UNC Functional Social Support Questionnaire at the screening session; 
 
d) participants who were experiencing, or who had recently experienced, stressful 
episodes in their life would be more likely to have more severe and more frequent 
IBS symptoms. The Survey of Recent Life Experiences (SRLE) was administered to 
participants at the screening session to examine their emotional responses to life 
stress and how this may have influenced their GI function via the brain-gut 
connection.  
 
4.5 Summary 
  
 Medical practitioners have long focused solely on the agent causing disease 
rather than on the effects psychological problems can have on health and disease (and 
the effects disease can have on the psyche) via the immune and nervous systems of 
the body.  This practice dates back to Pasteur who played a major role in the 
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development of the germ theory and spent most of his life finding substances that 
would kill the infecting organisms (see Chapter 1).  
 
 However, another nineteenth-century scientist, Claude Bernard, believed that 
the patient’s internal environment or “terrain” was more important than the pathogen 
and that physicians should focus more on enhancing the body’s own defences 
(Pelletier, 1995). Unfortunately, modern medicine has mostly forgotten the 
importance of the “terrain.”  
 
 Medical practitioners often attend only to the physical condition and ignore 
how the patients are reacting emotionally to their illness, but there is now a growing 
body of evidence to support the role emotional states have on a patient’s vulnerability 
to disease (Goleman, 1996). 
 
 IBS symptoms have been shown to be generated by abnormalities of the GI 
function such as abnormal GI motility and increased sensitivity of the intestine 
(Camilleri et al, 2001; Jarret et al., 2000) - one of the reasons being an involvement 
with the immune system.   
 
 Research has shown that IBS patients have an increased number of 
inflammatory cells in the colonic and ileal mucosa, resulting in disturbances of gut 
motility, smooth muscle contractility, and changes in the function of enteric nerves 
(Barbara et al., 2002; Gui, 1998).  IBS patients also have an increase in the numbers 
of T lymphocytes and macrophages in the colonic mucosa which result in abnormal 
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intestinal permeability in subgroups of diarrhoea-predominant IBS (Collins, 1996; 
Dunlop, 2006). 
 
 Evidence about the ways in which negative emotions, such as anxiety and 
depression, are generated by stressors and can be translated into physiological 
changes, are being provided by researchers in the field of psychoneuroimmunology 
(Webster, Tonelli & Sternberg, 2002; Padgett & Glaser, 2003).  
 
 Studies on the effect of emotions such as anger, fear, pain and anxiety have 
been shown to effect the enteric nervous system in the colon by increasing motility 
more in IBS sufferers than in healthy controls (Welgan & Meshkinpour, 2000; 
Blomhoff, Spetalen, Jacobsen & Malt, 2001) and evidence also suggests the entire GI 
tract to be involved (Whorwell et al., 1992). 
 
 
 Hypnosis has been shown to be effective in alleviating pain, boosting the 
immune system, addressing stress-related and psychological problems and, more 
recently, as a treatment option for GI problems (Handel, 2000; Waterfield, 2002; 
Gonsalkorale et al., 2003). 
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CHAPTER 5  METHODOLOGY AND INSTRUMENTS 
 
5.1         Introduction 
  
 Classic IBS symptoms are pain and alteration of bowel habit.  However, there 
are many different patterns or combinations of symptoms that can be caused by the 
gut failing to function properly.  Common complaints include a variation in bowel 
habit from diarrhoea to constipation (or both), excessive flatulence, abdominal 
bloating and abdominal pain and often a feeling of an incomplete evacuation of the 
bowel after defecation (Barbara et al., 2004; Blanchard & Galovski, 1999).  High 
levels of comorbidity with psychiatric illness, especially anxiety, anger and 
depression, have also been reported (Garakani et al., 2003; Sykes et al., 2003).   
  
 Even though the high prevalence of IBS accounts for a high percentage of the 
gastroenterologists’ workload, its aetiology and pathogenesis are still unknown.  
Several lines of evidence suggest that the cause of IBS is a result of a hypersensitive 
GI system which is exacerbated by stressful or emotional states (Bouchoucha et al., 
1999; Camilleri et al., 1999; Prior et al., 1990; Whitehead et al., 1990).  It has also 
been suggested that IBS could be the result of a previous viral or bacterial infection 
(Neal et al., 1997; Rodriguez & Ruigomez, 1999). 
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5.2  Scientific Aims of the Trial 
  
 This research proposed to evaluate the use of hypnosis and imagery in the 
treatment of IBS in an Australian population and, more specifically, to compare the 
use of “gut-directed” imagery used in previous hypnosis trials (Gonsalkorale et al., 
2002, 2003; Whorwell et al., 1984, 1987, 1991) which addressed the patients’ 
physiological symptoms only, with imagery that reflected the patients’ complete 
symptom picture.  
 
 The latter took into account the patients’ psychological and emotional 
symptoms as well as the physiological ones - the main hypothesis being that patients 
who were treated holistically would have a better outcome in the improvement of 
their IBS symptoms than those whose physiological symptoms alone were treated. 
 
 The progress of participants through the study is shown in Figure 4, as per the 
Consort statement (Appendix 13).  
 
5.3      Recruitment Processes, Inclusion and Exclusion Criteria 
  
 5.3.1 Subject Selection 
 
 Patient Population.  Fifty-one symptomatic volunteers aged between 
seventeen and seventy-five were recruited from the general public and medical and 
naturopathic clinics, and were invited to undergo screening tests. The participants 
were deemed suitable for the study after having met the Rome II criteria for IBS. 
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 Non-compliance and Discontinuations. Characteristics of patients who 
discontinued or showed non-compliance were omitted from the statistical analyses. 
 
 Inclusion Criteria. Participants who had been diagnosed with IBS by a 
primary care physician or gastroenterologist; who had been symptomatic for at least 
six months prior to the trial; had failed to respond adequately to conventional 
medicines; and, who had experienced at least four days with at least moderate pain 
over a two-week period after screening.   
 
 Exclusion Criteria. Participants who were not free of organic disease and who 
did not fit the inclusion criteria. 
 
 5.3.2 Gastroenterological Screening of Study Population 
  
 During the initial screening visit, participants completed the Irritable Bowel 
Symptom Questionnaire (IBSQ) (Appendix 4) to establish diagnosis and exclude 
other differential diagnoses, and the Bowel Symptom Severity Scale (BSSS-VI) 
(Appendix 5) to measure the severity of IBS symptoms.  
 
 At the commencement of each of the five visits to the clinic, participants were 
asked to complete a short IBS symptom scale (BSS 1-5) (Appendix 6) and the Bowel 
Symptom Severity Scale and hand them in to the receptionist who sealed them in an 
envelope and filed them. Two weeks after completion of the trial, and again three 
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months after completion, participants were asked to complete the Bowel Symptom 
Severity Scale and forward it to the clinic. 
 
 Patients were required to attend one initial screening visit which included 
completing the following questionnaires:  
 
  Irritable Bowel Syndrome Questionnaire (IBSQ)  (Appendix 4) 
  Bowel Symptom Severity Scale (BSSS) (Appendix 5) 
  SCL-90-R (Appendix 7) 
  SF-36 Health Survey (Appendix 8) 
  Duke-UNC Functional Social Support Questionnaire (Appendix 9) 
  Survey of Recent Life Experiences (SRLE) (Appendix 10) 
    
 They were then given a daily diary (Appendix 3) in which to record their 
symptoms and requested to hand it in at the beginning of their first treatment session 
in two weeks’ time. The diary helped subcategorise the IBS participants into one of 
three main subtypes: diarrhoea-predominant, constipation-predominant, and mixed 
(diarrhoea and constipation).  
 
 Using a linear scale, the participants were asked to rate daily the overall 
severity of symptoms, as well as the severity and degree of distress caused by the 
following GI symptoms:  
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• pain or discomfort in the stomach or abdomen 
• feeling as if the stomach or abdomen were bloated (excluding bloating due 
to a menstrual period) 
• constipation 
• diarrhoea.     
  
 Participants were then asked to attend a further five treatment sessions which 
were conducted fortnightly by the same practitioner at the same clinic location.   
  
 Before the commencement of each of these sessions they were asked to fill in 
a short Bowel Symptom Scale (BSS 1-5) (Appendix 6), the Bowel Symptom Severity 
Scale (Appendix 5) and the SF-36 General Health Questionnaire (Appendix 8) and, 
after the second and fourth sessions, they were also asked to complete the Credibility 
Scale (Appendix 11). These were handed in at reception where they were sealed in an 
envelope and filed. After the second session, each participant was given a 
CD/cassette of the script used in the session (see Appendix 12) and asked to practise it 
daily until the end of the trial.  
 
 5.3.3  Ethical Considerations, Confidentiality and Privacy 
  
 All subjects who participated in these studies read the Subject Information 
Statement (Appendix 1), gave written, informed consent (Appendix 2) and were free 
to withdraw from the trial at any time.  The protocols were approved by the Ethics 
Committee, University of Sydney, Australia. The confidentiality and privacy of 
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participants were taken into account by allocating all patients an identification code 
from the commencement of the trial. All questionnaires, documentation and data 
referred to patients by their identification code only. All clinical notes and 
questionnaires were sealed in an envelope and stored in a locked filing cabinet at the 
clinic and access was only possible by the investigator. 
 
5.4      Research Plan and Timetable 
  
 Randomisation. After screening, and after exclusion criteria were met, 51 
subjects were randomly allocated by means of random number tables (Boyer, 1968) 
to one of the three groups (2 experimental & 1 control).  
 
 Blinding.  Participants were randomly allocated to 3 groups by a random 
number table (Boyer [Ed.] 1968) and were unaware of which treatment group they 
were assigned to.  They were also unaware of other participants in their treatment 
group, or in the other two groups. Each participant was treated individually by the 
same therapist with a quarter of an hour’s break between his or her consultation and 
that of the next patient to minimise possible contact between patients. The waiting-
room was a common one for patients of all twelve practitioners working at the clinic, 
so participants would be unaware of which practitioner other patients were waiting to 
see. Also, consultations for private patients of the author were interspersed between 
those for IBS trial participants, again minimising contact between subjects.  
 The success in blinding was evaluated using a treatment credibility scale 
which was administered before the second and fourth sessions (Appendix 11). 
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 Baseline Period. Each participant was screened by means of the IBSQ to 
ensure that symptom frequency and severity were adequate before randomisation, and 
participants were each given a daily diary two weeks before treatment in which to 
record symptoms.  
 
 Follow-up.  At the end of the trial, two questionnaires (the Bowel Symptom 
Severity Scale and the SF-36 Health Survey) were completed (at two weeks and 
again at 3 months) by each participant to assess whether IBS symptoms had 
significantly changed, compared with baseline, after hypnotherapy or relaxation 
treatment.   Unlike previous trials (Whorwell et al., 1987; Gonsalkorale et al., 2002) 
no further treatment was given during the follow-up period, nor were participants 
invited to return for further treatment if symptoms returned. 
 
 Compliance:  daily diaries were completed during the two weeks prior to the 
commencement of treatment sessions and handed in at the first consultation. At each 
session, participants were asked how often they had practised their relaxation or 
hypnosis techniques since the last session. 
 
 Drugs:  concurrent medication could have an impact on outcome so patients 
were asked what drugs they are on before the trial and were asked to continue them 
for the duration of the trial.   
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Number of potential participants for the study is unknown
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5.5 Treatment schedule 
  
 The three groups consisted of two experimental (hypnosis) groups and one 
control group. At the end of the trial, participants in the control group were offered 
two complementary sessions in hypnosis. The assessment instruments completed by 
all participants prior to each consultation are shown in Table 12. 
   
 The first experimental group was read a script using “gut-related” imagery 
(physiological symptoms of IBS) while under hypnosis plus a further script 
containing the patient’s individual psychological symptoms (as evidenced by the 
SCL-90-R); the second experimental group was read the same script using “gut-
related” imagery while under hypnosis, (but no script pertaining to psychological 
symptoms); and the third group (the control group) was given a relaxation session in 
which no scripts pertaining to either physiological or psychological symptoms were 
presented.   
 
 There were six scripts in all – one for the “gut-related” imagery which related 
to physiological symptoms only, one script for the control (relaxation) group, and one 
script each for the four of the nine dimensions of the SCL-90-R which most reflected 
the psychological symptoms of the majority of the participants. The four dimensions 
were: obsessive-compulsive, interpersonal sensitivity, depression, and anxiety.  The 
appropriate script(s) was read to the participant during each treatment session.  The 
script(s) for each group of participants was identical (see Appendix 12) and 
participants were blinded as to which script was being read to them. 
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 Contact time. For all three groups: an initial consultation of a one-hour 
screening session plus five follow-up sessions of a half an hour each was the same for 
all randomised strata. 
 
• Experimental group 1.   In the first consultation, the patient’s full history was 
taken and the functioning of the GI tract was explained. The following 
procedure was then strictly adhered to for the remaining sessions in the trial. 
Hypnosis was induced, after which the therapist read two prepared scripts 
(Appendix 12) – one containing “gut-directed” imagery (physiological 
symptoms of IBS), plus a further script containing the patient’s individual 
psychological symptoms as evidenced by the SCL-90-R  (Appendix 7).  At the 
end of the second session a CD/cassette of the scripts used in this session was 
given to each patient to be taken home and practised daily.                                            
 
• Experimental group 2. The patient’s full history was taken in the first 
consultation followed by an explanation of the functioning of the GI tract. The 
following procedure was then strictly adhered to for the remainder of the trial. 
Hypnosis was induced in the same manner as for group 1, after which the 
therapist read the same prepared script containing “gut-directed” imagery 
(physiological symptoms of IBS) as for experimental group 1 (Appendix 12) 
but no script containing the patients’ psychological symptoms. At the end of 
the second session a CD/cassette of the “gut-directed” imagery script was 
given to each patient to be taken home and practised daily. 
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 Control group. The patient’s full history was taken in the first consultation 
and an explanation of the functioning of the GI tract was given. The following 
procedure was then strictly adhered to for the remainder of the trial. No 
hypnosis was induced. The therapist read a prepared script of a progressive 
relaxation exercise (Appendix 12) which contained neither the aforementioned 
“gut-related” imagery nor addressed the patients’ individual psychological 
symptoms.  At the end of the second session a CD/cassette of the relaxation 
exercise was given to each patient to be taken home and practised daily.  
  
 Trial Length:  The trial length was 23 weeks to allow for placebo response to 
 settle and to control for the fluctuating nature of IBS. 
 
5.6     Assessment Instruments 
 
5.6.1  The Irritable Bowel Symptom Questionnaire (IBSQ) 
   
 The Irritable Bowel Symptom Questionnaire (IBSQ), a modified version of 
the previously validated Bowel Symptom Questionnaire (BSQ) (Talley, Boyce, 
Owen, Newman & Paterson, 1995), was utilised in order to verify the diagnosis of 
IBS and to acquire general data on patients participating in the trial.  The IBSQ 
addressed aspects such as pain/discomfort, bloating, frequency and type of bowel 
movements, urgency, frequency of visits to doctor or alternative therapist, and daily 
amount of alcohol and coffee ingested. 
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Table 12                     Assessment Instruments Completed Prior to Each Session 
 
 Session 1  IBS Symptom Scale (BSS1) 
    Bowel Symptom Severity Scale (BSSS) 
    SF-36 Health Survey 
 
 Session 2  IBS Symptom Scale (BSS2) 
    Bowel Symptom Severity Scale (BSSS) 
    SF-36 Health Survey 
    Credibility Scale 
 
 Session 3  IBS Symptom Scale (BSS3) 
    Bowel Symptom Severity Scale (BSSS) 
    SF-36 Health Survey 
 
 Session 4  IBS Symptom Scale (BSS4) 
    Bowel Symptom Severity Scale (BSSS) 
    SF-36 Health Survey 
    Credibility Scale 
 
 Session 5  IBS Symptom Scale (BSS5) 
    Bowel Symptom Severity Scale (BSSS) 
    SF-36 Health Survey  
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 The IBSQ was a shorter form of questionnaire than the BSQ and therefore 
was more appropriate for use in this clinical trial as participants were required to 
complete several other instruments during the screening process and follow-up 
period, and on a regular basis prior to each treatment session.  
 
5.6.2  The Bowel Symptom Scales (BSS1-5) 
  
 The Bowel Symptom Scales (BSS) (Boyce et al., 2003) were used to assess 
change in IBS symptoms during the course of treatment.  The first item of all five 
BSS consists of five 100mm visual analogue scales (VAS) which refer to each of the 
principal symptoms of IBS (pain/discomfort, bloating, constipation, and diarrhoea), 
plus an overall symptom severity rating. Each of the 100mm lines is marked very 
extreme at the extreme right, and symptoms not present at the extreme left. Visual 
analogue scales are widely used and appear sufficiently sensitive to change (Agreus, 
1993).   
 
 All five of the BSS also assess stool form (which, to an extent, reflects bowel 
transit time – a concept that had previously been validated by Heaton et al., 1991), the 
degree to which IBS symptoms interfered with the patient’s life and activities, 
medication usage and fibre consumption.  BSS 2-5 compares the participants’ IBS 
symptoms to the previous time they had completed the questionnaire, and BSS 4 and 
5 also compares the participants’ symptoms to those stated in the questionnaire 
completed at the commencement of the trial. The participants’ compliance is assessed 
in BSS 3 and 4. 
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5.6.3  The Bowel Symptom Severity Scale (BSSS) 
  
 The validated Bowel Symptom Severity Scale (BSSS) was developed in the 
Nepean Hospital research unit by Boyce et al. (2000) and was based in part on the 
previously validated Bowel Symptom Questionnaire (BSQ) by Talley et al., (1995). 
The BSQ provides a measure of the frequency and duration of symptoms according 
to Rome 1 criteria. It has been found to have good validity, and test retest scores of 
two weeks have shown it to have good internal consistency (Talley et al., 1995). 
  
 Patients completed the BSSS at the initial screening, at the beginning of every 
treatment session, and as follow-up two weeks and three months after the completion 
of the trial.  
 
 The scale consists of eight questions relating to possible symptoms the patient 
may have endured between treatment sessions. The symptoms specific to this 
questionnaire were: stool formation (loose and watery/hard or lumpy), abdominal 
pain, frequency of bowel motions, bloating, urgency, inability to have a bowel 
motion, and a general feeling of discomfort in the abdomen.   
  
 Each question also had two sub-questions which asked how distressed the 
patient had been during this period and how much the specific symptom had 
interfered with his or her daily life. 
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5.6.4  The SCL-90-R  (Hopkins Symptom Checklist 90-Revised) 
  
 Clinical trials in IBS have noted that a variety of psychological conditions 
often co-exist with IBS and that a person’s psychological state may impact on 
symptom reporting (see Chapter 2).  
 
The Symptom Checklist-90-R (SCL-90-R) instrument from Pearson 
Assessments (Derogatis, Yevzeroff & Wittelsberger, 1975; Derogatis, 1994) is a 
widely used psychological status symptom inventory used by psychiatrists, clinical 
psychologists, medical practitioners, professionals involved in mental health, and for 
research purposes (Peveler & Fairburn, 1990; Schmitz et al., 2000).  
 
The SCL-90-R helps evaluate a broad range of psychological problems and 
symptoms of psychopathology (Coelho et al., 1999; Kaplan et al., 1998), and is also 
useful in measuring patient progress or treatment outcomes. It provides an overview 
of the patients’ symptoms and their intensity. 
 
The questionnaire consists of 90 items which measure nine primary symptom 
dimensions:  
  somatisation    hostility  
  obsessive-compulsive   phobic anxiety 
  interpersonal sensitivity  paranoid ideation 
  depression    psychoticism 
  anxiety 
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For the purpose of this trial, four of the nine primary symptom dimensions 
(anxiety, depression, interpersonal sensitivity, and obsessive-compulsive) which  
reflected the psychological symptoms of the majority of the participants, were 
measured, and relevant scripts were compiled and read to participants during 
treatment sessions.  The SCL-90-R is seen as a useful instrument in both measuring 
psychological status and screening for mental disorders (Schauenburg, 1999; Schmitz 
et al., 2000). 
 
5.6.5  The SF-36 General Health Survey 
  
 The Short Form (SF-36) General Health Questionnaire (Stewart, Hays & 
Ware, 1988) is a validated measure of general health status in IBS patients designed 
for use in clinical practice and research, health policy evaluations, and general 
population surveys.  It was constructed for use in the Medical Outcomes Study 
(MOS) to broaden the health concepts measured, and improve measurement precision 
for each concept over that achieved by the previous short-form questionnaire, the SF-
20.  
 
 The main improvements in the SF-36, compared to the SF-20, were the 
addition of items which addressed the patients’ vitality and their perception of their 
general health, and those that distinguished between the physical and mental causes 
of role limitations and increased measurement precision for physical, role, social, and 
bodily pain scales (McHorney & Ware, 1995; Ware & Sherbourne, 1992).  
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 The SF-36 has been applied widely to clinical trials and is capable of 
discriminating between healthy patients and those with moderate levels of psychiatric 
or physical illness (McHorney, Ware & Raczek, 1993; McHorney, Ware, Lu & 
Sherbourne, 1994; Russo et al., 1998). 
 
 The SF-36 is a 36-item questionnaire consisting of eight health concepts or 
sub-scales broadly related to quality of life, mental health and social activities: 
 
  physical functioning;  
  role functioning (physical health); 
  role-functioning (emotional health); 
  bodily pain; 
  general health perceptions; 
  vitality/fatigue; 
  social functioning;  
  general mental health; and 
  reported health transition  
  
 Each health concept is comprised of a number of specific questionnaire items 
and the SF-36 also includes a single item that provides an indication of the 
participants’ perceived change in health over the past week. The health concepts are 
summarised in Appendix 8.  
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 The sensitivity of the SF-36 to change in health status of IBS patients was 
tested by examining changes in SF-36 sub-scale scores throughout the treatment 
period and as follow-up two weeks and three months after the completion of the trial. 
  
5.6.6  The Duke-UNC Functional Social Support Questionnaire 
   
 Social support encompasses a number of functions or behaviours which can 
produce a beneficial effect on the health and well-being of people. Functions are 
usually grouped into one of two types: a health-facilitating function (gratifying 
human needs for affection, approval, identity) and a stress-reducing function 
(practical help, problem-solving, advice, information, education) (Suurmeijer et al., 
1995).  
 
 The Duke-UNC Functional Social Support Questionnaire (Duke-UNC) used 
in this trial was adapted, with permission, from Broadhead, Gehlbach, De Gruy, & 
Kaplan (1988).  
 
 The 8-item instrument (Appendix 9) contains questions in two content areas: 
confidant support (items 1,3,4,5,7) which reflects a confidant relationship where 
important matters in life such as social contact and personal/work/financial problems 
are discussed and shared; and affective support (items 2,6,8) which reflects a more 
emotional form of support or caring. 
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 Broadhead, Gehlbach, De Gruy & Kaplan (1988) view the Duke-UNC as a 
short, easy-to-complete questionnaire that should be a cost-effective measurement 
tool, but acknowledge that it does not cover all the dimensions of social support. 
 
5.6.7  The Survey of Recent Life Experiences (SRLE) 
  
 Emotional responses to life stress can influence gastrointestinal function via 
the brain-gut connection and produce symptoms such as pain and altered bowel 
function (Lundberg, 2005; Mayer, 2000).  In IBS sufferers, however, symptoms are 
more likely to be more severe and to occur more frequently (Drossman et al. 1999; 
Salt, 2002). (See Chapter 2).  
 
 The Survey of Recent Life Experiences (SRLE) was developed by Kohn and 
McDonald (1992) to measure daily hassles and to eliminate confusion between them 
and psychological distress that had existed in previous measurements of this kind. 
 
 The SRLE consists of 51 items, covering six concepts which are summarised 
in Appendix 10.  
 
 The six concepts are: 
 social and cultural difficulties  finances  
 work      social acceptability 
 time pressure     social victimisation 
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 Each of the 51 items has a possible score of from one to four and participants 
were asked to rate them accordingly.  
 
 The possible scores were:   
   1.  not at all part of my life 
   2. only slightly part of my life 
   3. distinctly part of my life 
   4. very much part of my life 
 
 5.6.8  The Credibility Scale 
  
 Research has shown that patient expectancy for improvement is an important 
variable affecting the outcome of clinical trials (Linde et al. 2007; O’Malley, Roddey, 
Gartsman & Cook, 2004). The Credibility Scale (Borkovec & Nau, 1972) has been 
successfully used in the evaluation of blinding and has been shown to have a good 
internal consistency and test-retest reliability (Vincent, 1989). The Credibility Scale 
(Appendix 11) was issued to subjects on two occasions throughout the trial (week two 
and week four) to assess the credibility of treatment as perceived by the participants 
and to test the success of patient blinding.  
 
 The 4-item assessment contains questions on how confident the patients are in 
the treatment they are receiving, how confident they are in recommending the 
treatment to a friend suffering a similar complaint, how logical the treatment seems to 
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them, and how successful they think this form of treatment would be in alleviating 
other complaints.   
 
 Each participant was asked to circle the number which most represented their 
credibility on each of the four questions.  The numbers range from one to six - 
number one, at the extreme left, is marked not at all confident and number six is at 
the extreme right is marked extremely confident.  
 
5.7 Summary 
  
 The methodological design of this trial was planned to accommodate results 
of previous trials of hypnotherapy and IBS and to extend them by taking into account 
the holistic view of a patient’s medical profile rather than the physiological aspects 
only. 
 
Important trial characteristics include: 
 
 
• a standardised population with defined baseline features 
• randomisation 
• verification of blinding 
• a parallel design with a placebo control group 
• an appropriate trial length with a baseline observation phase and extended 
follow-up 
• assessment of compliance  
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• outcome measures that are disease specific, symptom specific, and also 
included psychological aspects, degree of stress, quality of life and evidence 
of a support system 
• appropriate data handling and statistical analysis 
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CHAPTER 6           HYPNOTHERAPY AS A TREATMENT FOR IBS: 
   RESULTS OF A RANDOMISED CONTROLLED TRIAL 
 
 
6.1 Introduction 
 
  
 This chapter reports the results of a clinical trial comparing the use of 
standard “gut-directed” imagery (which addressed the participants’ physiological 
symptoms only) used in previous hypnosis trials, with individualised imagery that 
reflected the participants’ complete symptom picture (i.e. physiological, 
psychological, and emotional symptoms). The scientific aims of the trial and the 
methodology were described in detail in Chapter 5. 
  
 A total of 51 subjects diagnosed with IBS (44 females and 7 males) aged from 
17 to 75 years (mean age 40 years) were recruited over a period of twelve months. 
The participants were randomised into one of three groups: 17 into the individualised 
treatment group, 17 into the standard (“gut-directed”) group, and 17 into the control 
group.    
 
 Three participants withdrew during the three-month course of the trial - one 
participant from each group.  Participant 2 withdrew in week 2 due to her daughter’s 
illness; participant 15 in week 1 as her medical practitioner advised her against 
participating in the trial (her scores on the SCL-90-R were high in all four categories 
- anxiety, depression, interpersonal sensitivity, and obsessive-compulsive disorder - 
indicating possible major psychological problems); and participant 14 in week 4 with 
no reason given.  Six participants were excluded due to incomplete records, bringing 
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the total of participants completing the trial to 42 – 14 in each group (Table 13). 
Participants’ data on study entry are shown in Table 14.    
 
Table 13   Number of Participants Completed Bowel Symptom Severity Scores at  
            Each Session in the Study by Treatment Group 
 
Treatment Baseline Week 
1 
Week 
2 
Week 
3 
Week 
4 
Week 
5 
2 wks 3 mths Completed 
all sessions 
Group 1 17 17 17 16 16 16 16 15 14 
Group 2 17 16 16 15 15 15 15 17 14 
Group 3 17 17 17 17 16 16 15 14 14 
 
Note: ID# (Respondents) 2,9,10,14,15,21,31,45,51 (9) have been excluded due to incomplete or missing records 
    (Baseline – End of Treatment periods). 
  
 At the commencement of the trial period (as per the IBSQ), the majority of 
participants (81.6%) suffered abdominal pain most of the time (of these, 59.2% had 
mild to moderate pain and 40.8% had severe to very severe pain) with 61.2% of 
participants experiencing pain several times a week or daily.  Three months prior to 
treatment, 98.0% of participants experienced bloating and 78.4% of participants had 
visual abdominal swelling. Of the 51 participants, 51% were diarrhoea-predominant, 
44.9% constipation-dominant, and 4.1% had alternating diarrhoea and constipation.  
As evidenced in previous research (Chang & Heitkemper, 2002; Salt, 2002), the 
majority of participants in this study were women (86.3%), and the majority of 
sufferers were aged between 20-40 (82.3%).   
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BASELINE DATA – IRRITABLE BOWEL SYMPTOMS 
 
Table 14   Demographic and Baseline Data for Subjects Randomised to the 
Three Treatment Groups 
 
 
  
Variables Group 1 
‘Individualised’ 
Group 
(n=17) 
Group 2 
Standard ‘gut-
directed’ Group 
(n=17) 
Group 3 
Relaxation Group 
 
(n=17) 
Total 
 
 
(n=51) 
 Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
 
Age in year 47.8 38.6-57.1 37.4 31.1-43.6 34.9 27.5-42.4 40.0 35.6-44.5 
% Female 88.2 - 82.4  88.2 - 86.3 - 
Bowel symptom 
severity scale 
        
  Distress 18.7 14.9-22.5 17.8 15.0-20.6 21.8 17.9-25.6 19.3 17.4-21.3 
  Frequency 20.0 17.0-23.0 19.3 17.5-21.1 22.0 19.2-24.8 20.4 19.0-21.8 
  Interference 16.4 12.2-20.6 16.6 13.5-19.6 20.2 16.2-24.1 17.6 15.6-19.7 
SCL-R         
Total         
Depression 19.3 12.8-25.8 15.5 9.9-21.2 17.2 10.9-23.4 17.3 14.0-20.7 
Anxiety 8.7 5.8-11.7 9.2 5.1-13.3 10.5 4.8-16.1 9.5 7.1-11.8 
Obsessive-
Compulsive 
11.4 8.0-14.8 11.1 6.9-15.4 11.8 6.7-16.9 11.4 9.1-13.7 
Interpersonal 
Sensitivity 
10.5 6.0-15.1 8.8 4.9-12.6 8.5 4.9-12.1 9.3 7.1-11.4 
SF - 36         
Physical    
functioning 
75.7 64.0-87.4 92.3 87.3-97.3 79.6 68.8-90.4 82.9 77.4-88.3 
Role-physical 53.6 28.3-78.8 63.3 40.6-86.1 55.8 34.3-77.3 57.7 45.4-70.1 
Pain 53.0 38.8-67.2 65.3 55.9-74.7 54.7 42.4-67.0 57.9 51.4-64.5 
General health 51.6 38.8-64.3 62.7 50.4-75.1 60.0 45.7-73.7 58.1 51.1-65.1 
Vitality 45.4 32.4-58.3 49.3 41.7-56.9 35.8 26.3-45.2 43.8 38.2-49.5 
Social 
functioning 
55.4 36.274.5 73.3 59.5-87.1 59.6 47.2-72.0 63.1 54.6-71.6 
Role-emotional 
 
54.8 32.6-76.9 55.6 30.7-80.4 61.5 38.5-84.6 57.1 44.7-69.6 
Mental health 56.0 44.9-67.1 64.0 56.1-71.9 61.5 50.2-72.9 60.6 55.2-66.0 
 
Data are means +- and 95% CI unless otherwise specified. 
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6.2 Results 
  
 6.2.1 Reliability and Validity Testing 
  
 For the BSS, analysis of variance (ANOVA) was used to determine the 
differences among groups at baseline, end of treatment, and follow-up, and repeated 
measures for trend over time were also determined.  All P values were 2-tailed, 
unless otherwise indicated, and the alpha level of significance was set at 0.05. 
Missing scale and item scores were not replaced.  Data for all other outcome 
measures are presented as per protocol analysis. 
 
 6.2.2 Statistical Analysis 
  
 Bowel Symptom Severity Scale 
  
 Changes on the BSSS for the participants in the study were examined.  The 
BSSS produces three separate scores: symptom frequency, distress, and interference 
associated with each symptom. The results for each of the three groups, from baseline 
to the final session, are shown in Table 15; and changes over time in the Bowel 
Symptom Severity scores, tests of within subjects effects, linear trend, and treatment 
effect are shown in Table 16. 
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 Table 15   Bowel Symptom Severity Scale: Mean Scores and Standard  
           Deviation at Each Session from Randomisation 
 
Note: ID# (Respondents) 2,9,10,14,15, 21,31,45,51 (9) have been excluded due to incomplete or missing records    
                                       (Baseline – End of Treatment periods). 
 
 Table 16   Bowel Symptom Severity Scores changes over time: Tests of Within-
                  Subjects Effects, Linear Trend, and Treatment Effect 
BSSS df F p - value 
Frequency    
   Main effect of scores over time 5 9.65 .000** 
   Linear trend of scores to change over time 1 15.94 .000** 
   Treatment effect 2 .628                                        n.s. 
Distress    
    Main effect of scores over time 5 18.34 .000** 
    Linear trend of scores to change over time 1 44.65 .000** 
    Treatment effect 2 .924                                        n.s. 
Interference    
    Main effect of scores over time 5 16.20 .000** 
    Linear trend of scores to change over time 1 36.95 .000** 
    Treatment effect 2 .545                                         n.s. 
**p <0.01. *p <0.05. 
 
 
 
 
 Baseline Week-1 Week-2 Week-3 Week-4 Week5 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
 
Frequency             
Group 1 
 
20.0 5.4 21.3 5.3 19.6 4.8 18.7 6.1 17.7 6.0 17.5 6.3 
Group 2 19.3 3.2 22.3 4.0 20.1 3.1 20.8 4.7 18.8 4.9 18.5 5.1 
Group 3 22.0 4.6 23.2 4.9 21.9 4.2 20.3 4.8 20.2 5.8 17.5 4.9 
Distress             
Group 1 18.7 6.8 17.1 6.1 14.9 6.5 14.7 7.1 14.3 6.0 12.9 5.1 
Group 2 17.8 4.8 18.6 3.1 16.4 3.7 17.6 4.6 14.6 4.3 14.2 4.2 
Group 3 21.8 6.3 21.7 6.9 17.2 4.6 16.1 4.6 15.3 6.0 14.2 4.3 
Interference 
 
            
Group 1 
 
16.4 7.6 14.5 7.1 13.4 6.3 13.3 7.5 12.5 6.4 11.8 5.0 
Group 2 16.6 5.3 16.4 3.2 14.4 2.9 15.4 4.8 13.4 4.1 13.1 4.8 
Group 3 20.2 6.5 18.8 6.7 14.7 5.1 13.2 3.8 13.9 5.3 11.6 4.1 
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Frequency 
 The mean score for the total sample showed an improvement in symptoms 
from commencement of treatment (22.2) to the end of treatment (17.8) but the 
symptom frequency score increased at the two-week follow-up for Group 1 
(individualised group) and Group 3 (control group), with a further increase at the 
three-month follow-up for all 3 groups (see Table 17). There was a highly significant 
fall in the scores on the frequency subscale over time and a highly significant linear 
trend for scores to change over time. 
 
Table 17   Frequency of Bowel Symptom Severity: Mean Scores and Standard 
                   Deviation at Each Session from Randomisation 
  Bowel Symptoms Severity - Frequency       
Treatment Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD 
Mea
n 
S
D Mean 
S
D Mean 
S
D 
                 
Baseline 20.0 5.4 19.3 3.2 22.0 4.6 20.4 4.5 
Week 1 21.3 5.3 22.3 4.0 23.2 4.9 22.2 4.7 
Week 2 19.6 4.8 20.1 3.1 21.8 4.2 20.5 4.1 
Week 3 18.7 6.1 20.8 4.7 20.3 4.8 19.9 5.2 
Week 4 17.7 6.0 18.8 4.9 20.2 5.8 18.8 5.6 
Week 5 17.5 6.3 18.5 5.1 17.5 4.9 17.8 5.4 
2-week Follow-up 19.6 6.4 18.2 4.8 18.8 5.6 18.9 5.6 
3-month Follow-up 22.0 5.3 20.9 5.1 21.5 5.0 21.5 5.0 
8.89** 4.06* n.s. 
Total 19.5 5.7 19.9 4.5 20.7 5.1 20.0 5.2       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
 
Distress 
 A similar pattern emerged for the scores on the distress subscale with scores 
for the total sample falling from commencement of treatment (19.0) to the end of 
treatment (13.7) but a rise for Group 1 (individualised group) and Group 3 (control 
group) at the two-week follow-up and a further rise for all three groups at the three-
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month follow-up (see Table 18). There was a highly significant fall in the scores on 
the distress subscale over time with a highly significant linear trend for scores to 
change over time. 
 
Table 18   Distress due to Bowel Symptom Severity: Mean Scores and Standard   
                       Deviation at Each Session from Randomisation 
 
 
  Bowel Symptoms Severity - Distress       
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
                 
Baseline 18.7 6.8 17.8 4.8 21.8 6.3 19.3 6.2 
Week 1 17.1 6.1 18.6 3.1 21.7 6.9 19.0 5.8 
Week 2 14.9 6.5 16.4 3.7 17.2 4.6 16.1 5.1 
Week 3 14.7 7.1 17.6 4.6 16.1 4.6 16.1 5.6 
Week 4 14.3 6.0 14.6 4.3 15.3 6.0 14.7 5.4 
Week 5 12.9 5.1 14.2 4.2 14.2 4.3 13.7 4.5 
2-week Follow-
up 15.6 7.8 14.1 4.5 15.5 5.9 15.1 6.1 
3-month 
Follow-up 16.5 7.0 20.9 15.0 16.9 5.6 16.1 5.7 
13.50** 23.26** n.s. 
Total 15.6 6.6 16.0 4.4 17.3 6.0 16.3 5.8       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
 
 
 
Interference 
 A similar pattern emerged for the scores on the interference subscale with 
symptoms for the total sample improving from commencement of treatment (16.5) to 
the end of treatment (12.2). There was a rise in symptoms in Group 1 (individualised 
group) and Group 3 (control group) at the two-week follow-up and a further rise for 
all three groups at the three-month follow-up (see Table 19).  
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Table 19   Interference due to Bowel Symptom Severity: Mean Scores and Standard  
                         Deviation at Each Session from Randomisation 
 
  Bowel Symptoms Severity - Interference       
Treatment Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
                 
Baseline 16.4 7.6 16.6 5.3 20.2 6.5 17.6 6.6 
Week 1 14.5 7.1 16.4 3.2 18.8 6.7 16.5 6.1 
Week 2 13.4 6.3 14.4 2.9 14.7 5.1 14.1 4.9 
Week 3 13.3 7.5 15.4 4.8 13.2 3.7 14.0 5.6 
Week 4 12.5 6.4 13.4 4.1 13.9 5.3 13.2 5.3 
Week 5 11.8 4.9 13.1 4.8 11.6 4.1 12.2 4.6 
2-week Follow-up 13.7 7.5 12.0 4.3 14.2 5.9 13.3 6.0 
3-month Follow-up 15.3 8.3 13.8 4.7 15.5 5.4 14.8 6.3 
11.37*** 14.89*** n.s. 
Total 13.9 7.0 14.4 4.5 15.3 5.9 14.5 5.9       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
 
 The main effect and linear trend in all three symptom categories  (frequency, 
distress, and interference) for all three treatment groups were significant. 
 
Abdominal Pain 
 Abdominal pain for all three groups was then compared (see Table 20 and 
Figure 5).  
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had less abdominal pain than the other two 
groups in week 1 of treatment. Pain was slightly less in week 2 of treatment, 
increased slightly in week 3, lessened a little in week 4, and lessened more in week 5.  
At the end of treatment, Group 1 still had less abdominal pain than the other two 
groups. 
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Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had more abdominal pain at baseline 
and in week 1 than Group 1, but less than Group 3 (control group). The pain lessened 
in week 2 at the same rate as Group 1 then worsened in week 3 before lessening in 
weeks 4 and 5. At the end of the treatment period, Group 2 had more abdominal pain 
than the other two groups. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had more abdominal pain than the other two groups 
in the first week of treatment.  However, the pain lessened gradually over the 
remaining four weeks of treatment - weeks 2 to 5. At the end of treatment, Group 3 
had less pain than Group 2 but more than Group 1. 
 The mean score for the total sample showed a lessening of pain from 
commencement of treatment (4.5) to the end of treatment (3.1). The main effect and 
linear trend were highly significant. 
 
Table 20   Irritable Bowel Syndrome: Abdominal Pain: Mean Scores and  Standard                 
                       Deviation at Each Session from Randomisation 
 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Week 1 4.0 2.2 4.4 2.1 5.1 2.8 4.5 2.4 
Week 2 3.8 2.8 3.8 2.0 4.9 2.6 4.2 2.5 
Week 3 4.1 3.3 5.0 2.8 4.3 3.0 4.5 3.0 
Week 4 4.0 2.7 3.4 2.4 4.0 2.5 3.8 2.5 
Week 5 2.5 2.2 3.5 2.8 3.2 2.0 3.1 2.3 
5.54** 17.90** n.s. 
Total 3.7 2.6 4.0 2.4 4.3 2.6 4.0 2.6       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
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Figure 5        Irritable Bowel Syndrome - Abdominal Pain by Treatment Groups and 
     Control Group 
 
 
 
Bloating 
 Bloating was compared for all three groups (see Table 21 and Figure 6). 
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had less bloating overall at the 
commencement of treatment than the other two groups.  From week 2 to week 5 the 
bloating continued to lessen (with a slight rise in week 4) and, at the end of treatment, 
Group 1 still had less bloating overall than the other two groups. 
 
Comparison of Group 2 to Groups 1&3 
 At the commencement of treatment, Group 2 (standard ‘gut-directed’ group) 
had more bloating than Group 1, but less than Group 3.  In week 2, the bloating was 
less but the score was still higher than Group 1 and less than Group 3.  Bloating was 
more than the other two groups in week 3, and in week 4 the symptoms were the 
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same as group 1 but still more than group 3.  At the end of treatment, bloating was 
still more than Group 1 and slightly less than Group 3. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had the highest score for bloating overall than the 
other two groups at commencement of treatment.  Bloating lessened gradually over 
weeks 2 to 5 but, at the end of treatment, Group 3 still had higher scores for bloating 
than the other two groups. 
  
 The mean score for the total sample showed an improvement in bloating from 
commencement of treatment (5.2) to the end of treatment (3.3). The main effect and 
linear trend were highly significant.  
 
Table 21   Irritable Bowel Syndrome - Bloating: Mean Scores and Standard Deviation  
                                            at  Each Session from Randomisation 
 
  Irritable Bowel Syndrome - Bloating       
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Week 1 4.2 2.5 5.4 2.5 6.0 2.4 5.2 2.5 
Week 2 4.0 3.0 5.1 2.6 5.3 2.4 4.8 2.7 
Week 3 3.8 2.4 5.6 3.0 4.8 3.2 4.7 2.9 
Week 4 3.9 2.6 3.9 2.8 3.5 2.6 3.8 2.7 
Week 5 2.7 2.5 3.6 3.2 3.7 2.2 3.3 2.6 
9.23** 33.40** n.s. 
Total 3.7 2.6 4.7 2.9 4.7 2.7 4.4 2.8       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
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Figure 6     Irritable Bowel Syndrome - Bloating by Treatment Groups and Control  
         Group 
 
 
 
Constipation 
 The scores for constipation were then compared for all three groups (see 
Table 22 and Figure 7). 
 
Comparison of Group 1 to Groups 2&3 
 At week 1, the score for Group 1 (individualised group) was slightly higher 
than Group 2 but less than Group 3.  From week 2 to 4 constipation lessened, and in 
week 5 it rose slightly.  At the end of treatment, Group 1 had less constipation than 
the other two groups. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had less constipation at the 
commencement of treatment than the other two groups but the scores rose in weeks 2 
and 3.  In weeks 4 and 5 the scores for constipation dropped and, at the end of 
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treatment, Group 2 had a slightly higher score than Group 1 and a slightly lower score 
than Group 3. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had the highest score for constipation compared to 
the other two groups.  During weeks 2 to 4 constipation gradually lessened but 
increased in week 5. At the end of treatment, Group 3 still had the highest score for 
constipation.   
  
 The mean score for the total sample showed an improvement in symptoms 
from the commencement of treatment (4.0) to the end of treatment (3.2). The main 
effect and linear trend were significant. 
 
Table 22   Irritable Bowel Syndrome - Constipation: Mean Scores and Standard 
                                        Deviation at Each Session from Randomisation 
 
  Irritable Bowel Syndrome - Constipation       
     
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Week 1 3.6 3.0 3.5 2.9 4.9 2.6 4.0 2.9 
Week 2 3.5 3.5 3.8 3.1 4.0 2.9 3.8 3.1 
Week 3 3.3 2.8 4.5 3.2 3.2 2.7 3.6 2.9 
Week 4 2.8 2.4 3.2 2.5 2.6 2.4 2.9 2.4 
Week 5 3.1 2.5 3.2 3.2 3.4 3.0 3.2 2.8 
2.66* 5.43* n.s. 
Total 3.3 2.8 3.6 3.0 3.6 2.8 3.5 2.8       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
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Figure 7   Irritable Bowel Syndrome - Constipation by Treatment Groups and Control                  
                                                             Group 
  
 
Diarrhoea 
 Scores for diarrhoea were then examined for the three treatment groups (see 
Table 23 and Figure 8).   
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had higher scores than both Group 2 and 
Group 3 at the commencement of treatment.  Improvement was gradual through 
weeks 2 to 4 (with a slight rise in week 5), the final score being lower than the other 
two groups. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had a lower score than Group 1 but a 
higher score than Group 3 at the commencement of treatment.  Symptoms improved 
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in week 2, worsened in week 3, improved in week 4, and worsened again in week 5.  
At the end of treatment, Group 2 had higher scores than both the other two groups. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had the lowest score for diarrhoea at the 
commencement of treatment.  Symptoms lessened in week 2, worsened in weeks 3 
and 4, and then lessened again in week 5.  At the end of treatment, Group 3 had a 
higher score than Group 1 but a lower score than Group 2. 
 
 The mean score for the total sample showed a lessening of symptoms from 
commencement of treatment (3.1) to the end of treatment (2.6). The main effect and 
linear trend were not significant. 
 
Table 23   Irritable Bowel Syndrome - Diarrhoea: Mean Scores and Standard 
                                      Deviation at Each Session from Randomisation 
 
  Irritable Bowel Syndrome - Diarrhoea       
Treatment Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Week 1 3.3 2.7 3.1 3.1 2.9 2.6 3.1 2.7 
Week 2 3.2 2.7 2.9 2.1 2.5 3.0 2.9 2.6 
Week 3 3.0 2.9 3.5 3.1 3.4 2.9 3.3 2.9 
Week 4 1.9 2.4 2.8 2.8 3.5 3.1 2.7 2.8 
Week 5 2.1 2.5 3.2 2.8 2.5 2.4 2.6 2.6 
n.s. n.s. n.s. 
Total 2.7 2.6 3.1 2.8 3.0 2.7 2.9 2.7       
 
F1=main effect; F2=linear trend; F3=treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
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 Figure 8    Irritable Bowel Syndrome - Diarrhoea by Treatment Groups and Control 
             Group 
 
 
 
  
 
 The overall severity of symptoms (pain, bloating, constipation, and diarrhoea) 
had gradually decreased in all three groups from commencement of treatment (5.2) to 
the end of treatment (3.4) with Group 2 having a worsening of symptoms in week 3 
(see Table 24 and Figure 9).  The main effect and linear trend were highly 
significant.  
 
 
Table 24   Irritable Bowel Syndrome - Overall Severity: Mean Scores and Standard  
                       Deviation at Each Session from Randomisation 
 
  Irritable Bowel Syndrome - Overall Severity       
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Week 1 4.8 2.0 4.9 1.9 5.7 2.0 5.2 2.0 
Week 2 4.6 2.8 4.6 1.8 5.4 1.9 4.9 2.2 
Week 3 4.1 2.6 5.3 2.7 4.4 2.5 4.6 2.6 
Week 4 3.8 2.2 3.7 2.5 3.7 2.6 3.7 2.4 
Week 5 3.0 2.1 3.5 3.0 3.7 1.8 3.4 2.3 
8.67** 28.96** n.s. 
Total 4.1 2.4 4.4 2.4 4.6 2.3 4.4 2.4       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant. **P <0.01; *P <0.05 
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SF-36 General Health Survey 
Table 25    General Health Outcomes Short Form 36 (SF-36): Mean Scores and Standard  
Deviations, by Treatment Group, by Health Concepts at Each Session from Randomisation 
 Baseline Week-1 Week-2 Week-3 Week-4 Week5 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
 
Physical 
Functioning 
            
Group 1 75.7 20.3 81.8 14.9 81.8 17.5 84.6 12.6 84.6 14.6 84.3 17.9 
Group 2 92.3 9.0 91.3 12.2 92.0 10.1 89.3 12.8 96.0 7.6 94.7 6.1 
Group 3 79.6 17.9 78.1 22.6 80.4 22.2 80.8 24.7 80.8 24.5 82.7 25.3 
Role-Physical              
Group 1 53.6 43.7 58.9 42.3 60.7 41.3 51.8 46.5 50.0 40.4 60.7 45.7 
Group 2 63.3 41.0 65.0 40.0 68.3 36.0 63.3 35.2 75.0 37.8 81.7 29.1 
Group 3 55.8 35.6 51.9 45.2 51.9 37.5 65.4 31.5 51.9 42.7 51.9 45.0 
Pain             
Group 1 53.0 24.6 60.2 18.8 54.1 21.0 62.2 23.1 61.0 24.9 67.2 17.9 
Group 2 65.3 20.0 67.7 15.5 70.1 17.5 66.8 25.6 78.3 19.4 77.1 24.6 
Group 3 54.7 20.3 52.9 18.8 54.5 21.5 65.5 19.7 68.8 19.4 67.9 18.2 
General health             
Group 1 51.6 22.1 52.5 19.4 52.4 20.4 54.3 21.4 56.4 20.8 59.9 21.4 
Group 2 62.3 22.4 62.5 23.5 62.1 23.9 62.1 20.6 63.5 25.1 65.3 25.3 
Group 3 60.0 23.2 62.4 24.6 60.9 20.8 63.5 21.8 64.5 21.3 63.3 24.4 
Vitality             
Group 1 
 
45.4 22.5 42.1 21.6 43.2 26.0 41.8 26.6 43.6 29.6 48.9 27.8 
Group 2 49.3 13.7 50.0 21.8 48.0 21.3 51.3 18.0 58.0 20.7 59.7 23.3 
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Figure 9
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  Note: ID# (Respondents) 2,9,10,14,15,21,31,45,51 (9) have been excluded due to incomplete or missing records.  
  
Table 26   Medical Outcomes Index Mean Changes Over Time: Tests of Within-
Subjects Effects, Linear Trend, and Treatment Effect 
 
**p <0.01.*p <0.05.  Note: ID# (Respondents) 2,9,10,14,15,21,31,45,51 (9) have been excluded due to  
incomplete or missing records during sessions (Baseline – End of treatment periods). 
 
 
 The effects of the treatment on the subscales on the SF-36 (a measure of 
quality of life) were examined over the five treatment sessions; the results are shown 
in Table 25. Within-subjects effects, linear trend, and treatment effect are shown in 
SF-36 df F p - value 
Physical functioning    
   Main effect of scores over time  2.7 .022* 
   Linear trend of scores to change over time  6.48 .015* 
   Treatment effect  2.57 n.s. 
Role-physical    
    Main effect of scores over time 5 .35 n.s. 
    Linear trend of scores to change over time 1 .66 n.s. 
    Treatment effect 2 .99 n.s. 
Pain    
    Main effect of scores over time 5 6.23 .000** 
    Linear trend of scores to change over time 1 23.99 .000** 
    Treatment effect 2 2.15 n.s. 
General health    
    Main effect of scores over time 5 2.27 .049* 
    Linear trend of scores to change over time 1 6.00 .019* 
    Treatment effect 2 .704 n.s. 
Vitality    
    Main effect of scores over time 5 3.20 .008** 
    Linear trend of scores to change over time 1 5.68 .022* 
    Treatment effect 2 2.20 n.s. 
Social functioning    
    Main effect of scores over time 5 5.13 .000** 
    Linear trend of scores to change over time 1 11.77 .001** 
    Treatment effect 2 1.164 n.s. 
Role-emotional    
    Main effect of scores over time 5 1.63 .153 
    Linear trend of scores to change over time 1 4.45 .041* 
    Treatment effect 2 .586 n.s. 
Mental health    
    Main effect of scores over time 5 5.99 .000** 
    Linear trend of scores to change over time 1 15.61 .000** 
    Treatment effect 2 .488 n.s. 
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Table 26.  The SF-36 has eight subscales: physical functioning, role-physical, pain, 
general health, vitality, social functioning, role-emotional, and mental health. 
 
Physical Functioning 
 The scores relating to physical functioning indicate the extent to which health 
limits physical activities such as self-care, walking, climbing stairs, bending, lifting, 
and moderate and vigorous exercise.  A high score indicates that participants perform 
all types of physical activities without limitations due to health.  A low score 
indicates that participants are greatly limited in performing all physical activities. 
 
  All three groups had above average scores, indicating that there were few 
limitations in performing physical activities due to health (see Table 27 and Figure 
10), and all three groups showed improvement in physical functioning at the end of 
the follow-up period compared to baseline. 
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had lower scores at baseline than both Groups 
2 and 3 but, at the commencement of treatment, had lower scores than Group 2 and 
higher scores than Group 3.  Improvement was gradual during weeks 2 to 4 with a 
slight decline at week 5; lower at the two-week follow-up; then slightly higher than 
week 5, and higher than baseline, at the three-month follow-up. 
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Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had the highest score of the three 
groups both at baseline and at commencement of treatment.  There was a slight 
improvement in week 2; a slight decline in week 3; a greater improvement in week 4; 
and, although there was a slight decline again in week 5, the score for that week was 
higher than scores at both week 1 and baseline. There was an improvement in 
symptoms during both the two-week follow-up and the three-month follow-up (with a 
slightly lower score at the two-week follow–up). The scores for the follow-up period 
were higher than baseline and at the commencement of treatment. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had a higher baseline score than Group 1 and a lower 
baseline score than Group 2, but had the lowest score of all three groups at the 
commencement of treatment. There was a gradual improvement in symptoms during 
the remainder of the treatment sessions and during the follow-up period (with a 
slightly lower score at the three-month follow-up), with both scores at follow-up 
higher than those at baseline. 
 
 The mean score for the total sample showed improvement in physical 
functioning from commencement of treatment (84.0) to the end of treatment (87.5). 
The main effect and the linear trend were highly significant. 
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Table  27                      Secondary Health Outcome – Physical Functioning 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 75.7 20.3 92.3 9.0 79.6 17.8 82.9 17.5 
Week 1 81.8 14.9 91.3 12.2 78.1 22.6 84.0 17.4 
Week 2 81.8 17.5 92.0 10.1 80.4 22.2 85.0 17.5 
Week 3 84.6 12.6 89.3 12.8 80.8 24.7 85.1 17.2 
Week 4 84.6 14.6 96.0 7.6 80.8 24.5 87.5 17.5 
Week 5 84.3 17.9 94.7 6.1 82.7 25.3 87.5 18.2 
2-week 
Follow-up 80.7 26.0 96.7 5.2 90.4 14.2 89.4 18.1 
3-month 
Follow-up 84.6 18.5 96.0 5.4 90.0 13.1 90.4 13.9 
3.05** 9.99** n.s. 
Total 82.3 17.9 93.5 9.1 82.8 20.8 86.5 17.2       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant.  **P <0.01; *P <0.05 
 
Figure 10   Secondary Health Outcome - Physical Functioning by Treatment Groups 
                                  and Control Group 
 
 
Role Functioning – physical 
 Role functioning – physical is the extent to which physical health interferes 
with work or daily activities, such as accomplishing less than wanted, and limitations 
or difficulty in performing activities.  A high score indicates that there are no limits 
due to physical health.  A low score indicates that there are limits with work and daily 
activities due to physical health. 
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 At baseline, all three groups had only slightly above average scores which 
showed some indication of interference in their work or daily activities due to 
physical health. The scores for all three groups at the 3-month follow-up were higher 
than at baseline (see Table 28 and Figure 11). 
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had the lowest scores of the three groups at 
baseline and lower scores than Group 2, but higher scores than Group 3 at the 
commencement of treatment. The participants’ physical health improved slightly in 
week 2, lessened in weeks 3 and 4, and then improved to the same score as in week 2.  
Interference with work or activities worsened slightly during the 2-week follow-up 
and then, in the 3-month follow-up, the participants’ physical health improved to the 
same score as in week 1 and higher than baseline. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had higher scores than the other two 
groups at baseline and at the commencement of treatment, with a gradual 
improvement in symptoms (with the exception of week 3) through to week 5. There 
was a slight decline during the follow-up period but the follow-up scores were higher 
than at baseline and at the commencement of treatment. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had higher scores than Group 1 and lower scores than 
Group 2 at baseline, but lower scores than the other two groups at the commencement 
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of treatment.  There was an improvement in week 3 and then the scores for weeks 4 
and 5 were the same as at the commencement of treatment. However, symptoms 
improved during the follow-up period, both scores for the 2-week follow-up and the 
3-month follow-up being higher than the scores at baseline and at the commencement 
of treatment. 
 
 The mean score for the total sample showed improvement in participants’ 
limitations due to physical health from commencement of treatment (58.9) to the end 
of treatment (65.5). The main effect and linear trend were not significant. 
  
Table 28                  Secondary Health Outcome – Role Physical 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 53.6 43.7 63.3 41.0 55.8 35.6 57.7 39.6 
Week 1 58.9 42.3 65.0 39.9 51.9 45.0 58.9 41.6 
Week 2 60.7 41.3 68.3 35.9 51.9 37.4 60.7 37.9 
Week 3 51.8 46.5 63.3 35.2 65.4 31.5 60.1 37.9 
Week 4 50.0 40.4 75.0 37.8 51.9 42.6 59.5 40.9 
Week 5 60.7 45.7 81.7 29.1 51.9 45.0 65.5 41.3 
2-week 
Follow-up 51.8 46.5 80.0 35.6 63.5 44.0 65.5 42.8 
3-month 
Follow-up 58.9 40.0 71.7 41.0 65.4 38.9 65.5 39.4 
0.6 2.15 n.s. 
Total 55.8 42.2 71.0 36.7 57.2 39.4 61.7 39.9       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect ; n.s. = not significant.  **P <0.01; *P <0.05 
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Figure 11     Secondary Health Outcome - Role Physical -Treatment Groups and     
                                               Control Group 
 
  
Bodily Pain 
 Bodily pain is the intensity of pain and effect of pain on normal work, both 
inside and outside the home.   A high score indicates that there was no pain or limits 
in the week before the completion of the questionnaire. A low score indicates severe 
and extremely limiting pain. 
 
 The scores for all three groups indicated that pain had an effect on the 
participants’ normal work, and all three groups showed improvement in symptoms 
from the commencement of treatment (60.6) to the end of the treatment sessions 
(71.0)  (see Table 29 and Figure 12). 
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had the lowest score of the three groups at 
baseline, and a lower score than Group 2, and a higher score than Group 3 at the 
commencement of treatment.  Pain increased in week 2, lessened in week 3, increased 
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slightly again in week 4 and then lessened in week 5 to a higher score than at baseline 
and at the commencement of treatment.  During the 2-week follow-up, symptoms 
worsened slightly but improved in the three-week follow-up to higher scores than at 
baseline and at the commencement of treatment. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had higher scores than the other two 
groups both at baseline and at the commencement of treatment  - improvement in 
symptoms was also higher than the other two groups at the end of treatment.  Apart 
from a slight worsening of symptoms in week 3, symptoms gradually improved up 
until week 5.  There was a slight worsening of symptoms during the follow-up period, 
but the scores during both the 2-week follow-up and the 3-month follow-up were 
higher than the scores at baseline and at the commencement of treatment. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had higher scores than Group 1 and lower scores than 
Group 2 at baseline, but lower scores than either of the other two groups at the 
commencement of treatment, indicating that pain had more of an effect on their 
normal work than on participants in the other two groups.  Except for a slight decline 
in week 5, symptoms improved gradually over the treatment period with the scores in 
week 5 being higher than the scores for the group at baseline and at commencement 
of treatment.  Symptoms continued to improve at the 2-week follow-up but declined 
at the 3-month follow-up.  The follow-up scores were higher than the scores both at 
baseline and at the commencement of treatment. 
 238 
 The main effect and the linear trend were highly significant. 
 
Table  29      Secondary Health Outcome – Pain 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 
F
3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 53.0 24.6 65.3 16.9 54.7 20.3 57.9 21.0 
Week 1 60.2 18.8 67.6 15.5 52.9 18.8 60.6 18.3 
Week 2 54.1 21.0 70.1 17.5 54.5 21.5 60.0 21.0 
Week 3 62.2 23.1 66.8 25.5 65.5 19.7 64.9 22.6 
Week 4 61.0 24.9 78.3 19.4 68.8 19.4 69.6 22.1 
Week 5 67.2 17.9 77.1 24.6 67.8 18.2 71.0 20.7 
2-week 
Follow-up 58.1 23.5 76.7 22.8 72.8 20.3 69.3 23.2 
3-month 
Follow-up 61.3 23.6 71.2 17.7 61.8 19.8 65.0 20.5 
5.22** 13.05** 
 
n.s
. 
Total 59.7 22.0 71.7 20.3 62.4 20.4 64.8 21.5       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect ; n.s. = not significant. **P <0.01; *P <0.05 
 
 
Figure 12     Secondary Health Outcome - Pain by Treatment Groups and Control              
                                                          Group 
 
 
General Health Perceptions 
 General Health Perceptions are the personal evaluations of health by the 
participants.  A high score indicates that the participants perceive their health as 
excellent.  A low score indicates that participants perceive their health as poor. 
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 All participants rated their health as slightly above average at baseline (58.1) 
and at the commencement of treatment (59.1), and all felt they had improved a little 
by the end of the five weeks of treatment (62.9) (see Table 30 and Figure 13).  
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had lower scores than the other two groups at 
baseline and at the commencement of treatment but their perception of health 
continued to improve through to week 5.  During the follow-up period, scores 
dropped slightly in the 2-week follow-up but increased at the 3-month follow-up, 
with the final scores being higher than those in week 1 and at baseline. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had higher scores than the other two 
groups at baseline and at the commencement of treatment and, apart from slightly 
lower scores in weeks 2 and 3, continued to improve both throughout the treatment 
period and the follow-up period.  Scores at the end of both the treatment and follow-
up periods were slightly higher than at baseline and at the commencement of 
treatment. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had higher scores than Group 1 and lower scores than 
Group 2 at baseline, and slightly lower scores than group 2 and higher scores than 
group 1 at the commencement of treatment.  Even though there was a slight variation 
in scores throughout treatment, perception in health continued to improve overall 
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compared to baseline. At the two-week follow-up the scores were slightly higher than 
at the commencement of the treatment but at the 3-month follow-up the scores were 
slightly lower. The follow-up scores were higher than at baseline. 
 The main effect and linear trend were significant. 
 
Table 30                   Secondary Health Outcome – General Health Perceptions 
 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 51.6 22.1 62.7 22.4 59.7 23.2 58.1 22.5 
Week 1 52.5 19.4 62.5 23.5 62.4 24.6 59.1 22.5 
Week 2 52.4 20.3 62.1 23.9 60.8 20.8 58.5 21.7 
Week 3 54.3 21.4 62.1 20.6 63.5 21.8 60.0 21.1 
Week 4 56.4 20.8 63.5 25.1 64.5 21.3 61.5 22.4 
Week 5 59.9 21.3 65.3 25.3 63.3 24.4 62.9 23.3 
2-week 
Follow-up 57.8 18.7 66.1 23.8 62.8 26.8 62.3 22.9 
3-month 
Follow-up 59.4 20.4 67.3 23.4 60.2 24.9 62.5 22.7 
2.33* 5.73* 
 
n.s
. 
Total 55.5 20.2 63.9 22.9 62.2 22.8 60.6 22.2       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant.   **P <0.01; *P <0.05 
 
 
Figure 13   Secondary Health Outcome - General Health Perceptions by Treatment                                         
    Groups and Control Group 
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Vitality 
 Vitality indicates how energetic or tired participants are.  A high score 
indicates that the participants felt full of energy during the week prior to their 
treatment session. A low score on this health measure indicated that the participants 
felt tired and worn out all the time. The energy level increased in all three groups – 
the mean score for the total sample was 42.7 at the commencement of treatment and 
52.0 at the end of treatment  (see Table 31 and Figure 14). 
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had lower scores than Group 2 but higher 
scores than Group 3 at both baseline and at the commencement of treatment sessions.  
The participants showed a gradual improvement in energy levels throughout the 
treatment period with the exception of a slight decrease in week 3.  Scores decreased 
during the follow-up period. At the two-week follow-up, scores were higher than 
those at baseline and at the commencement of treatment, and at the three-month 
follow-up, scores were higher than at baseline but lower than at the commencement 
of treatment. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had higher scores than the other two 
groups at baseline and at the commencement of treatment and, except for a slight 
drop in week 2, continued to improve throughout the treatment period. During the 2-
week follow-up period, energy levels continued to rise but dropped slightly in the 3-
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month follow-up. Once again, the scores at the 3-month follow-up were higher than 
those at baseline and at the commencement of treatment. 
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had the lowest scores on vitality at baseline and at the 
commencement of treatment, and except for a slight decline in energy in week 4, 
participants continued to improve during the treatment period.  Symptoms worsened 
slightly during both the 2-week follow-up and the 3-month follow-up but the scores 
were still above those at baseline and at the commencement of treatment. 
 
 The main effect and linear trend were highly significant.  
 
 
Table 31      Secondary Health Outcome – Vitality 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 45.4 22.5 49.3 13.7 35.8 15.7 43.8 18.1 
Week 1 42.1 21.6 50.0 21.8 35.0 16.2 42.7 20.6 
Week 2 43.2 26.0 48.0 21.3 36.2 17.5 42.7 22.0 
Week 3 41.8 26.6 51.3 18.0 39.6 21.9 44.5 22.4 
Week 4 43.6 29.6 58.0 20.7 36.2 21.1 46.4 25.3 
Week 5 48.9 27.7 59.7 23.3 46.5 20.0 52.0 24.1 
2-week 
Follow-up 46.4 26.6 64.0 20.6 44.6 19.9 52.1 23.8 
3-month 
Follow-up 42.9 25.2 62.3 16.2 44.6 21.6 50.4 22.6 
4.66** 15.57** n.s. 
Total 44.3 25.1 55.3 20.0 39.8 19.2 46.8 22.6       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant.  **P <0.01; *P <0.05 
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Figure 14    Secondary Health Outcome - Vitality by Treatment Groups and Control 
                                                               Group 
 
  
Social Functioning 
 Social functioning is the extent to which physical health or emotional 
problems interfere with normal social activities.  A high score indicates that there is 
no interference from health in social activities. A low score indicates extreme 
interference with social activities. 
 
 The scores of all three groups indicated that the participants’ physical health 
or emotional problems interfered to some degree with their social activities.  All three 
groups showed improvement from commencement of treatment (72.3) to the end of 
treatment (80.4). (See Table 32 and Figure 15). 
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had lower scores than both Group 2 and 
Group 3 at baseline, and lower scores than Group 2 and slightly higher scores than 
Group 3 at the commencement of treatment. The participants showed a gradual 
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improvement in the extent to which physical health or emotional problems interfere 
with normal social activities throughout the treatment period with the exception of a 
slight decrease in weeks 3 and 4.  Scores decreased during the follow-up period to 
below those in week 1, but above the scores at baseline. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) showed the least interference from 
health in their social activities at baseline and at the commencement of treatment 
compared to the other two groups.  Except for a slight decrease in week 3, the group 
continued to improve throughout the treatment period with a decrease during the 
follow-up period. The follow-up scores, however, were higher than those at baseline 
and in the first week of treatment, indicating that their social functioning had 
improved. 
 
Comparison of Group 3 to Groups 1&2  
 Group 3 (control group) had higher scores than Group 1 and lower scores than 
Group 2 at baseline and the lowest scores of the three groups at the commencement 
of treatment. Scores declined slightly in week 2, rose sharply in week 3, decreased in 
weeks 4 and 5 with the scores at the end of treatment higher than those in week 1.  
Scores declined during the follow-up period but were higher than at baseline and in 
the first week of the treatment period. 
 
 The main effect was highly significant but the linear effect was not 
significant.   
 245 
Table 32                      Secondary Health Outcome – Social Functioning 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 55.4 33.1 73.3 24.9 59.6 20.5 63.1 27.3 
Week 1 69.6 28.9 78.3 21.4 68.3 23.2 72.3 24.5 
Week 2 73.2 25.9 79.2 19.9 64.4 22.7 72.6 23.1 
Week 3 68.8 25.4 74.2 20.3 80.8 18.8 74.4 21.7 
Week 4 69.6 28.0 80.8 21.1 76.0 20.1 75.6 23.3 
Week 5 75.0 29.0 87.5 23.1 77.9 22.9 80.4 25.2 
2-week 
Follow-up 65.2 26.5 80.8 20.0 76.0 23.6 74.1 23.8 
3-month 
Follow-up 60.7 30.2 80.8 18.2 71.2 21.3 71.1 24.6 
3.75** 3.91 n.s. 
Total 67.2 28.2 79.4 21.0 71.8 22.0 73.0 24.4       
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant.  **P <0.01; *P <0.05 
 
 
 
Figure 15   Secondary Health Outcome - Social Functioning by Treatment Groups and 
     Control Group 
 
 
Role Functioning-emotional  
 Role-functioning-emotional is the extent to which emotional problems 
interfere with work or other daily activities, including decreased time spent on 
activities, accomplishing less, and not working as carefully as usual.  A high score 
indicates no limits due to emotional problems. A low score indicates that there are 
limits due to emotional problems. 
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 At baseline, and in the first week of treatment, the scores for all three groups 
indicated that emotional problems were part of the patients’ symptom picture (see 
Table 33 and Figure 16). 
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had lower scores than the other two groups at 
baseline, and lower scores than Group 2, and higher scores than Group 3 at the 
commencement of treatment. There was a decline in scores in week 2, a gradual 
improvement through to week 5, and then a further decline during the follow-up 
period.  The scores in the 2-week follow-up period were the same as at baseline with 
the scores in the 3-month follow-up lower than scores both at baseline and in the first 
week of treatment. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had a higher score than Group 1 and a 
lower score than Group 3 at baseline with higher scores than the other two groups at 
the commencement of treatment. Group 2 showed improvement in emotional 
functioning with identical scores from week 3 to the 2-week follow-up.  The scores 
then increased further in the 3-month follow-up to a higher level than scores both at 
baseline and in week 1.  
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had the highest scores at baseline and the lowest 
scores of the three groups at the commencement of treatment.  Scores for weeks 1 and 
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2 were the same with an improvement in week 3.  Symptoms worsened slightly in 
week 4 and then improved in week 5.  There was a slight decline in scores during the 
2-week follow-up and an improvement in the 3-month follow-up, with scores for the 
two-week follow-up period being both lower, and scores for the three-month follow-
up being higher than at baseline and at the commencement of treatment. 
 
 The mean score for the total sample showed an improvement in limits due to 
emotional problems from the commencement of the treatment (53.2) to the end of 
treatment (65.1). The main effect and linear effect were not significant. 
 
Table 33                       Secondary Health Outcome – Role Emotional 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 54.8 38.4 55.6 44.8 61.5 38.1 57.1 39.8 
Week 1 52.4 44.7 57.8 38.8 48.7 44.3 53.2 41.7 
Week 2 42.9 42.2 66.7 43.6 48.7 46.4 53.2 44.2 
Week 3 54.8 50.0 73.3 36.1 69.2 37.2 65.9 41.3 
Week 4 59.5 41.7 73.3 40.2 51.3 44.3 61.9 42.0 
Week 5 59.5 39.6 73.3 45.8 61.5 44.8 65.1 42.9 
2-week 
Follow-up 54.8 40.5 73.3 42.2 59.0 47.4 62.7 43.1 
3-month 
Follow-up 50.0 40.8 80.0 35.2 64.1 44.0 65.1 41.0 
1.53 3.86 n.s. 
Total 53.6 41.3 69.2 40.6 58.0 42.6 60.5 41.9       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant.  **P <0.01; *P <0.05 
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Figure 16   Secondary Health Outcome - Role Emotional by Treatment Groups and  
     Control Group 
 
  
Mental Health 
 Mental health includes depression and anxiety.  A high score indicates that 
participants felt peaceful, happy and calm during the week prior to the treatment 
session. A low score indicates that the participants had felt nervous or depressed. 
 
 The scores at baseline and at the commencement of treatment for all three 
groups showed that participants had experienced some level of depression or anxiety 
(see Table 34 and Figure 17).  
 
Comparison of Group 1 to Groups 2&3 
 Group 1 (individualised group) had lower scores than Groups 2 and 3 at 
baseline and lower scores than Group 2 and slightly higher scores than Group 3 at the 
commencement of treatment.  Symptoms improved throughout the treatment period 
and declined slightly in weeks 4 and 5 and during the follow-up period, with the 
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scores at the 3-month follow-up being higher than scores at baseline and only slightly 
above those in the first week of treatment. 
 
Comparison of Group 2 to Groups 1&3 
 Group 2 (standard ‘gut-directed’ group) had higher scores than Groups 1 and 
3 both at baseline and at the commencement of treatment. Symptoms continued to 
gradually improve until a decline in week 5, with a further improvement in symptoms 
during the follow-up period.  The follow-up scores were higher than at baseline and 
at week 1 of treatment.  
 
Comparison of Group 3 to Groups 1&2 
 Group 3 (control group) had higher scores than Group 1 and lower scores than 
Group 2 at baseline, and lower scores than the other two groups at commencement of 
treatment. With the exception of a slight decline in scores in week 4, the participants 
continued to gradually improve during the treatment period.  Scores declined during 
the follow-up period but were higher than those at baseline and in the first week of 
treatment. 
 
 The mean score for the total sample showed improvement in mental health 
from the commencement of treatment (63.4) to the end of treatment (69.7). The main 
effect and linear trend were highly significant. 
 
 
 
 250 
Table  34                           Secondary Health Outcome – Mental Health 
Treatment 
Groups/ Group 1 Group 2 Group 3 Total F1 F2 F3 
Sessions Mean SD Mean SD Mean SD Mean SD 
Baseline 56.0 19.2 64.0 14.3 61.5 18.8 60.6 17.4 
Week 1 62.0 15.8 66.7 15.9 61.2 20.0 63.4 17.0 
Week 2 66.0 14.6 68.8 16.2 65.8 25.5 67.0 18.7 
Week 3 68.3 17.9 70.1 13.5 73.8 14.9 70.7 15.3 
Week 4 66.0 16.9 75.7 12.9 68.6 17.0 70.3 15.8 
Week 5 66.6 17.8 70.4 20.8 72.3 16.7 69.7 18.3 
2-week 
Follow-up 64.9 17.1 74.7 13.8 67.1 22.0 69.0 17.9 
3-month 
Follow-up 63.7 21.0 74.4 12.7 66.5 19.5 68.4 18.1 
4.89** 15.91** n.s. 
Total 64.2 17.4 70.6 15.3 67.1 19.3 67.4 17.5       
 
F1 = main effect; F2 = linear trend; F3 = treatment effect; n.s. = not significant.  **P <0.01; *P <0.05 
 
 
 
Figure 17    Secondary Health Outcome - Mental Health by Treatment Groups and Control                
                                                             Group 
 
 
 All participants demonstrated improvement in the overall severity of their 
individual IBS symptoms and functioning at the end of the treatment period (week 5), 
with the ‘individualised’ group (Group 1) having a numerically better outcome than the 
other two groups. 
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 The main effect and linear trend for all three treatment groups were significant 
but the treatment effect between groups was not significant. The differences in 
response between the groups, therefore, might be attributable to random factors.   
 
 Improvement in IBS symptoms and general health outcomes did not continue 
during the 3-month follow-up period. This increase in symptoms during the follow-up 
period was possibly due to both non-compliance and to no further contact with the 
therapist. 
 
Intercorrelations Among the Four Dimensions of the SCL-90-R at Baseline and the 
SF-36 Health Concepts at the End of Treatment 
 
  Some of the general health measures of degree of improvement in SF-36 at 
the end of the treatment sessions, and the SCL-90-R measures at baseline, are significantly 
correlated, indicating a better quality of life for the patients.  For example, as the pain level 
lessened, the extent to which the patients’ health limited their physical activities and 
interfered with their work or daily activities improved (see Table 35). 
 
  A higher index (0-100) on the SF-36 scale indicates better quality of life, and 
a higher score on the four dimensions of the SCL-90-R scale indicates more psychological 
problems.  The General Health Perceptions concept in SF-36 measure at the end of the 
treatment sessions is significantly related to all four dimensions of SCL-90-R (p <0 .01).  
A negative value indicates fewer psychological problems and better quality of life.  
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Table 35.                          Intercorrelations among four dimensions of the SCL-90-R at baseline and the SF-36 health concepts at the end of treatment. 
 
  Physical 
Functioning  
Role -
physical 
Pain General Health 
Perceptions 
Vitality Social  
Functioning 
Role-
emotional  
Mental 
Health  
Depression Obsessive-
Compulsive 
Anxiety Interpersonal 
Sensitivity 
Physical Functioning  
 
1            
Role-physical 
 
.495(**) 1           
Pain 
 
.431(**) .697(**) 1          
General Health  
Perceptions 
.199 .479(**) .603(**) 1         
Vitality 
 
.312(*) .559(**) .703(**) .491(**) 1        
Social Functioning 
 
.303 .681(**) .688(**) .374(*) .633(**) 1       
Role-emotional  
 
.141 .657(**) .579(**) .575(**) .538(**) .582(**) 1      
Mental Health  
 
.098 .248 .349(*) .462(**) .450(**) .260 .629(**) 1     
Depression 
 
-.081 -.329(*) -.389(*) -.572(**) -.429(**) -.366(*) -.619(**) -.521(**) 1    
Obsessive-Compulsive 
 
.058 -.287 -.334(*) -.408(**) -.192 -.234 -.601(**) -.456(**) .795(**) 1   
Anxiety 
 
-.067 -.328(*) -.193 -.571(**) -.094 -.150 -.539(**) -.384(*) .695(**) .725(**) 1  
Interpersonal Sensitivity 
 
.044 -.306 -.267 -.467(**) -.200 -.198 -.484(**) -.391(*) .814(**) .741(**) .805(**
) 
1 
 
 
** Correlation is significant at the 0.01 level (2-tailed). 
*  Correlation is significant at the 0.05 level (2-tailed). 
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Intercorrelations: SCL-90R Duke-UNC, BSSS and the Overall Severity of IBS at the end 
of treatment sessions,  
 
 Intercorrelations among the four dimensions of the SCL-90-R, the Duke-UNC 
Functional Support Scores at baseline, the BSSS, and the overall severity of IBS (BSS-5) 
at the end of the treatment sessions were then examined. 
 
 BSSS measures which are specific to the frequency of bowel motions, distress, and 
interference with daily life at the end of the treatment sessions; and the SCL-90-R 
measures including depression, obsessive-compulsive, and interpersonal sensitivity at 
baseline, are all significantly correlated (p<0.01), but anxiety was found to be unrelated. 
At the end of the treatment sessions, the overall severity of IBS is significantly correlated 
with all SCL-90-R scores, except for anxiety (p<0.05).  A positive value indicates that 
patients with more bowel symptoms had more psychological distress (see Table 36). 
 
 The confident social support score (Duke-UNC) is negatively correlated with all 
SCL-90-R scores as well as bowel symptom severity scores. The only significant 
correlation (p<0.05) was found between the confident support score and the depression 
score.  A negative value indicates that patients with less social support had more 
psychological distress (see Table 36).  
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Table 36.   Intercorrelations among four dimensions of the Symptom Checklist-90 R (SCL-90-R), the Duke-UNC Functional Social Support Scores at Baseline, the Bowel 
Symptom Severity Scale (BSSS), and the Overall Severity of IBS (BSS-5) at the end of treatment sessions. 
 
  
 
 
** Correlation is significant at the 0.01 level (2-tailed). 
*  Correlation is significant at the 0.05 level (2-tailed). 
 
 
 
 
Depression Obsessive-
Compulsive 
Anxiety Interpersonal 
Sensitivity 
Frequency Distress Interference Overall 
severity of IBS 
Confident 
Support 
Affective 
Support 
Depression 
 1          
Obsessive-Compulsive 
 .794(**) 1         
Anxiety 
 .699(**) .731(**) 1        
Interpersonal Sensitivity 
 .816(**) .746(**) .809(**) 1       
Frequency 
 .546(**) .588(**) .390(*) .543(**) 1      
Distress 
 .421(**) .431(**) .264 .425(**) .675(**) 1     
Interference 
 .464(**) .490(**) .270 .444(**) .684(**) .916(**) 1    
Overall severity of IBS 
 .351(*) .483(**) .285 .344(*) .613(**) .728(**) .730(**) 1   
Confident Support 
 -.322(*) -.242 -.091 -.270 -.150 -.044 -.041 -.163 1  
Affective Support 
 -.223 -.029 -.073 -.225 -.014 .096 .061 .028 .686(**) 1 
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The Survey of Recent Life Experiences 
 
 The SRLE covers six concepts which are considered to be stressful – social 
and cultural difficulties, work, time pressure, finances, social acceptability, and social 
victimisation (see Appendix 10).  
 
 The baseline data on the SRLE demonstrates that, for this particular sample of 
IBS patients, the emotional responses to life stress were more evident in relation to 
time pressure (e.g. having too many things to do at once, a lot of responsibilities, not 
enough leisure time); work (e.g. dissatisfaction with work, bored with work, conflicts 
at work); and social and cultural difficulties (e.g. conflicts with friends/family 
members, having trust betrayed by a friend, ethnic or racial conflicts).  
 
 The three groups showed similar responses to stress but, compared to the 
other two groups, Group 1 (individualised group) had higher scores on social 
acceptability and social victimisation; and Group 3 (control group) had higher scores 
on stress that was related to work, time pressure, and finances. See Table 37. 
 
 When correlations between the SRLE and the BSSS at baseline were 
examined, there were highly significant correlations between bowel frequency, and 
the distress and interference in the participants’ everyday lives.  There were also 
significant correlations between social and cultural difficulties and interference from 
the severity of bowel symptoms from which participants were suffering (see Table 
38). 
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       Table 37     Baseline Data on Survey of Recent Life Experiences (SRLE) 
   Mean Std. Deviation 
95% Confidence Interval for 
Mean 
      Lower Bound Upper Bound 
Social & Cultural 
Difficulties 
Group 1 16.1 4.1 14.0 18.2 
  Group 2 15.6 4.5 13.3 17.9 
  Control Group 16.1 3.0 14.5 17.6 
  Total 15.9 3.9 14.8 17.0 
Work Group 1 10.6 4.8 8.1 13.1 
  Group 2 11.8 4.2 10.0 14.0 
   Control Group 12.2 4.3 10.0 14.4 
  Total 11.5 4.4 10.3 12.8 
Time Pressure Group 1 15.9 6.3 12.7 19.1 
  Group 2 17.1 6.5 13.8 20.4 
  Control Group 17.2 4.9 14.7 19.8 
  Total 16.8 5.8 15.1 18.4 
Finances Group 1 8.4 2.7 7.0 9.8 
  Group 2 9.8 4.3 7.6 12.0 
  Control Group 10.2 3.7 8.3 12.1 
  Total 9.5 3.7 8.5 10.5 
Social Acceptability Group 1 9.4 3.6 7.6 11.3 
  Group 2 8.8 3.3 7.1 10.5 
  Control Group 8.3 2.0 7.3 9.3 
  Total 8.8 3.0 8.0 9.7 
Social Victimisation Group 1 6.8 2.2 5.7 8.0 
  Group 2 6.5 2.8 5.1 8.0 
  Control Group 6.5 2.0 5.5 7.6 
  Total 6.6 2.3 6.0 7.3 
Table 38   Correlations: SRLE & Bowel Symptom Severity Scale (BSSS) at Baseline   
  Frequency Distress Interference 
Social & 
Cultural 
Difficult. Work 
Time 
Pressure Finance 
Social 
Accept-
ability 
Social 
Victim 
Freq. 1         
Distr. .829** 1        
Interf. .731** .917** 1       
Social 
& 
Cult. 
Diff. 
.226 .278 .322* 1      
Work .293 .342* .342* .194 1     
Time 
Press. .121 .079 .168 .077 .380* 1    
Fin. .216 .258 .321* .370* .463** .400** 1   
Social 
Accept .192 .200 .250 .472** .411** .422** .431** 1  
Social 
Victim .078 .105 .200 .420** .352* .436** .606** .590** 1 
** Correlation is significant at the 0.01 level (2-tailed);  * Correlation is significant at the 0.05 level (2-tailed) 
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Credibility Scale 
 
 Participants’ expectancy for improvement is an important variable affecting 
the outcome of clinical trials (Linde et al. 2007; O’Malley et al. 2004) and, in this 
trial, the Credibility Scale (Appendix 6) was used for both measurement of this 
variable and to test the success of participant blinding.  The scale was issued to 
participants twice throughout the trial (in week 2 and week 4). 
 
 The participants were asked to indicate on the form how confident they felt 
that the treatment could alleviate their complaint; if they would be confident in 
recommending the treatment to a friend suffering a similar complaint; how logical the 
treatment seemed to them; and how successful they thought the treatment would be in 
alleviating other complaints (see Appendix 11).  All participants were blinded to both 
the treatment they were receiving, and to other participants in the study (see Chapter 
5).  
 
 Although the results do not show statistically significant differences among the 
three treatment groups, the participants in all three groups showed that their 
expectancy for improvement increased from the commencement of their treatment to 
the end of treatment (see Figure 18). 
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Figure 18   Credibility Scale:  Mean Scores between Week 2 and Week 4 by Treatment 
                                         Groups and Control Group 
 
 
 
 
 
6.2.3 Follow-up Assessment 
  
 Follow-up on all participants was performed at both two weeks and three 
months after completion of the initial trial.  The BSSS and the SF-36 General Health 
Survey, which had been administered to participants at the screening session and 
throughout the treatment periods, were also administered throughout the follow-up 
period.  The results of the BSSS during this period are shown in Tables 17-19, and 
the results of the SF-36 are shown in Tables 27-34. 
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CHAPTER 7  DISCUSSION 
    
 Research has demonstrated the consequences of IBS as being both an 
individual and economic burden to sufferers. Studies have repeatedly shown that 
patients with IBS are often restricted in recreational and work-related activities (Dean 
et al., 2005; Drossman et al., 1993), have reported a lower quality of life compared to 
controls (Creed et al., 2000; Hahn et al., 1999), and have been found to have higher 
levels of depression and anxiety relative to the general population (Garakani et al., 
2003; Sykes et al., 2003). Life stress contributes to symptom onset and exacerbation 
of symptoms in the majority of IBS patients, and the level of chronic life stress threat 
can predict the clinical outcome in most patients (Bennett et al., 1998).  
 
7.1 Hypotheses 
 
    Based on previous research and consistent with the aims of the 
study, the present research sought to empirically investigate four main hypotheses. 
 
 The first hypothesis was that participants who had been diagnosed 
with IBS would present with not only physiological symptoms but psychological 
ones as well and that, at the end of the study, participants who underwent 
individualised hypnotherapy (using imagery which addressed both the 
psychological/emotional aspects and the physiological symptoms of the syndrome), 
would have a better outcome in the improvement of their IBS symptoms than 
participants who underwent standard gut-directed hypnotherapy in which 
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physiological symptoms alone were treated. The group of participants whose 
treatment incorporated both psychological and physiological aspects of IBS, had a 
better outcome than the other two groups. 
 
  The second hypothesis was that participants’ IBS symptoms would 
improve during the trial period and, as a result, their quality of life would 
subsequently improve. Participants in all three groups demonstrated an improvement 
of overall severity in their IBS symptoms during the treatment period and a 
subsequent improvement in their quality of life. 
 
  The third hypothesis was that participants who had a support system in 
place would improve more quickly than those who hadn’t. The only significant 
correlation found was between the confident support score and the depression score. 
 
  The final hypothesis was that participants who were experiencing, or 
who had recently experienced, stressful episodes in their lives would be more likely 
to have more severe and more frequent IBS symptoms. Participants in all three 
groups demonstrated similar emotional responses to life stress and there were highly 
significant correlations between bowel frequency and its interference in the patients’ 
everyday lives.  
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7.2 ‘Individualised’ Imagery vs ‘Gut-directed’ Imagery 
  
 This study supports previous research that has shown that psychological 
disorders (especially depression and generalised anxiety disorder) are present in the 
majority of IBS patients who actively seek medical care (American College of 
Gastroenterology Functional Gastrointestinal Disorders Task Force, 2002; Blanchard, 
1993; Blanchard et al., 1990). 
 
 This overlap between psychological disorders and IBS has led to research 
which has found that there was a significant association of IBS with anxiety and 
depression (Gorard et al., 1996; Harris & Chang, 2006; Hazlett-Stevens et al., 2003) 
and also to studies which have been carried out to evaluate the benefits of 
hypnotherapy in reducing IBS symptoms (Gonsalkorale, 2002, 2006; Palsson, 1997, 
2006; Whorwell, 2006; Whorwell et al., 1992).  
 
 Most of these studies demonstrated that individual physiological IBS 
symptoms improved and that this improvement frequently correlated with 
improvement in anxiety symptoms and depression symptoms.  To date, however, 
there appears to be an absence of studies which target this apparent link between the 
physiological symptoms and the psychological/emotional symptoms of IBS.  
 
 The present study aimed at achieving a more holistic approach in the 
treatment of IBS patients by designing hypnotherapy sessions for the ‘individualised’ 
group (Group 1) which incorporated imagery for psychological as well as 
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physiological symptoms into the treatment plan. Scripts for the participants in this 
group were based on the results of the SCL-90-R which each participant was asked to 
complete before commencement of treatment to evaluate psychological problems and 
symptoms of psychopathology.  
 
 At baseline, the 51 participants in this study presented with depression, 
anxiety, obsessive-compulsive disorder, and interpersonal sensitivity – depression 
being the most prevalent psychological disorder. Thirty participants presented with 
depression, four with anxiety, two with obsessive-compulsive disorder and one with 
interpersonal sensitivity.  Of the remainder, five had both depression and anxiety, five  
had depression and obsessive-compulsive disorder, and four presented with 
depression and interpersonal sensitivity. 
 
 The original 17 participants in the ‘individualised” group (Group 1) presented 
with all four primary symptom dimensions of the SCL-90-R – depression, anxiety, 
obsessive-compulsive disorder, and interpersonal sensitivity, and, as indicated in 
previous research, depression was the most prevalent psychological disorder.  Nine 
participants presented with depression, two with anxiety, two with anxiety and 
depression, three with depression and obsessive-compulsive disorder, and one with 
interpersonal sensitivity. 
 
 At the end of the treatment sessions, all participants in this study 
demonstrated improvement in their IBS symptoms with the ‘individualised’ group, 
whose hypnotherapy sessions included scripts which incorporated both their  
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psychological and physiological aspects of IBS, having a better outcome than the 
other two groups. 
  
7.3 Quality of Life 
 
 Previous research has demonstrated that diminished QOL is another aspect of 
IBS which needs to be addressed when treating the disorder. Studies have shown that 
IBS poses a financial burden on the patient through medical expenses such as 
investigations, treatments and medications, and loss of pay through illness (Cash et 
al., 2005; Leong et al., 2003). 
 
 Research has also shown that diminished QOL also affects the day-to-day 
functioning of the IBS sufferer, and patients with IBS were found to have 
significantly lower scores in all domains of the SF-36 questionnaire, indicating poorer 
functioning outcomes (Akehurst et al., 2002; Dean et al., 2005). 
 
  In the present study, participants in all three groups completed the SF-
36 questionnaire prior to commencement of treatment sessions. The SF-36 is a 36-
item questionnaire consisting of 8 health concepts or subscales broadly related to 
quality of life, mental health and social activities.  
 
 The results supported those of previous research in that all IBS patients in this 
trial had low scores in the SF-36 questionnaire.  With the exception of physical 
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functioning, in which all participants indicated few limitations in performing physical 
activities, scores for the other seven health concepts were low.  
 
 Results of all three groups demonstrated that participants showed some 
indication of interference in their work or daily activities due to physical health, that 
pain had an effect on the participants’ normal work, and vitality was low.  Scores also 
indicated that participants viewed their health as only slightly above average and that 
all participants found that physical health or emotional problems interfered to some 
extent with their social activities and that emotional problems interfered with work or 
daily activities.  All participants experienced some level of depression or anxiety. 
   
 Participants in all three groups demonstrated an improvement of overall 
severity in their IBS symptoms during the treatment period and a subsequent 
improvement in their quality of life. There was a highly significant decrease in the 
level of pain, and also a highly significant improvement in the patients’ vitality, 
social functioning, and mental health.  There was also significant improvement in 
physical functioning, general health, and the extent to which emotional problems 
interfered with the patients’ work or daily activities.  
 
7.4 Social Support 
 
 Social support encompasses a number of functions or behaviours which can 
produce a beneficial effect on the health and well-being of people.  Functions are 
usually grouped into one of two types: a health-facilitating function (gratifying 
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human needs for affection, approval, identity) and a stress-reducing function 
(practical help, problem-solving, advice, information, education) (Suurmeijer et al., 
1995).  
 In previous studies on IBS, the data suggested a need for support groups, 
opportunities for patients, medical health-care professionals, and supportive others to 
share experiences and concerns, and informational support within the areas of 
symptom interpretation and illness management (Coulson, 2005; Meadows et al., 
1997).   
 
 Participants in the present study were asked to complete the Duke-UNC 
questionnaire prior to commencement of treatment.  This 8-item instrument contains 
questions in two content areas: confidant support, which reflects a confidant 
relationship where important matters in life such as social contact and 
personal/work/financial problems are discussed and shared; and affective support 
which reflects a more emotional form of support or caring. 
 
 In this trial, there was no significant correlation between support and 
improvement in the overall severity of IBS symptoms.  The only significant 
correlation found was between the confident support score and the depression score 
indicating that patients with less social support had more psychological distress. 
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7.5   Stress 
 
 Researchers in the field of psychoneuroimmunology are providing evidence 
about the ways in which negative emotions generated by stressors can be translated 
into physiological changes (Webster et al., 2002; Padgett & Glaser, 2003).  Research 
has shown that ligands and their receptors communicate biochemically between, and 
within, the immune and endocrine systems and that stressors can activate the HPA 
axis releasing pituitary and adrenal hormones, commonly know as “stress” hormones 
(Blalock, 1994; Pert, 1997; Glaser & Kiecolt-Glaser, 2005). Studies have also shown 
that stressful episodes can influence GI function (Lundberg, 2005) and that, in IBS 
sufferers, the symptoms are more likely to be more severe (Drossman et al., 1999).  
 
 Further studies have shown that patients who confronted stress with problem-
solving, active behavioural approaches, and self-management programmes, had 
significantly better quality of life, a decrease in pain and depression, and had fewer 
visits to medical practitioners (Blixen & Kippes, 1999; Swindells et al., 1999).  This 
aspect was not investigated in the present study. 
 
 Prior to the treatment sessions in the present study, participants were asked to 
complete the SRLE questionnaire which consists of 51 items covering six concepts: 
social & cultural difficulties, work, time pressure, finances, social acceptability, and 
social victimisation.  
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 Participants in all three groups demonstrated similar emotional responses to 
life stress (such as time pressure, work, and social and cultural difficulties) and there 
were highly significant correlations between bowel frequency and its interference in 
the patients’ everyday lives. There were also significant correlations between social 
and cultural difficulties and interference from the severity of bowel symptoms from 
which patients were suffering. 
 
 Hypnosis is thought to be able to strengthen the body’s immunological 
functions and assist in fighting off disease and is therefore commonly used in the 
treatment of stress disorders (Rossi, 1993; Wickramasekera, 1999). 
 
7.6   Hypnotherapy 
 
 Numerous studies have been done to evaluate the benefits of complementary 
therapies such as hypnotherapy to reduce IBS symptoms because of the overlap 
between psychological disorders and IBS (Drossman et al, 2003; Guthrie, Creed, 
Dawson & Tomenson, 1993; Blanchard et al., 1993; Whorwell, Prior & Faragher, 
1984; Whorwell, 2006). Research has also been carried out on complementary 
therapies to identify those that can complement current medical care and improve 
clinical outcomes.  This has been considered necessary because of the lack of 
significant relief in a large proportion of patients using only conventional medical 
treatment for IBS (Poitras et al., 2002; Tillisch, 2006).   
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 Research has suggested that the brain, gut, and the autonomic nervous system 
are involved in the pathology of IBS, and researchers are more widely acknowledging 
the link between the mind and body (Salt & Neimark, 2002; Smith & Morton, 2001). 
One of the successful interventions aimed at breaking cycles within the brain-gut axis 
is hypnotherapy (Gonsalkorale, 2006; Palsson & Drossman 2005; Whorwell, 2006). 
 
 The mechanisms responsible for the therapeutic success of hypnotherapy are 
largely unknown, but research has shown that it may act by modulating visceral 
sensitivity, motor function and psychological distress (Guzelier et al., 2001; 
Houghton et al., 1999; Marchioro et al., 2000).  Research in the area of the effects of 
imagery and hypnosis on the immune and nervous systems indicates that hypnotic 
intervention can moderate the functioning of these two systems (Glaser et al. 2001; 
Whorwell et al., 1992).  
 
 Imagery is a major component of hypnosis, and research has provided 
numerous examples of the physiological effects imagery has on the body (Graham, 
1995).  In hypnosis, suggestions are usually given in the form of imagery, which can 
be any perception that comes through any of the senses (McGill, 1996; Olness, 1995), 
and, as the body is thought to be unable to discriminate between sensory images in 
the mind and reality, these images are interpreted as almost real events (Gindes, 
1976; Naparstek, 1994).   
 
 Participants in the two hypnosis groups in this trial were asked to imagine 
themselves in a peaceful, safe, place, and suggestions given during the trance state 
 270 
were in the form of therapeutic suggestions to help patients overcome the difficulties 
or problems associated with their IBS symptoms.  
 
 Suggestions which related to the participants’ physiological IBS symptoms, 
and which aimed at modulating visceral sensitivity and motor function, were given to 
both hypnosis groups (Group 1 - “individualised” imagery, and Group 2 – standard 
“gut-related” imagery). After suggestions of relaxation and safety, participants were 
guided through a visualisation of drinking a liquid that would heal and soothe the 
digestive tract, make the muscles strong and give them tone, allow the correct 
processing and absorption of food, and regulate peristalsis. 
 
 In addition, participants in Group 1 (“individualised” imagery) were given 
suggestions relating to each participant’s individual psychological IBS symptoms, as 
evidenced by the SCL-90-R (Appendix 7), with the aim of reducing psychological 
distress.  Depending on each participant’s specific need, suggestions were given to 
reduce anxiety, depression, obsessive-compulsive behaviour, or interpersonal 
sensitivity. 
 
 The success of the hypnotherapy sessions and of the goal the patient 
wishes to achieve is very much dependent on the words used (Cunningham & Ralph, 
1980) and so, the words in the scripts that were read to patients in the hypnosis 
groups were carefully selected to help target each patient’s symptoms (whether 
psychological and/or physiological) in order to improve/change a sensation, belief or 
behaviour. 
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7.7 Reflections on the Study 
 
 This study follows on previous research which has shown hypnotherapy to be 
of benefit to patients with IBS and, as far as the author is aware, is the first clinical 
trial in Australia using hypnotherapy as a treatment for IBS, and the first to 
incorporate both physiological and specific psychological imagery into the 
hypnotherapy scripts.  
 
In the present study, participants presented with high scores in psychological 
ratings and there were correlations between three of the four subgroups (anxiety, 
depression, and obsessive-compulsive symptoms) indicating a non-specific 
psychological characteristic of IBS patients, which was consistent with previous 
studies.   
 
As mentioned in Chapter 4, the aim of the present trial was to examine 
whether hypnosis using imagery which combined both this psychological 
characteristic of IBS as well as the physiological aspects of the illness, would benefit 
IBS sufferers more than either hypnosis with imagery which only addressed the 
physiological symptoms, or relaxation therapy.  
 
The study found that the group which combined both psychological and 
physiological  aspects of the IBS symptom picture (Group 1), improved more than the 
other two groups (Group 2 - hypnosis targeting physiological symptoms only; and  
Group 3 - relaxation therapy).  
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 The participants’ improvements in abdominal complaints related to 
improvements in quality of life. The mean bowel scores for the whole sample for all 
physiological IBS symptoms had fallen by the end of the treatment period with a 
significant linear trend for scores to change over time. Significant changes over time 
were found for physical functioning, general health, vitality, and the social 
functioning scales on the SF-36; with all three arms showing similar improvement. 
 
 The results of this trial in the use of hypnosis as a treatment for IBS, indicate a 
significant difference within groups on both physiological and psychological 
symptoms of IBS. However, there was no significant difference among the three 
treatment groups which suggests that neither individualised hypnosis nor relaxation 
therapy were superior to the standard “gut-related” hypnotherapy, and that all three 
treatment options were of benefit to participants. 
 
7.8   Limitations  
 
 One limitation of the study was that it was insufficiently powered.  Due to 
time limits and the fact that the therapist was the only person recruiting, the sample 
size was small. A much larger sample size would have been required to detect such a 
small effect size difference among the groups, but such a difference would possibly 
not have been clinically significant.   
 
 It was hypothesised a priori that, with respect to the abdominal pain subscale of the 
SCL-90, the control group would not change on average, the standard therapy group 
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would improve by one point and the individualised therapy by two points. Under these 
conditions and with an assumed SD=2.0 n=25 subjects per study group would have 
yielded statistical power >0.85 at the 0.05 (two-tailed) level of statistical significance. 
Due to difficulty with recruitment, n=17 subjects were actually recruited per group and 
this yields statistical power of approximately 0.72 under the same conditions. While this 
power is less than the desired 0.8 it is unlikely to have materially affected the statistical 
analysis. 
 
 Also, although participants demonstrated improvements in their IBS 
symptoms at the end of the treatment sessions, these improvements did not persist at 
the three-month follow-up.  One possible explanation for this could be that, again, the 
study was insufficiently powered to detect differences. 
 
 During the follow-up period in previous trials in hypnotherapy (Whorwell et 
al., 1984, 1987; Gonsalkorale et al., 2002, 2003), participants continued to receive 
hypnosis sessions on a monthly basis and were asked to telephone if they experienced 
a relapse so that a further session of hypnotherapy could be arranged.  
 
 In this study, there was no further contact with the therapist by the 
participants, adherence to treatment protocols during the follow-up period was not 
checked, and participants were not given further hypnosis sessions (either on a 
regular basis or in case of relapse) to maintain remission.   This could be another 
possible explanation for the lack of improvement in IBS symptoms during the follow-
up period. With continued checking of adherence to autohypnotic practice and 
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ongoing hypnosis sessions with the therapist, improvement in scores may have 
increased but, in the author’s view, to do so would not have constituted a pure trial. 
 
 Another limitation in this study was an absence of data on eligible subjects 
who did not complete all the questionnaires. 
 
 Research has indicated that brain wave changes associated with hypnosis can 
also be triggered by other methods of deep concentration, such as the relaxation 
response - the difference being that there is higher theta activity in relaxation and 
higher alpha activity in the hypnotic experience (Jacobs & Friedman, 2004; Williams 
& Gruzelier, 2001).   
 
 The control group in this trial underwent sessions in relaxation as a treatment 
for their IBS symptoms, whereas treatment for the other two experimental groups (the 
individualised group and the standard ‘gut-directed’ group) involved sessions in 
hypnosis.  Considering that the relaxation response can trigger brain wave changes 
associated with hypnosis, and that the hypnosis sessions themselves involved deep 
relaxation, participants in the control group could have easily lapsed into hypnosis.   
 
 In other words, the treatment for the control group was too similar to the 
treatment for the other two groups.  This could account for the similarities in 
treatment outcome and the small effect size difference between the groups. Other 
possibilities for the control group could have been to have patients on a waiting-list; 
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receiving education on IBS to allay concerns; or discussing their problems within 
their group under the guidance of a counsellor. 
 
7.9 Strengths 
 
 The present study also has a number of strengths.  All of the participants were 
provided with information on IBS, and the functioning of the gastrointestinal tract 
was explained.  Careful attention was given to blinding throughout the trial and the 
therapist (the author) who administered the therapy was an experienced and qualified 
hypnotherapist. 
  
 Further strengths of the study lie in the fact that participants were recruited 
prospectively; participants with other pre-existing functional gastrointestinal diseases 
were carefully excluded; and validated, standardised questionnaires to define the 
outcomes measures of IBS, and strict criteria for diagnosing IBS were utilised.  Also, 
the drop-out rate during the trial period was small. 
 
 Anecdotally, one of the participants in the ‘gut-directed’ experimental group 
reported as being symptom-free for the first time in twenty years.  Eighteen months 
later, she was still symptom-free. Another, also from the same experimental group 
was symptom-free a year after the trial. 
 
 Notwithstanding the limitations of this clinical trial, and that the findings need 
further confirmation, this study appears to support a psychophysiological hypothesis 
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that successful treatment of the psychological aspects is accompanied by 
improvement in IBS symptoms.  
 
7.10   Future Research 
 
 Research has been slowly moving away from the biomedical approach that 
has been dominant for the greater part of medical history since the 17th century and 
interest in the mind-body connection is becoming more and more prevalent. 
 
 There is no single pathophysiological marker and, therefore, no effective 
treatment for the whole symptom complex in IBS patients, so further research needs 
to increase the knowledge of how the ENS controls or modulates motility, exocrine 
and endocrine secretions and immune and inflammatory processes, and how this 
knowledge can contribute to the creation of new approaches in treatment. 
 
 Future research also needs to continue the investigation of the brain-gut axis 
in IBS and the role of hypnosis (which addresses both the psychological and 
physiological aspects of this disorder) as an effective and viable treatment option. 
There is also a possible need to identify the types of patients, as early as possible in 
their treatment, who are most likely to respond positively to hypnotherapeutic 
intervention to help them cope with their symptoms, and also reduce healthcare use 
and cost in the long term. 
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 More well-designed and executed studies with adequate sample sizes are 
needed to examine the effect of hypnosis on IBS and to compare the different ways of 
implementing the treatment (e.g. groups, one-to-one, or CDs of the sessions for home 
use).  Also, the methods of hypnotic induction and scripts used should be reported in 
detail so that they can easily be reproduced by others both in future research and in 
the clinical setting. 
 
7.11 Conclusions 
  
 Despite ongoing research as to its aetiology and pathophysiology, IBS 
remains a poorly understood condition. Many recent findings add to a growing body 
of evidence that a subset of IBS sufferers have a visceral hypersensitivity or an 
increased perception of sensations of the gut (Bouchoucha et al., 1999; Camilleri et 
al., 2001), and that IBS, at least in part, may result from previous gastroenteritis, 
small intestine bacterial over-growth, psychosocial factors, a genetic contribution, or 
an imbalance of neurotransmitters (Gershon, 2004; Neal et al., 1997; Pimentel et al., 
2000).  It is generally agreed that a patient’s emotional response to stress can 
exacerbate the condition (Gorard et al., 1996; Salt, 2002). 
 
 Diminished quality of life affects the day-to-day functioning of the IBS 
sufferer, and patients with IBS were found to have significantly lower scores on all 
domains in the SF-36 questionnaire, indicating poorer functioning outcomes 
(Akehurst et al., 2002; Dean et al., 2005). IBS also poses a financial burden on the 
patient through loss of pay through illness and the cost of healthcare such as visits to 
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primary care physicians and gastroenterologists, plus the added cost of investigations, 
treatments and medications (Cash et al., 2005; Leong et al., 2003). Suggested 
strategies to reduce direct costs include physician/patient education, avoidance of 
unnecessary investigations, the setting-up of support groups and the early 
consideration of psychosocial issues and psychological treatments (Camilleri & 
Williams, 2000).  
 
 Nowadays there is a better understanding of IBS (and other functional GI 
disorders) with a subsequent moving away from a disease-based model to a 
biopsychosocial one which takes into account not only the numerous physiological 
symptoms of IBS but also the effects that sociocultural and psychosocial influences 
have on these symptoms (Bennett et al., 1998; Farhadi et al., 2001). 
 
 This study highlighted the use of hypnosis as a treatment for IBS.  Previous 
studies have demonstrated the beneficial effects of hypnosis in the treatment of IBS 
and its sustained effect (Gonsalkorale et al., 2002; Palsson et al., 2000). Studies have 
been carried out to investigate the differences, if any, between individual sessions 
versus group sessions, and audiotape versus therapist, with the results showing little 
difference in outcome. All of these trials were considered as having a relatively high 
success rate in alleviating IBS symptoms.  
 
 Through research and clinical trials, hypnosis is beginning to lose its 
association with the occult and power control, and has come to be regarded as a 
situation which involves co-operation and trust between the hypnotherapist and the 
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patient. It is now being considered as a genuine and useful treatment which is 
gradually becoming acknowledged by medical authorities (Waterfield, 2002). 
 
 This change in attitude towards the application of hypnotherapy is considered 
to be due to more information coming to light about the complexities of the brain 
systems and also to a more rigorous application of scientific methodology and 
experimental design (Gruzelier, 1996).   
 
 The influences the mind has on the body (and the body has on the mind), in 
both psychosomatic disorders and physiological conditions such as IBS, are 
becoming more widely acknowledged; and the use of imagery in hypnotherapy, in 
which the therapist can address both the physiological and the psychological aspects 
of IBS symptomatology, is an important link. 
 
 This paper also discussed research into psychoneuroimmunology and the role 
of the brain-gut-axis in disease.  Studies have shown that emotions can affect colonic 
motility more in IBS patients than in healthy controls (Drossman et al., 1999; 
Garakani et al., 2003) and that stress can exacerbate IBS symptoms (Levy et al., 
1997; Locke et al., 2004).   
 
 The mind and the neurological and immunological systems of the body 
communicate through the bi-directional flow of hormones, neuropeptides and 
cytokines (Martin, 1997; Watkins, 1997).  The brain translates thoughts, feelings, 
beliefs and memories into complex patterns of nerve cell firing and chemical release 
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which affect both the physiology and biochemistry of the body. This is clearly 
evidenced in the symptomatology of IBS (Salt & Neimark, 2002). 
 
 A better understanding of the neural regulation of the enteric nervous system 
and how action by the sympathetic branch of the autonomic nervous system can 
inhibit or stimulate activity in the GI tract, makes it easier to understand the 
interrelationship between emotions, GI function, and pain, in IBS (and other 
functional disorders), and subsequently, how mind-body treatments such as 
hypnotherapy can be of benefit. 
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THE UNIVERSITY OF SYDNEY 
         
              FACULTY OF HEALTH SCIENCES 
                     School of Behavioural & Community Health Sciences 
 
SUBJECT INFORMATION STATEMENT 
 
 Irritable Bowel Syndrome: clinical trial in relaxation therapies. 
 
      The purpose of this study is to investigate the use of progressive relaxation and hypnosis 
to help in the treatment of irritable bowel syndrome.  
 
Irritable bowel syndrome (IBS), which can affect up to one in four people, can be 
extremely debilitating yet tests to investigate the cause of these symptoms are always 
normal and the reasons why people suffer from the symptoms of IBS are still unknown.  
As the various symptomatic treatments given to patients with IBS are not always 
successful, this study aims to trial the effects of relaxation/hypnosis techniques in 
relieving the symptoms of IBS. 
 
After being randomly allocated to one of three groups, all you need to do in this study is 
to attend an initial one hour consultation in which you will be asked to complete 
questionnaires, regularly practise the relaxation or hypnosis technique which will be 
taught to you, present for a further five ½ hour sessions, and keep a daily diary for the 
two weeks prior to your first session. The sessions will take place at a private clinic 
located at 31 Rowe Street Woollahra. Please be assured that you may withdraw from the 
study at any time.  All data collected will be kept confidential, and your name, address 
and other identifying details will not be stored in the computer database. 
 
Should you wish to discuss the study or its outcomes, please contact the researcher (see 
below for address). Any person with concerns or complaints about the conduct of the 
study can contact the Secretary of the Human Ethics Committee, University of Sydney on 
(02) 9351 4811. 
 
Researcher: 
Julie Phillips-Moore - doctoral student 
School of Behavioural & Community Health Sciences 
Faculty of Health Sciences 
University of Sydney 
P.O. Box 170, Lidcombe N.S.W., 1825 
Ph. (02) 9351 9228 
 Supervisors: Dr. Gomathi Sitharthan, Prof. Nick Talley. 
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THE UNIVERSITY OF SYDNEY 
 
    FACULTY OF HEALTH SCIENCES 
                       School of Behavioural & Community Health Sciences 
 
CONSENT FORM 
 
Irritable Bowel Syndrome:  clinical trial in relaxation therapies. 
 
             Researcher:  Julie Phillips-Moore - doctoral student 
School of Behavioural & Community Health Sciences 
Faculty of Health Sciences 
University of Sydney 
P.O. Box 170, Lidcombe, N.S.W., 1825 
Ph. (02) 9351 9228 
 
Supervisors:  Dr. Gomathi Sitharthan, Prof. Nick Talley. 
 
I, _________________________________________________________     (name) 
 
of _________________________________________________________    (address) 
 
hereby consent to taking part in the research project about the efficacy of progressive 
relaxation and hypnosis in the treatment of irritable bowel syndrome.  I understand that 
this will involve six consultations, the first of which will take approximately one hour – 
the remaining five, approximately ½ an hour. 
 
1. The study and the procedure of the study have been explained to me by Julie 
 Phillips-Moore. 
 
2. I have read and understood the SUBJECT INFORMATION STATEMENT and 
 am aware of the general purpose and methods. 
 
3. I understand that I am free to withdraw from this study at any time without 
penalty or prejudice. 
 
4. I understand that all the information I provide to the study will be kept 
 completely confidential. 
 
     Signature_________________________               Date_________________ 
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DAY OF THE WEEK:      DATE: 
         Patient’s ID: 
 
PLEASE RATE THE SEVERITY OF YOUR SYMPTOMS today by marking a 
cross on the line ( _____________ ) at the appropriate place: 
 
1. Pain or discomfort in your stomach or abdomen (do not include chest pain or 
 period pain) 
 
 ____________________________________________________________ 
 
 not              very 
 present              severe 
 
 
2. Feeling as if your stomach or abdomen were bloated (do not include    
 bloating due to a menstrual period): 
 
 ____________________________________________________________ 
 
 not               very 
 present               severe 
 
 
3. Constipation (very hard or lumpy stools or straining to pass stool): 
 
 ____________________________________________________________ 
 
 not              very 
 present              severe 
 
 
4. Diarrhoea (very soft or watery stools or very urgent need to pass stool): 
 
 ____________________________________________________________ 
 
 not              very 
 present              severe 
 
 
5. Please rate the overall severity of your IBS symptoms today: 
 
 ____________________________________________________________ 
 
 not                    very 
 present              severe 
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IRRITABLE BOWEL SYNDROME QUESTIONNAIRE – IBSQ 
 
Date: __/__/__      Patient ID No.: ___________ 
       Patient Initials: ___________ 
 
Thank you for participating in this important research.  All you need to do is tick the 
answers.  Some of the questions are of a sensitive nature.  You do not have to answer any 
question that you don’t want to, but please remember all answers are kept totally 
confidential.  If you are NOT SURE or CAN’T REMEMBER the answer to a question, 
just tick your best guess. 
 
 
1. How old are you? __________ years 
 
2. Are you (tick answer): 
 
   1  FEMALE 
                   2                      MALE 
 
FIRST, WE WOULD LIKE TO GET SOME DETAILS ABOUT ONLY THE PAST 3 
MONTHS.  Stomach, abdominal or stomach pain or discomfort can be difficult to 
describe and sometimes more than one type of pain can occur.  We would like to ask you 
some questions only about the usual or primary pain or discomfort in your stomach or 
abdomen in the past year. 
 
 
3. IN THE PAST 3 MONTHS has there been a time when you KEPT GETTING 
pains or discomfort in your stomach or abdomen? (Please do NOT count cramps 
or pain with menstrual periods, and do NOT count pain in your chest).  (Tick 
answer). 
 
 1  YES 
 0   NO 
 
  
 IF NO, PLEASE GO TO QUESTION 11 
 
 
 IF YES, PLEASE ANSWER THE FOLLOWING QUESTIONS: 
 
4. Over MOST of the PAST 3 MONTHS, have you KEPT GETTING this pain or 
discomfort?  (Tick answer) 
            
1  YES 
           0    NO 
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5. IN THE PAST 3 MONTHS, how bad has the pain or discomfort been, usually?  
(Tick one answer) 
 
1 VERY MILD: can usually be ignored 
2 MILD: can be ignored if you don’t think about it 
3 MODERATE: cannot be ignored but does not affect your 
lifestyle 
4 SEVERE: affects your lifestyle 
5 VERY SEVERE: markedly affects your lifestyle 
 
6. IN THE PAST 3 MONTHS, ON AVERAGE, how often have you had this pain 
or discomfort?  (Tick one answer) 
 
1 LESS THAN ONCE A MONTH 
2 ABOUT ONCE A MONTH 
3 ABOUT TWO OR THREE TIMES A MONTH 
4 ABOUT ONCE A WEEK 
5 SEVERAL TIMES A WEEK 
6 DAILY 
 
 
7. Please look at Diagram 1 (below).  IN THE PAST 3 MONTHS, has this pain or 
discomfort in your abdomen usually been: (tick one answer) 
 
1  IN THE AREA MARKED A 
2  IN THE AREA MARKED B 
3  IN BOTH AREAS (A AND B) 
 
 
8. IN THE PAST 3 MONTHS, has your pain or discomfort EVER WOKEN YOU 
from your sleep at night? (Tick one answer) 
 
1 YES 
0   NO 
 
9. Does this pain or discomfort COME AND GO PERIODICALLY?  Periodically 
here means periods of at least a month with no pain or discomfort, with periods 
in-between of weeks to months when there is pain or discomfort. (Tick answer) 
 
1 YES 
0 NO 
 
 
PLEASE NOTE: WHEN WE SAY OFTEN WE MEAN MORE THAN 25% (ONE 
QUARTER) OF THE TIME. 
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10. IN THE PAST 3 MONTHS, WOULD YOU SAY THAT: (tick YES or NO for 
each item) 
 
     Yes   No 
 
This pain or discomfort was OFTEN made BETTER by having a bowel    
movement (passing stool)?  
 
You OFTEN had MORE bowel movements than usual when this pain 
or discomfort began?  
 
You OFTEN had FEWER bowel movements than usual when this pain   
or discomfort began?  
 
You OFTEN had LOOSER bowel movements (stools) than usual when  
       
this pain or discomfort began? 
 
You OFTEN had HARDER bowel movements (stools) than usual when  
       
this pain or discomfort began?  
 
This pain or discomfort OFTEN occurred AFTER meals?    
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11. IN THE PAST 3 MONTHS, WOULD YOU SAY THAT: (tick YES or NO for 
each item) 
                                                                                                                              
               Yes              No 
 
You OFTEN had MORE than 3 bowel movements each DAY?   
       
You OFTEN had FEWER than 3 bowel movements each WEEK?   
       
Your stools were OFTEN VERY LUMPY or HARD? 
          
After finishing a bowel movement, you OFTEN felt there was still 
stool needed to be passed? 
             
You OFTEN experienced an URGENT need to have a bowel 
movement that made you rush or hurry to a toilet?  
 
You OFTEN felt FULL soon after starting to eat so that you    
could not finish a normal meal? 
 
You OFTEN needed to STRAIN a lot to have a bowel movement?   
             
 
PLEASE CHECK THAT YOU HAVE ANSWERED ALL THE ITEMS IN 
QUESTIONS 10 AND 11. 
 
 
12. IN THE PAST 3 MONTHS, have you OFTEN been troubled by feeling as if you 
stomach or abdomen were swollen (BLOATED)? (Tick answer) 
 
1 YES 
0   NO 
 
 
IF YES, PLEASE ANSWER QUESTION 13. IF NO, PLEASE GO TO QUESTION 14. 
 
 
13. Please look at Diagram 1 (page 2).  IN THE PAST 3 MONTHS, has your bloated 
feeling usually been (tick one answer): 
 
 
1 IN THE AREA MARKED A 
2 IN THE AREA MARKED B 
3 IN THE BOTH AREAS (A AND B) 
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14. IN THE PAST 3 MONTHS, have you OFTEN seen your stomach or abdomen swell 
up, or had to loosen your belt or clothes because of swelling? (Tick answer). 
 
1 YES 
0 NO 
 
 
15. IN THE PAST 3 MONTHS, have your stools been VERY LOOSE or WATERY?               
(Tick one answer). 
 
0 SOMETIMES (LESS THAN ONE QUARTER OF THE 
TIME) OR NEVER 
1 OFTEN (MORE THAN ONE QUARTER OF THE 
TIME) 
2 USUALLY (MORE THAN THREE QUARTERS OF 
THE TIME) 
 
 
16. IN THE PAST 3 MONTHS, have you EVER seen MUCUS (white or green slimy 
material) in your stools?  (Tick one answer). 
 
1 YES 
0  NO 
 
 
 
WE WOULD LIKE TO ASK YOU ABOUT PAIN OR DISCOMFORT IN YOUR 
STOMACH OR ABDOMEN DURING YOUR WHOLE LIFETIME, EXCEPT FOR 
THE PAST YEAR. 
 
 
17. IN YOUR LIFETIME BEFORE THE PAST 3 MONTHS, was there ever a time 
when you KEPT GETTING pains or discomfort in your stomach or abdomen? (Please do 
NOT count cramps or pain with menstrual periods, and do NOT count pain in your 
chest). (Tick one answer). 
 
1 YES 
0 NO 
 
 
 
IF YES, PLEASE ANSWER THE 
FOLLOWING QUESTIONS. 
IF NO, PLEASE GO TO QUESTION 22. 
 
 
 
 
 
 
 354 
18. When in your life did this pain or discomfort FIRST begin, as close as you can recall? 
(Tick one answer). 
 
 
1 UP TO 2 YEARS AGO 
2 MORE THAN 2 YEARS TO 5 YEARS AGO 
3 MORE THAN 5 YEARS TO 10 YEARS AGO 
4 MORE THAN 10 YEARS TO 20 YEARS AGO 
5 MORE THAN 20 YEARS AGO 
 
 
19. IN YOUR LIFETIME BEFORE THE LAST 3 MONTHS, were you ever 
TROUBLED by pain or discomfort in your stomach or abdomen over a period of 
THREE MONTHS OR LONGER?  (Tick one answer). 
 
 
1 YES 
0   NO 
 
 
20. Please look at Diagram 1 (page 2).   IN YOUR LIFETIME BEFORE THE PAST 3 
MONTHS, was that pain or discomfort in your stomach or abdomen USUALLY: (tick 
one answer) 
 
 
1 IN THE AREA MARKED A 
2 IN THE AREA MARKED B 
3 IN BOTH AREAS (A AND B) 
 
 
21. IN YOUR LIFETIME BEFORE THE PAST 3 MONTHS, when you were 
TROUBLED BY that pain or discomfort, were you also TROUBLED BY BOWEL 
DISTURBANCES (such as CONSTIPATION and/or DIARRHOEA)?  (Tick one 
answer). 
 
 
0 YES 
1 NO 
 
 
 
NOW WE NEED TO KNOW ABOUT YOUR GENERAL HEALTH AND LIFESTYLE 
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22. IN THE PAST 12 MONTHS, how frequently have you visited a doctor for any 
reason (for yourself)?  (Tick one answer). 
 
 
0  NEVER 
1  OCCASIONALLY 
2  SOMETIMES 
3  OFTEN 
 
23. IN THE PAST 12 MONTHS, how frequently have you sought alternative therapy of 
any kind (acupuncture, naturopathy, homoeopathy, herbal medicine etc.) for any reason 
(for yourself)?  (Tick one answer). 
 
 
0 NEVER 
1 OCCASIONALLY 
2 SOMETIMES 
3 OFTEN 
 
24. IN THE PAST 12 MONTHS, how frequently were your visits to a doctor or 
alternative therapist for pain or discomfort in your stomach or abdomen?  (Tick 
one answer). 
 
 
0 NEVER 
1 OCCASIONALLY 
2 SOMETIMES 
3 OFTEN 
 
 
25.      IN YOUR LIFETIME BEFORE THE PAST 12 MONTHS, about how frequently 
have you visited any doctor or alternative therapist for pain or discomfort in your 
stomach or abdomen?  (Tick one answer). 
 
 
0 NEVER 
1 OCCASIONALLY 
2 SOMETIMES 
3 OFTEN  
 
 
26.      What is your CURRENT marital status: (tick one answer) 
 
1  MARRIED 
2 DE FACTO/LIVING WITH 
3 NEVER MARRIED 
4 WIDOWED 
5 DIVORCED 
6 SEPARATED 
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27.  Please indicate your HIGHEST level of EDUCATIONAL training, or equivalent:     
(tick one answer) 
 
1 POSTGRADUATE QUALIFICATIONS 
2 UNIVERSITY GRADUATE (3 YEARS OR MORE) 
3 COMPLETED TAFE CERTIFICATE/ASSOCIATE 
DIPLOMA, TRADES APPRENTICESHIP, OR 2 
YEARS UNIVERSITY 
4 H.S.C. (HIGHER SCHOOL CERTIFICATE) 
5 COMPLETEDYEAR10 (FOURTHFORM/SCHOOL 
CERTIFICATE) 
6 SOME YEARS AT HIGH SCHOOL 
7 PRIMARY SCHOOL ONLY 
 
 
28.      Please indicate how much coffee or alcohol you have ON AVERAGE EACH  
            DAY. 
   
Number of cups of coffee per day  ____________________ 
 
Number of alcoholic drinks per day ____________________ 
 
 
29.     If relevant, please indicate whether you are taking hormonal pills including oral 
 contraception or hormone replacement therapy. 
 
1 YES 
0 NO 
 
  Please specify the date of your last menstrual period: ______________ 
 
 
PLEASE CHECK THAT YOU HAVE ANSWERED ALL THE QUESTIONS. 
 
 
Thank you for your participation in this research – it is very much appreciated.  You are 
welcome to make any comments or ask any questions. 
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BOWEL SYMPTOM SEVERITY SCALE (VI) 
 
 
Subject No.        Date   
 
General Instructions. 
 
Please indicate below, how often you may have had each symptom of bowel disease over 
the past 2 weeks.  Do this by placing a cross neatly in the small box.  If you do not have 
the symptom, place a cross in the “not at all” box.  Please ensure you answer all of the 
questions. 
 
1a.  Over the past two weeks, how often have you had loose or watery bowel 
 motions? 
  
Not at all 
 
Every other day 
 
Every day 1-3 times a day More than 3 times a 
day 
 
 
 
1b. How distressed were you by this? 
 
Not at all 
 
A little bit Moderately Quite a bit Extremely 
 
 
 
1c. How much did this interfere with your everyday life? 
 
Not at all 
 
A little bit Moderately Quite a bit Extremely 
 
 
       
 
2a. Over the past two weeks, on how many occasions did you have hard or lumpy 
stools when you had a bowel motion? 
 
Not at all 
 
Occasionally Sometimes Most times Every time 
 
 
2b. How distressed were you by this? 
 
Not at all 
 
A little bit Moderately Quite a bit Extremely 
 
 
2c. How much did this interfere with your everyday life? 
  
Not at all 
 
A little bit Moderately Quite a bit Extremely 
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3a. Over the past two weeks, how often have you had abdominal (tummy)     
 pain? 
 
Not at all Once or twice 3-5 times Every day More than once 
a day 
 
 
3b. How distressed were you by this? 
 
Not at all A little bit Moderately Quite a bit Extremely 
 
 
3c. How much did this interfere with your everyday life? 
  
Not at all A little bit Moderately Quite a bit Extremely 
 
 
 
 
4a. Over the past two weeks, on how many days have you had more than 3    
 bowel motions a day? 
 
Not at all 1 2-3 4-5 6-7 
 
 
4b. How distressed were you by this? 
  
Not at all A little bit Moderately Quite a bit Extremely 
 
 
4c. How much did this interfere with your everyday life? 
  
Not at all A little bit Moderately Quite a bit Extremely 
 
 
 
 
5a. Over the past two weeks, how often have you felt bloated or had an 
uncomfortable fullness in your abdomen? 
 
Not at all Once or twice 3-5 times Every day More than once a 
day 
 
 
5b. How distressed were you by this? 
  
Not at all A little bit Moderately Quite a bit Extremely 
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5c. How much did this interfere with your everyday life? 
 
Not at all A little bit Moderately Quite a bit Extremely 
 
 
____________________________________________________________________ 
 
6a. Over the past two weeks, how often have you had an urgent need to have a 
bowel motion? 
 
Not at all Once or twice 3-5 times Every day More than once a 
day 
 
 
6b. How distressed were you by this? 
 
Not at all A little bit Moderately Quite a bit Extremely 
 
 
 
6c. How much did this interfere with your everyday life? 
 
Not at all A little bit Moderately Quite a bit Extremely 
 
 
 
 
7a. Over the past two weeks, how many days have there been when you were 
unable to have a bowel motion? 
 
Not at all 1 2-3 4-5 6-7 
 
 
7b. How distressed were you by this? 
 
Not at all A little bit Moderately Quite a bit Extremely 
 
 
7c. How much did this interfere with your everyday life? 
 
Not at all A little bit Moderately Quite a bit Extremely 
 
 
 
8a. Over the past two weeks, how often have you had a general feeling of 
discomfort in your abdomen (tummy)? 
 
Not at all Once or twice 3-5 times Every day More than once 
a day 
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8b. How distressed were you by this? 
 
Not at all A little bit Moderately Quite a bit Extremely 
 
 
8c. How much did this interfere with your everyday life? 
 
Not at all A little bit Moderately Quite a bit Extremely 
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IRRITABLE BOWEL SYNDROME – SYMPTOM SCALE (BSS1) 
 
Date:  ___/___/___      Patient ID:        __________ 
Patient Initials:________ 
INSTRUCTIONS.  This questionnaire asks for your views about your health, how you feel, 
and how well you are able to do your usual activities.  If you are unsure about how to answer 
any question, please give the best answer you can.  
 
1. PLEASE RATE THE SEVERITY OF YOUR SYMPTOMS over the last two weeks by 
marking a cross on the line ( ____________ ) at the appropriate place: 
 
      Pain or discomfort in your stomach or abdomen (do not include chest pain or period 
      pain):                              
 
         ____________________________________________________ 
 
          Not        Very 
                present        severe 
 
      Feeling as if your stomach  or  abdomen  were  bloated  or  swollen (do  not  include     
      bloating due to a menstrual period): 
 
        ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Constipation (very hard or lumpy stools or fewer than 3 bowel movements a week or  
   straining to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Diarrhoea (very soft or watery stools or more than 3 bowel movements a day or very  
   urgent need to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
 
   Please rate the overall severity of your IBS symptoms over THE LAST TWO WEEKS: 
 
  ____________________________________________________ 
 
  Not        Very 
                    present        severe 
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2. Please TICK the description below which BEST FITS YOUR BOWEL MOVEMENTS 
in the last two weeks: 
 
 Separate hard lumps 
 Sausage-shaped but lumpy 
 Like a sausage or snake, but with cracks in its surface 
 Like a sausage or snake, smooth and soft 
 Soft blobs with clear-cut edges 
 Fluffy pieces with ragged edges, a mushy stool 
 Watery, no solid pieces 
 
3. Over the last two weeks, how much has your irritable bowel syndrome INTERFERED 
WITH YOUR LIFE AND ACTIVITIES?  (tick one answer): 
 
 Not at all 
 A little 
 Some 
 A lot 
 Extreme interference 
 
 
4. Please WRITE THE NAMES of any MEDICATIONS you have taken in the last two 
weeks, and how often you took them (e.g. “once only”, “twice a day for four days”, etc.).  
Include ALL medications, even headache tablets, antacids and other digestion 
medication, contraceptive pills, high doses of vitamins, sedatives, and any herbal or 
homoeopathic medications.  If you cannot remember exactly, please write your best 
guess. 
 
MEDICATION    HOW OFTEN? 
 
 ______________________________  ____________________________
 ______________________________  ____________________________ 
  
 ______________________________  ____________________________
 ______________________________  ____________________________ 
 
 ______________________________  ____________________________
 ______________________________  ____________________________ 
 
 ______________________________  ____________________________ 
 
 
 
5. In the last two weeks, have you eaten MORE FIBRE (e.g. wholemeal bread, high-fibre 
breakfast cereals, fruit and vegetables, fibre supplements, etc.) than you USUALLY eat? 
 
 No 
 
 A little more 
 
 A lot more 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSS2 
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IRRITABLE BOWEL SYNDROME – SYMPTOM SCALE (BSS2) 
 
Date:  ___/___/___      Patient ID:        __________ 
Patient Initials: __________ 
__________ 
INSTRUCTIONS.  This questionnaire asks for your views about your health, how you feel, 
and how well you are able to do your usual activities.  If you are unsure about how to answer 
any question, please give the best answer you can.  
 
1. PLEASE RATE THE SEVERITY OF YOUR SYMPTOMS over the last week by 
marking a cross on the line ( ___________ ) at the appropriate place: 
 
      Pain or discomfort in your stomach or abdomen (do not include chest pain or period 
      pain):                          
 
         ____________________________________________________ 
 
          Not        Very 
                  present        severe 
 
      Feeling as if your stomach  or  abdomen  were  bloated  or  swollen (do  not  include     
      bloating due to a menstrual period): 
 
        ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Constipation (very hard or lumpy stools or fewer than 3 bowel movements a week or  
   straining to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Diarrhoea (very soft or watery stools or more than 3 bowel movements a day or very  
   urgent need to pass stool): 
 
  ____________________________________________________ 
 
  Not       Very 
          present       severe 
 
 
   Please rate the overall severity of your IBS symptoms over THE LAST WEEK: 
 
  ____________________________________________________ 
 
  Not        Very 
                    present        severe 
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2. Please TICK the description below which BEST FITS YOUR BOWEL MOVEMENTS 
in the last week: 
 
 Separate hard lumps 
 Sausage-shaped but lumpy 
 Like a sausage or snake, but with cracks in its surface 
 Like a sausage or snake, smooth and soft 
 Soft blobs with clear-cut edges 
 Fluffy pieces with ragged edges, a mushy stool 
 Watery, no solid pieces 
 
3. Over the last week, how much has your irritable bowel syndrome INTERFERED WITH 
YOUR LIFE AND ACTIVITIES?  (tick one answer): 
 
 Not at all 
 A little 
 Some 
 A lot 
 Extreme interference 
 
4. COMPARED TO LAST TIME you filled in this questionnaire (a week ago), do you feel 
that your irritable bowel syndrome symptoms have: (tick one answer) 
 
 Improved ------------------------>  If improved, are your symptoms: (tick one answer): 
 
 Stayed the same             A little better 
 
 Worsened       Moderately better 
 
A lot better 
 
5. Please WRITE THE NAMES of any MEDICATIONS you have taken in the last week   
and how often you took them (e.g. “once only”, “twice a day for four days”, etc.).  
Include ALL medications, even headache tablets, antacids and other digestion 
medication, contraceptive pills, high doses of vitamins, sedatives, and any herbal or 
homoeopathic medications.  If you cannot remember exactly, please write your best 
guess. If your medications have not changed since you last filled in this form, just write 
“same as before”. 
 
MEDICATION    HOW OFTEN? 
 
 ______________________________   _____________________
 ______________________________   _____________________ 
  
 ______________________________   _____________________
 ______________________________   _____________________ 
 
6. In the last week, have you eaten MORE FIBRE (e.g. wholemeal bread, high-fibre 
breakfast cereals, fruit and vegetables, fibre supplements, etc.) than you USUALLY eat? 
 
No                          A little more                           A lot more 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSS3 
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IRRITABLE BOWEL SYNDROME – SYMPTOM SCALE (BSS3) 
 
Date:  ___/___/___      Patient ID:      ___________ 
Patient Initials: __________ 
 
INSTRUCTIONS.  This questionnaire asks for your views about your health, how you feel, 
and how well you are able to do your usual activities.  If you are unsure about how to answer 
any question, please give the best answer you can.  
 
1. PLEASE RATE THE SEVERITY OF YOUR SYMPTOMS over the last two weeks by 
marking a cross on the line ( _____________ ) at the appropriate place: 
 
      Pain or discomfort in your stomach or abdomen (do not include chest pain or period  
      pain): 
 
         ____________________________________________________ 
 
          Not        Very 
                present        severe 
 
      Feeling as if your stomach  or  abdomen  were  bloated  or  swollen (do  not  include     
      bloating due to a menstrual period): 
 
        ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Constipation (very hard or lumpy stools or fewer than 3 bowel movements a week or  
   straining to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Diarrhoea (very soft or watery stools or more than 3 bowel movements a day or very  
   urgent need to pass stool): 
 
  ____________________________________________________ 
 
  Not       Very 
          present       severe 
 
 
   Please rate the overall severity of your IBS symptoms over THE LAST TWO WEEKS: 
 
  ____________________________________________________ 
 
  Not       Very 
                    present       severe 
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2. Please TICK the description below which BEST FITS YOUR BOWEL MOVEMENTS 
in the last two weeks: 
 
 Separate hard lumps 
 Sausage-shaped but lumpy 
 Like a sausage or snake, but with cracks in its surface 
 Like a sausage or snake, smooth and soft 
 Soft blobs with clear-cut edges 
 Fluffy pieces with ragged edges, a mushy stool 
 Watery, no solid pieces 
 
3. Over the last two weeks, how much has your irritable bowel syndrome INTERFERED 
WITH YOUR LIFE AND ACTIVITIES?  (tick one answer): 
 
 Not at all 
 A little 
 Some 
 A lot 
 Extreme interference 
 
4. COMPARED TO LAST TIME you filled in this questionnaire (two weeks ago), do you 
feel that your irritable bowel syndrome symptoms have: (tick one answer) 
 
 Improved ------------------------>  If improved, are your symptoms: (tick one answer): 
 Stayed the same             A little better 
 Worsened       Moderately better 
A lot better 
 
5. Please WRITE THE NAMES of any MEDICATIONS you have taken in the last two 
weeks, and how often you took them (e.g. “once only”, “twice a day for four days”, etc.).  
Include ALL medications, even headache tablets, antacids and other digestion 
medication, contraceptive pills, high doses of vitamins, sedatives, and any herbal or 
homoeopathic medications.  If you cannot remember exactly, please write your best 
guess. If your medications have not changed since you last filled in this form, just write 
“same as before”. 
 
MEDICATION    HOW OFTEN? 
 ______________________________   ______________________
 ______________________________   ______________________ 
  
 ______________________________   ______________________
 ______________________________   ______________________ 
 
 ______________________________   ______________________
 ______________________________   ______________________ 
 
 ______________________________   ______________________
 ______________________________   ______________________ 
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6. In the last two weeks, how many times did you COMPLETELY MISS doing your 
relaxation exercise? 
(Please write the number of times) 
 
7. In the last two weeks, have you eaten MORE FIBRE (e.g. wholemeal bread, high-fibre 
breakfast cereals, fruit and vegetables, fibre supplements, etc.) than you USUALLY eat? 
 
No                          A little more                             A lot more 
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IRRITABLE BOWEL SYNDROME – SYMPTOM SCALE (BSS4) 
 
Date:  ___/___/___      Patient ID:            ________ 
Patient Initials:     ________ 
________ 
INSTRUCTIONS.  This questionnaire asks for your views about your health, how you feel, 
and how well you are able to do your usual activities.  If you are unsure about how to answer 
any question, please give the best answer you can.  
 
1. PLEASE RATE THE SEVERITY OF YOUR SYMPTOMS over the last two weeks by 
marking a cross on the line ( ____________ ) at the appropriate place: 
 
      Pain or discomfort in your stomach or abdomen (do not include chest pain or period  
      pain): 
 
         ____________________________________________________ 
 
          Not        Very 
                present        severe 
 
      Feeling as if your stomach  or  abdomen  were  bloated  or  swollen (do  not  include     
      bloating due to a menstrual period): 
 
        ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Constipation (very hard or lumpy stools or fewer than 3 bowel movements a week or  
   straining to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Diarrhoea (very soft or watery stools or more than 3 bowel movements a day or very  
   urgent need to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
 
   Please rate the overall severity of your IBS symptoms over THE LAST TWO WEEKS: 
 
  ____________________________________________________ 
 
  Not        Very 
                    present        severe 
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2. Please TICK the description below which BEST FITS YOUR BOWEL MOVEMENTS 
in the last two weeks: 
 
 Separate hard lumps 
 Sausage-shaped but lumpy 
 Like a sausage or snake, but with cracks in its surface 
 Like a sausage or snake, smooth and soft 
 Soft blobs with clear-cut edges 
 Fluffy pieces with ragged edges, a mushy stool 
 Watery, no solid pieces 
 
3. Over the last two weeks, how much has your irritable bowel syndrome INTERFERED 
WITH YOUR LIFE AND ACTIVITIES?  (tick one answer): 
 
 Not at all 
 A little 
 Some 
 A lot 
 Extreme interference 
 
4. COMPARED TO LAST TIME you filled in this questionnaire (two weeks ago), do you 
feel that your irritable bowel syndrome symptoms have: (tick one answer) 
 
 Improved ------------------------>  If improved, are your symptoms: (tick one answer): 
 Stayed the same             A little better 
 Worsened       Moderately better 
A lot better 
 
5. COMPARED TO BEFORE YOU COMMENCED THE TRIAL, do you feel that your 
irritable bowel syndrome symptoms have: (tick one answer) 
 
 Improved ------------------------>  If improved, are your symptoms: (tick one answer): 
 Stayed the same             A little better 
 Worsened       Moderately better 
A lot better 
 
6. Please WRITE THE NAMES of any MEDICATIONS you have taken in the last two 
weeks, and how often you took them (e.g. “once only”, “twice a day for four days”, etc.).  
Include ALL medications, even headache tablets, antacids and other digestion 
medication, contraceptive pills, high doses of vitamins, sedatives, and any herbal or 
homoeopathic medications.  If you cannot remember exactly, please write your best 
guess. If your medications have not changed since you last filled in this form, just write 
“same as before”. 
 
MEDICATION    HOW OFTEN? 
 ______________________________   ______________________
 ______________________________   ______________________ 
  
 ______________________________   ______________________
 ______________________________   ______________________ 
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7. In the last two weeks, how many times did you COMPLETELY MISS doing your 
relaxation 
exercise?  (Please write the number of times) 
 
 
8. In the last two weeks, have you eaten MORE FIBRE (e.g. wholemeal bread, high-fibre 
breakfast cereals, fruit and vegetables, fibre supplements, etc.) than you USUALLY eat? 
 
No                          A little more                           A lot more 
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IRRITABLE BOWEL SYNDROME – SYMPTOM SCALE (BSS5) 
 
Date:  ___/___/___      Patient ID:      ___________ 
Patient Initials: __________ 
 
INSTRUCTIONS.  This questionnaire asks for your views about your health, how you feel, 
and how well you are able to do your usual activities.  If you are unsure about how to answer 
any question, please give the best answer you can.  
 
1. PLEASE RATE THE SEVERITY OF YOUR SYMPTOMS over the last two weeks by 
marking a cross on the line ( _____________ ) at the appropriate place: 
 
      Pain or discomfort in your stomach or abdomen (do not include chest pain or period  
      pain): 
         ____________________________________________________ 
 
          Not        Very 
                present        severe 
 
      Feeling as if your stomach  or  abdomen  were  bloated  or  swollen (do  not  include     
      bloating due to a menstrual period): 
 
        ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Constipation (very hard or lumpy stools or fewer than 3 bowel movements a week or  
   straining to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
   Diarrhoea (very soft or watery stools or more than 3 bowel movements a day or very  
   urgent need to pass stool): 
 
  ____________________________________________________ 
 
  Not        Very 
          present        severe 
 
 
   Please rate the overall severity of your IBS symptoms over THE LAST TWO WEEKS: 
 
  ____________________________________________________ 
 
  Not        Very 
                    present        severe 
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2. Please TICK the description below which BEST FITS YOUR BOWEL MOVEMENTS 
in the last two weeks: 
 
 Separate hard lumps 
 Sausage-shaped but lumpy 
 Like a sausage or snake, but with cracks in its surface 
 Like a sausage or snake, smooth and soft 
 Soft blobs with clear-cut edges 
 Fluffy pieces with ragged edges, a mushy stool 
 Watery, no solid pieces 
 
3. Over the last two weeks, how much has your irritable bowel syndrome INTERFERED 
WITH YOUR LIFE AND ACTIVITIES?  (tick one answer): 
 
 Not at all 
 A little 
 Some 
 A lot 
 Extreme interference 
 
4. COMPARED TO LAST TIME you filled in this questionnaire (two weeks ago), do you 
feel that your irritable bowel syndrome symptoms have: (tick one answer) 
 
 Improved ------------------------>  If improved, are your symptoms: (tick one answer): 
 Stayed the same             A little better 
 Worsened       Moderately better 
A lot better 
5. COMPARED TO BEFORE YOU COMMENCED THE TRIAL, do you feel that your 
irritable bowel syndrome symptoms have: (tick one answer) 
 
 Improved ------------------------>  If improved, are your symptoms: (tick one answer): 
 Stayed the same             A little better 
 Worsened       Moderately better 
A lot better 
 
6. Please WRITE THE NAMES of any MEDICATIONS you have taken in the last two 
weeks, and how often you took them (e.g. “once only”, “twice a day for four days”, etc.).  
Include ALL medications, even headache tablets, antacids and other digestion 
medication, contraceptive pills, high doses of vitamins, sedatives, and any herbal or 
homoeopathic medications.  If you cannot remember exactly, please write your best 
guess. If your medications have not changed since you last filled in this form, just write 
“same as before”. 
 
MEDICATION    HOW OFTEN? 
 ______________________________   ______________________
 ______________________________   ______________________ 
 ______________________________   ______________________ 
 ______________________________   ______________________ 
 ______________________________   ______________________ 
 ______________________________   ______________________ 
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7. In the last two weeks, have you eaten MORE FIBRE (e.g. wholemeal bread, high-fibre 
breakfast cereals, fruit and vegetables, fibre supplements, etc.) than you USUALLY eat? 
 
 No                           A little more                                            A lot more 
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SF-36 HEALTH SURVEY(VI) 
 
 
 
 
Subject No.             Date   
  
 
 
INSTRUCTIONS:  This survey asks for your views about your health.  This information 
will help keep track of how you feel and how well you are able to do your usual 
activities. 
 
 
Answer every question by marking the answer as indicated.  If you are unsure about how 
to answer a question, please give the best answer you can. 
 
1. In general, would you say your health is:             (cross one) 
 
Excellent....................................... 
      
  Very Good   .................................. 
         
   Good  ........................................... 
  
                         Fair ............................................... 
     
                         Poor ............................................. 
     
 
2. Compared to two weeks ago, how would you rate your health now?   
 (cross one) 
 
   Excellent ..................................... 
     
   Very Good ................................... 
     
   Good ........................................... 
     
    Fair ............................................. 
     
    Poor ............................................  
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3. The following items are about activities you might do during a typical day.  Does  
    your health now limit you in these activities?  If so, how much?   
 
Activities Yes. 
Limited a 
lot. 
Yes. 
Limited a 
little. 
No. Not 
limited at 
all. 
 
a. Vigorous activities such as running, lifting heavy objects, 
participating in strenuous sports 
   
 
b.  Moderate activities such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf 
   
 
c.     Lifting or carrying groceries 
   
 
d.     Climbing several flights of stairs 
   
 
e.     Climbing one flight of stairs 
   
 
f.      Bending, kneeling or stooping 
   
 
g.     Walking more than a mile 
   
 
h.     Walking several blocks 
   
 
i.       Walking one block 
   
 
j.      Bathing or dressing yourself 
   
 
 
4. During the past two weeks, have you had any of the following problems with your 
    work or other regular daily activities as a result of your physical health?  (cross one box 
      on each line)  
 
 YES NO 
a. Cut down on the amount of time you spent on work or other activities 
 
  
b. Accomplished less than you would like 
 
  
c. Were limited in the kind of work or other activities 
 
  
d. Had difficulty performing the work or other activities (e.g. it took 
extra effort) 
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5.  During the past two weeks, have you had any of the following emotional problems 
with your work or other daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)?                 (cross one box on each line) 
 
 
 YES NO 
a. Cut down on the amount of time you spent on work or other activities 
 
  
b. Accomplished less than you would like 
 
  
c. Didn’t do work or other activities as carefully as usual 
 
  
 
 
6.   During the past two weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbours, or 
groups? 
                       (cross one) 
Not at all.............................  
 
Slightly ...............................  
 
Moderately ......................... 
 
Quite a bit .......................... 
 
Extremely .......................... 
 
 
7. How much bodily pain have you had during the past two weeks?                    (cross one) 
    
 
None .................................. 
 
Very Mild ............................ 
 
Mild ................................... 
 
Moderate ............................. 
 
                                               Severe ................................. 
 
Very Severe ...................... 
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8.   During the past two weeks, how much did the pain interfere with your normal work 
(including both work outside the home and housework)?                   (cross one)  
     
Not at all .......................... 
 
A little bit .......................... 
 
Moderately ....................... 
 
Quite a bit ........................ 
 
Extremely .........................        
 
9.  These questions are about how you feel and about how things have been with you 
during the past two weeks.  For each question, please give the answer that comes closest 
to the way you have been feeling.   
 
How much of the time during the last two weeks ...   (cross one box on each line) 
 
 
 All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little 
of the 
time 
None of 
the time 
a.  Did you feel full of pep? 
 
      
b.  Have you been a very nervous 
      person? 
 
      
c.  Have you felt so down in the 
     dumps that nothing could  
     cheer you up? 
               
d. Have you felt calm and 
      peaceful? 
 
      
e. Did you have a lot of energy? 
 
      
f.   Have you felt downhearted 
      and blue? 
 
      
g. Did you feel worn out? 
 
      
h. Have you been a happy  
    person? 
 
      
i.  Did you feel tired? 
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10.  During the past two weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, relatives, 
etc.)?   
(cross one) 
 
All of the time ..............................  
 
Most of the time .......................... 
 
Some of the time ......................... 
 
A little of the time ........................ 
 
None of the time ......................... 
 
 
11.  How TRUE or FALSE is each of the following statements for you?    (cross one box on      
 each line) 
 
 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
a.  I seem to get sick a little easier than 
    other people. 
 
     
b.  I am as healthy as anybody I know. 
 
     
c.  I expect my health to get worse. 
 
     
 
d.  My health is excellent. 
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SF-36 Health Survey 
Concepts No. of items Meaning of low 
score 
Meaning of high 
score 
Summary of content 
Physical 
functioning 
10 Limited a lot in 
performing all 
physical activities 
Performs all types 
of physical 
activities without 
limitations due to 
health 
Extent to which health 
limits physical activities 
such as self-care, walking, 
climbing stairs, bending, 
lifting, and moderate and 
vigorous exercises 
 
Role functioning - 
physical 
4 Limits with work & 
daily activities due 
to physical health 
No limits due to 
physical health 
Extent to which physical 
health interferes with 
work or other daily 
activities, including 
accomplishing less than 
wanted, limitations in the 
kind of activities, or 
difficulty in performing 
activities 
 
Bodily pain 2 Severe, extremely 
limiting pain 
No pain or limits 
in the past week 
Intensity of pain and 
effect of pain on normal 
work, both inside and 
outside the home 
 
General health 5  Perceives health as 
poor 
Perceives health 
as excellent 
Personal evaluation of 
health 
 
Vitality 4 Feeling tired, worn 
out all the time 
Feeling full of 
energy during the 
past week 
 
How energetic or tired 
Social functioning 2 Extreme 
interference with 
social activities 
No interference 
from health in 
social activities 
Extent to which physical 
health or emotional 
problems interfere with 
normal social activities 
 
Role functioning - 
emotional 
3 Limits due to 
emotional problems 
No limits due to 
emotional 
problems 
Extent to which emotional 
problems interfere with 
work or other daily 
activities, including 
decreased time spent on 
activities, accomplishing 
less, and not working as 
carefully as usual 
 
Mental health 5 Feeling nervous or 
depressed in the past 
week 
Feeling peaceful, 
happy and calm in 
the past week 
General mental health 
including depression, 
anxiety 
 
Reported health 
transition 
1 Health poor and 
likely to get worse 
Believes health is 
excellent 
Evaluation of health 
compared to a week ago 
 
Health concepts, items, levels and summary of content for SF36 sub-scales 
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Duke-UNC Functional Social Support Questionnaire 
 
(Adapted from Broadhead, W.E., Gehlbach,S.H., De Gruy, F.V. & Kaplan, 
BB.H.(1988). The Duke-UNC Functional Social Support Questionnaire: measurement 
of social support in family medicine patients. Medical Care, 26, 709-723). 
 
Here is a list of some things that other people do for us or give us that may be helpful or supportive.  
Please read each statement carefully and place a tick (  ) in the blank that is closest to your situation. 
Here is an example: 
I get ….     As much as              Much less than 
holiday time    I would like    I would like 
 
    l_______l_______l_______l_______l_______l 
 
If you put a tick where we have, it means that you get almost as much holiday time as you would like, 
but not quite as much as you would like. 
 
Answer each item as best you can.  There are NO right or wrong answers. 
 
I get ….    As much as               Much less than 
     I would like    I would like 
 
1. invitations to go out and so things 
with other people   l_______l_______l_______l_______l_______l 
 
 
2.    love and affection   l_______l_______l_______l_______l_______l 
 
 
3. chances to talk to someone about 
problems at work or with my house- 
work    l_______l_______l_______l_______l_______l 
 
4. chances to talk to someone I trust 
about my personal and family 
problems     l_______l_______l_______l_______l_______l 
 
5.   chances to talk about money matters l_______l_______l_______l_______l_______l 
 
 
6.   people who care what happens to me l_______l_______l_______l_______l_______l 
 
7. useful advice about important things 
in life    l_______l_______l_______l_______l_______l 
 
 
8.   help when I’m sick in bed  l_______l_______l_______l_______l_______l 
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Scoring:  Each item is scored on a five point scale (1= As much as I would like, 5= 
Much less than I would like).  Item scores are summed for confidant support (Items 
1,3,4,5,7) and affective support (Items 2,6,8) 
____________________________________________________________________ 
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SURVEY OF RECENT LIFE EXPERIENCES. 
(SRLE) 
 
Following is a list of experiences which many people have some time or other.  Please 
indicate for each experience how much it has been a part of your life over the past month.  
Put a “1” in the space provided next to an experience if it was not at all part of your life 
over the past month; “2” for an experience which was only slightly part of your life over 
that time; “3” for an experience which was distinctly part of your life; and “4” for an 
experience which was very much part of your life over the past month. 
 
Intensity of Experience over the Past Month. 
 
1. not at all part of my life 
2. only slightly part of my life 
3. distinctly part of my life 
4. very much part of my life 
__________________________________________________________________ 
 
1.   Disliking your daily activities                 _______ 
 
2.   Lack of privacy                   _______ 
 
3.   Disliking your work                   _______ 
 
4.   Ethnic or racial conflict                  _______ 
  
5.   Conflicts with in-laws or boyfriend’s/girlfriend’s family              _______ 
 
6.   Being let down or disappointed by friends                _______ 
  
7.   Conflict with supervisor(s) at work                 _______ 
 
8.   Social rejection                   _______ 
 
9.   Too many things to do at once                             _______ 
 
10. Being taken for granted                  _______ 
 
11. Financial conflicts with family members                 _______ 
 
12. Having your trust betrayed by a friend                _______ 
 
13. Separation from people you care about                _______ 
 
14. Having your contributions overlooked                _______ 
 
15. Struggling to meet your own standards of performance & accomplishment     _______ 
 
16. Being taken advantage of                  _______ 
 
17. Not enough leisure time                  _______ 
 
18. Financial conflict with friends or fellow workers               _______ 
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19. Struggling to meet other people’s standards of performance &  
      accomplishment                                                                                     _______ 
 
20. Having your actions misunderstood by others               _______ 
 
21. Cash-flow difficulties                  _______ 
 
22. A lot of responsibilities                  _______ 
 
23. Dissatisfaction with work                  _______ 
 
24. Decisions about intimate relationship(s)                    _______ 
 
25. Not enough time to meet your obligations                            _______ 
 
26. Dissatisfaction with your mathematical ability                 _______ 
 
27. Financial burdens                   _______ 
 
28. Lower evaluation of your work than you think you deserve              _______ 
 
29. Experiencing high levels of noise                 _______ 
 
30. Adjustments to living with unrelated person(s) (e.g. roommate)             _______ 
 
31. Lower evaluation of your work than you hoped for               _______ 
 
32. Conflicts with family member(s)                 _______ 
 
33. Finding your work too demanding                 _______ 
 
34. Conflict with friend(s)                  _______ 
 
35. Hard effort to get ahead                  _______ 
 
36. Trying to secure loan(s)                  _______ 
 
37. Getting “ripped off” or cheated in the purchase of goods              _______ 
 
38. Dissatisfaction with your ability at written expression              _______ 
 
39. Unwanted interruptions of your work                            _______ 
 
40. Social isolation                   _______ 
 
41. Being ignored                               _______ 
 
42. Dissatisfaction with your physical appearance               _______ 
 
43. Unsatisfactory housing conditions                 _______ 
 
44. Finding work uninteresting                              _______ 
 
45. Failing to get money you expected                             _______ 
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46. Gossip about someone you care about                _______ 
 
47. Dissatisfaction with your physical fitness                _______ 
 
48. Gossip about yourself                  _______ 
 
49. Difficulty dealing with modern technology (e.g. computers)              _______ 
 
50. Car problems                   _______ 
 
51. Hard work to look after and maintain home                _______ 
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The Six Concepts of the SRLE. 
 
 
Social and Cultural Difficulties. 
 
Gossip about someone you care about 
Being let down or disappointed by friends 
Having your trust betrayed by a friend 
Conflict with friend(s) 
Gossip about yourself 
Decisions about intimate relationship(s) 
Conflicts with family member(s) 
Experiencing high levels of noise 
Ethnic or racial conflict 
Difficulty dealing with modern technology (e.g. computers) 
Conflicts with in-laws or boyfriend’s/girlfriend’s family 
 
 
Work. 
 
Dissatisfaction with work 
Disliking your work 
Finding work uninteresting 
Disliking your daily activities 
Conflict with supervisor(s) at work 
Lower evaluation of your work than you think you deserve 
Lower evaluation of your work than you hoped for 
 
 
Time Pressure. 
 
Too many things to do at once 
Not enough time to meet your obligations 
A lot of responsibilities 
Not enough leisure time 
Finding your work too demanding 
Hard work to look after and maintain home 
Unwanted interruptions of your work 
Struggling to meet your own standards of performance and accomplishment 
 
 
Finances. 
 
Cash-flow difficulties 
Financial burdens 
Trying to secure loan(s) 
Failing to get money you expected 
Unsatisfactory housing conditions 
Financial conflicts with family members 
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Social Acceptability. 
 
 
Dissatisfaction with your physical fitness 
Being ignored 
Social isolation 
Dissatisfaction with your physical appearance 
Social rejection 
 
 
Social Victimisation. 
 
 
Being taken for granted 
Being taken advantage of 
Getting “ripped off” or cheated in the purchase of goods 
Having your contributions overlooked 
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IRRITABLE BOWEL SYNDROME – CREDIBILITY SCALE. 
 
 
Date: __/__/__           Patient ID:  _________ 
       Patient Initials ________ 
 
 
Please answer the following additional questions. Circle the number which best expresses 
your answer. 
 
 
A. How confident do you feel that the treatment you are receiving can alleviate 
your complaint? 
 
  1                          2                                3                                  4                                 5                               
 
__________________________________________________________________ 
 not at all                                                               extremely 
confident                  confident 
                                   
 
B. How confident would you be in recommending this form of treatment to a 
friend who suffers from similar complaints? 
 
 1                           2                                 3                                 4                               5                               
 
__________________________________________________________________ 
 not at all                                           extremely 
confident                           confident 
 
    
C. How logical does the treatment you are receiving seem to you? 
 
 1                           2                               3                               4                               5                             
 
 _________________________________________________________________ 
not at all               extremely  
confident               confident 
           
     
D. How successful do you think this form of treatment would be in          
 alleviating other complaints? 
 
 1                           2                                 3                                 4                                5                               
 
  _________________________________________________________________ 
  not at all                   extremely 
  confident                confident  
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                THE GOLDEN WATER. 
 
Imagine that you are in your special place.  The sun is shining and the breeze is soft 
and gentle.  It feels warm against your skin.  It is such a lovely day.  Next to you is a 
table.  On the table is a clear glass jug of sparkling water.  Look at the water and see 
that it contains tiny gold flecks.  They sparkle and glimmer in the sun.  The flecks in 
the water are very good for you.  You feel and know this.  In this place it seems that 
you are fearless and courageous.  You realise that life is a process of give and take, 
and you are in control of this process. 
 
You feel free in this place and you trust that everything is really okay.  You are filled 
with positive energy and you pick up the jug and pour yourself a glass of this special 
water.  Drink the water.  The water goes down your throat and into your digestive 
tract.  Feel how the golden flecks in the water sparkle in your body.  The flecks are 
healing you as it goes throughout your digestive tract.  Now feel the golden-flecked 
water reach your intestines and colon.  Soothing the sides, healing everything that 
needs to be healed.  Feel the healing taking place. 
 
Feel the water absorbing into all the muscles in your digestive tract, making them 
strong and giving them good tone.  Feel this now.  The golden-flecked water is 
throughout your digestive tract, making you able to process and absorb food 
correctly.  Making you regular in elimination.  Making everything in perfect working 
order.  You know this is happening right now.   Feel the healing. 
 
If you need more water, keep drinking as much as you need.  After each drink, feel 
how the gold-flecked water is healing you.  Giving you what you need.  Empowering 
you and repairing your body at the same time.  You know that everything inside and 
outside your body is perfect in every way.  You desire to eat only the right foods for 
your body.  You desire to drink the right amount of liquids for your body every day.  
Everything in your body is working correctly and properly.  You feel balanced, 
centred, and happy.  These feelings will stay with you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANXIETY 
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ANXIETY. 
 
 
Imagine that you are standing in a room.  Look up over your head.  See a light. …. It 
is the most beautiful light you have ever seen.  Look at it shine ... sparkle ... glimmer.  
Watch as this light starts to surround the right side of your body.  Watch as it forms 
an outline around you.  It feels so safe.  It feels so comfortable. 
 
You feel this light absorbing all the stress, all the tension from your body.  Watch as 
it goes down the right side of your body down to your right foot.  Watch and feel all 
the stress and all the tension being absorbed by this light as it goes underneath your 
foot and outlines your inner right leg.  See the light go down your inner left leg and 
under your left foot.  So soothing.  So comforting.  Now feel the light go up your left 
leg and up your torso, your arm, your shoulder.  Outlining the body.  Drawing away 
all the tension all the stress.  Making you feel so calm, so centred. 
 
Watch as this light attaches to where it started.  Fully outlining your body.  Feel the 
glow of the light around you.  Feel it absorbing any stress or tension that is left in 
your body.  Making you feel calm and safe right here, in this time, in this place.  You 
feel peaceful in this light.  You are centred.  This is your protective light.  You are 
safe within this light.  You can imagine this light whenever you need it.  Whenever 
you feel anxious, this light will surround your body.  Absorbing the tension.  
Absorbing the stress.  Making you feel centred and safe.  This feeling will stay with 
you. 
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DEPRESSION. 
 
 
With peace of mind, calm, and at ease, being able to look out at every part of the 
universe, at every person around you, at every flower and tree and plant, grass and 
children, and in a new way, as you begin, starting now, to see the world in a new way, 
with a freshness, and wonder, and awe of a little child. 
 
You begin now to see the world again as you once did when you were an unspoilt 
child, and you can regain that capacity again to see and appreciate everything freshly, 
and naively, in a simple way as you can begin once again to see things anew, fresh, 
wonderful, clean. 
 
Now you can begin to look at every sunrise as if it’s the first sunrise you’ve ever 
seen, and every sunset, and you will see the colours, and the wonder, and the beauty 
surrounding you again, as if it’s the first time you’ve ever seen it. 
 
Starting now, every bird that you see will be as if you’ve never seen a bird before, as 
if you’re a new child, and you’re beginning again to look with wonder and 
amazement at the world around you.  You see every bird in a new way, and every 
tree, and the leaves of the tree, and the seeds on the tree, and the bark on the tree, and 
the green leaves and the sun shining, and the grass around you, you’ll be able to see it 
in a new way, fresh, with wonder and awe.  As you again the capacity to appreciated 
everything as you once did. 
 
Everything that’s become stale over the years will no longer be stale for you, as you 
become aware again that we can be the way we once were, looking at each thing as 
miraculous, as beautiful, as wonderful as the first time we saw them, when we were 
children. 
 
As if we’re here now, again, for the first time.  As if we’re here from another planet.  
We’ve just landed and we see the wonders of the Earth, and we see the people on the 
Earth, and we see their hair, and their faces, and their noses, and their skin, and the 
wonders of their being and their minds.  And we see each person as if we’ve never 
seen this person before.. We see them fresh and new, and we see all the wonderful 
aspects of their being. 
 
And we look again at every cloud and we feel every breeze.  And we begin to feel the 
air around us, and we become more aware of the oxygen we breathe, and we become 
more aware of the colours and the details of the flowers and the trees, and the people, 
and the buildings, and the grass, and the books, and everything that surrounds us, 
every day, every person, every child, every adult, every animal, every plant – we see 
it anew. 
 
Experiencing every moment in a new way, starting now, as if a fog has been lifted, as 
if everything is becoming sparkling clean, as if we’ve come from another planet and 
we look around, and we see, and we feel, and we experience in a new way, starting 
now, and every day. 
 
And this feeling will grow more and more as time goes on – you will be able to feel 
more and more at ease and calm and peaceful with vibrant energy, enjoying every 
aspect of your being, feeling strong, healthy, with peace of mind, calm mind, body at 
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ease, and yet very vibrant and energetic, looking at everything in a new way, as if 
you’ve been here now, just a short time. 
 
You’re beginning to experience the world again, fresh, clean, sparkling new, new 
perceptions, aware of everything around you freshly, once again.  And this will grow 
every day. 
 
With this new way of looking at life, you’ll find every day that your energy will 
increase and you’ll feel so healthy, and you feel healthy and free, you’ll feel all the 
tensions will leave.  You’ll feel at ease and calm, and free as you become more aware 
of the blood circulating in your body, and the strength in your muscles, and the 
wonders of your strong, healthy being. 
 
You begin to feel that you’re living, you’re beginning to live more and more, growing 
every day, becoming more aware, more filled with energy, more vibrant. 
 
Starting today, you’ll begin to feel that life is just beginning, that your potential for 
living a very good life is there, and it will increase and you’ll become more aware of 
the potential, and you’ll become aware of how you can enjoy life more and more 
every day. 
 
And you’ll look forward to every coming day as another exciting day that you can 
live fully, growing, changing, maturing, healthy, strong, vibrant, and energetic.  You 
will realise that you have the potential to be happy, strong and much greater than you 
thought.  That you have vibrant energy, that you’re able to flow and move with every 
person, every individual you meet.  You’ll be able to feel with them, be able to feel 
with every animal, and every plant, and every part of the Earth. 
 
From this day on, you’ll begin to live fully, moment by moment, every day.  You’ll 
get so much out of every day, more and more, starting now, every day, every hour, 
every second, will become more and more exciting, full, enthralling, amazing.  You’ll 
become more and more aware of the wonders of your being, yourself, the Earth, and 
everything around you.  You’ll become more and more deeply involved in everything 
that is happening around you, the people you meet, the tasks you meet, and the 
children that you see, and everything that comes into your life. 
 
You’ll be aware, and become more and more involved, like a child, living fully, 
enjoying every moment, being unselfconscious, feeling free.  You’ll be able to enjoy 
more and more activities, and your activities will be the way they were when you 
were a child, free and unspoilt, at ease, enjoying, able to get into things, more and 
more, as you were once able to be creative, ingenious, able to make everything into a 
fun game.  You’ll again remember how to play and have fun, by your own creativity 
and imagination, using your own ingenuity, able to regain your lost spontaneity, your 
naturalness, your freshness – it will come out and you will feel at ease with it. 
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OBSESSIVE COMPULSIVE. 
 
 
Look above your head and see a light … it’s a colour you really like.  It’s the most 
beautiful light you’ve ever seen.  Look at it shine … sparkle … glimmer.  Watch as 
this light starts to surround your head.  It feels so safe.  It feels so comfortable.  You 
feel this light absorbing any repeated, unpleasant thoughts that may occur in your 
head … clearing your mind so that you no longer have difficulty remembering things 
… from now on you can remember things easily.  Feel the healing.  Feel the light 
clearing your mind and allowing you to concentrate more easily … allowing you to 
make decisions more easily.  From now, on concentrating and making decisions will 
be easy for you. 
 
Watch as this light goes down the right side of your body from your head down to 
your right foot.  You feel this light absorbing all the stress, all the tension from your 
body.  Watch and feel all the stress and all the tension being absorbed by this light as 
it goes underneath your foot and outlines your inner right leg.  See the light go down 
your inner left leg and under your left foot.  So soothing.  So comforting.  Now feel 
the light go up your left leg and up your torso, your arm, your shoulder.  Outlining the 
body.  Drawing away all the tension, all the stress.  Making you feel so calm, so 
centred. 
 
Watch as this light attaches to where it started.  Fully outlining your body.  Feel the 
glow of the light around you.  Feel it absorbing any stress or tension that is left in 
your body.  Making you feel calm and safe right here, in this time, in this place.  As 
the stress and tension leave your body, you are calm and peaceful … calm and 
peaceful … able to carry out any action without unnecessarily repeating it. 
 
You are peaceful in this special light.  You are centred.  This is your protective light.  
You are safe within this light.  You can imagine this light whenever you need it. 
Whenever you feel the need, this light will surround your body.  Absorbing the 
tension … absorbing the stress.  Making you able to concentrate more easily … 
making you able to make decisions … taking away any anxiety, any unnecessary, 
repetitive actions.  Making you feel centred and safe.  Any outside negative actions, 
words or thoughts will just bounce off this protective shield … bounce off and away.  
Leaving you protected, calm and peaceful.  These feelings will stay with you. 
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INTERPERSONAL SENSITIVITY. 
 
 
Feel each breath lead you into deeper relaxation as if the very air surrounding your 
body were a vast ocean of peace.  Each inward and outward breath like a wave on the 
shore of that ocean, softly in, softly out.  As you breathe quietly, send a wave of 
relaxation from the top of your head all the way down to the tips of your toes.  If you 
have an area of tension in your body, bring your awareness to that area now and 
breathe quietly into that tension, allowing it to soften and relax.  Devote the next little 
while to nurturing yourself.  A special time that is just for you. 
 
If there is any tightness in your solar plexus, just above your navel, visualise that area 
as a pool of water and see a pebble dropped right into its centre … spreading ripples 
of relaxation out from its centre..  Let your heart be cradled in peace, visualising it as 
a flower bud, that in the presence of peace, opens to its full blossom, revealing deep 
in the heart of that flower all its beauty and simplicity.  Allow these qualities to 
spread like a perfume all throughout your body … easing all the tension.  Imagine 
feeling two hands resting on those shoulders, hands of a loved one or an angel … 
absorbing all the tension … sending ripples of healing and love into your body. 
 
From now on, you’ll always be aware of your surroundings, you’re not going to be 
asleep.  You’ll always hear those sounds around you that are perfectly normal for 
where you are … any sounds you hear will not affect or disturb you in any way … 
those sounds will actually help you to relax even more deeply. 
 
Now visualise yourself standing on a cliff top, above a rainforest that stretches out 
endlessly.  Feel the spaciousness around your body, the touch of the sun against your 
skin, the vast dome of the sky stretching above.  Deep within the heart of this forest 
there is a special place just for you … a place of nurturing, of understanding … a 
place where you receive replenishment.  The sky is clear after recent rain.  You can 
walk down into the forest via a path or you can simply let yourself drift like a feather 
… easily and softly floating down in the air … a feather supported … carried gently 
down … floating soft and light. 
 
As you near the canopy of the leaves you see they open to allow you to float down 
into the forest until you come to rest on the forest floor.  Allow your eyes to become 
accustomed to the colours … the greens and brown of the forest … perhaps there are 
brightly-coloured birds.  Feel the peace of the forest … its ancientness … the strength 
of the earth beneath your feet.  And as you begin to walk along the path towards the 
pool in the centre of the forest, feel yourself become part of the forest … not so much 
a visitor but as an expression of the forest … all of its beauty and peace.  With each 
step, your body is becoming more relaxed, your mind at peace, until you see a little 
way ahead a pool that sparkles in the sunshine … its surface too bright to look at. 
 
On the far side of the pool there’s a waterfall … and as you stand at the edge of the 
pool, looking into the water, you see that it is crystal clear and the waterfall is 
splashing, creating rainbows all around you.  You may want to test the water with 
your foot, finding it just the right temperature for you … and you let yourself enter 
into the water … feeling it wash over your skin … refreshing, revitalising every cell 
in your body. You may like to swim over to the waterfall … feeling the joy of having 
all your needs met right now.  Let yourself stand under that waterfall … feeling it 
cascade down onto your head, your shoulders … every cell in your body sparkling 
 397 
and alive … the water so fine it passes right through the centre of your body.  Every 
cell sparkling like a rainbow within your body. 
 
Allow all the anxieties and fears, old attitudes and beliefs, to wash away … washed 
out through the sole of your feet.  Allow yourself the pleasure of being free … 
releasing the past … and the future.  Feel the vitality flow freely within you.   
Breathing in the sunshine as soft, golden, sparkling light that flows into your body 
with each inward breath, filling the chest with its light and spreading beyond … 
flowing out to every fibre of your being. You deserve to be happy … allow that light 
to flow freely.  Feel yourself worthy of your own love.  Allow appreciation and 
gratitude for your body … mind at peace … full of joy. 
 
Allow an image of yourself to arise in your mind’s eye.  See yourself at peace with 
others and with yourself … look into your own eyes and see the peace that’s there … 
see the joy that sparkles there … a confidence in yourself and in your own abilities.  
See yourself able to accomplish whatever you set your heart to … full of enthusiasm 
for life … brimmed full of vitality.  See yourself worthy of your own love … 
deserving to be happy … giving value to yourself.  Allow that image to become 
strong in your mind’s eye and see it become small enough to place inside your heart 
… put it there … breathing in the qualities that would bring that image to life.  
Breathing in vitality and love to yourself … breath in compassion for yourself … and 
see the image within your heart grow strong … so strong that your heart can no 
longer contain it … and see it spill over as light that radiates throughout the whole of 
your being … every cell bathed in the light of your own confidence … your peace 
and love … spreading beyond your body to form a cocoon of light that surrounds and 
heals and nourished you.  A light that you can draw on always … breathe that light in, 
allowing it to flow out from yourself to touch others. 
 
Then allow your breathing to deepen … and as it deepens, feel the energy flooding 
back into your body as if again you are standing under that waterfall of light … its 
vitality showering down onto your head and shoulders … energising ever cell within 
your body … energising your mind. 
 
Feel the muscle tone returning to your arms and legs … begin moving your hands and 
feet just a little … and, keeping your eyes closed, let yourself stretch the way a cat 
stretches after a sleep.  Feel the refreshment and relaxation in all the tissues of your 
body … the mind at peace and confident … full of joy … enjoying the stretch.  And 
when you’re ready, allow your eyes to open gently and easily … no need to hurry … 
just take your time. 
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RELAXATION. 
 
I’d like you to begin by just resting back, very comfortably, and closing your eyes.  
Just rest back in the way that is most comfortable for you right now, just resting your 
hands on your thighs, or on the arms of the chair.  And as you just settle back 
comfortably, this will be an opportunity for you to become even more comfortable, 
and to experience a hypnotic state, very easily, and very gently, and very 
comfortably. 
 
 And as you rest back, you can begin noticing the feelings, and sensations in 
your body right now.  Just notice some of the sensations, that you can be aware of 
right now.  For instance, you may become aware of the feel of the shoes on your feet; 
or you may notice the sensations in your hands as they rest there; or perhaps you may 
be aware of how the chair supports your body. And as you continue to listen to me, 
and breathing easily and comfortably, and deeply, you may become aware of the 
sensations as you breathe, noticing for example that the sensations are different when 
you breathe in...... and when you breathe out.....  Just notice those feelings as you 
breathe in .... and fill your lungs; and then notice the sense of release, as you breathe 
out ...... 
 
 And now I’d like you to concentrate particularly on the feelings in your toes 
and feet.  Just allow all the muscles and fibres in your toes and feet, to become very 
deeply relaxed. Perhaps even picturing in your mind’s eye what they would look like, 
for all those little muscles and tissues to relax, loosely and deeply.  Allowing yourself 
to get that kind of feeling you have when you take off a pair of tight shoes that you’ve 
had on for a long time.  And you can just let go of all the tension in your toes and feet 
and feel the relaxation spread..... 
 
 And now imagine that this comfort and relaxation, is beginning to spread and 
flow, like a gentle river of relaxation, upward, through your ankles and all through 
your calves.  Letting go of all the tension in your calves, allowing them to deeply, and 
restfully, and comfortably relax.   
 
 And allow that comfort to continue, flowing upward, into your knees, and 
behind your knees and through your knees, and into your thighs, letting go of all the 
tension in your thighs.  Perhaps once again imagining what they might look like, for 
all those large muscles and tissues, to become soft and loose, and deeply relaxed.  
Perhaps already noticing that sense of gentle heaviness in your legs, as they just sink 
down, limply and comfortably. 
 
And continue to allow that comfort, to flow and spread upward, at its own pace and 
speed, into the middle part of your body.  Flowing into your pelvis and abdomen and 
stomach..... through your hips and into your lower back.  Letting that soothing, deep 
comfort spread, inch by inch, up through your body, spreading from muscle group to 
muscle group.  Gradually, progressively flowing into your chest.... into your back.... 
between your shoulder blades, and into your shoulders.  Just allow all the tension to 
loosen, and flow away.  As if somehow, just the act of breathing is increasing your 
comfort.  As if somehow, every breath you take, is just draining the tension out of 
your body, taking you deeper ... and deeper, into comfort, with every breath you take.   
And allow that comfort to flow into your neck and throat.  Perhaps imagining once 
again what that would look like, for all the little fibres and muscles in your neck and 
throat, to deeply, softly, comfortably relax.  Let that relaxation sink deep into your 
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neck.  and it can gradually flow up your neck, up into your scalp, and all out across 
your scalp, as if it’s just bathing your head, with waves of comfort and relaxation.  
And that relaxation can flow down, into your forehead, and like a gentle wave, down 
across your face, into your eyes, your cheeks, your mouth and jaw.  Just let go of all 
the tension in your face, your mouth, your jaw, allowing those tissues and muscles to 
sag down, slack and relaxed. 
 
And now allow that comfort to flow back down your neck, and across your shoulders, 
and down into your arms, through your elbows....through your wrists, through your 
hands and fingers, right down through your fingertips.  Letting go of all the tension, 
and tightness, letting go of all the stress, and strain, all through your body.  Just 
allowing your body to rest, and relax. 
 
Now remain for a few moments in this relaxed, comfortable state and then gently, 
gradually, bring yourself back to awareness … to the present … to where you are 
now … and open your eyes. 
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